0001493152-21-028267.txt : 20211115 0001493152-21-028267.hdr.sgml : 20211115 20211112214826 ACCESSION NUMBER: 0001493152-21-028267 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211115 DATE AS OF CHANGE: 20211112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSISTED 4 LIVING, INC. CENTRAL INDEX KEY: 0001719435 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 821884480 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-226979 FILM NUMBER: 211405881 BUSINESS ADDRESS: STREET 1: 5115 EAST STATE ROAD 64 CITY: BRADENTON STATE: FL ZIP: 34208 BUSINESS PHONE: 8556683331 MAIL ADDRESS: STREET 1: 5115 EAST STATE ROAD 64 CITY: BRADENTON STATE: FL ZIP: 34208 10-Q 1 form10-q.htm
0001719435 false --12-31 Q3 P1Y P84M P5Y 0001719435 2021-01-01 2021-09-30 0001719435 2021-11-12 0001719435 2021-09-30 0001719435 2020-12-31 0001719435 us-gaap:ProductAndServiceOtherMember 2021-07-01 2021-09-30 0001719435 us-gaap:ProductAndServiceOtherMember 2020-07-01 2020-09-30 0001719435 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-09-30 0001719435 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-09-30 0001719435 ASLI:RentalRevenueMember 2021-07-01 2021-09-30 0001719435 ASLI:RentalRevenueMember 2020-07-01 2020-09-30 0001719435 ASLI:RentalRevenueMember 2021-01-01 2021-09-30 0001719435 ASLI:RentalRevenueMember 2020-01-01 2020-09-30 0001719435 ASLI:OtherRevenueMember 2021-07-01 2021-09-30 0001719435 ASLI:OtherRevenueMember 2020-07-01 2020-09-30 0001719435 ASLI:OtherRevenueMember 2021-01-01 2021-09-30 0001719435 ASLI:OtherRevenueMember 2020-01-01 2020-09-30 0001719435 2021-07-01 2021-09-30 0001719435 2020-07-01 2020-09-30 0001719435 2020-01-01 2020-09-30 0001719435 us-gaap:CommonStockMember 2019-12-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001719435 ASLI:SubscriptionReceivableMember 2019-12-31 0001719435 us-gaap:RetainedEarningsMember 2019-12-31 0001719435 2019-12-31 0001719435 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001719435 ASLI:SubscriptionReceivableMember 2020-01-01 2020-03-31 0001719435 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001719435 2020-01-01 2020-03-31 0001719435 us-gaap:CommonStockMember 2020-03-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001719435 ASLI:SubscriptionReceivableMember 2020-03-31 0001719435 us-gaap:RetainedEarningsMember 2020-03-31 0001719435 2020-03-31 0001719435 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001719435 ASLI:SubscriptionReceivableMember 2020-04-01 2020-06-30 0001719435 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001719435 2020-04-01 2020-06-30 0001719435 us-gaap:CommonStockMember 2020-06-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001719435 ASLI:SubscriptionReceivableMember 2020-06-30 0001719435 us-gaap:RetainedEarningsMember 2020-06-30 0001719435 2020-06-30 0001719435 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001719435 ASLI:SubscriptionReceivableMember 2020-07-01 2020-09-30 0001719435 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001719435 us-gaap:CommonStockMember 2020-09-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001719435 ASLI:SubscriptionReceivableMember 2020-09-30 0001719435 us-gaap:RetainedEarningsMember 2020-09-30 0001719435 2020-09-30 0001719435 us-gaap:CommonStockMember 2020-12-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001719435 ASLI:SubscriptionReceivableMember 2020-12-31 0001719435 us-gaap:RetainedEarningsMember 2020-12-31 0001719435 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001719435 ASLI:SubscriptionReceivableMember 2021-01-01 2021-03-31 0001719435 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001719435 2021-01-01 2021-03-31 0001719435 us-gaap:CommonStockMember 2021-03-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001719435 ASLI:SubscriptionReceivableMember 2021-03-31 0001719435 us-gaap:RetainedEarningsMember 2021-03-31 0001719435 2021-03-31 0001719435 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001719435 ASLI:SubscriptionReceivableMember 2021-04-01 2021-06-30 0001719435 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001719435 2021-04-01 2021-06-30 0001719435 us-gaap:CommonStockMember 2021-06-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001719435 ASLI:SubscriptionReceivableMember 2021-06-30 0001719435 us-gaap:RetainedEarningsMember 2021-06-30 0001719435 2021-06-30 0001719435 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001719435 ASLI:SubscriptionReceivableMember 2021-07-01 2021-09-30 0001719435 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001719435 us-gaap:CommonStockMember 2021-09-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001719435 ASLI:SubscriptionReceivableMember 2021-09-30 0001719435 us-gaap:RetainedEarningsMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2021-01-01 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2020-01-01 2020-12-31 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2021-06-09 2021-06-10 0001719435 us-gaap:AccountingStandardsUpdate201409Member 2021-01-01 2021-09-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-03-22 2021-03-23 0001719435 2021-03-23 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-03-23 0001719435 2021-03-22 2021-03-23 0001719435 ASLI:NoteHolderMember 2021-04-01 2021-06-30 0001719435 2020-11-06 0001719435 2021-11-06 0001719435 ASLI:AssistedTwoLivingIncMember 2021-04-29 2021-04-30 0001719435 ASLI:AssistedTwoLivingIncMember ASLI:PurchaseAndSaleOptionAgreementMember 2020-11-07 0001719435 ASLI:AssistedTwoLivingIncMember ASLI:PurchaseAndSaleOptionAgreementMember ASLI:RomulusBarrMember 2020-11-07 0001719435 2021-04-29 2021-04-30 0001719435 2021-04-30 0001719435 ASLI:AssistedTwoLivingIncMember 2021-07-01 2021-09-30 0001719435 ASLI:AssistedTwoLivingIncMember 2020-07-01 2020-09-30 0001719435 ASLI:AssistedTwoLivingIncMember 2021-01-01 2021-09-30 0001719435 ASLI:AssistedTwoLivingIncMember 2020-01-01 2020-09-30 0001719435 ASLI:TrilliumSubsidiariesMember 2021-01-01 2021-09-30 0001719435 ASLI:PurchaseAgreementMember 2021-01-01 2021-09-30 0001719435 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001719435 us-gaap:CommonStockMember ASLI:PurchaseAgreementMember ASLI:TrilliumSubsidiariesMember 2021-09-30 0001719435 us-gaap:CommonStockMember ASLI:PurchaseAgreementMember 2021-09-30 0001719435 ASLI:PurchaseAgreementMember 2021-09-30 0001719435 ASLI:TrilliumSubsidiariesMember 2021-09-30 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember 2021-09-30 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember 2020-12-31 0001719435 ASLI:NuViewTrustCoMember 2021-09-30 0001719435 ASLI:NuViewTrustCoMember 2020-12-31 0001719435 ASLI:GrandTrinityPlazaLLCMember 2021-09-30 0001719435 ASLI:GrandTrinityPlazaLLCMember 2020-12-31 0001719435 ASLI:ReliantMember 2021-09-30 0001719435 ASLI:ReliantMember 2020-12-31 0001719435 ASLI:HCSGMember 2021-09-30 0001719435 ASLI:HCSGMember 2020-12-31 0001719435 ASLI:MedlineMember 2021-09-30 0001719435 ASLI:MedlineMember 2020-12-31 0001719435 ASLI:SLRRLOCMember 2021-09-30 0001719435 ASLI:SLRRLOCMember 2020-12-31 0001719435 ASLI:NotesPayableMember 2021-09-30 0001719435 ASLI:NotesPayableMember 2020-12-31 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2020-09-18 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2020-09-17 2020-09-18 0001719435 ASLI:ExcelFamilyPartnersLLLPMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2020-09-18 0001719435 ASLI:BanyanPediatricCareCentersIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2020-09-18 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2021-03-23 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2021-09-30 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2020-12-31 0001719435 ASLI:NuViewTrustCoMember us-gaap:NotesPayableOtherPayablesMember 2020-11-05 2020-11-06 0001719435 ASLI:NuViewTrustCoMember us-gaap:NotesPayableOtherPayablesMember 2020-11-06 0001719435 ASLI:NuViewTrustCoMember us-gaap:NotesPayableOtherPayablesMember 2020-09-30 0001719435 ASLI:NuViewTrustCoMember us-gaap:NotesPayableOtherPayablesMember 2020-12-31 0001719435 ASLI:GrandTrinityPlazaLLCMember us-gaap:NotesPayableOtherPayablesMember 2020-12-15 0001719435 ASLI:GrandTrinityPlazaLLCMember us-gaap:NotesPayableOtherPayablesMember 2020-12-14 2020-12-15 0001719435 srt:MinimumMember ASLI:TrilliumHealthcareGroupLLCMember 2019-12-31 0001719435 srt:MaximumMember ASLI:TrilliumHealthcareGroupLLCMember 2019-12-31 0001719435 ASLI:ReliantMember us-gaap:NotesPayableOtherPayablesMember 2019-01-01 2019-12-31 0001719435 ASLI:ReliantMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0001719435 ASLI:HCSGMember us-gaap:NotesPayableOtherPayablesMember 2019-01-01 2019-12-31 0001719435 ASLI:MedlineMember us-gaap:NotesPayableOtherPayablesMember 2019-01-01 2019-12-31 0001719435 ASLI:MedlineMember us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0001719435 ASLI:TrilliumHealthcareGroupLLCMember ASLI:GeminoHealthcareFinanceLLCMember us-gaap:LineOfCreditMember 2019-05-09 0001719435 ASLI:TrilliumHealthcareGroupLLCMember ASLI:GeminoHealthcareFinanceLLCMember us-gaap:LineOfCreditMember 2019-05-08 2019-05-09 0001719435 ASLI:TrilliumHealthcareGroupLLCMember ASLI:GeminoHealthcareFinanceLLCMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-05-08 2019-05-09 0001719435 ASLI:TrilliumHealthcareGroupLLCMember ASLI:GeminoHealthcareFinanceLLCMember us-gaap:LineOfCreditMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LineOfCreditMember 2021-01-01 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LineOfCreditMember 2021-09-29 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LineOfCreditMember 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001719435 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2021-01-01 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2021-01-01 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember ASLI:SarasotaFloridaMember 2020-12-31 0001719435 us-gaap:LeaseholdImprovementsMember ASLI:SarasotaFloridaMember 2020-01-01 2020-12-31 0001719435 us-gaap:LeaseholdImprovementsMember ASLI:NewPortRicheyFloridaMember 2020-12-31 0001719435 us-gaap:LeaseholdImprovementsMember ASLI:NewPortRicheyFloridaMember 2020-01-01 2020-12-31 0001719435 us-gaap:LeaseholdImprovementsMember ASLI:StPetersburgFloridaMember 2020-12-31 0001719435 us-gaap:LeaseholdImprovementsMember ASLI:StPetersburgFloridaMember 2020-01-01 2020-12-31 0001719435 us-gaap:LeaseholdImprovementsMember ASLI:TrilliumHealthcareGroupLLCMember 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2021-07-01 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2020-07-01 2020-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-09-30 0001719435 us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-09-30 0001719435 ASLI:ComputersEquipmentSoftwareMember 2021-01-01 2021-09-30 0001719435 ASLI:MotorVehiclesMember 2021-01-01 2021-09-30 0001719435 ASLI:BuildingsMember 2021-01-01 2021-09-30 0001719435 ASLI:BanyanMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2021-06-09 2021-06-10 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:FurnitureAndFixturesMember 2021-07-01 2021-09-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember ASLI:NortheastPlazaVentureILLCMember 2019-08-24 0001719435 ASLI:BanyanPediatricCareCentersIncMember ASLI:NortheastPlazaVentureILLCMember 2019-08-23 2019-08-24 0001719435 ASLI:KidzClubStPeteLLCMember 2019-10-15 0001719435 ASLI:KidzClubStPeteLLCMember 2019-10-14 2019-10-15 0001719435 ASLI:GrandTrinityPlazaLLCMember 2020-04-02 0001719435 ASLI:GrandTrinityPlazaLLCMember 2020-04-01 2020-04-02 0001719435 ASLI:DexImagingMember 2020-06-09 0001719435 ASLI:DexImagingMember srt:MaximumMember 2020-06-08 2020-06-09 0001719435 ASLI:DexImagingMember 2020-06-08 2020-06-09 0001719435 ASLI:AscentiumCapitalLLCMember 2020-08-25 0001719435 ASLI:AscentiumCapitalLLCMember 2020-08-24 2020-08-25 0001719435 ASLI:AscentiumCapitalLLCMember 2020-10-20 0001719435 ASLI:AscentiumCapitalLLCMember 2020-10-19 2020-10-20 0001719435 ASLI:DexImagingMember 2021-04-30 0001719435 ASLI:DexImagingMember 2021-04-01 2021-04-30 0001719435 ASLI:AscentiumCapitalLLCMember 2021-07-31 0001719435 ASLI:DexImagingMember 2021-08-31 0001719435 ASLI:DexImagingMember 2021-08-01 2021-08-31 0001719435 ASLI:DexImagingMember 2021-07-31 0001719435 ASLI:RJKoolMember 2021-08-31 0001719435 ASLI:SoutheasternLaundryEquipmentSalesMember 2021-07-31 0001719435 ASLI:CretePlusFivePropertyLLCMember 2021-01-01 2021-09-30 0001719435 ASLI:CretePlusFivePropertyLLCMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2021-06-10 0001719435 ASLI:CTRPartnershipLPMember 2021-01-01 2021-09-30 0001719435 ASLI:CTRPartnershipLPMember 2021-09-30 0001719435 ASLI:CTRPartnershipLPMember 2021-06-10 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2021-01-01 2021-09-30 0001719435 srt:MinimumMember 2021-09-30 0001719435 srt:MaximumMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LongTermDebtMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LongTermDebtMember 2021-01-01 2021-09-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-02-11 2021-03-31 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-03-31 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-06-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-04-01 2021-06-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember us-gaap:LongTermDebtMember 2021-06-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember ASLI:TrilliumHealthcareGroupLLCMember 2021-09-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-07-01 2021-09-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-09-30 0001719435 2021-08-26 0001719435 ASLI:TenEmployeesMember ASLI:TwoThousandAndTwentyOneIncentiveAwardPlanMember 2021-09-30 0001719435 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001719435 us-gaap:NotesPayableOtherPayablesMember us-gaap:CommonStockMember 2020-09-17 2020-09-19 0001719435 us-gaap:NotesPayableOtherPayablesMember 2020-09-17 2020-09-19 0001719435 ASLI:KidzClubStPeteLLCMember 2019-09-27 0001719435 ASLI:KidzClubStPeteLLCMember 2019-12-31 0001719435 ASLI:KidzClubStPeteLLCMember 2020-01-01 2020-12-31 0001719435 ASLI:KidzClubStPeteLLCMember 2020-12-31 0001719435 ASLI:KidzClubStPeteLLCMember 2021-01-01 2021-09-30 0001719435 ASLI:KidzClubStPeteLLCMember 2021-09-30 0001719435 srt:ChiefExecutiveOfficerMember 2021-01-29 2021-02-01 0001719435 srt:ChiefExecutiveOfficerMember 2021-02-01 0001719435 srt:ChiefExecutiveOfficerMember ASLI:WithinFiveDaysMember 2021-02-01 0001719435 srt:ChiefExecutiveOfficerMember ASLI:WithinNinetyDaysMember 2021-02-01 0001719435 srt:ChiefExecutiveOfficerMember ASLI:WithinOneHundredAndEightyDaysMember 2021-02-01 0001719435 ASLI:RestrictedCommonStockMember 2021-04-01 2021-06-30 0001719435 srt:DirectorMember 2021-07-01 2021-09-30 0001719435 srt:DirectorMember 2020-07-01 2020-09-30 0001719435 ASLI:PresidentAndChiefExecutiveOfficerMember 2021-09-30 0001719435 ASLI:PresidentAndChiefExecutiveOfficerMember 2021-01-01 2021-09-30 0001719435 us-gaap:OperatingSegmentsMember ASLI:PediatricExtendedCareCentersMember 2021-01-01 2021-09-30 0001719435 us-gaap:OperatingSegmentsMember ASLI:TrilliumSubsidiariesMember 2021-01-01 2021-09-30 0001719435 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-09-30 0001719435 us-gaap:OperatingSegmentsMember ASLI:PediatricExtendedCareCentersMember 2021-09-30 0001719435 us-gaap:OperatingSegmentsMember ASLI:TrilliumSubsidiariesMember 2021-09-30 0001719435 us-gaap:IntersegmentEliminationMember 2021-09-30 0001719435 ASLI:TwoThousandAndTwentyOneIncentiveAwardPlanMember 2021-08-26 0001719435 ASLI:TwoThousandAndTwentyOneIncentiveAwardPlanMember 2021-09-01 2021-09-30 0001719435 ASLI:TwoThousandAndTwentyOneIncentiveAwardPlanMember 2021-09-30 0001719435 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember ASLI:MedicareMember 2021-07-01 2021-09-30 0001719435 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember ASLI:MedicareMember 2021-01-01 2021-09-30 0001719435 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember ASLI:MedicaidMember 2021-07-01 2021-09-30 0001719435 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember ASLI:MedicaidMember 2021-01-01 2021-09-30 0001719435 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember ASLI:PrivatePayResidentsMember 2021-07-01 2021-09-30 0001719435 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember ASLI:PrivatePayResidentsMember 2021-01-01 2021-09-30 0001719435 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember ASLI:MedicareMember 2021-01-01 2021-09-30 0001719435 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember ASLI:MedicaidMember 2021-01-01 2021-09-30 0001719435 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember ASLI:PrivatePayMember 2021-01-01 2021-09-30 0001719435 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember ASLI:CommercialInsuranceMember 2021-01-01 2021-09-30 0001719435 ASLI:PurchaseAgreementMember ASLI:SellerMember 2021-09-30 0001719435 ASLI:GeminoHealthcareFinanceLLCMember 2021-09-30 0001719435 ASLI:GeminoHealthcareFinanceLLCMember 2021-01-01 2021-09-30 0001719435 ASLI:CreditAgreementMember ASLI:TrilliumGroupMember ASLI:FirstAmendmentMember 2021-01-01 2021-09-30 0001719435 ASLI:CreditAgreementMember ASLI:SecondAmendmentMember 2021-01-01 2021-09-30 0001719435 ASLI:GuarantyAgreementMember us-gaap:SubsequentEventMember 2021-10-08 0001719435 ASLI:GuarantyAgreementMember us-gaap:SubsequentEventMember 2021-10-07 2021-10-08 0001719435 us-gaap:SubsequentEventMember 2021-10-08 0001719435 us-gaap:SubsequentEventMember 2021-10-12 2021-10-13 0001719435 us-gaap:SubsequentEventMember 2021-10-13 0001719435 ASLI:GraceCareCentersMember us-gaap:SubsequentEventMember 2021-10-17 2021-10-18 0001719435 us-gaap:SubsequentEventMember 2021-10-18 0001719435 us-gaap:SubsequentEventMember ASLI:GraceCareCentersMember 2021-10-17 2021-10-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft ASLI:Property ASLI:Agreement

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
  For the quarterly period ended: September 30, 2021

 

OR

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
  For the transition period from ___________ to ___________
   
  Commission File Number: 333-226979

 

Assisted 4 Living, Inc.
(Exact name of registrant as specified in its charter)

 

Nevada   82-1884480

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

     
5115 East SR 64 Bradenton, FL   34240
(Address of principal executive offices)   (Zip Code)

 

(855) 668-3331

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ NoExplanatory Note: Even though not required, registrant has filed all Exchange Act reports for the preceding 12 months.

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No

 

The number of shares of the issuer’s common stock outstanding as of November 12, 2021 was 45,345,418  shares, par value $0.0001 per share.

 

 

 

 
 

 

TABLE OF CONTENTS

 

PART I – FINANCIAL INFORMATION  
     
Item 1.

Financial Statements

F-1
 

Condensed Consolidated Balance sheet

F-1
  Condensed Consolidated Statement of Operations F-2
 

Condensed Consolidated Statement of Stockholder’s Equity

F-3
 

Condensed Consolidated Statement of Cash Flows

F-4
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 3
Item 3. Quantitative and Qualitative Disclosures About Market Risk 10
Item 4. Controls and Procedures 10
     
PART II – OTHER INFORMATION  
     
Item 1. Legal Proceedings 11
Item 1A. Risk Factors 11
Item 6. Exhibits 11
     
SIGNATURES 12

 

2
 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

ASSISTED 4 LIVING, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

           
   September 30, 2021   December 31, 2020 
   (UNAUDITED)     
ASSETS          
Current assets:          
Cash  $3,894,536   $345,982 
Accounts receivable, net   7,490,091    97,073 
Prepaid expenses and other current assets   3,747,240    207,592 
Total current assets   15,131,867    650,647 
           
Operating Lease right-of-use assets   46,089,030    3,977,988 
Goodwill   15,513,677    3,431,148 
Leasehold improvements, net   3,766,330    2,614,391 
Property and equipment, net   2,680,115    128,475 
Other assets   2,950,265    - 
           
Total assets   86,131,284   $10,802,649 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable and accrued expenses   10,879,082    148,180 
Notes payable   7,041,759    2,385,010 
Accrued interest, Including related party   42,567    48,601 
Loans Payable - other   498,140    63,907 
Operating Lease obligations - current portion   8,311,905    189,397 
Advanced payments   1,671,698    - 
Deferred Revenue   596,227    - 
Deferred HHS Revenue   778,408    25,703 
Liability to issue shares   5,000,000    - 
Due to Seller for acquisition   902,847    - 
Total current liabilities   35,722,633    2,860,798 
           
Operating Lease obligations - net of current portion   38,089,042    3,864,321 
Liability to issue shares - long term   4,750,000    - 
Notes payable, net of current portion   265,117    322,490 
Total liabilities   78,826,792    7,047,609 
           
Stockholders’ equity:          
           
Common stock, par value $0.0001; 100,000,000 shares authorized, 45,345,418, and 4,165,418 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively   4,535    417 
Additional paid-in capital   17,876,115    7,460,348 
Subscription receivable   -    (30)
Accumulated deficit   (10,576,158)   (3,705,695)
Total stockholders’ equity   7,304,492   $3,755,040 
           
Total liabilities and stockholders’ equity   86,131,284   $10,802,649 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-1
 

 

ASSISTED 4 LIVING, INC.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)

 

                 
   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
                 
Service Revenue  $21,602,984   $654,351   $27,581,902   $1,088,341 
Rental income   11,275    5,625    22,875    7,500 
Other revenue   760,833    (527)   1,489,068    7,000 
Net Revenue   22,375,092    659,449    29,093,845    1,102,841 
                     
Cost of services provided   12,310,011    256,825    15,477,070    409,838 
                     
Gross profit   10,065,081    402,624    13,616,775    693,003 
                     
Operating expenses                    
Salaries and payroll expense   5,068,423    320,404    6,671,656    870,191 
General and administrative   4,978,559    205,818    6,591,749    454,482 
Lease expense   2,991,078    88,691    3,912,133    193,365 
Professional fees   1,722,741    70,819    2,707,511    134,829 
Marketing and advertising   236,499    4,276    336,984    12,378 
Depreciation and amortization expense   159,750    16,744    318,324    24,135 
Total operating expenses   15,157,050    706,752    20,538,357    1,689,380 
                     
Loss from operations   (5,091,969)   (304,128)   (6,921,582)   (996,377)
                     
Other income (expense)                    
Loss on disposal of asset   -    (22,753)   -    (22,753)
Interest expense   (179,293)   (7,920)   (317,881)   (7,923)
Total other income (expense)   (179,293)   (30,673)   (317,881)   (30,676)
                     
LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES AND RESULTS FROM DISCONTINUED OPERATIONS   (5,271,262)   (334,801)   (7,239,463)   (1,027,053)
                     
Income taxes   -    -    -    - 
                     
LOSS FROM CONTINUING OPERATIONS BEFORE DISCONTINUED OPERATIONS   (5,271,262)   (334,801)   (7,239,463)   (1,027,053)
                     
Loss from discontinued operations   -    -    (26,500)   - 
Gain on disposal of discontinued operations   -    -    395,500    - 
Income from discontinued operations   -    -    369,000    - 
                     
Net loss attributable to common shareholders  $(5,271,262)  $(334,801)  $(6,870,463)  $(1,027,053)
Continuing Operations                    
Loss per share - basic and diluted - Continuing operations  $(0.12)  $(0.08)  $(0.24)  $(0.25)
                     
Weighted average number of shares outstanding - basic and diluted   42,783,081    4,221,021    29,984,191    4,064,414 
                     
Discontinued operations net income per share                    
Earnings per share - basic   n/a    n/a   $0.01    n/a  
Earnings per share - diluted   n/a    n/a   $0.01    n/a  
Weighted average number of shares - basic   n/a    n/a    29,984,191    n/a  
Weighted average shares outstanding - diluted   n/a    n/a    34,705,065    n/a  

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-2
 

 

ASSISTED 4 LIVING, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30

(UNAUDITED)

 

                         
                         
   Common Stock   Additional           Total 
   Number of   paid-in   Subscription   Accumulated   stockholders’ 
   shares   Amount   Capital   Receivable   deficit   Equity 
For the Three and Nine Months Ended September 30, 2020                        
                         
Balance at December 31, 2019   4,008,443    401    6,618,364    (170)   (2,407,760)   4,210,835 
                               
Net loss for the period   -    -    -    -    (443,375)   (443,375)
                               
Balance at March 31, 2020   4,008,443    401    6,618,364    (170)   (2,851,135)   3,767,460 
                               
Net loss for the period   -    -    -    -    (692,252)   (692,252)
                               
Balance at June 30, 2020   4,008,443    401    6,618,364    (170)   (3,543,387)   3,075,208 
                               
Issuance of stock warrant expense   -    -    342,000    -    -    342,000 
                               
Issuance of shares for conversion of debt   166,667    16    499,984    -    -    500,000 
                               
Net loss for the period   -    -    -    -    (1,027,054)   (1,027,054)
                               
Balance at September 30, 2020   4,175,110    417    7,460,348    (170)   (4,570,441)   2,890,154 
                               
For the Three and Nine Months Ended September 30, 2021                              
                               
Balance at December 31, 2020   4,165,418    417    7,460,348    (30)   (3,705,695)   3,755,040 
                               
Collection on subscription receivable   -    -    -    30    -    30 
                               
Issuance of shares for acquisition   31,230,000    3123    3,039,874    -    -    3,042,997 
                               
Net loss for the period   -    -    -    -    (579,061)   (579,061)
                               
Balance at March 31, 2021   35,395,418    3,540    10,500,222    -    (4,284,756)   6,219,006 
                               
Issuance of shares via private placement   1,150,000    115    574,885    -    -    575,000 
                               
Issuance of shares for the conversion of debt   4,000,000    400    1,999,600    -    -    2,000,000 
                               
Shares returned and cancelled for transfer of discontinued operations   (200,000)   (20)   (369,980)   -    -    (370,000)
                               
Net loss for the period   -    -    -    -    (1,020,140)   (1,020,140)
                               
Balance at June 30, 2021   40,345,418    4,035    12,704,727    -    (5,304,896)   7,403,866 
                               
Issuance of shares via private placement   5,000,000    500    4,999,500    -    -    5,000,000 
                               
Stock-based compensation and issuance of employee stock award plan   -    -    171,888    -    -    171,888 
                               
Net loss for the period   -    -    -    -    (5,271,262)   (5,271,262)
                               
Balance at September 30, 2021   45,345,418    4,535    17,876,115    -    (10,576,158)   7,304,492 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-3
 

 

ASSISTED 4 LIVING, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

           
   For the Nine Months Ended 
   September 30, 
   2021   2020 
         
Cash flows from operating activities          
Net loss  $(6,870,463)  $(1,027,054)
Adjustments to reconcile net loss to cash used in operating activities:          
           
Net gain from discontinued operations   (369,000)   - 
Depreciation and amortization   318,324    - 
(Increase) decrease in assets          
Prepaid expenses and other current assets   (1,824,624)   (2,877)
Deposits and other assets   (2,003,607)   - 
Accounts receivable   435,016    (145,225)
Increase (decrease) in liabilities          
Accounts payable and accrued expenses   2,373,538    249,999 
Deferred Revenues   1,331,333    55,371 
Advance payments   (3,396,502)   - 
Accrued interest   (6,034)   - 
Cash used in operating activities    (10,012,019)   (870,286)
           
Cash flows from investing activities           
Goodwill from acquisition   -    (3,431,148)
Non-cash operating lease expense   212,326    28,541 
Cash and assets from acquisition   3,432,847    - 
Investment in leasehold improvements   -    (1,852,465)
Purchase of property and equipment   (76,317)   (61,083)
Cash used in investing activities    3,568,856    (5,316,155)
           
Cash flows from financing activities          
Repayment of principal on notes payable   (776,207)   - 
Proceeds from the sale of common stock   575,000    - 
Proceeds from notes payable   5,212,234    2,664,234 
Repayment on loans payable   (18,810)   - 
Warrants to be issued   -    342,000 
Proceeds from the issuance of registered shares   4,999,500    328 
Cash provided by financing activities    9,991,717    3,006,562 
Net increase (decrease) in cash    3,548,554    (3,179,879)
           
Cash, beginning of year    345,982    4,044,700 
Cash, end of period   $3,894,536   $864,821 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS           
Interest Paid   275,831    - 
Taxes Paid   -    - 
NON-CASH ITEMS           
Liability to issue shares for acquisition   9,750,000      
Goodwill from acquisition   12,082,529      
Recognition of lease liability and right of use asset at inception   46,089,030    3,976,562 
Conversion of notes payable and accrued interest for common stock   2,000,000    500,000 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

F-4
 

 

ASSISTED 4 LIVING, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Assisted 4 Living, Inc. (“the Company,” “we”, “our” or “us”) was incorporated in the state of Nevada on May 24, 2017, and is based in Bradenton, Florida. Our accounting and reporting policies conform to accounting principles generally accepted in the United States of America (“GAAP”), and the fiscal year end is December 31.

 

As discussed in NOTE 3, on March 23, 2021, we entered into a Plan of Merger with our wholly-owned subsidiary, BPCC Acquisition, Inc., a Florida corporation (“Merger Sub”) and Banyan Pediatric Care Centers, Inc. (“Banyan”). Under the terms of the Plan of Merger, Merger Sub merged with and into Banyan with Banyan surviving the merger (the “Surviving Entity”) and becoming a wholly-owned subsidiary of the Company (the “Merger”). Pursuant to the Merger, we succeeded to the business of Banyan. The Merger has been treated as a recapitalization and reverse acquisition of the Company for financial accounting purposes, and Banyan is considered the acquirer for financial reporting purposes. This means that the Company’s historical financial statements before the Merger have been replaced with the historical financial statements of Banyan before the Merger in this Quarterly Report and future filings with the SEC.

 

Banyan, operates three pediatric extended care centers (“PPECs”) in southwest Florida. A PPEC is a nurse-staffed pediatric day care center for medically complex children age birth to 21 years. Our staff includes Registered Nurses (RNs), Licensed Practical Nurses (LPNs), Certified Nursing Assistants (CNAs) and Caregivers, who attend to the children’s medical conditions throughout the day in classroom, dining, play, and clinical settings. Banyan is fully licensed and accepts Florida Medicaid.

 

As discussed in NOTE 5, on June 10, 2021, we entered into an Amended and Restated Membership Interest Purchase Agreement (the “Restated Purchase Agreement”), by and among the Company, Richard T. Mason (“Mason”), G. Shayne Bench (“Bench”) and Trillium Healthcare Group, LLC, a Florida limited liability company (“Trillium”) to acquire all of the issued and outstanding ownership interests of Fairway Healthcare Properties, LLC (“FHP”) and Trillium Healthcare Consulting, LLC (together with FHP, the “Trillium Subsidiaries”) from Trillium. The transaction closed and was effective June 10, 2021.

 

Trillium subsidiaries lease and operate 26 facilities in four states: Florida, Georgia, Iowa, and Nebraska with 1,685 total licensed beds (1,546 skilled nursing, 139 assisted living) and 36 independent living apartments. The breakdown by state is as follows: Florida – 1 skilled nursing facility; Georgia – 1 skilled nursing facility; Iowa – 16 skilled nursing facilities, 2 independent living centers and 1 assisted living centers; Nebraska – 4 skilled nursing facilities and 1 assisted living center.

 

The facilities provide room and board, routine daily care services, post-acute care including rehabilitation and memory care. The Trillium Subsidiaries were organized under the laws of the State of Florida on February 9, 2012, for the purpose of acquiring and managing long term care facilities, such as skilled nursing facilities and assisted living centers.

 

We are headquartered in Bradenton, Florida.

 

The corporate website is www.assisted4living.com.

 

COVID-19

 

In March 2020, the World Health Organization declared the outbreak of COVID-19 as a pandemic based on the rapid increase in global exposure. COVID-19 continues to spread throughout the world. We are closely monitoring developments and are taking steps to mitigate the potential risks related to the COVID-19 pandemic to the Company, its employees, as well as its residential and consulting clients.

 

Our evaluations of our practices, procedures, and operations, related to COVID-19, is ongoing. Additional updates to policies, procedures and operations will occur as best practices are adopted and as we deem necessary or advisable, or as further governmental guidance or regulations are implemented.

 

F-5
 

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company (“Financial Statements”) have been prepared in accordance with GAAP for interim financial statements and with the instructions to Form 10-Q and Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.

 

In the opinion of management, the accompanying condensed consolidated Financial Statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2021, and the results of operations and cash flows for the periods presented. The results of operations for the nine months ended September 30, 2021, are not necessarily indicative of the operating results for the full fiscal year or any future period. These condensed consolidated Financial Statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021 and Current Report on Form 8-K on June 2, 2021. As of April 30, 2021, we had discontinued operations reflected in the accompanying condensed consolidated Financial Statements. As a result of the Plan of Merger completed on March 23, 2021 (see NOTE 3) we have changed our year end reporting period from November to December.

 

Capital Requirements, Liquidity and Going Concern Considerations

 

These condensed consolidated Financial Statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Although we had cash and accounts receivable in the amount of approximately $11.4 million at September 30, 2021, we had accrued expenses and current notes payable in excess of cash and accounts receivable in the amount of approximately $6.5 million, and a deficiency in working capital of approximately $20.6 million. For the nine months ended September 30, 2021, our net loss was approximately $6.9 million.

 

As a result of these factors, we determined it was necessary to review our cash flow for 2021 and an overall analysis of market trends to determine whether or not we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report. We also determined it was necessary to take certain corporate actions, including reducing discretionary expenses (and reduced reliance on agency staffing), improving revenue (including added Therapy and Rehab services), and raising additional capital, in order to ensure we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report.

 

During the three months ended September 30, 2021 we sold 5.0 million shares for an aggregate total of $5.0 million. This capital raise will be used for additional growth through acquisitions and for working capital. However, no assurances can be given that we will be successful. If management is not able to timely and successfully raise additional capital and/or refinance indebtedness, the implementation of the Company’s business plan, financial condition and results of operations will be materially affected.

 

Basis of Consolidation

 

These condensed consolidated Financial Statements include the accounts of the Company and the wholly-owned subsidiaries, Banyan Pediatric Care Centers – OPS, LLC, Banyan Pediatric Care Centers – St. Petersburg, LLC, Banyan Pediatric Care Centers, - Pasco, LLC and Banyan Pediatric Care Centers – Sarasota, LLC and the discontinued operations of Assisted 2 Live, Inc., the wholly owned subsidiary that was discontinued as of April 30, 2021. All material intercompany balances and transactions have been eliminated. The condensed consolidated Financial Statements also include the accounts of the Trillium Subsidiaries from June 10, 2021, the effective date of the transaction with Trillium.

 

Use of Estimates and Assumptions

 

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

 

F-6
 

 

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at September 30, 2021 and December 31, 2020.

 

Accounts Receivable

 

Accounts receivable primarily consists of amounts due from third-party payers (non-governmental), governmental payers and private pay patients and is recorded net of contractual allowances and reserves for doubtful accounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s Financial Statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimation of net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies’ denial of claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.

 

The Company’s accounts receivable from third-party payers are recorded net of estimated contractual adjustments and allowances from third-party payers, which are estimated based on the historical trend of the Company’s facilities’ cash collections and contractual write-offs, accounts receivable aging, established fee schedules, relationships with payers and procedure statistics. While changes in estimated reimbursement from third-party payers remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on the Company’s financial condition or results of operations. The Company’s collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of the facilities to ensure the proper collection and aged category. The operating systems generate reports that assist in the collection efforts by prioritizing patient accounts. Collection efforts include direct contact with insurance carriers or patients and written correspondence.

 

Allowance for Doubtful Accounts, Contractual and Other Discounts

 

Management estimates the allowance for contractual and other discounts based on its historical collection experience and contracted relationship with the payers. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account may be written-off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.

 

COVID-19 Pandemic and CARES Act Funding

 

COVID-19 Pandemic. In January 2020, the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel strain of coronavirus. In March 2020, the World Health Organization declared the outbreak of COVID-19, a disease caused by this coronavirus, a pandemic. The resulting measures to contain the spread and impact of COVID-19 and other developments related to COVID-19 have materially affected the Company’s results of operations during 2020. Where applicable, the impact resulting from the COVID-19 pandemic during the year ended December 31, 2020, has been considered, including updated assessments of the recoverability of assets and evaluation of potential credit losses. As a result of the COVID-19 pandemic, federal and state governments have passed legislation, promulgated regulations and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency. Sources of relief include the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020, the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), which was enacted on April 24, 2020, and the Consolidated Appropriations Act, 2021 (the “CAA”), which was enacted on December 27, 2020. In total, the CARES Act, PPPHCE Act and the CAA authorize $178 billion in funding to be distributed to hospitals and other healthcare providers through the Public Health and Social Services Emergency Fund (the “PHSSEF”). In addition, the CARES Act provide for an expansion of the Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers were able to request accelerated payment of up to 100% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments. Various other state and local programs also exist to provide relief, either independently or through distribution of monies received via the CARES Act. During the period ended September 30, 2021, the Company was a beneficiary of these stimulus measures, including the Medicare Accelerated and Advance Payment Program.

 

F-7
 

 

The Company’s accounting policies for the recognition of these stimulus monies is as follows:

 

Pandemic Relief Funds

 

Trillium received an aggregate of $13,487,923 in PHSSEF payments, of which $4,242,796 was applied during 2020. Prior to the acquisition date of June 10, 2021 Trillium had recognized $7,081,557 as other operating income. During the three and nine-month period ended September 30, 2021 we recognized $1,385,162 as other operating income resulting in a remaining balance of $778,408 which is classified on the balance sheet as Deferred HHS Revenue. The recognition of amounts received is conditioned upon the provision of care for individuals with possible or actual cases of COVID-19 after January 31, 2020, certification that payment will be used to prevent, prepare for and respond to coronavirus and shall reimburse the recipient only for healthcare-related expenses or lost revenues, as defined by HHS, that are attributable to coronavirus, as well as receipt of the funds. Amounts are recognized as a reduction to operating costs and expenses only to the extent the Company is reasonably assured that underlying conditions have been met.

 

The Company’s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the CAA and all frequently asked questions and other interpretive guidance issued by HHS, including the Post-Payment Notice of Reporting Requirements issued on January 15, 2021 (the “January 15, 2021 Notice”) and frequently asked questions issued by HHS on January 28, 2021 which clarified previously issued guidance, as well as expenses incurred attributable to the coronavirus and the Company’s results of operations during such period as compared to the Company’s budget. Such guidance, specifically the various Post-Payment Notice of Reporting Requirements and frequently asked questions issued by HHS, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to coronavirus that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. On the basis of guidance available at the time, the Company’s estimate of lost revenues was first based on the negative change in year-over-year net patient care operating revenue, then on the negative change in year-over-year net patient care operating income and finally on the difference between budgeted and actual revenue for calendar year. The calculation as of September 30, 2021 is in accordance with the CAA which indicates that lost revenues may be calculated pursuant to frequently asked questions published by HHS in June 2020, including the difference between a provider’s budgeted and actual revenue if such budget had been established prior to March 27, 2020. The use of funds calculation as of September 30, 2021 takes into account expenses attributable to each respective entity, which primarily relate to incremental labor and supply costs, as well as lost revenues. General fund distributions were allocated among subsidiaries according to total unreimbursed losses. Targeted distributions were not allocated or transferred among subsidiaries. While the CAA, January 15, 2021 Notice and frequently asked questions published by HHS on January 28, 2021 indicate that targeted distribution payments may be allocated or transferred to subsidiaries, distinct conditions exist for such allocations or transfers including that the parent organization have a “direct ownership relationship” with the subsidiary who received the targeted distribution payment. Additionally, the subsidiary that was the recipient of the targeted distribution payment retains responsibility for reporting to HHS on the use of such funds even if they are transferred or allocated to other subsidiaries. There are significant uncertainties as to the meaning and interpretation of conditions specific to the allocation or transfer of targeted distribution payments such that as of September 30, 2021, the Company is not reasonably assured that it can or will choose to comply with such conditions in order to allocate or transfer targeted distribution payments.

 

HHS’ interpretation of the underlying terms and conditions of such PHSSEF payments, including auditing and reporting requirements, continues to evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such PHSSEF payments may result in changes in the Company’s estimate of amounts for which the terms and conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in the Company’s inability to recognize additional PHSSEF payments or may result in the de recognition of amounts previously recognized, which (in any such case) may be material.

 

Medicare Accelerated Payments

 

The Company recorded payments under the Medicare Accelerated and Advance Payment program in accordance with FASB ASC 606 and has recorded amounts as a contract liability under FASB ASC 606-10-45-2. The contract liability will be reduced over time as revenue is recognized for claims submitted for services provided after the recoupment period begins. Effective October 1, 2020, the program was amended such that providers are required to repay accelerated payments beginning one year after the payment was issued. After such one-year period, Medicare payments owed to providers will be recouped according to the repayment terms. The repayment terms specify that for the first 11 months after repayment begins, repayment will occur through an automatic recoupment of 25% of Medicare payments otherwise owed to the provider. At the end of the eleven-month period, recoupment will increase to 50% for six months. At the end of the six months (or 29 months from the receipt of the initial accelerated payment), Medicare will issue a letter for full repayment of any remaining balance, as applicable. In such event, if payment is not received within 30 days, interest will accrue at the annual percentage rate of four percent (4%) from the date the letter was issued and will be assessed for each full 30-day period that the balance remains unpaid. As of September 30, 2021, $1,671,698 of Medicare accelerated payments are reflected on the balance sheet within advance payments line.

 

F-8
 

 

The company receives a substantial portion of our revenues from the Medicare and Medicaid programs. Included in Managed Care and other third-party payors is operating revenues from insurance companies with which we have insurance provider contracts, Medicare managed care, insurance companies for which we do not have insurance provider contracts, workers’ compensation carriers and non-patient service revenue, such as rental income and cafeteria sales. In the future, we generally expect the portion of revenues received from the Medicare and Medicaid programs to increase over the long-term due to the general aging of the population and the impact of the Affordable Care Act. The Affordable Care Act has increased the number of insured patients in states that have expanded Medicaid, which in turn, has reduced the percentage of revenues from self-pay patients. However, it is unclear whether the trend of increased coverage will continue, due in part to the impact of the COVID-19 pandemic and the elimination of the financial penalty associated with the individual mandate, effective January 1, 2019. Further, the Affordable Care Act imposes significant reductions in amounts the government pays Medicare managed care plans. Moreover, the trend toward increased enrollment in Medicare and Medicaid managed care may adversely affect our operating revenue. An executive order issued in October 2019 seeks to accelerate this shift away from traditional fee-for-service Medicare to Medicare managed care. We may also be impacted by regulatory requirements imposed on insurers, such as minimum medical-loss ratios and specific benefit requirements. Furthermore, in the normal course of business, managed care programs, insurance companies and employers actively negotiate the amounts paid to hospitals. Our relationships with payors may be impacted by price transparency initiatives and out-of-network billing restrictions. There can be no assurance that we will retain our existing reimbursement arrangements or that these third-party payors will not attempt to further reduce the rates they pay for our services.

 

Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-based reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for the treatment of patients covered by Medicare, Medicaid and non-governmental payors are generally less than our standard billing rates. We account for the differences between the estimated program reimbursement rates and our standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at net operating revenues. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known.

 

Fair Value of Financial Instruments

 

The carrying amount of accounts receivable and accounts payable approximate their respective fair values due to the short- term nature. The carrying amount of the line of credit and note payable approximates fair values due to their market interest rates. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Depreciation of owned assets and amortization of leasehold improvements are computed using the straight-line method over the shorter of the estimated useful lives of the related assets or the lease term. The cost of assets sold or retired, and the related accumulated depreciation are removed from the accounts and any resulting gains or losses are reflected in other income (expense) for the year. Expenditures for maintenance and repairs are charged to expense as incurred.

 

Goodwill

 

Our goodwill represents the excess of the purchase price over the fair value of the net identifiable assets acquired in business combinations. The goodwill generated from the business combinations is primarily related to the value placed on the employee workforce and expected synergies. Judgment is involved in determining if an indicator or change in circumstances relating to impairment has occurred. Such changes may include, among others, a significant decline in expected future cash flows, a significant adverse change in the business climate, and unforeseen competition. There was no goodwill impairment for the periods presented.

 

F-9
 

 

The Company tests goodwill for impairment on an annual basis, and when events or circumstances indicate the fair value of a reporting unit may be below its carrying value.

 

Long-Lived Assets

 

Long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There were no impairments of long-lived assets for the years presented.

 

Advertising and Marketing

 

The Company uses advertising and marketing to promote its services. Advertising and marketing costs are expensed as incurred.

 

Earnings (Loss) Per Share

 

Basic Earnings (loss) per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per common share is determined using the weighted-average of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of the conversion option embedded in convertible debt. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would have an anti-dilutive effect.

 

Fixed grantee stock options (fixed awards) and nonvested stock (including restricted stock) shall be included in the computation of diluted earnings per common share. Even though their issuance may be contingent upon vesting, they shall be considered to be contingently issuable shares. Because issuance of performance based stock options (and performance based nonvested stock) is contingent upon satisfying conditions in addition to the mere passage of time, those options and non vested stock shall be considered to be contingently issuable shares in the computation of diluted earnings per common share.

 

The dilutive effect of outstanding call options and warrants (and their equivalents) are reflected in diluted earnings per common share by application of the treasury stock method unless another method is required. Equivalents of options and warrants include nonvested stock granted under a share based payment arrangement, stock purchase contracts, and partially paid stock subscriptions. Antidilutive contracts such as purchased put options and purchased call options shall be excluded from diluted earnings per common share.

 

The Company has included shares issuable under its 2021 Incentive Award Plan in deriving its fully diluted earnings per common share using the Treasury Method in accordance with ASC 260-10-45.

 

Income Taxes

 

The Company uses the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets, liabilities, the carry forward of operating losses and tax credits, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. An allowance against deferred tax assets is recorded when it is more likely than not that such tax benefits will not be realized.

 

Any future benefit arising from losses have been offset by a valuation allowance. Accordingly, no provision for income taxes is reflected in the condensed consolidated financial statements. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. Interest and penalties related to income tax matters, if any, would be recognized as a component of income tax expense. At September 30, 2021 and December 31, 2020, the Company had no liabilities for uncertain tax positions. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Currently, the tax years subsequent to 2017 are open and subject to examination by the taxing authorities.

 

Revenue Recognition

 

We follow ASC 606, “Revenue from Contracts with Customers.” Revenues are recognized when promised services are transferred to a customer, in an amount that reflects the consideration that we expect to receive in exchange for those services. We derive our revenues from the rendering of services, such as skilled nursing services. The five-step armodel defined by ASC 606 requires us to: (i) identify our contracts with customers, (ii) identify our performance obligations under those contracts, (iii) determine the transaction prices of those contracts, (iv) allocate the transaction prices to our performance obligations in those contracts and (v) recognize revenue when each performance obligation under those contracts is satisfied.

 

F-10
 

 

Reimbursement rates to provide services in our facilities are determined by the fee schedules set by the government programs and negotiated in contracts with non-governmental third-party payors and private pay patients. Fees are billed to the payors and private pay patients weekly and monthly following billing guidelines and contract requirements.

 

Net Patient Revenue

 

Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions.

 

The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed.

 

The estimates for implicit price concessions are based upon management’s assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable.

 

Reclassification

 

Certain amounts from prior periods have been reclassified to conform to the current period presentation.

 

NOTE 3BANYAN MERGER

 

Effective March 23, 2021, we entered into a Plan of Merger with Merger Sub and Banyan. Under the terms of the Plan of Merger, Merger Sub merged with and into Banyan with Banyan as the Surviving Entity and wholly owned subsidiary of the Company.

 

The Merger has been treated as a recapitalization and reverse acquisition of the Company for financial accounting purposes, and Banyan is considered the acquirer for accounting purposes. This means that the Company’s historical financial statements before the Merger have been replaced with the historical financial statements of Banyan.

 

In connection with the Merger, we issued 4,165,418 shares of our common stock in exchange for 49,984,649 outstanding shares of Banyan’s common stock held by 64 shareholders, based on an exchange ratio of one (1) share of our common stock for every twelve (12) shares of Banyan common stock. We also issued a warrant to purchase 75,000 shares of our common stock (the “Warrant”) in exchange for a warrant to purchase 900,000 shares of Banyan’s common stock. The Warrant is held by one investor and is exercisable for cash only until May 2, 2030 at an exercise price of $0.38 per share. The number of shares of common stock deliverable upon exercise of the Warrant contains provisions for standard anti-dilution adjustments.

 

The Surviving Entity assumed Banyan’s $2,300,000 of outstanding debt, and the $2,000,000 of such debt that was convertible into 20,000,000 shares of Banyan common stock was converted at $0.50 per share into 4,000,000 shares of our common stock, effective March 30, 2021. During the three months ended June 30, 2021, shares were issued to the Noteholders of the $2,000,000 convertible note. The remaining $300,000 of outstanding debt, evidenced by a promissory note dated November 6, 2020, accrues interest at the annual rate of 12%. Interest is payable on the sixth day of each month in the amount of $3,000 until the maturity date of this note on November 6, 2021, at which time, the remaining principal balance, if any, is due and payable.

 

F-11
 

 

NOTE 4 – DISCONTINUED OPERATIONS

 

On April 30, 2021, our Board of Directors (the “Board”) approved the discontinuance of our wholly owned subsidiary, Assisted 2 Live, Inc. (the “Discontinued Subsidiary”). The operations of the Discontinued Subsidiary are reflected on our condensed consolidated statement of operations from the date of the Merger as a loss from discontinued operations in the amount of $26,500.

 

The April 30, 2021, Board decision was the result of the Purchase and Sale Option Agreement (the “Option Agreement”) with Romulus Barr (“Barr”) which we entered into on November 7, 2020. The Option Agreement provided us with the option to sell all of our interest in Assisted 2 Live, Inc., consisting of 1,000 shares of common stock of the discontinued subsidiary, to Barr in exchange for 200,000 shares of our common stock (the “Shares”) held by Barr. The returned Shares were cancelled and included in authorized but unissued shares of common stock of the Company. The number of issued and outstanding shares of common stock was decreased by 200,000 as of April 30, 2021. The transfer resulted in a gain on disposal of discontinued operations in the amount of $395,500. A share price of $1.85 was used to determine the gain on disposal of discontinued operations based on the share price value on April 30, 2021.

 

   2021   2020   2021   2020 
  

For the three months ended

September 30,

  

For the nine months ended

September 30,

 
   2021   2020   2021   2020 
Net revenues  $-   $-   $76,847   $- 
Cost of net revenues   -    -    -    - 
Gross profit   -    -    -    - 
                     
Operating expenses:                    
Salary and tax expense   -    -    46,813    - 
General and administrative   -    -    52,555    - 
Lease expense   -    -    3,979    - 
Total operating expenses   -    -    103,347    - 
                     
Income from discontinued operations   -    -    (26,500)   - 
Interest and other, net   -    -    -    - 
Income from discontinued operations before income taxes   -    -    (26,500)   - 
Provision for income taxes        -         - 
Income from discontinued operations, net of income taxes  $-   $-   $(26,500)  $- 

 

NOTE 5 – TRILLIUM ACQUISITION

 

On June 10, 2021, we entered into the Restated Purchase Agreement, by and among the Company, Mason, Bench and Trillium to acquire all of the issued and outstanding ownership interests of the Trillium Subsidiaries from Trillium (the “Transaction”). The Transaction closed and was effective June 10, 2021.

 

Pursuant to the terms and conditions of the Restated Purchase Agreement, the aggregate purchase price consists of: (i) a cash payment of $902,847, minus certain transaction related costs, fees and expenses set forth in the Restated Purchase Agreement and determined post-closing; (ii) 2,500,000 shares of the Company’s Series A Preferred Stock (the “Preferred Shares”); and (iii) shares of the Company’s common stock (“Common Shares”) having an aggregate value of $5,000,000, based on the stock price at the time of issuance, upon the earlier of an initial public offering by the Company or June 10, 2022. Trillium will have the right to acquire an additional 2,500,000 Common Shares during the two-year period after the Transaction closes pursuant to a Business Development Agreement, a copy of which is attached as Exhibit 10.1 to this Quarterly Report.

 

F-12
 

 

As a condition to closing, the Trillium Subsidiaries paid with cash on hand $1,200,000 to one of its landlord, CTR Partnership, L.P. (“CTR”), as an additional security deposit under a lease between Greenside Healthcare Properties, LLC, a wholly-owned subsidiary of FHP and CTR and $3,000,000 to Crete Plus Five Property, L.L.C. (“Omega,” and together with CTR, the “Landlords”) as a deposit on the Company’s purchase of 16 facilities on 14 properties (the “Properties”) currently being leased by FHP’s wholly-owned subsidiaries from Omega and its affiliates. The $3,000,000 deposit to Omega is non-refundable and is subject to forfeiture if the purchase of the Properties is not closed by December 30, 2021. If the $3,000,000 deposit is forfeited, Trillium forfeits its right to receive $3,000,000 of the purchase price, first, from the cash payment mentioned in subsection (i) above, and second, from the value of common stock to be issued to Trillium mentioned in subsection (iii) above. In any event, no cash payments may be made to Trillium until the purchase of the Properties closes.

 

The Preferred Shares, with respect to rights on liquidation, winding up and dissolution, rank pari passu with the Common Shares. The holders of Preferred Shares have the right to cast one (1) vote for each Preferred Share held of record on all matters submitted to a vote of holders of the Common Shares, including the election of directors, and all other matters as required by law. The Preferred Shares are not convertible into Common shares at the election of the holder. However, the Preferred Shares do automatically convert into Common Shares at a one-to-one ratio two years from date of issuance. In lieu of converting the Preferred Shares, the holders thereof may elect to have the Company redeem one or more Preferred Shares at the redemption price of $1.00 per share two years from the date of issuance. The Company is required to issue the Preferred Shares to Trillium within 30 days after the purchase of the Properties closes. In connection with the issuance of the Preferred Shares, the Company will file a Certificate of Designation with the Nevada Secretary of State prior to such issuance.

 

In connection with obtaining the Landlords’ consent to the Transaction, the Company entered into: (i) a guaranty agreement with each Landlord under which the Company agreed to guaranty all obligations and liabilities under master leases for property and facilities owned by the Landlords’ and their affiliates and leased by FHP’s direct and indirect wholly-owned subsidiaries; and (ii) a Consent Agreement and Fifth Amendment to Master Lease with Omega (the “Consent”) regarding the Properties. Under the terms of the Consent, until the earlier of the purchase of the Properties closes or the expiration of the master lease agreement for the Properties in 2027: (a) Mason and Bench must remain responsible for, and have authority over, the day to day management and operations of the Properties and related facilities; and (b) the Company may not make any payment, transfer or distribution of cash or any assets to one or more equity holders or any person or entity with possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of the Company, through the ownership of voting securities (an “Affiliate”), or return any capital, redemption of any security, or making or assumption of any loans, advances or extension of credit or capital contribution to, or any other investment in, any Affiliate, including, but not limited to, a fee for management, a payment for services rendered, a reimbursement for expenditures or overhead incurred on behalf of the Company or a payment on any debt of an Affiliate; provided, however, the Company may contribute or transfer cash or other assets to its, direct or indirect, wholly-owned subsidiaries, and pay reasonable cash compensation to the members of the Board and executive officers provided that such compensation does not in the aggregate, exceed $600,000 in any six month period.

 

The initial purchase price has been allocated to the acquired assets and assumed liabilities based on estimated fair values. The purchase price allocation is preliminary pending a final determination of the fair values of the assets and liabilities. The table below provides a preliminary recording of assets acquired and liabilities assumed as of the acquisition date. During the three month period ended September 30, 2021 certain adjustments were made to the fair value of accounts receivable, share liability and goodwill. The amounts recorded for property, plant and equipment, leasehold improvements and goodwill are preliminary and pending finalization of valuation efforts.

 

Assets acquired     
Cash  $3,432,847 
Accounts receivable   5,521,080 
Prepaid expenses and other current assets   2,661,683 
Property and equipment   2,380,635 
Goodwill   12,082,529 
Leasehold improvements   1,213,273 
Lease right of use asset   44,196,092 
Total identifiable assets acquired  $71,488,139 
Liabilities assumed     
Advance payments  $2,905,234 
Accounts payable and accrued expenses   8,783,508 
Deferred revenue   2,162,966 
Loan Payable - other   453,043 
Lease liability - current portion   7,837,406 
Notes payable   2,309,884 
Lease liability - net of current portion   36,383,251 
Cash due to seller   902,847 
Share liability   9,750,000 
 Total identifiable liabilities acquired  $71,488,139 

 

F-13
 

 

NOTE 6– ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Our accounts payable and accrued liabilities at September 30, 2021 and December 31, 2020 consisted of the following:

 

   September 30, 2021   December 31, 2020 
         
Accounts payable  $6,299,400   $16,298 
Credit Card   37,712    1,050 
Accrued Expense   3,513,517    130,832 
Accrued Salary   995,265    - 
Payroll Tax Payable   33,189    - 
 Accounts Payable and Accrued Liabilities  $10,879,082   $148,180 

 

NOTE 7 – NOTES PAYABLE

 

Notes payable at September 30, 2021 and December 31, 2020 consisted of the following:

 

      September 30, 2021   December 31, 2020 
Excel Family Partners, LLLP / Banyan Pediatric Investment, Inc. (Sep 2020)  a  $-   $2,000,000 
NuView Trust Co. (Nov 2020)  b   300,000    300,000 
Grand Trinity Plaza, LLC (Dec 2020)  c   346,174    407,500 
Reliant  d.i   808,310    - 
HCSG  d.ii   397,191    - 
Medline  d.iii   242,967    - 
SLR - RLOC  e   5,212,234    - 
      $7,306,876   $2,707,500 

 

a. On September 18, 2020, through Banyan, we entered into a Convertible Note and Securities Purchase Agreement with two investors for the aggregate principal in the amount of $2,000,000. The note had a maturity date of September 18, 2022, and an interest rate of 8% to be paid quarterly. The principal was funded by two investors (“Purchasers”), both related parties. Excel Family Partners, LLLP invested $1,500,000 and Banyan Pediatric Investments, LLC invested $500,000. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. Written consent from shareholders holding a majority of the issued and outstanding shares of common stock of Banyan was obtained, not including such shares currently held by the Purchasers or their affiliates, consenting to the note contemplated hereby, in a form and substance acceptable to the Purchasers, in their respective reasonable discretion. Both Purchasers were permitted to convert their respective portions of the note at a conversion price of $0.10 per share. Subsequent to the Merger (see NOTE 3), the Board revised the conversion price of the note to $0.50 per share. Effective March 30, 2021, the Purchasers exercised their right to convert all outstanding principal. As of September 30, 2021, and December 31, 2020, there was $0 and $45,589 of accrued interest, respectively and is reflected in accrued interest balances on the condensed consolidated balance sheet at September 30, 2021 and December 31, 2020.
   
b. On November 6, 2020, through Banyan, we entered into a one-year note in the principal amount of $300,000 with NuView Trust Company. The note has a 12% interest rate with interest only payments until date of maturity. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. As of September 30, 2021, and December 31, 2020, there was no accrued interest. (see NOTE 3)

 

F-14
 

 

c. On December 15, 2020, through Banyan Pediatric Care Centers – Pasco, LLC, we entered into a note payable with Grand Trinity Plaza, LLC in the principal amount of $407,500, which is guaranteed by Banyan. The term of the note is 48 months with an interest rate of 6%. The maturity date of the note is January 1, 2025. The note is in conjunction with the 84-month facility lease for the Pasco County location, pursuant to which the landlord also provided the construction of the buildout and financed $407,500 of the construction costs.
   
d. In 2019, certain vendors of Trillium agreed to extend payment terms by converting then outstanding amounts of accounts payable balances to long-term debt bearing interest at rates ranging from 0% to 6%.
   
    i. Reliant note payable - Past due balances with vendor Reliant were converted to a note payable in 36 equal monthly installments of principal and interest of $69,568 from October 2019 through September 2022. The note bears interest at a rate of 6%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
 

 

    ii. HCSG note payable – Past due balances with vendor HCSG were converted to a non-interest-bearing note payable; payable in 36 equal monthly principal installments of $33,099 from October 2019 through September 2022. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
         
    iii. Medline note payable – Past due balances with vendor Medline were converted to a note payable; payable in 36 equal monthly installments of principal and interest of $20,911 from October 2019 through September 2022; note bears interest at a rate of 6%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
   
e. SLR revolving line of credit - On May 9, 2019, Trillium entered into a financing agreement (“the GHF Line”) with Gemino Healthcare Finance, LLC (DBA SLR Healthcare ABL), the lender, which allows the Trillium Subsidiaries to borrow up to the lesser of $10 million or 85% of eligible accounts receivable. The GHF Line bears interest at the greater of one-month LIBOR or 2%, plus 4.95%, applied daily, and continues to be applied to outstanding principal until the expiration of one business day after such principal has been repaid. The Trillium Subsidiaries also incur monthly collateral management fees under the line of 1 % of the average daily balance of the preceding month and is subject to a monthly unused line fee of 0.75% of the difference between revolving loan commitment and the average daily balance outstanding during the preceding month. The GHF Line is secured by cash, accounts receivable, and substantially all intangible assets of the Trillium Subsidiaries and terminates on May 9, 2022. On July 12, 2021, the agreement was amended whereas Assisted 4 Living, Inc was named as the Guarantor of the line. At September 30, 2021, the outstanding balance on the line was $5,212,234.  On September 30, 2021 we entered into a Second Amendment of the financing agreement with GHF. The Second Amendment amended the Credit Agreement by: (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; and (7) increasing the maximum amount of the credit facility from $10 million to $25 million. The above changes are the primary changes to the credit facility.

 

The entire balance due on each line has been classified as a current liability in accordance with FASB ASC Topic 470-10-45-5, Classification of Revolving Credit Agreements Subject to Lock-Box Arrangements. FASB guidance stipulates that if the contractual provisions of a loan arrangement require, in the ordinary course of business and without another event occurring, the cash receipts of a debtor to be used to repay the existing obligation, the credit agreement should be considered a short-term obligation.

 

F-15
 

 

NOTE 8 – LEASEHOLD IMPROVEMENTS

 

The Company had the following leasehold improvements as of September 30, 2021 and December 31, 2020:

 

   September 30,   December 31,   Amortization 
   2021   2020   Period 
Leasehold improvements   3,984,470    2,669,047    15-17 years 
Less: amortization   (218,140)   (54,656)     
                
Net   3,766,330    2,614,391      

 

During the year ended December 31, 2020, we recorded $2,669,047 of leasehold improvements. These amounts include costs related to the build out of the Sarasota location in the amount of $1,245,950. These costs will be amortized over the expected term of the lease including extensions that management expects to be 15 years. We also recorded costs in the amount of $1,021,793 related to the New Port Richey location buildout. The expected amortization of the improvements for the New Port Richey location is 17 years. Also recorded were $401,303 of improvements as part of the St. Petersburg-Kidz Club Acquisition. The expected amortization of the improvements for the St. Petersburg location is 15 years. We also recorded $1,213,273 in lease improvements as part of the Trillium acquisition, during the nine-month period ending September 30, 202.

 

Amortization expense for the three months ended September 30, 2021 and 2020 was $70,193 and $13,593, respectively.

 

Amortization expense for the nine months ended September 30, 2021 and 2020 was $218,140 and $54,656, respectively.

 

NOTE 9 – PROPERTY AND EQUIPMENT

 

   September 30,   December 31,   Amortization Period 
   2021   2020     
Furniture and fixtures   987,904    73,594    5 
Computers / equipment / software   95,952    50,401    5 
Motor vehicles   12,084    12,084    5 
Buildings   1,060,000    -    39 
Land   500,000    -      
Construction in progress   100,699    -      
Less: depreciation   (76,524)   (7,604)     
Net   2,680,115    128,475      

 

During the year ended December 31, 2020 we recorded $136,079 in property plant and equipment. These expenses were related to furniture and fixtures and for the new Banyan Sarasota and Pasco locations. We also recorded expenses related to computers and equipment for these new locations, as well as the St Petersburg location acquired in May of 2020. We also purchased buses for the St. Petersburg location, as of the year ended December 2020 we had one bus that was purchased for cash and is being depreciated. Other buses have been purchased with finance leases and are reflected in Right of Use Assets and Lease Liabilities.

 

During the nine month period ending September 30, 2021 we recorded additional furniture and fixtures related to the Banyan locations in the amount of approximately $23,000   and additional computers and equipment in the amount of approximately $41,000. These purchases were related to the completion of the Banyan Sarasota and Pasco locations that opened in May and July of 2021.

 

Through the Trillium acquisition on June 10, 2021 we recorded approximately $3.6M in property, plant and equipment consisting of furniture and fixtures, equipment, leasehold improvements in construction and a building. During the three month period ended September 30, 2021 we recorded approximately $69,487 in additional furniture and fixtures for the Trillium locations  .

 

NOTE 10 – OPERATING AND CAPITAL LEASES

 

On August 24, 2019, through Banyan Pediatric Care Centers-Sarasota, LLC, we entered into an operating lease with Northeast Plaza Venture I, LLC for the premises located in the Northeast Plaza Shopping Center located on the Northeast corner of 17th Street & Lockwood Ridge Road, in the County of Sarasota, Florida. The initial term of the lease is five years with minimum annual rent of $180,000. The landlord granted rent abatement for this lease until February 24, 2020. The lease end date, including two successive 5-year renewal options, is January 31, 2035. A right of use asset and lease liability in the amount of $1,899,869 associated with this lease was recognized. This lease is treated as an operating lease for accounting purposes.

 

F-16
 

 

On October 15, 2019, through Banyan, we entered into an assignment and assumption of lease agreement with The Kidz Club – St. Pete, LLC whereby we assumed approximately 12,137 square feet of space at the southeast corner of 3rd Avenue S. and 9th Street N., Webb’s Plaza, St. Petersburg, FL 33701. The minimum annual rent for the first year of the lease was $113,681. The current lease termination date, with extensions expected to be exercised, is October 31, 2024. Upon the exercise of each extension the base rent shall increase by 1.5%. This assignment of lease was subject to the terms of the Asset Purchase Agreement with The Kidz Club-St. Pete, LLC. A right of use asset and lease liability in the amount of $875,539 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

Effective April 1, 2020, through Banyan Pediatric Care Centers – Pasco, LLC, we entered into an 84-month facility lease with Grand Trinity Plaza, LLC for the premises located in the shopping center known as the Grand Trinity Plaza located in New Port Richey, Florida. The initial term of the lease had a minimum annual base rent of $94,500. The landlord granted rent abatement until September 2020. The lease end date, including two successive 5-year renewals is August 31, 2037. A right of use asset and lease liability in the amount of $1,143,743 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

On June 9, 2020, through Banyan, we entered into a 36-month copier lease with Dex Imaging. The lease was for one copier and a printer. The minimum annual lease payment is $5,376 with annual increases not to exceed 12% annually. This lease will auto renew in 12-month increments. The equipment under this lease has a fixed $1 payment buyout option. This equipment was purchased for the St. Petersburg location. A right of use asset and lease liability in the amount of $16,066 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

On August 25, 2020, through Banyan, we entered into a 60-month financing agreement with Ascentium Capital LLC for two 2020 Turtletop Terra Transit passenger buses for the St. Petersburg location. This lease is considered an operating lease for accounting purposes because the lease period is less than the economic life of the asset being leased. Minimum annual rent payments under this lease are $24,859. At our discretion, we may exercise a purchase option, by giving written notice no later than 30 days but not more than 120 days before the expiration of the initial term. The purchase option price is $23,920 for each bus, based on reasonably predicted fair market value. A right of use asset and lease liability in the amount of $102,393 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

On October 20, 2020, through Banyan, we entered into a 60-month financing agreement with Ascentium Capital LLC for a 2020 Eldorado National Advance 220 p/t 14 passenger bus for the St. Petersburg location. This lease is considered an operating lease for accounting purposes because the lease period is less than the economic life of the asset being leased. Minimum annual rent payments under this lease are $13,381. At our discretion, we may exercise a purchase option, by giving written notice no later than 180 days but not more than 360 days before the expiration of the initial term. The purchase option price is $12,891 based on reasonably predicted fair market value. A right of use asset and lease liability in the amount of $55,345 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

In April of 2021, through Banyan, we entered into a 36-month copier lease with Dex Imaging. The lease was for one copy machine. The minimum annual lease payment is $4,920. The equipment under this lease has a fixed $1 payment buyout option. The equipment was purchased for the Banyan Sarasota location. A right of use asset and lease liability in the amount of $14,693 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

In July of 2021, through Banyan, we entered into a 60-month financing agreement with Ascentium Capital LLC for a 2021 Diamond VIP 2200 passenger bus for the Pasco location. This lease is considered an operating lease for accounting purposes. Minimum annual rent payments under this lease are $15,654 and the purchase option price is $15,193 based on reasonably predicted fair market value. A right of use asset and lease liability in the amount of $65,772 was recognized with this lease.

 

In August of 2021, through Banyan we entered into a 36-month financing agreement with Dex Imaging. The lease was for one copy machine. The minimum annual lease payment is $4,920. The equipment under this lease has a fixed $1 payment buyout option. The equipment was purchased for the Banyan Pasco location. A right of use asset and lease liability in the amount of $14,040 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

In July of 2021, through Trillium we entered into a 60-month financing agreement with Dex Imaging. The lease was for one copy machine. The minimum annual lease payment is $1,920. A right of use asset and lease liability in the amount of $8,049 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

F-17
 

 

In August of 2021, through Trillium we entered into a 60-month financing agreement with RJKool for a Unimac commercial washing machine. The minimum annual lease payment is $4,321. A right of use asset and lease liability in the amount of $18,476 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

In July of 2021, through Trillium we entered into a 36-month financing agreement with Southeastern Laundry Equipment Sales for a Unimac commercial washing machine. The minimum annual lease payment is $5,094. A right of use asset and lease liability in the amount of $13,054 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

The leases assumed in the Trillium acquisition effective June 10, 2021 are reflected in accordance with FASB ASC Topic 842-10-65 which states; for leases in which the acquiree is a lessee, the acquirer shall measure the lease liability at the present value of the remaining lease payments, as if the acquired lease were a new lease of the acquirer at the acquisition date. The acquirer shall measure the right-of-use asset at the same amount as the lease liability as adjusted to reflect favorable or unfavorable terms of the lease when compared with market terms.

 

Through the Trillium acquisition (see NOTE 5) we assumed two master lease agreements. The first master lease agreement with Omega consists of 14 properties. The master lease with Omega was entered into on May 13, 2015, with an initial lease term that expires on May 31, 2027. The Omega master lease provides for two 10-year renewal options. At June 10, 2021 we recognized a right of use asset and lease liability in the amount of $29,906,314 in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

The second master lease with CTR accounts for 10 properties. The master lease with CTR was entered into on August 16, 2019, with an initial lease term that expires on November 30, 2030. The CTR lease provides for two 5-year renewal options. At June 10, 2021 we recognized a right of use asset and lease liability in the amount of $14,468,509 in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

Through the Trillium acquisition we also assumed 27   capital leases for the following:

 

  2 phone systems for facilities
  6 van leases for facilities to transport residents
  15 copy machine leases for use at the facilities
  3 postage machine leases for use at the facilities
  1 lease for a washing machine at a facility

 

These leases are treated as capital leases for accounting purposes.

 

In accordance with ASC 842, we recorded the operating lease right of use asset and lease liability as follows:

 

   September 30, 2021   December 31, 2020 
Right of Use (ROU) assets  $46,089,030   $3,977,988 

 

   September 30, 2021   December 31, 2020 
Operating lease obligations:          
Current  $8,311,905   $189,397 
Non-Current   38,089,042    3,864,321 
Total  $46,400,947   $4,053,718 

 

Maturity of Operating Lease obligations for period ended September 30, 2021 ,

 

      
2021 (three months)  $1,990,630 
2022   8,545,124 
2023   9,950,470 
2024   8,305,778 
2025   5,840,681 
After 2025  $11,768,262 
Total lease obligation   46,400,947 

 

F-18
 

 

Information associated with the measurement of our remaining operating lease obligations as of September 30, 2021 is as follows:

 

The operating leases range from a term of 2.89 years to 15.93 years with a weighted average lease term of 5.47 years.

 

The capital leases range from a term of 1 to 4.96 years with a weighted average lease term of 3.72 years.

 

The weighted average discount rate for operating leases is 7.80%.

 

The weighted average discount rate for capital leases is 7.81%.

 

The lease expense for the three and nine month periods ended September 30, 2021 were $2,991,078 and $3,912,133, respectively, compared to $95,319 and $193,365, during the same periods in the prior year.

 

NOTE 11 - EQUITY

 

Preferred Stock

 

We have authorized 25,000,000 preferred shares with a par value of 0.0001 per share. The Board is authorized to divide the authorized preferred shares into one or more series, each of which shall be so designated as to distinguish the shares thereof from the shares of all other series and classes. As of September 30, 2021 and December 31, 2020, we had no classes of preferred shares designated.

 

As discussed in NOTE 5, as part of the Trillium acquisition, Trillium is entitled to 2,500,000 shares of the Company’s Series A Preferred Stock. The Preferred Shares, with respect to rights on liquidation, winding up and dissolution, rank pari passu with the Common Shares. The holders of Preferred Shares have the right to cast one (1) vote for each Preferred Share held of record on all matters submitted to a vote of holders of the Common Shares, including the election of directors, and all other matters as required by law. The Preferred Shares are not convertible into Common shares at the election of the holder. However, the Preferred Shares do automatically convert into Common Shares at a one to one ratio two years from date of issuance. In lieu of converting the Preferred Shares, the holders thereof may elect to have the Company redeem one or more Preferred Shares at the redemption price of $1.00 per share two years from the date of issuance. The Company is required to issue the Preferred Shares to Trillium within 30 days after the purchase of the Properties closes. In connection with the issuance of the Preferred Shares, the Company will file a Certificate of Designation with the Nevada Secretary of State prior to such issuance. A liability to issue the 2,500,000 shares is reflected as a long-term liability on the condensed consolidated balance sheet as of September 30, 2021in the amount of $4,750,000.

 

Common Stock

 

We have authorized 100,000,000 Common Shares with a par value of $0.0001 per share. Each Common Share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought. As of September 30, 2021, we had 45,345,418 Common Shares issued and outstanding.

 

Fiscal Year 2021

 

On March 23, 2021, we entered into a Plan of Merger with Banyan (See NOTE 3).

 

In connection with the Merger, we issued 4,165,418 Common Shares in exchange for 49,984,649 outstanding shares of Banyan’s common stock held by 64 shareholders, based on an exchange ratio of one (1) Common Share of our common stock for every twelve (12) shares of Banyan common stock.

 

In conjunction with the Merger, the previously issued 31,230,000 Common Shares prior to the Merger were deemed issued for the Merger.

 

During the period from February 11, 2021 through March 31, 2021 we issued 7,080,000 Common Shares at $0.50 per share for an aggregate consideration of $3,540,000.

 

F-19
 

 

During the three months ended June 30, 2021, noteholders of the $2,000,000 convertible note exercised their right to convert the note with an effective date of March 30, 2021 (see NOTE 3), 4,000,000 Common Shares were issued for the conversion of the note. The conversion was previously recorded as a liability to issue shares in the amount of $2,000,000.

 

During the three months ended June 30, 2021, we issued Common Shares in satisfaction of a liability to issue shares in the amount of $575,000 for stock purchases of 1,150,000 Common Shares at $0.50 per share.

 

As discussed in NOTE 5, as part of the Trillium acquisition, Trillium is entitled to Common Shares having an aggregate value of $5,000,000, based on the stock price at the time of issuance, upon the earlier of an initial public offering by the Company or June 10, 2022. A share liability is recorded as a current liability in the amount of $5,000,000 on the condensed consolidated balance sheet as of September 30, 2021.

 

During the three month period ended September 30, 2021 we issued 5,000,000 Common Shares at $1.00 per share for an aggregate consideration of $5,000,000.

 

On August 26, 2021, a majority of the stockholders approved, by written consent without a meeting, the 2021 Incentive Award Plan (“Award Plan”). The Award Plan was approved by the board of directors on August 19, 2021, and recommended to the stockholders for their approval. Under the Award Plan, 4,500,000 shares of our common stock will be initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents or other stock or cash based awards. As of the nine month period ending September 30, 2021 2,750,208 of the reserved shares were provided as stock options to 10 employees as part of the 2021 Incentive Award Plan. (See NOTE 14)

 

Fiscal Year 2020

 

During the year ended December 31, 2020, $140 was received against a subscription receivable balance for the 2019 authorization of the issuance of Founders shares. On December 31, 2020, we had a subscription receivable of $30 for shares issued where payments were not received.

 

On September 19, 2020, we issued 2,000,000 restricted Common Shares to a noteholder for the conversion of $500,000 of note principal.

 

Warrants

 

In association with the September 27, 2019, Asset Purchase Agreement (The Kidz Club St Pete, LLC), we issued 75,000 common stock warrants (post-merger exchange adjusted) having an exercise price of $0.38 per share. These warrants have an expiration of September 27, 2029.

 

           Weighted     
       Weighted-   Average     
       Average   Remaining   Aggregate 
       Exercise   Contractual   Intrinsic 
   Shares   Price   Term   Value 
                 
Outstanding at January 1, 2020   -    -    -   $- 
                     
Granted   75,000   $0.38    10.0 Years   $- 
Expired   -    -    -      
Exercised   -    -    -      
                     
Outstanding at December 31, 2020   75,000   $0.38    9.74 Years   $1.62 
                     
Granted   -    -    -      
Expired   -    -    -      
Exercised   -    -    -      
                     
Outstanding and exercisable September 30, 2021   75,000   $0.38    8.99 Years   $3.12 

 

 

F-20
 

 

NOTE 12 – RELATED PARTY TRANSACTIONS

 

On February 1, 2021 (the “Effective Date”), we signed an employment agreement with our new CEO, Louis Collier (“Collier”). Collier will be paid a base salary of $400,000, which will be reassessed and renegotiated in good faith after we are profitable over a fiscal year. Collier will also receive a signing bonus of $150,000, which will be payable as follows: $50,000 within five days of the Effective Date (paid); $50,000 within 90 days of the Effective Date; and $50,000 within 180 days of the Effective Date. Collier will also be issued 1,250,000 phantom shares within ten days after the approval and adoption a Phantom Equity Plan. The phantom shares will be subject to a phantom unit interest award agreement, which will set forth the vesting of the phantom shares.

 

On March 23, 2021, we entered into a Plan of Merger (See NOTE 3) whereas we assumed debt of $2,000,000 that was convertible into 20,000,000 shares of common stock. After the Merger the debt was converted into 4,000,000 restricted Common Shares of the Company. One of the debt holders is majority owned by a director of the Company. During the three month period ending June 30, 2021, 4,000,000 restricted Common Shares were issued.

 

During the three months ended September 30, 2021 and 2020, we compensated members of the Board $42,000 and $0, respectively.

 

During the three months ended September 30, 2021 accrued payroll of $60,000 was paid and $6,277 interest was paid.  We had accrued payroll of $60,000 and accrued interest on that payroll for the President and the Chief Financial Officer of Banyan. These unpaid amounts were the result of 2020 furloughed salaries. Interest was accrued on these unpaid balances effective May 15, 2020 at a rate of 8% per annum.

 

NOTE 13 SEGMENT INFORMATION

 

The Company has adopted provisions of ASC 280-10 Segment Reporting for the three and nine months ended September 30, 2021, and 2020. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. The Company and its Chief Operating Decision Makers determined that the Company’s operations consist of two segments: (i) Banyan’s three pediatric extended care centers (“PPECs”) in southwest Florida, and (ii) the second segment is the Trillium Subsidiaries consisting of senior housing communities including skilled nursing facilities, assisted living facilities and independent living facilities.

 

The table below reflects the segment operations for the nine months ended September 30, 2021.

 

   PPEC   Trillium   Adjustments, eliminations and unallocated items   Consolidated 
Total revenue, net  $2,094,905   $26,998,940   $-   $29,093,845 
Cost of Sales   (810,114)   (14,666,956)   -    (15,477,070)
Gross Profit   1,284,792    12,331,983    -    13,616,775 
                     
Salaries and payroll expense   610,183    5,521,454    540,019    6,671,656 
General and administrative   828,543    5,409,409    353,797    6,591,749 
Lease expense   383,501    3,528,632    -    3,912,133 
Professional fees   255,218    1,450,431    1,001,862    2,707,511 
Marketing and advertising   164,800    172,184    -    336,984 
Depreciation and amortization expense   206,777    111,336    211    318,324 
Operating Loss  $(1,164,231)  $(3,861,462)  $(1,895,889)  $(6,921,582)
                     
Total Assets  $10,206,083   $73,191,222   $2,733,979   $86,131,284 
Total Liabilities  $4,954,086   $63,148,235   $10,724,471   $78,826,792 
                     
Cash used in operating activities  $(917,789)  $(6,699,086)  $(2,395,144)  $(10,012,019)
Cash used in investing activities  $(51,972)  $3,620,828        $3,568,856 
Cash provided by financing activities  $(211,903)  $4,724,102   $5,479,518   $9,991,717 

 

F-21
 

 

NOTE 14 – STOCK-BASED COMPENSATION

 

On August 26, 2021, a majority of the stockholders approved, by written consent without a meeting, the 2021 Incentive Award Plan (“Award Plan”). The Award Plan was approved by the board of directors on August 19, 2021 and recommended to the stockholders for their approval. Under the Award Plan, 4,500,000 shares of our common stock will be initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents or other stock or cash based awards. As of the nine month period ending September 30, 2021 2,750,208 of the reserved shares were provided as stock options to 10 employees as part of the 2021 Incentive Award Plan. The shares vest over a 4 year period with a vesting commencement date of September 1, 2021, as of September 30, 2021 there were 57,296 of the shares vested with 2,692,912 options outstanding.

 

The following table summarizes our Stock Options activity under the Award Plan for the nine months ended September 30, 2021:

 

   Shares   Weighted Average Exercise Price   Weighted Average Remaining Vesting Period (Years) 
Outstanding At December 31, 2020   -           
                
Granted   2,750,208   $1.00    3.92 
Forfeited   -    -      
Exercised   -    -      
                
Outstanding September 30, 2021   2,750,208           

 

At September 30, 2021 the weighted average period over which compensation cost on non-vested Stock Options expected to be recognized is 3.92 years and the unrecognized expense is approximately $8.1 million.

 

Stock-based compensation before income taxes included in salaries and wages in the condensed consolidated statement of operations was $171,888 for the three months ended September 30, 2021. We did not recognize compensation cost in the three or nine month periods ended September 30, 2020 since the Stock Options were not awarded during the period.

 

We did not have any cash proceeds or income tax benefits realized from the exercise of Stock Options for the three and nine months ended September 30, 2021.

 

Valuation Assumptions

 

Calculating the fair value of employee stock options requires estimates and significant judgement. We use the Binomial option pricing model to estimate the fair value of the employee stock options.

 

We have included shares issuable under the Award Plan in deriving fully diluted earnings per share using the Treasury Method in accordance with ASC 260-10-45. Under the Treasury Method, nonvested stock options granted, where the only satisfying condition is the mere passage of time, shall be assumed exercised at the beginning of the period (or at time of issuance, if later). The proceeds from exercise of stock options shall be assumed to be used to purchase common stock at the average market price during the period using daily closing prices

 

F-22
 

 

NOTE 15 – CONCENTRATIONS AND CREDIT RISKS 

 

Cash

 

The Company places its cash with high credit quality financial institutions. The Company had balances in excess of the Federal Deposit Insurance Corporation (“FDIC”) coverage of $250,000 at September 30, 2021, the aggregate amount in excess of the coverage limit was approximately $2.8 million consisting of three accounts. The Company maintains its cash in accounts at financial institutions, which may, at times, exceed federally-insured limits. The Company has not experienced any losses on such accounts and does not feel it is exposed to any significant risk with respect to cash.

 

Revenues and Accounts Receivable

 

For the three and nine months ended September 30, 2021, approximately 15% of our revenue was generated from Medicare, 67% was generated from Medicaid and approximately 13% of our revenue was generated from private pay residents. The balance consisted of other payors including managed care programs, VA programs and commercial insurance.

 

At September 30, 2021 18% of our accounts receivable balances consisted of Medicare receivables, 54% consisted of Medicaid receivables, 13% consisted private pay and 11% consisted of commercial insurance. The balance of the accounts receivable consisted of VA and other payors.

 

NOTE 16 – SUBSEQUENT EVENTS

 

We have evaluated subsequent events from September 30, 2021 through the date of these financial statements were issued and determined the following events require disclosure:

 

Autumn Accolade

 

On September 30, 2021,we entered into an Agreement for the Purchase and Sale of Business Assets and Real Estate (the “Purchase Agreement”), with Autumn Accolade, Inc., (“Asset Seller”), Deborah S. Penn, as Trustee under the provisions of a Trust Agreement dated October 8, 2012, and known as the Denton M. Penn Jr. Trust, as to an undivided one-half interest; Deborah S. Penn, as Trustee under the provisions of a Trust Agreement dated October 8, 2012, and known as the Deborah S. Penn Trust, as to an undivided one-half interest (together, “RE Seller,” and collectively with Asset Seller, the “Seller”).

 

Asset Seller owns and operates a licensed assisted living facility located in Green Valley; Illinois known as Autumn Accolade (the “Business”). Asset Seller also owns various assets in conjunction with the operation of the Business, including all assets that are located at, on or within the Premises including those assets that are affixed to the Premises (collectively, “Assets”). RE Seller is the owner in fee simple of the real estate upon which the Assets are located (the “Premises”).

 

Subject to the terms of the Purchase Agreement, we are acquiring the Assets and the Premises from the Sellers in exchange for $2,300,000 and the assumption of certain liabilities. We paid a $110,000 deposit (the “Deposit”) upon execution of the Purchase Agreement, which is being held in escrow and will be applied to the purchase price at closing or refunded if the closing doesn’t occur. We paid an additional $15,000 deposit to the Seller upon execution of the Purchase Agreement, which is not refundable.

 

The closing shall take place promptly following the satisfaction or waiver of the conditions to closing (but in no event less than 30 days thereafter unless otherwise agreed to by the parties). In the event the closing has not taken place by March 31, 2022, then either party may terminate the Purchase Agreement by written notice to the other party so long as such party is not then in breach of the Purchase Agreement, and the Deposit will be immediately returned , less $35,000 to be paid to the Seller if the Seller is able to close but we have failed to meet a financing contingency prior to the March 31, 2022 closing date. We may extend the March 31, 2022 closing date to no later than June 30, 2022 upon written notice to the Seller prior to the March 31, 2022 and the payment to the Seller of a non-refundable amount of $20,000, which shall not be applied to the purchase price.

 

F-23
 

 

Gemino Healthcare Finance

 

On September 30, 2021 we entered into a Second Amendment to our credit agreement with Gemino Healthcare Finance, LLC. The Credit Agreement was entered into in connection with a $10 million credit facility to be used for working capital and general business purposes, and secured by a first priority perfected security interest in the assets of Trillium and the Trillium Group. The credit facility terminates on May 9, 2022. Each revolving loan under the credit facility bears interest on the outstanding principal amount thereof from the date made until paid in full, at a rate per annum equal to the greater of: (i) the annual rate reported as the London Interbank Offer Rate applicable to ninety (90) day deposits of United States Dollars as reported in the Money Rates Section of The Wall Street Journal on the date of determination; and (ii) 2.00%, plus 4.95% (together, the “Interest Rate”). The Interest Rate on all amounts outstanding under the credit facility is adjusted daily based on any changes in the amount under subsection (i) above and subsection (ii) above, as applicable. There are also various fees paid in connection with the credit facility, including: (1) a monthly collateral monitoring fee of 1.00% of the average borrowing base during the prior month; (2) a monthly unused line fee equal to 0.75% per annum of the unused portion of the maximum amount of credit facility; (3) a minimum use fee if the outstanding revolving loan balance is less than $2 million equal to the Interest Rate times the minimum balance of $2 million; and (4) a termination fee of $100,000 if the credit facility is terminated by A4L prior to May 9, 2022. The credit facility also contains typical affirmative and negative covenants found in credit facilities of this type and amount.

 

The First Amendment amended the Credit Agreement by: (1) releasing seven entities from the Trillium Group of their obligations under the credit facility in connection with Trillium’s sale of those entities; (2) increasing to 5.95% the rate used to calculate the Interest Rate; (3) increasing the monthly collateral monitoring fee to 1.50%; (4) lowering the revolving commitment amount from $10 million to $7 million; and (5) waiving borrower’s failure to comply with the fixed charge coverage ratio for the fiscal quarters ending September 30, 2019, December 31, 2019, and March 31, 2020.

 

The Second Amendment further amended the Credit Agreement by: (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; (7) increasing the maximum amount of the credit facility from $10 million to $25 million; and (8) revising terms regarding financial statements and collateral reports, limitations on certain corporate guarantors and curing defaults.

 

Debt

 

On October 8, 2021 we entered into a guaranty agreement in connection with a loan made to our wholly-owned subsidiary, Assisted 4 Living Consulting, Inc. in the principal amount of $1,250,000 (the “Loan”). Pursuant to the terms of the guaranty agreement, the A4L has unconditionally guaranteed the payment of all indebtedness, liabilities and obligations of every kind and nature of Assisted 4 Living Consulting, LLC to the lender whether absolute or contingent, direct or indirect, due or to become due, heretofore or hereafter created, arising or exiting including any additional advances or future advances, renewals or extensions without limitation as to amount. The Loan is evidenced by a promissory note. Outstanding principal accrues interest at an annual rate of ten percent (10%). Monthly payments in the amount of $10,416.67 commence on November 8, 2021 and continue for 12 months until the maturity date of October 8, 2022, at which time the remaining principal balance, if any, is due and payable. The Loan is secured by a first mortgage lien on property that is owned by Borrower and serves as the A4L corporate headquarters.

 

If any portion of the principal is paid prior to July 8, 2022, then Assisted 4 Living Consulting, LLC must pay a prepayment fee calculated as the difference between nine months of interest on the amount of principal being prepaid and the amount of interest paid to date on the amount of principal being prepaid. The lender is guaranteed nine months of interest regardless of when Loan is paid off.

 

After the maturity date or due date of the promissory note, interest shall be charged on the respective principal amount remaining unpaid at a rate equivalent to the highest lawful rate or twenty-five percent (25%) per annum, whichever is less, until paid.

 

If any payment of principal or interest or both is more than five days late, Borrower agrees to pay lender a late charge equal to five percent (5.0%) of the payment.

 

Crete Plus Five Property

 

On October 13, 2021 we entered into an Agreement of Purchase and Sale with Crete Plus Five Property, LLC, Iowa Lincoln County Property LLC, Muscatine Toledo Properties, LLC and Avery Street Property, LLC (collectively, “Owners” ). The Owners owns 13 senior housing facilities located in Iowa, Nebraska and Florida (collectively, the “Facilities”) as well the real property underlying the Facilities (the “Properties”). The Agreement of Purchase and Sale is for the purchase of the Facilities, the Properties and all of Owner’s right, title and interest in all of the personal property located at the Properties, other than certain personal property described in Exhibit B attached to the Agreement of Purchase and Sale, such as cash and the tradenames and books and records of Owner. The A4L indirect wholly-owned subsidiaries currently lease the Properties from Owner, and operate the Facilities, pursuant to an Master Lease dated as of May 13, 2015, as amended.

 

F-24
 

 

The purchase price for the Facilities and the Properties is $59,000,000. A4L paid a $3,000,000 deposit (the “Deposit”) in June upon execution of a letter of intent with Owner as part of the Trillium transaction, and A4L will receive a credit at closing against the purchase price in the amount of the Deposit. If the Agreement of Purchase and Sale is Terminated prior to closing for any reason other than breach of the agreement by Owner, the Deposit will be paid to Owner as liquidated damages. The closing is to occur on March 1, 2022; provided, however, A4L may extend the March 1, 2022 closing date to no later than March 31, 2022, upon written notice to Owner prior to the February 15, 2022.

 

Grace Care Centers

 

On October 18, 2021 we completed the acquisition from Grace Care Centers and its affiliates (collectively, “Grace”) of three skilled nursing facilities located in Texas (the “Skilled Facilities”), including the real property, buildings, structures, improvements, fixtures and certain other assets comprising the Skilled Facilities (together with the Skilled Facilities, the “Assets”) in exchange for an aggregate purchase price of $7,750,000 (the “Purchase Price”). The Assets were acquired pursuant to and in accordance with three Purchase and Sale Agreements and three Management Transfer Agreements (collectively, the “Agreements”).

 

The Skilled Facilities, located in Olney, Nocona and Henrietta, Texas, are all 5-star rated by CMS for quality and have a combined 258 beds. The Skilled Facilities will continue to be leased to local hospital districts, who will continue to be the licensed operators of the Skilled Facilities. A4L, through indirect wholly-owned subsidiaries, now owns the Assets and will manage the day-to-day activities of the Skilled Facilities pursuant to management agreements which it assumed in connection with the transaction.

 

A4L, through its indirect wholly-owned subsidiary, financed part of the Purchase Price with a loan from Arena Limited SPV, LLC (“Lender”) in the principal amount of $6,600,000 (the “Loan”). Outstanding principal accrues interest at a rate per annum equal to the sum of the Prime Rate plus 4.125%, with a minimum interest rate per annum of not less than 7.875%. Monthly interest only payments commence on December 15, 2021, and continue each month until the maturity date of the Loan on April 18, 2023, at which time any outstanding principal and accrued and unpaid interest is due and payable. If any principal, interest or any other sums due under the Loan (other than the payment of principal due on the maturity date), is not paid on or prior to the due date, A4L is required to pay Lender upon demand an amount equal to 5% of such unpaid sum. In connection with any repayment or prepayment of principal, a non-refundable fee equal to 0.5% of the principal amount of such repayment or prepayment is due. A4L may prepay the outstanding amount in whole, but not part, upon prior written notice to Lender.

 

A4L has the right to extend the initial maturity date to October 15, 2023 upon prior written notice to Lender and the payment to Lender of a non-refundable fee equal to 1% of the outstanding principal balance no later than 30 days prior to the maturity date. A4L may extend the maturity date further, to April 15, 2024, upon prior written notice to Lender and the payment to Lender of a non-refundable fee equal to 1% of the outstanding principal balance prior to the extended maturity date.

 

The Loan is secured by a first priority lien on the Assets, including all amounts received by A4L or any subsidiaries constituting rent or other payment under any leases or management fees under each of the management agreements, which must be deposited into a segregated account at a bank and held in trust for Lender. The Loan is subject to customary affirmative and negative covenants, as well as customary default provisions for late or non-payments or breach of covenants, for loans of this nature. Pursuant to the terms of a guaranty agreement, A4L and several of its direct and indirect wholly-owned subsidiaries, have each unconditionally guaranteed to Lender the payment of all indebtedness, liabilities and obligations of every kind and nature under the Loan.

 

F-25
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of our results of operations and financial condition for quarterly period ended September 30, 2021, should be read in conjunction with our condensed consolidated financial statements and the related notes and the other financial information that are included elsewhere in this Quarterly Report. This discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations, and intentions. Forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results, or other developments. Forward-looking statements are based upon estimates, forecasts, and assumptions that are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.

 

As used in this quarterly report, the terms “we,” “us,” “our” and the “Company” means, collectively, Assisted 4 Living, Inc. (“A4L”) and its wholly owned subsidiaries, Banyan Pediatric Care Centers, Inc, including its wholly owned subsidiaries (“Banyan”) and the Trillium Subsidiaries, including their wholly owned subsidiaries (“Trillium”), unless otherwise indicated.

 

General Overview

 

Assisted 4 Living, Inc was incorporated in Nevada on May 24, 2017, with an objective to operate as a facilitator of assisted living projects and related services. On March 23, 2021, A4L entered into a Plan of Merger (the “Plan of Merger”) with its wholly owned subsidiary, BPCC Acquisition, Inc., a Florida corporation (“Merger Sub”), and Banyan Pediatric Care Centers, Inc., a Florida corporation (“Banyan”).

 

Under the terms of the Plan of Merger, Merger Sub merged with and into Banyan with Banyan surviving the merger and becoming a wholly owned subsidiary of A4L.

 

A4L also had a wholly owned subsidiary, Assisted 2 Live, Inc., a Florida corporation (“A2L”), which was incorporated on June 15, 2017. On April 30, 2021, the Board of Directors of A4L approved the discontinuance and disposal of the operations in A2L. The operations of A2L are reflected on our condensed consolidated statement of operations for the first thirty days of the three-month period ended June 30, 2021 as a loss from discontinued operations.

 

On June 10, 2021, we entered into an Amended and Restated Membership Interest Purchase Agreement (the “Restated Purchase Agreement”), by and among the Company, Richard T. Mason (“Mason”), G. Shayne Bench (“Bench”) and Trillium Healthcare Group, LLC, a Florida limited liability company (“Trillium”) to acquire all of the issued and outstanding ownership interests of Fairway Healthcare Properties, LLC (“FHP”) and Trillium Healthcare Consulting, LLC (together with FHP, the “Trillium Subsidiaries”) from Trillium. The Trillium acquisition closed and was effective June 10, 2021.

 

As a result of the above stated transactions A4L now operates as the parent company of an organization that delivers skilled nursing and therapy services to pediatric patients through Banyan and to the senior population through our senior living communities in the Trillium subsidiaries.

 

Our principal executive office is located at 5115 East SR 64 Bradenton, Florida 34208 and our telephone number is (855) 668-3331. Our corporate website is www.assisted4living.com.

 

We have not been subject to any bankruptcy, receivership or similar proceeding.

 

Our Current Business

 

Banyan was organized under the laws of the State of Florida on January 15, 2019, for the purpose of providing health care services for medically fragile and chronically ill children. Specifically, to open and operate Prescribed Pediatric Extended Care (“PPEC”) centers in the State of Florida. Our PPEC centers provide, among other services, daily medical care for medically fragile and chronically ill children whose current locations are in Florida.

 

PPEC centers provide up to 12 hours of daily care for families struggling with the unique and complex medical needs of their children and allow the parents of children with special needs some independence and the opportunity to still pursue their professional goals.

 

On May 1, 2020, we acquired a PPEC facility located in St. Petersburg, Florida. The facility is licensed to provide PPEC services for up to 81 children. All State and County accreditations to run the facility through January 2022 are in place.

 

3
 

 

On October 12, 2019, we entered into a lease for commercial real estate in New Port Richey Florida. The lease commenced on September 1, 2020, with an initial term of 7 years. Construction for this location has been completed and all State and County accreditations to run the facility through July of 2023.

 

On August 24, 2019, we entered into a lease for commercial real estate in Sarasota Florida. The lease commenced on February 1, 2020, with an initial term of 5 years. Construction for this location has been completed and all State and County accreditations to run the facility through April of 2023. In May of 2021 this location opened and started to admit children for services.

 

The Trillium Subsidiaries were organized under the laws of the State of Florida on February 9, 2012, for the purpose of acquiring and managing long term care facilities, such as skilled nursing facilities and assisted living centers.

 

Trillium has 26 facilities which primarily provide health care services for seniors that require daily care services. The facilities provide room and board, routine daily care services, post-acute care including rehabilitation and memory care.

 

A Skilled Nursing Facility is a state licensed and regulated in-patient rehabilitation and medical treatment center staffed with trained medical professionals. They provide the medically necessary services of licensed nurses, physical and occupational therapists, and speech pathologists.

 

The residents who come to our Trillium facilities receive skilled medical, respiratory, physical, occupational, and other therapies tailored to their individual needs. Trillium facilities are operated and staffed by registered nurses, licensed practical nurses, and other qualified personnel such as certified nursing assistants, physical and occupational therapists, and speech language pathologists. These specialized health care professionals are experienced in treating the frail and medically complex elderly residents and administering required medications and other therapies.

 

The Trillium facilities provide 24/7 care for their residents.

 

We lease and operate 26 Trillium facilities in four states: Florida, Georgia, Iowa, and Nebraska with 1,685 total licensed beds (1,546 skilled nursing, 139 assisted living) and 36 independent living apartments. The breakdown by state is as follows: Florida – 1 skilled nursing facility; Georgia – 1 skilled nursing facility; Iowa – 16 skilled nursing facilities, 2 independent living centers and 1 assisted living centers; Nebraska – 4 skilled nursing facilities and 1 assisted living center.

 

Skilled nursing and assisted living facilities are regulated and licensed by each state’s licensing agency. The licensing agency is responsible for the administration of the Medicaid program, licensure and regulation of health facilities. Our skilled nursing facilities are also Medicare certified with Centers of Medicare and Medicaid Services (CMS).

 

Trillium and Banyan reimbursement rates are determined by CMS for Medicare and each state’s Medicaid program. These rates could be significantly affected by any future changes in Medicare or Medicaid reimbursement. To receive authorization to be admitted to a skilled nursing facility or a PPEC facility a resident or child must have a qualifying diagnosis and a doctor’s order from a physician.

 

Our plans include expansion into multiple states, and we will be subject to the regulations, licensure requirements and processes, and reimbursement rates in each of those states. Each state manages their own program requirements, regulations and reimbursement programs. Our projected financial plans in these expansion states could be impacted by any changes or barriers to entry in each of these states as they expand.

 

Regulatory Matters

 

Health care operations are highly regulated by both state and federal government agencies. Regulation of health care services is an ever-evolving area of law that varies from jurisdiction to jurisdiction. Regulatory agencies generally have discretion to issue regulations and interpret and enforce laws and rules. Changes in applicable laws, statutes, regulations and interpretive guidance occur frequently. In addition, government agencies may impose taxes, fees or other assessments upon Banyan at any time.

 

We are also subject to certain state laws prohibiting the payment of remuneration for patient or business referrals and the provision of services where a financial relationship exists between a referring person or entity and the entity providing the service. Federal laws governing our activities include regulation under the Medicare and Medicaid programs. Federal fraud and abuse laws prohibit or restrict, among other things, the payment of remuneration to parties in a position to influence or cause the referral of patients or business, as well as the filing of false claims. Government enforcement authorities have become increasingly active in recent years in their review and scrutiny of various sectors of the health care industry.

 

4
 

 

Changes in or new interpretations of these laws could have an adverse effect on our methods and costs of doing business. Further, failure to comply with such laws could adversely affect the ability to continue to provide, or receive reimbursement for, our services, and could subject A4L, its subsidiaries, and its officers and employees to civil and criminal penalties. There can be no assurance that A4L or its subsidiaries will not encounter regulatory impediments that could adversely affect the ability to open facilities or to expand the services currently planned to provide at the facilities.

 

HIPAA, HITECH Act, State Privacy Laws and Breach Notification Laws.

 

HIPAA and the regulations adopted under HIPAA are intended to improve the portability and continuity of health insurance coverage and simplify the administration of health insurance claims and related transactions.

 

The HITECH Act modified certain provisions of HIPAA by, among other things, extending the privacy and security provisions to business associates, mandating new regulations around electronic health records, expanding enforcement mechanisms, and increasing penalties for violations.

 

On January 25, 2013, the U.S. Department of Health and Human Services (“HHS”), as required by the HITECH Act, issued the Final Omnibus Rules that provide final modifications to HIPAA rules to implement the HITECH Act.

 

The HITECH Act also contains a number of provisions that provide incentives for states to initiate certain programs related to health care and health care technology, such as electronic health records. While provisions such as these will not apply to us directly, states wishing to apply for grants under the HITECH Act, or otherwise participating in such programs, may impose new health care technology requirements on us through our expected contracts with state Medicaid agencies.

 

All health plans are considered covered entities subject to HIPAA. HIPAA generally requires health plans, as well as their providers and vendors, to: (1) protect patient privacy and safeguard individually identifiable health information; and (2) establish the capability to receive and transmit electronically certain administrative health care transactions, such as claims payments, in a standardized format.

 

Specifically, the HIPAA Privacy Rule regulates use and disclosure of individually identifiable health information, known as “protected health information” (“PHI”). The HIPAA Security Rule requires covered entities to implement administrative, physical and technical safeguards to protect the security of electronic PHI. Certain provisions of the security and privacy regulations apply to business associates (entities that handle PHI on behalf of covered entities), and business associates are subject to direct liability for violation of these provisions. Furthermore, a covered entity may be subject to penalties as a result of a business associate violating HIPAA, if the business associate is found to be an agent of the covered entity.

 

Covered entities must report breaches of unsecured PHI to affected individuals without unreasonable delay, but not to exceed 60 days of discovery of the breach by a covered entity or its agents. Notification must also be made to HHS and, in certain situations involving large breaches, to the media. HHS is required to publish on its website a list of all covered entities that report a breach involving more than 500 individuals. All non-permitted uses or disclosures of unsecured PHI are presumed to be breaches unless the covered entity or business associate establishes that there is a low probability the information has been compromised. Various state laws and regulations may also require us to notify affected individuals in the event of a data breach involving individually identifiable information.

 

HIPAA violations by covered entities may result in civil and criminal penalties. Covered entities could face civil monetary penalties up to an annual maximum of $1,500,000 for uncorrected violations based on willful neglect. HHS enforces the regulations and performs audits to confirm compliance. Investigations of violations that indicate willful neglect, for which penalties are mandatory, are statutorily required. HHS may also resolve HIPAA violations through informal means, such as allowing a covered entity to implement a corrective action plan, but HHS has the discretion to move directly to impose monetary penalties and is required to impose penalties for violations resulting from willful neglect. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations of HIPAA privacy and security regulations that threaten the privacy of state residents.

 

A4L and its subsidiaries enforce a HIPAA compliance plan, which complies with the HIPAA privacy and security regulation, also provided are dedicated resources to monitor compliance with our HIPAA compliance program.

 

5
 

 

A4L and subsidiaries, its providers, and certain of its vendors are also subject to numerous other privacy and security laws and regulations at the federal and state levels. We remain subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and violations may result in additional penalties.

 

Fraud and Abuse Laws. Federal and state enforcement authorities have prioritized the investigation and prosecution of health care fraud, waste and abuse. Fraud, waste and abuse prohibitions encompass a wide range of operating activities, including kickbacks or other inducements for referral of members, billing for unnecessary medical services by a provider and improper marketing and violation of patient privacy rights. Companies involved in public health care programs such as Medicaid and Medicare are required to maintain compliance programs to detect and deter fraud, waste and abuse, and are often the subject of fraud, waste and abuse investigations and audits. The regulations and contractual requirements applicable to participants in these public-sector programs are complex and subject to change. Although we have structured a compliance program with care in an effort to meet all statutory and regulatory requirements, our policies and procedures will be continuously under review and subject to updates and our training and education programs will always be evolving. We intend to invest significant resources towards our compliance efforts.

 

False Claims Act. We are subject to federal and state laws and regulations that apply to the submission of information and claims to various agencies. For example, the federal False Claims Act provides, in part, that the federal government may bring a lawsuit against any person or entity who it believes has knowingly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim approved. The federal government has taken the position that claims presented in violation of the federal anti-kickback statute may be considered a violation of the federal False Claims Act. Violations of the False Claims Act are punishable by treble damages and penalties of up to a specified dollar amount per false claim. In addition, a special provision under the False Claims Act allows a private person (for example, a “whistleblower” such as a disgruntled former associate, competitor or member) to bring an action under the False Claims Act on behalf of the government alleging that an entity has defrauded the federal government and permits the private person to share in any settlement of, or judgment entered in, the lawsuit. A number of states, including Florida, have adopted false claims acts that are similar to the federal False Claims Act.

 

Medicare and Medicaid Regulations. As a provider of services under the Medicare and Medicaid programs (the “Programs”), we are subject to federal and state laws and regulations governing reimbursement procedures and practices. These laws include the Medicare and Medicaid fraud and abuse statutes and regulations which, among other provisions, prohibit the payment or receipt of any form of remuneration in return for referring business or patients to providers for which payments are made by a governmental health care program. Violation of these laws may result in civil and criminal penalties, including substantial fines, loss of the right to participate in the Programs and imprisonment of responsible individuals. In addition, HIPAA expanded the federal government’s fraud and abuse enforcement powers. Among other provisions, HIPAA expands the federal government’s authority to prosecute fraud and abuse beyond Medicare and Medicaid to all payors; makes exclusion from the Programs mandatory for a minimum of five years for any felony conviction relating to fraud; requires that organizations contracting with another organization or individual take steps to be informed as to whether the organization or individual is excluded from Medicare and Medicaid participation; and enhances civil penalties by increasing the amount of fines permitted. These laws also include a prohibition on referrals contained in the Omnibus Budget Reconciliation Act of 1989, which prohibits referrals by physicians to clinical laboratories where the physician has a financial interest, and further prohibitions contained in the Omnibus Budget Reconciliation Act of 1993, which prohibits such referrals for a more extensive range of services, including durable medical equipment. Various federal and state laws impose civil and criminal penalties against participants in the Programs who make false claims for payment for services or otherwise engage in false billing practices.

 

Many state laws prohibit the payment or receipt or the offer of anything of value in return for, or to induce, a referral for health care goods or services. In addition, there are several other statutes that, although they do not explicitly address payments for referrals, could be interpreted as prohibiting the practice. While similar in many respects to the federal laws, these state laws vary from state to state, are often vague and have sometimes been interpreted inconsistently by courts and regulatory agencies. Private insurers and various state enforcement agencies have also increased their scrutiny of health care providers’ practices and claims.

 

There can be no assurance that we will not become the subject of a regulatory or other investigation or proceeding or that our interpretations of applicable health care laws and regulations will not be challenged. The defense of any such challenge could result in substantial cost to us, diversion of management’s time and attention, and could have a material adverse effect on The Company.

 

6
 

 

The Social Security Act, as amended by HIPAA, provides for the mandatory exclusion of providers and related persons from participation in the Programs if the individual or entity has been convicted of a criminal offense related to the delivery of an item or service under the Programs or relating to neglect or abuse of patients. Further, individuals or entities may be, but are not required to be, excluded from the Programs in circumstances including, but not limited to, convictions relating to fraud; obstruction of an investigation of a controlled substance; license revocation or suspension; filing claims for excessive charges or unnecessary services or failure to furnish medically necessary services; or ownership or control by an individual who has been excluded from the Programs, against whom a civil monetary penalty related to the Programs has been assessed, or who has been convicted of a crime described in this section. The illegal remuneration provisions of the Social Security Act make it a felony to solicit, receive, offer to pay, or pay any kickback, bribe, or rebate in return for referring a patient for any item or service, or in return for purchasing, leasing or ordering any good, service or item, for which payment may be made under the Programs. Other provisions in HIPAA proscribe false statements in billing and in meeting reporting requirements and in representations made with respect to the conditions or operations of providers. A violation of the illegal remuneration statute is a felony and may result in the imposition of criminal penalties, including imprisonment for up to five years and/or a fine of up to $25,000. Further, a civil action to exclude a provider from participation in the Programs could occur. There are also other civil and criminal statutes applicable to the industry, such as those governing false billings and the health care/services offenses contained in HIPAA, including health care/services fraud, theft or embezzlement, false statements and obstruction of criminal investigation of offenses. Criminal sanctions for these health care criminal offenses can be severe, including imprisonment for up to 20 years.

 

Results of Operations

 

COVID-19

 

In March 2020, the World Health Organization declared the outbreak of COVID-19 as a pandemic based on the rapid increase in global exposure. COVID-19 continues to spread throughout the world. We are closely monitoring developments and taking steps to mitigate the potential risks related to the COVID-19 pandemic to the Company, its employees, as well as its residential and pediatric patients.

 

Our evaluations of our practices, procedures, and operations, related to COVID-19, is ongoing. Additional updates to policies, procedures and operations will occur as best practices are adopted and as we deem necessary or advisable, or as further governmental guidance or regulations are implemented.

 

The following summary of our operations should be read in conjunction with our unaudited financial statements for the period ended September 30, 2021 which are included in this quarterly report.

 

For the three and nine months ended September 30, 2021 compared to the three and nine months ended September 30, 2020

 

   Three Months Ended       Nine Months Ended     
   September 30,   September 30,       September 30,   September 30,     
   2021   2020   Change   2021   2020   Change 
Revenue   22,375,092    659,449    21,715,643    29,093,845    1,102,841    27,991,004 
Cost of services provided   12,310,011    256,825    12,053,186    15,477,070    409,838    15,067,232 
Operating expenses   15,157,050    706,752    14,450,298    20,538,357    1,689,380    18,848,977 
Other income (expense)   (179,293)   (30,673)   (148,620)   (317,881)   (30,676)   (287,205)
Net Loss   (5,271,262)   (334,802)   (4,936,460)   (7,239,463)   (1,027,054)   (6,212,409)

 

We recognized revenue of $22,375,092 for the three months ended September 30, 2021, compared to $659,449 for the three months ended September 30, 2020.

 

The first operating PPEC facility began in May of 2020 with the acquisition of the St. Petersburg location and revenues began being reported at that time. The Sarasota PPEC facility began reporting revenue in May of 2021 and the Pasco location started reporting revenue in July of 2021. The Banyan revenue for the nine months ended September 2021 was $2,094,905 compared to $1,102,841 for the same period in 2020. Operating expenses for the nine months ended September 30, 2021 and 2020 were 2,449,042 and $1,689,380 respectively. Net losses were $1,164,31 and $1,027,054 for the nine months ended September 30 2021 and 2020, respectively.

 

The Trillium acquisition closed on June 10, 2021, revenue reflected for the three- and nine-month periods ending September 2021 include 20 days and 92 days of revenue from the Trillium Subsidiaries respectively; compared to the revenue for the same period ending in 2020.

 

7
 

 

Operating expenses for the three months ended September 30, 2021, increased to $15,470,758 from $706,752 from the three months ended September 30, 2020. Operating expenses consist of salary expenses, general and administrative and professional fees. The increase in operating expense was primarily due to the acquisition of Trillium.

 

Our net loss for the three months ended September 30, 2021, increased to $4,671,262 from $344,802 for the three months ended September 30, 2020.

 

For the nine month period ended September 30,2021 and 2020 we recognized revenue of $29,693,845 and $1,102,841, respectively. The increase in revenue is mainly due to the Trillium acquisition on June 10, 2021 and the consolidation of the companies. Operating expenses for the nine month periods ending September 30, 2021 and 2020 were also increased to $20,538.359 from $1,689,380; operating expenses are increased primarily from the Trillium acquisition.

 

Net loss for the nine month period ended September 30, 2021 increased to $7,239.465 from $1,027,054 for the same period in 2020.

 

Liquidity and Capital Resources

 

The following table provides selected financial data about us as of September 30, 2021 and December 31, 2020.

 

   September 30,   December 30,     
   2021   2020   Change 
Cash  $3,894,536   $345,982   $3,548,554 
Current Assets  $15,131,867   $650,647   $14,481,220 
Current Liabilities   35,722,633    2,860,798    32,861,835 
Working Capital  $(20,590,766)  $(2,210,151)  $(18,380,615)

 

As of September 30, 2021, our working capital decreased $18,380,615, primarily due to an increase in liabilities assumed in the Trillium acquisition.

 

As of September 30, 2021 and December 31, 2020, current assets consisted of cash, accounts receivable and other current assets. The increase in cash was primarily due to the issuance of shares of restricted common stock at a purchase price of $0.50 per share for an aggregate amount of $4,115,000 during the period of February 11, 2021 through April 30, 2021. During the period of August 13, 2021 to September 30, 3031 we also sold shares at a purchase price of $1.00 for an aggregate amount of $5,000,000. Cash and other current assets also increased due to the Trillium acquisition.

 

As of September 30, 2021, current liabilities consisted of notes and loans payable in the amount of $7,539,899, accrued expenses and accounts payable of $10,879,082, lease obligation of $8,311,905, share liability of $ $5,000,000, deferred revenue of $1,374,635, advance payments of $1,671,698 and a liability due to the Trillium sellers in the amount of $902,847. The increases in liabilities are due to the Trillium acquisition and the liabilities assumed in that transaction.

 

Going Concern and Liquidity Considerations

 

At September 30, 2021, we had accrued expenses and current notes payable in excess of cash and accounts receivable, we had cash and accounts receivable in the amount of approximately $11.4 million and a deficiency in working capital of approximately $20.1 million. For the nine months ended September 30, 2021, our net loss was approximately $6.9 million.

 

As a result of these factors, we determined it was necessary to review our cash flow for 2021 and an overall analysis of market trends to determine whether or not we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report. We also determined it was necessary to take certain corporate actions, including reducing discretionary expenses, raising additional capital and improving revenue, as discussed below, in order to ensure we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report.

 

Below is a summary of the corporate actions being taken to address liquidity.

 

Of the $20.6 million working capital deficit, $5 million is related to a liability to issue Common Shares to Trillium as part of the acquisition. This liability will not have an impact to cash and working capital resources.

 

8
 

 

Additional actions being taken are as follows, with expected impacts over the next 12 months following the filing of this report:

 

  Exploring opportunities related to therapy and medical management contracts and improved pricing
  Purchase of 16 Omega properties (own vs lease) (see NOTE 5) – planned impact to net operating income is approximately $2.7 million
  Certain Medicaid rate increases that were effective July 1, 2021 – planned impact to net operating income is $3.2 million
    Medicaid reimbursement rates are controlled by each state specific Medicaid program. Additional rate increases could also be recognized over the next 12 months following the filing of this report
  Current managed care payer contracts are being reviewed for improved reimbursement structure to be negotiated
  Since the acquisition date of June 10, 2021 our patient census has grown month over month, this continued trend would sustain consistent increased revenue over the next 12 months

 

The Company has also partnered with certain investment banking relationships for future acquisition and growth strategies.

 

As such, the Company believes it will be able fund future liquidity and capital requirements through cash flows generated from its operating activities for a period of at least twelve months from the date its Financial Statements are issued.

 

Cash Flows

 

The below chart summarizes the Company’s cash flows for the nine months ended September 30:

 

   September 30,   September 30,     
   2021   2020   Change 
Cash used in operating activities  $(10,012,019)  $(870,286)  $(9,141,734)
Cash provided by investing activities   3,568,856    (5,316,155)   8,885,011 
Cash provided by financing activities   9,991,717    3,006,562    6,985,155 
Net change in cash for period  $3,548,554   $(3,179,879)  $6,728,433 

 

Cash flow from Operating Activities

 

During the nine months ended September 30, 2021, we used $10,012,019 for operating activities compared to $870,286 cash used for operating activities during the nine months ended September 30, 2020. The change in cash used for operating activities is due to the Trillium acquisition.

 

Cash flow from Investing Activities

 

The cash from investing activities for the nine months ended September 30, 2021 was $3,568,856 compared to cash used in investing activities of $5,316,155 for the nine months ended September 30, 2020. This is primarily due to the cash acquired in the Trillium acquisition and the consolidation of the Company as a result of the acquisition.

 

Cash flow from Financing Activities

 

The cash flow from financing activities in the nine months ended September 30, 2021, was $9,991,717 compared to $3,006,562 for the nine months ended September 30, 2020. The increase is primarily due to cash received from use of the line of credit and cash received from the issuance of restricted common stock.

 

Critical Accounting Policies

 

We prepare our financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our financial statements.

 

While we believe that the historical experience, current trends, and other factors considered support the preparation of our financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

 

See Note 2 - Significant Accounting Policies and the Financial Statements that are included in this Quarterly Report.

 

Off Balance Sheet Arrangements

 

We do not engage in any activities involving variable interest entities or off-balance sheet arrangements.

 

9
 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a “smaller reporting company,” we are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934, as amended (the “Exchange Act”) reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

As further discussed below, we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our chief executive officer and chief financial officer concluded that, because of certain material weaknesses in our internal control over financial reporting our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act were not effective as of September 30, 2021. The material weaknesses relate to the absence of in-house accounting personnel with the ability to properly account for complex transactions and a lack of separation of duties between accounting and other functions.

 

We hired a consulting firm to advise on technical issues related to U.S. GAAP as related to the maintenance of our accounting books and records and the preparation of our condensed consolidated financial statements. Although we are aware of the risks associated with not having dedicated accounting personnel, we are also at an early stage in the development of our business. We anticipate expanding our accounting functions with dedicated staff and improving our internal accounting procedures and separation of duties when we can absorb the costs of such expansion and improvement with additional capital resources. In the meantime, management will continue to observe and assess our internal accounting function and make necessary improvements whenever they may be required. If our remedial measures are insufficient to address the material weakness, or if additional material weaknesses or significant deficiencies in our internal control over financial reporting are discovered or occur in the future, our condensed consolidated financial statements may contain material misstatements, and we could be required to restate our financial results. In addition, if we are unable to successfully remediate this material weakness and if we are unable to produce accurate and timely financial statements, our stock price may be adversely affected, and we may be unable to maintain compliance with applicable stock exchange listing requirements.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Because of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Based on our evaluation under the framework in Internal Control—Integrated Framework (2013), our management concluded that, because of certain material weaknesses in our internal control over financial reporting our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act were not effective as of September 30, 2021.

 

10
 

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time, we may become involved in litigation relating to claims arising out of its operations in the normal course of business. To the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on us.

 

Item 1A. Risk Factors

 

As a “smaller reporting company,” we are not required to provide the information required by this Item.

 

Item 6. Exhibits

 

2.1   Agreement for the Purchase and Sale of Business Assets and Real Estate by and between Assisted 4 Living, Inc. and Autumn Accolade, Inc., Deborah S. Penn, as Trustee under the provisions of a Trust Agreement dated October 8, 2012, and known as the Denton M. Penn Jr. Trust, as to an undivided one-half interest; Deborah S. Penn, as Trustee under the provisions of a Trust Agreement dated October 8, 2012, and known as the Deborah S. Penn Trust, as to an undivided one-half interest, dated as of September 30, 2021 (Previously filed on October 6, 2021 as Exhibit 2.1 of the Company’s Current Report on Form 8-K).
     

10.1(a)

  Credit Agreement dated May 9, 2019 by and among Trillium Healthcare Group, LLC, its direct and indirect wholly-owned subsidiaries and Gemino Healthcare Finance, LLC (Previously filed on October 7, 2021 as Exhibit 10.1(a) of the Company’s Current Report on Form 8-K).
     

10.1(b)

  Waiver and First Amendment to Credit Agreement made as of April 30, 2020 by and among Trillium Healthcare Group, LLC, its direct and indirect wholly-owned subsidiaries and Gemino Healthcare Finance, LLC (Previously filed on October 7, 2021 as Exhibit 10.1(b) of the Company’s Current Report on Form 8-K).
     

10.1(c)

  Second Amendment to Credit Agreement made as of September 30, 2021 by and among Assisted 4 Living, Inc., its direct and indirect wholly-owned subsidiaries and Gemino Healthcare Finance, LLC (Previously filed on October 7, 2021 as Exhibit 10.1(c) of the Company’s Current Report on Form 8-K).
     
10.2   2021 Incentive Award Plan (Previously filed on August 30, 2021 as Exhibit 10.1 of the Company’s Current Report on Form 8-K).
     
10.3   Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan (Previously filed on August 30, 2021 as Exhibit 10.2 of the Company’s Current Report on Form 8-K).
     
31.1   Certification of Principal Executive Officer filed pursuant to Exchange Act Rules 13a-14(a) and 15d- 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2   Certification of Principal Financial Officer filed pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1   Certification of Chief Executive Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2   Certification of Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

11
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ASSISTED 4 LIVING, INC.
  (Registrant)
   
Dated: November 12, 2021 /s/ Louis Collier
  Louis Collier
 

Chief Executive Officer

(principal executive officer)

 

12

 

EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO

EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Louis Collier, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Assisted 4 Living, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have;

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
     
   b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
   c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
   d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weakness in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 12, 2021 /s/ Louis Collier
  Louis Collier
  Principal Executive Officer

 

 

 

EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION PURSUANT TO

EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Diane Harden, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Assisted 4 Living, Inc.;
   
 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
 4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have;

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
     
   b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
   c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
   d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weakness in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 12, 2021 /s/ Diane Harden
  Diane Harden
  Principal Financial Officer

 

 

 

EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of Assisted 4 Living, Inc., (the “Company”) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Louis Collier, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that;

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
   (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

/s/ Louis Collier  
Name: Louis Collier  
Title: Chief Executive Officer  
Date: November 12, 2021  

 

 

 

EX-32.2 5 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of Assisted 4 Living, Inc., (the “Company”) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Diane Harden, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that;

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
   (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

/s/ Diane Harden  
Name: Diane Harden  
Title: Chief Financial Officer  
Date: November 12, 2021  

 

 

 

 

 

 

 

EX-101.SCH 6 asli-20210930.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statement of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - BANYAN MERGER link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - TRILLIUM ACQUISITION link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - LEASEHOLD IMPROVEMENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - OPERATING AND CAPITAL LEASES link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - CONCENTRATIONS AND CREDIT RISKS link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - TRILLIUM ACQUISITION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - LEASEHOLD IMPROVEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - OPERATING AND CAPITAL LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - BANYAN MERGER (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - TRILLIUM ACQUISITION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - SCHEDULE OF LEASESHOLD IMPROVEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - LEASEHOLD IMPROVEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - OPERATING AND CAPITAL LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - SCHEDULE OF SEGMENT REPORTING INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - SUMMARY OF STOCK OPTIONS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - CONCENTRATIONS AND CREDIT RISKS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 asli-20210930_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 asli-20210930_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 asli-20210930_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Product and Service [Axis] Product and Service, Other [Member] Rental revenue [Member] Other revenue [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Subscription receivable [Member] Retained Earnings [Member] Related Party [Axis] Trillium Healthcare Group, LLC [Member] Accounting Standards Update [Axis] Accounting Standards Update 2014-09 [Member] Business Acquisition [Axis] Banyan Pediatric Care Centers, Inc [Member] Title of Individual [Axis] Note Holder [Member] Consolidated Entities [Axis] Assisted 2 Living, Inc [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Purchase and Sale Option Agreement [Member] Romulus Barr [Member] Trillium Subsidiaries [Member] Purchase Agreement [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Excel Family Partners, LLLP and Banyan Pediatric Investment, Inc [Member] Series [Axis] NuView Trust Co [Member] Grand Trinity Plaza LLC [Member] Reliant [Member] HCSG [Member] Medline [Member] SLR - RLOC [Member] Short-term Debt, Type [Axis] Notes Payable [Member] Convertible Note And Securities Purchase Agreement [Member] Excel Family Partners, LLLP [Member] Notes Payable, Other Payables [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Debt Instrument [Axis] Gemino Healthcare Finance, LLC [Member] Credit Facility [Axis] Line of Credit [Member] Variable Rate [Axis] London Interbank Offered Rate (LIBOR) [Member] Long-Lived Tangible Asset [Axis] Leasehold Improvements [Member] Geographical [Axis] Sarasota [Member] New Port Richey [Member] St. Petersburg [Member] Furniture and Fixtures [Member] Computers Equipment Software [Member] Motor Vehicles [Member] Buildings [Member] Banyan [Member] Northeast Plaza Venture I, LLC [Member] Kidz Club - St. Pete, LLC [Member] Dex Imaging [Member] Ascentium Capital LLC [Member] RJ Kool [Member] Southeastern Laundry Equipment Sales [Member] Crete Plus Five Property LLC [Member] CTR Partnership LP [Member] Extinguishment of Debt [Axis] Long-term Debt [Member] 10 Employees [Member] Plan Name [Axis] 2021 Incentive Award Plan [Member] Chief Executive Officer [Member] Scenario [Axis] Within Five Days [Member] Within 90 Days [Member] Within 180 Days [Member] Restricted Common Stock [Member] Director [Member] President and Chief Executive Officer [Member] Consolidation Items [Axis] Operating Segments [Member] Segments [Axis] Pediatric Extended Care Centers [Member] Intersegment Eliminations [Member] Concentration Risk Type [Axis] Product Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Medicare [Member] Medicaid [Member] Private Pay Residents [Member] Customer Concentration Risk [Member] Accounts Receivable [Member] Private Pay [Member] Commercial Insurance [Member] Seller [Member] Credit Agreement [Member] Trillium Group [Member] First Amendment [Member] Second Amendment [Member] Guaranty Agreement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Grace Care Centers [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash Accounts receivable, net Prepaid expenses and other current assets Total current assets Operating Lease right-of-use assets Goodwill Leasehold improvements, net Property and equipment, net Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable and accrued expenses Notes payable Accrued interest, Including related party Loans Payable - other Operating Lease obligations - current portion Advanced payments Deferred Revenue Deferred HHS Revenue Liability to issue shares Due to Seller for acquisition Total current liabilities Operating Lease obligations - net of current portion Liability to issue shares - long term Notes payable, net of current portion Total liabilities Stockholders’ equity: Common stock, par value $0.0001; 100,000,000 shares authorized, 45,345,418, and 4,165,418 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively Additional paid-in capital Subscription receivable Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Statement [Table] Statement [Line Items] Net Revenue Cost of services provided Gross profit Operating expenses Salaries and payroll expense General and administrative Lease expense Professional fees Marketing and advertising Depreciation and amortization expense Total operating expenses Loss from operations Other income (expense) Loss on disposal of asset Interest expense Total other income (expense) LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES AND RESULTS FROM DISCONTINUED OPERATIONS Income taxes LOSS FROM CONTINUING OPERATIONS BEFORE DISCONTINUED OPERATIONS Loss from discontinued operations Gain on disposal of discontinued operations Income from discontinued operations Net loss attributable to common shareholders Continuing Operations Loss per share - basic and diluted - Continuing operations Weighted average number of shares outstanding - basic and diluted Discontinued operations net income per share Earnings per share - basic Earnings per share - diluted Weighted average shares outstanding - basic Weighted average shares outstanding - diluted Beginning balance, value Balance, shares Issuance of stock warrant expense Issuance of shares for the conversion of debt Issuance of shares for conversion of debt, shares Collection on subscription receivable Issuance of shares for acquisition Issuance of shares for acquisition, shares Issuance of shares via private placement Issuance of shares via private placement, shares Shares returned and cancelled for transfer of discontinued operations Shares returned and cancelled for transfer of discontinued operations, shares Stock-based compensation and issuance of employee stock award plan Net loss for the period Ending balance, value Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss Adjustments to reconcile net loss to cash used in operating activities: Net gain from discontinued operations Depreciation and amortization (Increase) decrease in assets Prepaid expenses and other current assets Deposits and other assets Accounts receivable Increase (decrease) in liabilities Accounts payable and accrued expenses Deferred Revenues Advance payments Accrued interest Cash used in operating activities Cash flows from investing activities Goodwill from acquisition Non-cash operating lease expense Cash and assets from acquisition Investment in leasehold improvements Purchase of property and equipment Cash used in investing activities Cash flows from financing activities Repayment of principal on notes payable Proceeds from the sale of common stock Proceeds from notes payable Repayment on loans payable Warrants to be issued Proceeds from the issuance of registered shares Cash provided by financing activities Net increase (decrease) in cash Cash, beginning of year Cash, end of period SUPPLEMENTAL DISCLOSURE OF CASH FLOWS Interest Paid Taxes Paid NON-CASH ITEMS Liability to issue shares for acquisition Goodwill from acquisition Recognition of lease liability and right of use asset at inception Conversion of notes payable and accrued interest for common stock Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Combination and Asset Acquisition [Abstract] BANYAN MERGER Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS TRILLIUM ACQUISITION Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Debt Disclosure [Abstract] NOTES PAYABLE Leasehold Improvements LEASEHOLD IMPROVEMENTS Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Operating And Capital Leases OPERATING AND CAPITAL LEASES Equity [Abstract] EQUITY Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Segment Reporting [Abstract] SEGMENT INFORMATION Share-based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Risks and Uncertainties [Abstract] CONCENTRATIONS AND CREDIT RISKS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Capital Requirements, Liquidity and Going Concern Considerations Basis of Consolidation Use of Estimates and Assumptions Cash and Cash Equivalents Accounts Receivable Allowance for Doubtful Accounts, Contractual and Other Discounts COVID-19 Pandemic and CARES Act Funding Pandemic Relief Funds Medicare Accelerated Payments Fair Value of Financial Instruments Property and Equipment Goodwill Long-Lived Assets Advertising and Marketing Earnings (Loss) Per Share Income Taxes Revenue Recognition Net Patient Revenue Reclassification SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES SCHEDULE OF NOTES PAYABLE SCHEDULE OF LEASESHOLD IMPROVEMENTS SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY SCHEDULE OF WARRANTS OUTSTANDING SCHEDULE OF SEGMENT REPORTING INFORMATION SUMMARY OF STOCK OPTIONS ACTIVITY Restated purchase agreement Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Cash and accounts receivable Accrued expenses and current notes payable cash and accounts payable Working capital deficiency Net loss Stock Issued During Period, Shares, Other Stock Issued During Period, Value, Other Cash equivalents Percentage of accelerated payment Proceeds from pandemic relief funds Other Operating Income Accelerated Payments term Accelerated payments Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Number of shares issued upon conversion Number of shares converted Warrants to purchase common stock Warrants exercise price Stock conversion description Outstanding debt assumed Convertible debt Debt conversion shares Debt conversion price per share Convertible notes Outstanding note Interest rate Interest payable each month Maturity date Net revenues Cost of net revenues Gross profit Operating expenses: Salary and tax expense General and administrative Lease expense Total operating expenses Income from discontinued operations Interest and other, net Income from discontinued operations before income taxes Provision for income taxes Loss from discontinued operations Shares owned Common stock, shares outstanding Issued and outstanding shares Disposal of discontinued Disposal of discontinued price per share Cash Accounts receivable Prepaid expenses and other current assets Property and equipment Goodwill Leasehold improvements Lease right of use asset Total identifiable assets acquired Advance payments Accounts payable and accrued expenses Deferred revenue Loan Payable - other Lease liability - current portion Notes payable Lease liability - net of current portion Cash due to seller Share liability  Total identifiable liabilities acquired Effective Date of Acquisition Cash payment Preferred Stock Shares Issued Right to receive purchase price Additonal Shares Acquired during the period Payment to acquire property Business Combination Deposits Non Refundable Amount Deposits Amount Forfeited Business Acquisition Description Share Based Compensation Aggregate Amount Accounts payable Credit Card Accrued Expense Accrued Salary Payroll Tax Payable  Accounts Payable and Accrued Liabilities Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Aggregate principal amount Debt Instrument, Convertible, Conversion Price Interest Payable, Current Maturity term Lease term Construction costs Debt Instrument, Payment Terms Principal and interest amount Debt Instrument, Periodic Payment, Principal Line of credit facility, maximum borrowing capacity Accounts receivable percentage Bears interest rate Management fee percentage Unused capacity, percentage Line of credit facility Debt description Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Leasehold improvements Amortization Period Less: amortization Net Amortization expense Furniture and fixtures Amortization period Computers / equipment / software Motor vehicles Buildings Land Construction in progress Less: depreciation Property plant and equipment Computers and equipment Property plant and equipment, addition Schedule Of Operating Lease Right Of Use Asset And Lease Liability Right of Use (ROU) assets Operating lease obligations: Current Non-Current Total Schedule Of Maturity Of Operating Lease Liability 2021 (three months) 2022 2023 2024 2025 After 2025 Total lease obligation Minimum annual rent Lease description Lessee, operating lease, option to extend Lease renewal term Lease liability Area under lease Lease termination date Lease percentage of increase in base rent Lease right of use asset Lease purchase option price Number of Lease Agreement Properties Capital lease description Lessee, Operating Lease, Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Lessee, Finance Lease, Remaining Lease Term Finance Lease, Weighted Average Remaining Lease Term Operating lease, weighted average discount rate, percent Capital lease, weighted average discount rate, percent Operating Lease, Expense Shares, Outstanding, Beginning Balance Weighted-Average Exercise Price, Outstanding, Beginning Balance Shares, Granted Weighted-Average Exercise Price, Granted Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance Shares, Expired Weighted-Average Exercise Price, Expired Shares, Exercised Weighted-Average Exercise Price, Exercised Weighted Average Remaining Contractual Term, Outstanding Aggregate Intrinsic Value, Outstanding, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance Weighted-Average Exercise Price, Outstanding, Ending Balance Aggregate Intrinsic Value, Outstanding, Ending Balance Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred stock, shares authorized Preferred stock, par value Preferred Stock, Shares Issued Common stock, shares authorized Common stock per share Common stock issued Shares issuable for Banyan Acquisition, shares Shares issued price per share Aggregate consideration amount Convertible Debt Conversion of Stock, Amount Issued Purchase of common stock Liabilities, Current Common Stock, Capital Shares Reserved for Future Issuance Proceeds forn subscription Subscription receivable Debt conversion share issued Debt conversion principal amount Warrants expiration date Base salary Bonus payable Shares issued for services Stock Issued During Period, Shares, New Issues Accrued Salary Accrued interest on payroll Accrued Salaries, Current Interest percentage on accrued payroll Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Total revenue, net Cost of Sales Gross Profit Salaries and payroll expense Lease expense Marketing and advertising Operating Loss Total Assets Total Liabilities Cash used in operating activities Cash used in investing activities Cash provided by financing activities Number of shares outstanding, beginning balance Number of shares granted Number of shares outstanding, weighted average exercise price Number of shares outstanding, weighted average remaining vesting period Number of shares outstanding forfeited Number of shares outstanding, exercised Number of shares outstanding, closing balance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Shares reserved as common stock Vesting peirod Number of shares vested Share options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Stock or Unit Option Plan Expense Stock based compensation Concentration Risk [Table] Concentration Risk [Line Items] Cash, FDIC Insured Amount Cash, Uninsured Amount Concentration risk percentage, Revenues Subsequent Event [Table] Subsequent Event [Line Items] Acquisition transaction cost Deposits Payment to seller Payment to seller non refundable Credit facility termination date Termination fees Debt principal amount Debt rate Monthly payments Payments to Acquire Productive Assets Payment to acquire business Non refundable fee description Leasehold improvements, net amortization. Payments made in advance. Deferred Health and Human Services Revenue Current. Liability To Issue Shares Of Common Stock. Liability to issue shares - long term Non current. Rental revenue [Member]. Other revenue [Member]. The total expense recognized in the period for promotion, public relations, and brand or product advertising. Subscription receivable [Member]. Issuance of stock warrant expense. Stock issued during period value private placement. Shares returned and cancelled for transfer of discontinued operations value. Stock issued during period shares private placement. Shares returned and cancelled for transfer of discontinued operations shares. Increase decrease in deposits and other assets. Increase decrease in advance payments. Goodwill acquisition. Non-cash operating lease expense. Investment in leasehold improvements. Proceeds from the issuance of registered shares. Liability to issue shares for acquisition. Goodwill from acquisition. Income from discontinued operations net of tax. Loss on disposal of asset. Restated purchase agreement. Accrued expenses and current notes payable accounts and other receivables net current. Working Capital Deficiency. Percentage of accelerated payment. Proceeds From Pandemic Relief Funds. Reduction of operating cost expenses recognized. Accelerated Payments Terms. Accelerated Payments. Capital requirements liquidity and going concern considerations policy text block. COVID19 Pandemic and CARES Act Funding Policy Text Block. Pandemic Relief Funds Policy Text Block. Medicare Accelerated Payments Policy Text Block. Net Patient Revenue [Policy Text Block] Banyan Pediatric Care Centers, Inc [Member] Number of shareholders. Note Holder [Member] Assisted 2 Living, Inc [Member] Purchase and Sale Option Agreement [Member] Romulus Barr [Member] Issued and outstanding shares Disposal group including discontinued operation salary and tax expense Disposal group including discontinued operation lease expense Disposal group including discontinued operation interest and other expense net Trillium Subsidiaries [Member] Purchase Agreement [Member] Business Acquisition Additional Share Price. Business Combination Deposits Non Refundable Amount. Business Combination Of Deposits Amount Forfeited. Schedule Of Acquired Assets And Liabilties Acquired [Table Text Block] Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Goodwill. Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed lease improvements. Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Lease Right of use assets. Advance payments. Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Accounts Payable and Accrued Expenses. Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Lease Liability Net. Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities, due from seller. Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, shares liability. Credit card. Excel Family Partners, LLLP and Banyan Pediatric Investment, Inc [Member] NuView Trust Co [Member] Grand Trinity Plaza LLC [Member] Reliant [Member] HCSG [Member] Medline [Member] SLR - RLOC [Member] Notes Payable [Member] Convertible Note and Securities Purchase Agreement [Member] Excel Family Partners, LLLP [Member] Trillium Health care Group LLC [Member] Gemino Healthcare Finance, LLC [Member] Percentage of financing accounts receivable. Line of credit facility unused capacity management fee percentage. Leaseshold Improvements [Text Block] Schedule Of Leaseshold Improvements [Table Text Block] Sarasota [Member] New Port Richey [Member] St. Petersburg [Member] Banyan [Member] Motor Vehicles Gross. Computers Equipment Software [Member] Motor Vehicles [Member] Buildings [Member] Northeast Plaza Venture I, LLC [Member] Kidz Club - St. Pete, LLC [Member] Lease, termination date. Lease percentage of increase in base rent. Dex Imaging [Member] Ascentium Capital LLC [Member] Lease purchase option price. RJ Kool [Member] Southeastern Laundry Equipment Sales [Member] Number of Lease agreement properties. Crete Plus Five Property LLC [Member] CTR Partnership LP [Member] Lessee, operating lease, liability, to be paid, after year four. Ten Employees [Member] Two Thousand And Twenty One Incentive Award Plan [Member] Schedule Of Operating Lease Right Of Use Asset And Lease Liability [Table Text Block] Weighted-Average Exercise Price, Outstanding. Weighted-Average Exercise Price, Granted. Weighted-Average Exercise Price, Expired. Weighted-Average Exercise Price, Exercised. Weighted Average Remaining Contractual Term, Granted Term. Weighted Average Remaining Contractual Term, Outstanding. Aggregate Intrinsic Value, Outstanding, Balance. Within Five Days [Member] Within 90 Days [Member] Within 180 Days [Member] Restricted Common Stock [Member] President and Chief Executive Officer [Member] Payment Of Accrued Payroll. Operating Loss. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Pediatric Extended Care Centers [Member] Medicaid [Member] Medicare [Member] Private Pay Residents [Member] Private Pay [Member] Commercial Insurance [Member] Lease Expense. Seller [Member] Payment to Seller. Payment To Seller Non Refundable Amount. Credit Agreement [Member] Trillium Group [Member] First Amendment [Member] Second Amendment [Member] Guaranty Agreement [Member] Grace Care Centers [Member] Non Refundable Fee Description. Assets, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) LossOnDisposalOfAsset Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding IncomeFromDiscontinuedOperationsNetOfTax Increase (Decrease) in Prepaid Expenses, Other Increase Decrease In Deposits And Other Assets Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Payable and Accrued Liabilities Repayments of Notes Payable Repayments of Long-term Debt Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations GoodwillFromAcquisition Goodwill and Intangible Assets, Policy [Policy Text Block] Net Income (Loss) Attributable to Parent Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Disposal Group, Including Discontinued Operation, General and Administrative Expense Disposal Group Including Discontinued Operation Lease Expense Disposal Group, Including Discontinued Operation, Operating Expense Disposal Group Including Discontinued Operation Interest And Other Expense Net Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Goodwill [Default Label] Advance Payments BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Weighted-Average Exercise Price, Outstanding Aggregate Intrinsic Value, Outstanding, Balance Payment Of Accrued Payroll Salary and Wage, Excluding Cost of Good and Service Sold Marketing and Advertising Expense Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number EX-101.PRE 10 asli-20210930_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001719435 2021-01-01 2021-09-30 0001719435 2021-11-12 0001719435 2021-09-30 0001719435 2020-12-31 0001719435 us-gaap:ProductAndServiceOtherMember 2021-07-01 2021-09-30 0001719435 us-gaap:ProductAndServiceOtherMember 2020-07-01 2020-09-30 0001719435 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-09-30 0001719435 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-09-30 0001719435 ASLI:RentalRevenueMember 2021-07-01 2021-09-30 0001719435 ASLI:RentalRevenueMember 2020-07-01 2020-09-30 0001719435 ASLI:RentalRevenueMember 2021-01-01 2021-09-30 0001719435 ASLI:RentalRevenueMember 2020-01-01 2020-09-30 0001719435 ASLI:OtherRevenueMember 2021-07-01 2021-09-30 0001719435 ASLI:OtherRevenueMember 2020-07-01 2020-09-30 0001719435 ASLI:OtherRevenueMember 2021-01-01 2021-09-30 0001719435 ASLI:OtherRevenueMember 2020-01-01 2020-09-30 0001719435 2021-07-01 2021-09-30 0001719435 2020-07-01 2020-09-30 0001719435 2020-01-01 2020-09-30 0001719435 us-gaap:CommonStockMember 2019-12-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001719435 ASLI:SubscriptionReceivableMember 2019-12-31 0001719435 us-gaap:RetainedEarningsMember 2019-12-31 0001719435 2019-12-31 0001719435 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001719435 ASLI:SubscriptionReceivableMember 2020-01-01 2020-03-31 0001719435 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001719435 2020-01-01 2020-03-31 0001719435 us-gaap:CommonStockMember 2020-03-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001719435 ASLI:SubscriptionReceivableMember 2020-03-31 0001719435 us-gaap:RetainedEarningsMember 2020-03-31 0001719435 2020-03-31 0001719435 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001719435 ASLI:SubscriptionReceivableMember 2020-04-01 2020-06-30 0001719435 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001719435 2020-04-01 2020-06-30 0001719435 us-gaap:CommonStockMember 2020-06-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001719435 ASLI:SubscriptionReceivableMember 2020-06-30 0001719435 us-gaap:RetainedEarningsMember 2020-06-30 0001719435 2020-06-30 0001719435 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001719435 ASLI:SubscriptionReceivableMember 2020-07-01 2020-09-30 0001719435 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001719435 us-gaap:CommonStockMember 2020-09-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001719435 ASLI:SubscriptionReceivableMember 2020-09-30 0001719435 us-gaap:RetainedEarningsMember 2020-09-30 0001719435 2020-09-30 0001719435 us-gaap:CommonStockMember 2020-12-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001719435 ASLI:SubscriptionReceivableMember 2020-12-31 0001719435 us-gaap:RetainedEarningsMember 2020-12-31 0001719435 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001719435 ASLI:SubscriptionReceivableMember 2021-01-01 2021-03-31 0001719435 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001719435 2021-01-01 2021-03-31 0001719435 us-gaap:CommonStockMember 2021-03-31 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001719435 ASLI:SubscriptionReceivableMember 2021-03-31 0001719435 us-gaap:RetainedEarningsMember 2021-03-31 0001719435 2021-03-31 0001719435 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001719435 ASLI:SubscriptionReceivableMember 2021-04-01 2021-06-30 0001719435 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001719435 2021-04-01 2021-06-30 0001719435 us-gaap:CommonStockMember 2021-06-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001719435 ASLI:SubscriptionReceivableMember 2021-06-30 0001719435 us-gaap:RetainedEarningsMember 2021-06-30 0001719435 2021-06-30 0001719435 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001719435 ASLI:SubscriptionReceivableMember 2021-07-01 2021-09-30 0001719435 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001719435 us-gaap:CommonStockMember 2021-09-30 0001719435 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001719435 ASLI:SubscriptionReceivableMember 2021-09-30 0001719435 us-gaap:RetainedEarningsMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2021-01-01 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2020-01-01 2020-12-31 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2021-06-09 2021-06-10 0001719435 us-gaap:AccountingStandardsUpdate201409Member 2021-01-01 2021-09-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-03-22 2021-03-23 0001719435 2021-03-23 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-03-23 0001719435 2021-03-22 2021-03-23 0001719435 ASLI:NoteHolderMember 2021-04-01 2021-06-30 0001719435 2020-11-06 0001719435 2021-11-06 0001719435 ASLI:AssistedTwoLivingIncMember 2021-04-29 2021-04-30 0001719435 ASLI:AssistedTwoLivingIncMember ASLI:PurchaseAndSaleOptionAgreementMember 2020-11-07 0001719435 ASLI:AssistedTwoLivingIncMember ASLI:RomulusBarrMember ASLI:PurchaseAndSaleOptionAgreementMember 2020-11-07 0001719435 2021-04-29 2021-04-30 0001719435 2021-04-30 0001719435 ASLI:AssistedTwoLivingIncMember 2021-07-01 2021-09-30 0001719435 ASLI:AssistedTwoLivingIncMember 2020-07-01 2020-09-30 0001719435 ASLI:AssistedTwoLivingIncMember 2021-01-01 2021-09-30 0001719435 ASLI:AssistedTwoLivingIncMember 2020-01-01 2020-09-30 0001719435 ASLI:TrilliumSubsidiariesMember 2021-01-01 2021-09-30 0001719435 ASLI:PurchaseAgreementMember 2021-01-01 2021-09-30 0001719435 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001719435 ASLI:TrilliumSubsidiariesMember us-gaap:CommonStockMember ASLI:PurchaseAgreementMember 2021-09-30 0001719435 us-gaap:CommonStockMember ASLI:PurchaseAgreementMember 2021-09-30 0001719435 ASLI:PurchaseAgreementMember 2021-09-30 0001719435 ASLI:TrilliumSubsidiariesMember 2021-09-30 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember 2021-09-30 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember 2020-12-31 0001719435 ASLI:NuViewTrustCoMember 2021-09-30 0001719435 ASLI:NuViewTrustCoMember 2020-12-31 0001719435 ASLI:GrandTrinityPlazaLLCMember 2021-09-30 0001719435 ASLI:GrandTrinityPlazaLLCMember 2020-12-31 0001719435 ASLI:ReliantMember 2021-09-30 0001719435 ASLI:ReliantMember 2020-12-31 0001719435 ASLI:HCSGMember 2021-09-30 0001719435 ASLI:HCSGMember 2020-12-31 0001719435 ASLI:MedlineMember 2021-09-30 0001719435 ASLI:MedlineMember 2020-12-31 0001719435 ASLI:SLRRLOCMember 2021-09-30 0001719435 ASLI:SLRRLOCMember 2020-12-31 0001719435 ASLI:NotesPayableMember 2021-09-30 0001719435 ASLI:NotesPayableMember 2020-12-31 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2020-09-18 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2020-09-17 2020-09-18 0001719435 ASLI:ExcelFamilyPartnersLLLPMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2020-09-18 0001719435 ASLI:BanyanPediatricCareCentersIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2020-09-18 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2021-03-23 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2021-09-30 0001719435 ASLI:ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember ASLI:ConvertibleNoteAndSecuritiesPurchaseAgreementMember 2020-12-31 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:NuViewTrustCoMember 2020-11-05 2020-11-06 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:NuViewTrustCoMember 2020-11-06 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:NuViewTrustCoMember 2020-09-30 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:NuViewTrustCoMember 2020-12-31 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:GrandTrinityPlazaLLCMember 2020-12-15 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:GrandTrinityPlazaLLCMember 2020-12-14 2020-12-15 0001719435 ASLI:TrilliumHealthcareGroupLLCMember srt:MinimumMember 2019-12-31 0001719435 ASLI:TrilliumHealthcareGroupLLCMember srt:MaximumMember 2019-12-31 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:ReliantMember 2019-01-01 2019-12-31 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:ReliantMember 2019-12-31 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:HCSGMember 2019-01-01 2019-12-31 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:MedlineMember 2019-01-01 2019-12-31 0001719435 us-gaap:NotesPayableOtherPayablesMember ASLI:MedlineMember 2019-12-31 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LineOfCreditMember ASLI:GeminoHealthcareFinanceLLCMember 2019-05-09 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LineOfCreditMember ASLI:GeminoHealthcareFinanceLLCMember 2019-05-08 2019-05-09 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LineOfCreditMember ASLI:GeminoHealthcareFinanceLLCMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-05-08 2019-05-09 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LineOfCreditMember ASLI:GeminoHealthcareFinanceLLCMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LineOfCreditMember 2021-01-01 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LineOfCreditMember 2021-09-29 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LineOfCreditMember 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001719435 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-09-30 0001719435 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-09-30 0001719435 ASLI:SarasotaFloridaMember us-gaap:LeaseholdImprovementsMember 2020-12-31 0001719435 ASLI:SarasotaFloridaMember us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001719435 ASLI:NewPortRicheyFloridaMember us-gaap:LeaseholdImprovementsMember 2020-12-31 0001719435 ASLI:NewPortRicheyFloridaMember us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001719435 ASLI:StPetersburgFloridaMember us-gaap:LeaseholdImprovementsMember 2020-12-31 0001719435 ASLI:StPetersburgFloridaMember us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-12-31 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:LeaseholdImprovementsMember 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2021-07-01 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2020-07-01 2020-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-09-30 0001719435 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-09-30 0001719435 us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-09-30 0001719435 ASLI:ComputersEquipmentSoftwareMember 2021-01-01 2021-09-30 0001719435 ASLI:MotorVehiclesMember 2021-01-01 2021-09-30 0001719435 ASLI:BuildingsMember 2021-01-01 2021-09-30 0001719435 ASLI:BanyanMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2021-06-09 2021-06-10 0001719435 ASLI:TrilliumHealthcareGroupLLCMember us-gaap:FurnitureAndFixturesMember 2021-07-01 2021-09-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember ASLI:NortheastPlazaVentureILLCMember 2019-08-24 0001719435 ASLI:BanyanPediatricCareCentersIncMember ASLI:NortheastPlazaVentureILLCMember 2019-08-23 2019-08-24 0001719435 ASLI:KidzClubStPeteLLCMember 2019-10-15 0001719435 ASLI:KidzClubStPeteLLCMember 2019-10-14 2019-10-15 0001719435 ASLI:GrandTrinityPlazaLLCMember 2020-04-02 0001719435 ASLI:GrandTrinityPlazaLLCMember 2020-04-01 2020-04-02 0001719435 ASLI:DexImagingMember 2020-06-09 0001719435 srt:MaximumMember ASLI:DexImagingMember 2020-06-08 2020-06-09 0001719435 ASLI:DexImagingMember 2020-06-08 2020-06-09 0001719435 ASLI:AscentiumCapitalLLCMember 2020-08-25 0001719435 ASLI:AscentiumCapitalLLCMember 2020-08-24 2020-08-25 0001719435 ASLI:AscentiumCapitalLLCMember 2020-10-20 0001719435 ASLI:AscentiumCapitalLLCMember 2020-10-19 2020-10-20 0001719435 ASLI:DexImagingMember 2021-04-30 0001719435 ASLI:DexImagingMember 2021-04-01 2021-04-30 0001719435 ASLI:AscentiumCapitalLLCMember 2021-07-31 0001719435 ASLI:DexImagingMember 2021-08-31 0001719435 ASLI:DexImagingMember 2021-08-01 2021-08-31 0001719435 ASLI:DexImagingMember 2021-07-31 0001719435 ASLI:RJKoolMember 2021-08-31 0001719435 ASLI:SoutheasternLaundryEquipmentSalesMember 2021-07-31 0001719435 ASLI:CretePlusFivePropertyLLCMember 2021-01-01 2021-09-30 0001719435 ASLI:CretePlusFivePropertyLLCMember 2021-09-30 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2021-06-10 0001719435 ASLI:CTRPartnershipLPMember 2021-01-01 2021-09-30 0001719435 ASLI:CTRPartnershipLPMember 2021-09-30 0001719435 ASLI:CTRPartnershipLPMember 2021-06-10 0001719435 ASLI:TrilliumHealthcareGroupLLCMember 2021-01-01 2021-09-30 0001719435 srt:MinimumMember 2021-09-30 0001719435 srt:MaximumMember 2021-09-30 0001719435 us-gaap:SeriesAPreferredStockMember ASLI:TrilliumHealthcareGroupLLCMember 2021-09-30 0001719435 us-gaap:LongTermDebtMember ASLI:TrilliumHealthcareGroupLLCMember 2021-09-30 0001719435 us-gaap:LongTermDebtMember ASLI:TrilliumHealthcareGroupLLCMember 2021-01-01 2021-09-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-02-11 2021-03-31 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-03-31 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-06-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-04-01 2021-06-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember us-gaap:LongTermDebtMember 2021-06-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember ASLI:TrilliumHealthcareGroupLLCMember 2021-09-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-07-01 2021-09-30 0001719435 ASLI:BanyanPediatricCareCentersIncMember 2021-09-30 0001719435 2021-08-26 0001719435 ASLI:TenEmployeesMember ASLI:TwoThousandAndTwentyOneIncentiveAwardPlanMember 2021-09-30 0001719435 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001719435 us-gaap:NotesPayableOtherPayablesMember us-gaap:CommonStockMember 2020-09-17 2020-09-19 0001719435 us-gaap:NotesPayableOtherPayablesMember 2020-09-17 2020-09-19 0001719435 ASLI:KidzClubStPeteLLCMember 2019-09-27 0001719435 ASLI:KidzClubStPeteLLCMember 2019-12-31 0001719435 ASLI:KidzClubStPeteLLCMember 2020-01-01 2020-12-31 0001719435 ASLI:KidzClubStPeteLLCMember 2020-12-31 0001719435 ASLI:KidzClubStPeteLLCMember 2021-01-01 2021-09-30 0001719435 ASLI:KidzClubStPeteLLCMember 2021-09-30 0001719435 srt:ChiefExecutiveOfficerMember 2021-01-29 2021-02-01 0001719435 srt:ChiefExecutiveOfficerMember 2021-02-01 0001719435 ASLI:WithinFiveDaysMember srt:ChiefExecutiveOfficerMember 2021-02-01 0001719435 ASLI:WithinNinetyDaysMember srt:ChiefExecutiveOfficerMember 2021-02-01 0001719435 ASLI:WithinOneHundredAndEightyDaysMember srt:ChiefExecutiveOfficerMember 2021-02-01 0001719435 ASLI:RestrictedCommonStockMember 2021-04-01 2021-06-30 0001719435 srt:DirectorMember 2021-07-01 2021-09-30 0001719435 srt:DirectorMember 2020-07-01 2020-09-30 0001719435 ASLI:PresidentAndChiefExecutiveOfficerMember 2021-09-30 0001719435 ASLI:PresidentAndChiefExecutiveOfficerMember 2021-01-01 2021-09-30 0001719435 us-gaap:OperatingSegmentsMember ASLI:PediatricExtendedCareCentersMember 2021-01-01 2021-09-30 0001719435 us-gaap:OperatingSegmentsMember ASLI:TrilliumSubsidiariesMember 2021-01-01 2021-09-30 0001719435 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-09-30 0001719435 us-gaap:OperatingSegmentsMember ASLI:PediatricExtendedCareCentersMember 2021-09-30 0001719435 us-gaap:OperatingSegmentsMember ASLI:TrilliumSubsidiariesMember 2021-09-30 0001719435 us-gaap:IntersegmentEliminationMember 2021-09-30 0001719435 ASLI:TwoThousandAndTwentyOneIncentiveAwardPlanMember 2021-08-26 0001719435 ASLI:TwoThousandAndTwentyOneIncentiveAwardPlanMember 2021-09-01 2021-09-30 0001719435 ASLI:TwoThousandAndTwentyOneIncentiveAwardPlanMember 2021-09-30 0001719435 ASLI:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0001719435 ASLI:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0001719435 ASLI:MedicaidMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0001719435 ASLI:MedicaidMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0001719435 ASLI:PrivatePayResidentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0001719435 ASLI:PrivatePayResidentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0001719435 ASLI:MedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001719435 ASLI:MedicaidMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001719435 ASLI:PrivatePayMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001719435 ASLI:CommercialInsuranceMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001719435 ASLI:SellerMember ASLI:PurchaseAgreementMember 2021-09-30 0001719435 ASLI:GeminoHealthcareFinanceLLCMember 2021-09-30 0001719435 ASLI:GeminoHealthcareFinanceLLCMember 2021-01-01 2021-09-30 0001719435 ASLI:FirstAmendmentMember ASLI:CreditAgreementMember ASLI:TrilliumGroupMember 2021-01-01 2021-09-30 0001719435 ASLI:SecondAmendmentMember ASLI:CreditAgreementMember 2021-01-01 2021-09-30 0001719435 us-gaap:SubsequentEventMember ASLI:GuarantyAgreementMember 2021-10-08 0001719435 us-gaap:SubsequentEventMember ASLI:GuarantyAgreementMember 2021-10-07 2021-10-08 0001719435 us-gaap:SubsequentEventMember 2021-10-08 0001719435 us-gaap:SubsequentEventMember 2021-10-12 2021-10-13 0001719435 us-gaap:SubsequentEventMember 2021-10-13 0001719435 ASLI:GraceCareCentersMember us-gaap:SubsequentEventMember 2021-10-17 2021-10-18 0001719435 us-gaap:SubsequentEventMember 2021-10-18 0001719435 us-gaap:SubsequentEventMember ASLI:GraceCareCentersMember 2021-10-17 2021-10-18 iso4217:USD shares iso4217:USD shares pure utr:sqft ASLI:Property ASLI:Agreement 0001719435 false --12-31 Q3 P1Y P84M P5Y 10-Q true 2021-09-30 2021 false 333-226979 Assisted 4 Living, Inc. NV 82-1884480 5115 East SR 64 Bradenton FL 34240 (855) 668-3331 No Yes Non-accelerated Filer true true false false 45345418 3894536 345982 7490091 97073 3747240 207592 15131867 650647 46089030 3977988 15513677 3431148 3766330 2614391 2680115 128475 2950265 86131284 10802649 10879082 148180 7041759 2385010 42567 48601 498140 63907 8311905 189397 1671698 596227 778408 25703 5000000 902847 35722633 2860798 38089042 3864321 4750000 265117 322490 78826792 7047609 0.0001 0.0001 100000000 100000000 45345418 45345418 4165418 4165418 4535 417 17876115 7460348 30 -10576158 -3705695 7304492 3755040 86131284 10802649 21602984 654351 27581902 1088341 11275 5625 22875 7500 760833 -527 1489068 7000 22375092 659449 29093845 1102841 12310011 256825 15477070 409838 10065081 402624 13616775 693003 5068423 320404 6671656 870191 4978559 205818 6591749 454482 2991078 88691 3912133 193365 1722741 70819 2707511 134829 236499 4276 336984 12378 159750 16744 318324 24135 15157050 706752 20538357 1689380 -5091969 -304128 -6921582 -996377 22753 22753 179293 7920 317881 7923 -179293 -30673 -317881 -30676 -5271262 -334801 -7239463 -1027053 -5271262 -334801 -7239463 -1027053 -26500 395500 369000 -5271262 -334801 -6870463 -1027053 -0.12 -0.08 -0.24 -0.25 42783081 4221021 29984191 4064414 0.01 0.01 29984191 34705065 4008443 401 6618364 -170 -2407760 4210835 -443375 -443375 4008443 401 6618364 -170 -2851135 3767460 -692252 -692252 4008443 401 6618364 -170 -3543387 3075208 342000 342000 166667 16 499984 500000 -1027054 -1027054 4175110 417 7460348 -170 -4570441 2890154 4165418 417 7460348 -30 -3705695 3755040 30 30 31230000 3123 3039874 3042997 -579061 -579061 35395418 3540 10500222 -4284756 6219006 1150000 115 574885 575000 4000000 400 1999600 2000000 -200000 -20 -369980 -370000 -1020140 -1020140 40345418 4035 12704727 -5304896 7403866 5000000 500 4999500 5000000 171888 171888 -5271262 -5271262 45345418 4535 17876115 -10576158 7304492 -6870463 -1027054 369000 318324 1824624 2877 2003607 -435016 145225 2373538 249999 1331333 55371 -3396502 -6034 -10012019 -870286 -3431148 212326 28541 3432847 -1852465 76317 61083 3568856 -5316155 776207 575000 5212234 2664234 18810 342000 4999500 328 9991717 3006562 3548554 -3179879 345982 4044700 3894536 864821 275831 9750000 12082529 46089030 3976562 2000000 500000 <p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z0rJX0z5CHK6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 1 – <span id="xdx_829_ztFGj7SPyBSe">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Assisted 4 Living, Inc. (“the Company,” “we”, “our” or “us”) was incorporated in the state of Nevada on May 24, 2017, and is based in Bradenton, Florida. Our accounting and reporting policies conform to accounting principles generally accepted in the United States of America (“GAAP”), and the fiscal year end is December 31.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As discussed in NOTE 3, on March 23, 2021, we entered into a Plan of Merger with our wholly-owned subsidiary, BPCC Acquisition, Inc., a Florida corporation (“Merger Sub”) and Banyan Pediatric Care Centers, Inc. (“Banyan”). Under the terms of the Plan of Merger, Merger Sub merged with and into Banyan with Banyan surviving the merger (the “Surviving Entity”) and becoming a wholly-owned subsidiary of the Company (the “Merger”). Pursuant to the Merger, we succeeded to the business of Banyan. The Merger has been treated as a recapitalization and reverse acquisition of the Company for financial accounting purposes, and Banyan is considered the acquirer for financial reporting purposes. This means that the Company’s historical financial statements before the Merger have been replaced with the historical financial statements of Banyan before the Merger in this Quarterly Report and future filings with the SEC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Banyan, operates three pediatric extended care centers (“PPECs”) in southwest Florida. A PPEC is a nurse-staffed pediatric day care center for medically complex children age birth to 21 years. Our staff includes Registered Nurses (RNs), Licensed Practical Nurses (LPNs), Certified Nursing Assistants (CNAs) and Caregivers, who attend to the children’s medical conditions throughout the day in classroom, dining, play, and clinical settings. Banyan is fully licensed and accepts Florida Medicaid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As discussed in NOTE 5, on June 10, 2021, we entered into an Amended and Restated Membership Interest Purchase Agreement (the “Restated Purchase Agreement”), by and among the Company, Richard T. Mason (“Mason”), G. Shayne Bench (“Bench”) and Trillium Healthcare Group, LLC, a Florida limited liability company (“Trillium”) to acquire all of the issued and outstanding ownership interests of Fairway Healthcare Properties, LLC (“FHP”) and Trillium Healthcare Consulting, LLC (together with FHP, the “Trillium Subsidiaries”) from Trillium. The transaction closed and was effective June 10, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--RestatedPurchaseAgreement_c20210101__20210930" title="Restated purchase agreement">Trillium subsidiaries lease and operate 26 facilities in four states: Florida, Georgia, Iowa, and Nebraska with 1,685 total licensed beds (1,546 skilled nursing, 139 assisted living) and 36 independent living apartments. The breakdown by state is as follows: Florida – 1 skilled nursing facility; Georgia – 1 skilled nursing facility; Iowa – 16 skilled nursing facilities, 2 independent living centers and 1 assisted living centers; Nebraska – 4 skilled nursing facilities and 1 assisted living center</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The facilities provide room and board, routine daily care services, post-acute care including rehabilitation and memory care. The Trillium Subsidiaries were organized under the laws of the State of Florida on February 9, 2012, for the purpose of acquiring and managing long term care facilities, such as skilled nursing facilities and assisted living centers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We are headquartered in Bradenton, Florida.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The corporate website is <span style="text-decoration: underline">www.assisted4living.com</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>COVID-19</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In March 2020, the World Health Organization declared the outbreak of COVID-19 as a pandemic based on the rapid increase in global exposure. COVID-19 continues to spread throughout the world. We are closely monitoring developments and are taking steps to mitigate the potential risks related to the COVID-19 pandemic to the Company, its employees, as well as its residential and consulting clients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our evaluations of our practices, procedures, and operations, related to COVID-19, is ongoing. Additional updates to policies, procedures and operations will occur as best practices are adopted and as we deem necessary or advisable, or as further governmental guidance or regulations are implemented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> Trillium subsidiaries lease and operate 26 facilities in four states: Florida, Georgia, Iowa, and Nebraska with 1,685 total licensed beds (1,546 skilled nursing, 139 assisted living) and 36 independent living apartments. The breakdown by state is as follows: Florida – 1 skilled nursing facility; Georgia – 1 skilled nursing facility; Iowa – 16 skilled nursing facilities, 2 independent living centers and 1 assisted living centers; Nebraska – 4 skilled nursing facilities and 1 assisted living center <p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zfVgd6ja0Oj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 2 - <span id="xdx_829_zbU7QwDGwgx2">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zasCi5bQuwca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Basis of Presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements of the Company (“Financial Statements”) have been prepared in accordance with GAAP for interim financial statements and with the instructions to Form 10-Q and Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In the opinion of management, the accompanying condensed consolidated Financial Statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2021, and the results of operations and cash flows for the periods presented. The results of operations for the nine months ended September 30, 2021, are not necessarily indicative of the operating results for the full fiscal year or any future period. These condensed consolidated Financial Statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021 and Current Report on Form 8-K on June 2, 2021. As of April 30, 2021, we had discontinued operations reflected in the accompanying condensed consolidated Financial Statements. As a result of the Plan of Merger completed on March 23, 2021 (see NOTE 3) we have changed our year end reporting period from November to December.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_ecustom--CapitalRequirementsLiquidityAndGoingConcernConsiderationsPolicyTextBlock_zDt7MT1MVV19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_869_zFZTIUDSEhhi">Capital Requirements, Liquidity and Going Concern Considerations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These condensed consolidated Financial Statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Although we had cash and accounts receivable in the amount of approximately $<span id="xdx_900_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_pn5n6_c20210930_z6kTKzuYu4wa" title="Cash and accounts receivable">11.4</span> million at September 30, 2021, we had accrued expenses and current notes payable in excess of cash and accounts receivable in the amount of approximately $<span id="xdx_90D_ecustom--AccruedExpensesAndCurrentNotesPayableAccountsAndOtherReceivablesNetCurrent_iI_pn5n6_c20210930_zJQwGmzbCCqa" title="Accrued expenses and current notes payable cash and accounts payable">6.5</span> million, and a deficiency in working capital of approximately $<span id="xdx_90E_ecustom--WorkingCapitalDeficiency_iI_pn5n6_c20210930_zlPx6u3TYcI8" title="Working capital deficiency">20.6</span> million. For the nine months ended September 30, 2021, our net loss was approximately $<span id="xdx_908_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20210101__20210930_zk11XIUm1MQ8" title="Net loss">6.9</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As a result of these factors, we determined it was necessary to review our cash flow for 2021 and an overall analysis of market trends to determine whether or not we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report. We also determined it was necessary to take certain corporate actions, including reducing discretionary expenses (and reduced reliance on agency staffing), improving revenue (including added Therapy and Rehab services), and raising additional capital, in order to ensure we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the three months ended September 30, 2021 we sold <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesOther_pn6n6_c20210701__20210930_zPFkDpM2M91e">5.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million</span><span style="font: 10pt Times New Roman, Times, Serif"> shares for an aggregate total of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueOther_pn6n6_c20210701__20210930_zLPbjSK84qO7">5.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million. This capital raise will be used for additional growth through acquisitions and for working capital. However, no assurances can be given that we will be successful. If management is not able to timely and successfully raise additional capital and/or refinance indebtedness, the implementation of the Company’s business plan, financial condition and results of operations will be materially affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zbxivMGeeey2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zBs7Vh4NzMs1">Basis of Consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">These condensed consolidated Financial Statements include the accounts of the Company and the wholly-owned subsidiaries, Banyan Pediatric Care Centers – OPS, LLC, Banyan Pediatric Care Centers – St. Petersburg, LLC, Banyan Pediatric Care Centers, - Pasco, LLC and Banyan Pediatric Care Centers – Sarasota, LLC and the discontinued operations of Assisted 2 Live, Inc., the wholly owned subsidiary that was discontinued as of April 30, 2021. All material intercompany balances and transactions have been eliminated. The condensed consolidated Financial Statements also include the accounts of the Trillium Subsidiaries from June 10, 2021, the effective date of the transaction with Trillium.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_843_eus-gaap--UseOfEstimates_zAxcHCD6cdmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_861_zru1C7riGWGk">Use of Estimates and Assumptions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zApAlFyk9wrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zPy3oZJ2iMj4">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company had <span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_do_c20210930_zssx828iGB67" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_do_c20201231_zUGRp9s6C9xa" title="Cash equivalents">no</span></span> cash equivalents at September 30, 2021 and December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84C_eus-gaap--ReceivablesPolicyTextBlock_zrQt7UJpIwC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zNiK6i0xjJU9">Accounts Receivable</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Accounts receivable primarily consists of amounts due from third-party payers (non-governmental), governmental payers and private pay patients and is recorded net of contractual allowances and reserves for doubtful accounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s Financial Statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimation of net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies’ denial of claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s accounts receivable from third-party payers are recorded net of estimated contractual adjustments and allowances from third-party payers, which are estimated based on the historical trend of the Company’s facilities’ cash collections and contractual write-offs, accounts receivable aging, established fee schedules, relationships with payers and procedure statistics. While changes in estimated reimbursement from third-party payers remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on the Company’s financial condition or results of operations. The Company’s collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of the facilities to ensure the proper collection and aged category. The operating systems generate reports that assist in the collection efforts by prioritizing patient accounts. Collection efforts include direct contact with insurance carriers or patients and written correspondence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zuX4mghzHt2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zuFn4SegWQEk">Allowance for Doubtful Accounts, Contractual and Other Discounts</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Management estimates the allowance for contractual and other discounts based on its historical collection experience and contracted relationship with the payers. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account may be written-off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84A_ecustom--COVID19PandemicAndCARESActFundingPolicyTextBlock_zPDAgLKi2Bv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zPMqJxsbISij">COVID-19 Pandemic and CARES Act Funding</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">COVID-19 Pandemic. In January 2020, the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel strain of coronavirus. In March 2020, the World Health Organization declared the outbreak of COVID-19, a disease caused by this coronavirus, a pandemic. The resulting measures to contain the spread and impact of COVID-19 and other developments related to COVID-19 have materially affected the Company’s results of operations during 2020. Where applicable, the impact resulting from the COVID-19 pandemic during the year ended December 31, 2020, has been considered, including updated assessments of the recoverability of assets and evaluation of potential credit losses. As a result of the COVID-19 pandemic, federal and state governments have passed legislation, promulgated regulations and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency. Sources of relief include the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020, the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), which was enacted on April 24, 2020, and the Consolidated Appropriations Act, 2021 (the “CAA”), which was enacted on December 27, 2020. In total, the CARES Act, PPPHCE Act and the CAA authorize $178 billion in funding to be distributed to hospitals and other healthcare providers through the Public Health and Social Services Emergency Fund (the “PHSSEF”). In addition, the CARES Act provide for an expansion of the Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers were able to request accelerated payment of up to <span id="xdx_90E_ecustom--PercentageOfAcceleratedPayment_pid_dp_uPure_c20210101__20210930_zS8DFhrMWfWd" title="Percentage of accelerated payment">100</span>% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments. Various other state and local programs also exist to provide relief, either independently or through distribution of monies received via the CARES Act. During the period ended September 30, 2021, the Company was a beneficiary of these stimulus measures, including the Medicare Accelerated and Advance Payment Program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s accounting policies for the recognition of these stimulus monies is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_848_ecustom--PandemicReliefFundsPolicyTextBlock_z4Aaelcaahfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86D_zcAE5Wi19IZd">Pandemic Relief Funds</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Trillium </span><span style="font: 10pt Times New Roman, Times, Serif">received an aggregate of $<span id="xdx_900_ecustom--ProceedsFromPandemicReliefFunds_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrilliumHealthcareGroupLLCMember_zIA8pnIRdJVa">13,487,923 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in PHSSEF payments, of which $<span id="xdx_902_ecustom--ProceedsFromPandemicReliefFunds_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrilliumHealthcareGroupLLCMember_zmnqgauLjdI6">4,242,796 </span></span><span style="font: 10pt Times New Roman, Times, Serif">was applied during 2020. Prior to the acquisition date of June 10, 2021 Trillium had recognized $<span id="xdx_90B_eus-gaap--OtherOperatingIncome_c20210609__20210610__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrilliumHealthcareGroupLLCMember_zkfYFsC73ai">7,081,557 </span></span><span style="font: 10pt Times New Roman, Times, Serif">as other operating income.</span><span style="font: 10pt Times New Roman, Times, Serif"> During the three and nine-month period ended September 30, 2021 we recognized $<span id="xdx_906_eus-gaap--OtherOperatingIncome_c20210101__20210930_zlZr23e9bBxe">1,385,162 </span></span><span style="font: 10pt Times New Roman, Times, Serif">as other operating income resulting in a remaining balance of $<span id="xdx_90E_ecustom--DeferredHealthAndHumanServicesRevenueCurrent_iI_c20210930_z63VuXS7LWR6">778,408 </span></span><span style="font: 10pt Times New Roman, Times, Serif">which is classified on the balance sheet as Deferred HHS Revenue. The recognition of amounts received is conditioned upon the provision of care for individuals with possible or actual cases of COVID-19 after January 31, 2020, certification that payment will be used to prevent, prepare for and respond to coronavirus and shall reimburse the recipient only for healthcare-related expenses or lost revenues, as defined by HHS, that are attributable to coronavirus, as well as receipt of the funds. Amounts are recognized as a reduction to operating costs and expenses only to the extent the Company is reasonably assured that underlying conditions have been met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the CAA and all frequently asked questions and other interpretive guidance issued by HHS, including the Post-Payment Notice of Reporting Requirements issued on January 15, 2021 (the “January 15, 2021 Notice”) and frequently asked questions issued by HHS on January 28, 2021 which clarified previously issued guidance, as well as expenses incurred attributable to the coronavirus and the Company’s results of operations during such period as compared to the Company’s budget. Such guidance, specifically the various Post-Payment Notice of Reporting Requirements and frequently asked questions issued by HHS, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to coronavirus that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. On the basis of guidance available at the time, the Company’s estimate of lost revenues was first based on the negative change in year-over-year net patient care operating revenue, then on the negative change in year-over-year net patient care operating income and finally on the difference between budgeted and actual revenue for calendar year. The calculation as of September 30, 2021 is in accordance with the CAA which indicates that lost revenues may be calculated pursuant to frequently asked questions published by HHS in June 2020, including the difference between a provider’s budgeted and actual revenue if such budget had been established prior to March 27, 2020. The use of funds calculation as of September 30, 2021 takes into account expenses attributable to each respective entity, which primarily relate to incremental labor and supply costs, as well as lost revenues. General fund distributions were allocated among subsidiaries according to total unreimbursed losses. Targeted distributions were not allocated or transferred among subsidiaries. While the CAA, January 15, 2021 Notice and frequently asked questions published by HHS on January 28, 2021 indicate that targeted distribution payments may be allocated or transferred to subsidiaries, distinct conditions exist for such allocations or transfers including that the parent organization have a “direct ownership relationship” with the subsidiary who received the targeted distribution payment. Additionally, the subsidiary that was the recipient of the targeted distribution payment retains responsibility for reporting to HHS on the use of such funds even if they are transferred or allocated to other subsidiaries. There are significant uncertainties as to the meaning and interpretation of conditions specific to the allocation or transfer of targeted distribution payments such that as of September 30, 2021, the Company is not reasonably assured that it can or will choose to comply with such conditions in order to allocate or transfer targeted distribution payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">HHS’ interpretation of the underlying terms and conditions of such PHSSEF payments, including auditing and reporting requirements, continues to evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such PHSSEF payments may result in changes in the Company’s estimate of amounts for which the terms and conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in the Company’s inability to recognize additional PHSSEF payments or may result in the de recognition of amounts previously recognized, which (in any such case) may be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_ecustom--MedicareAcceleratedPaymentsPolicyTextBlock_zApDEobqH6za" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_ziO0zWjKgeDb">Medicare Accelerated Payments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded payments under the Medicare Accelerated and Advance Payment program in accordance with FASB ASC 606 and has recorded amounts as a contract liability under FASB ASC 606-10-45-2. The contract liability will be reduced over time as revenue is recognized for claims submitted for services provided after the recoupment period begins. Effective October 1, 2020, the program was amended such that providers are required to repay accelerated payments beginning one year after the payment was issued. After such one-year period, Medicare payments owed to providers will be recouped according to the repayment terms. <span id="xdx_903_ecustom--AcceleratedPaymentsTerms_c20210101__20210930__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201409Member" title="Accelerated Payments term">The repayment terms specify that for the first 11 months after repayment begins, repayment will occur through an automatic recoupment of 25% of Medicare payments otherwise owed to the provider. At the end of the eleven-month period, recoupment will increase to 50% for six months. At the end of the six months (or 29 months from the receipt of the initial accelerated payment), Medicare will issue a letter for full repayment of any remaining balance, as applicable. In such event, if payment is not received within 30 days, interest will accrue at the annual percentage rate of four percent (4%) from the date the letter was issued and will be assessed for each full 30-day period that the balance remains unpaid. As of September 30, 2021, $<span id="xdx_907_ecustom--AcceleratedPayments_c20210101__20210930_zsKiZZPc2eG3" title="Accelerated payments">1,671,698</span> of Medicare accelerated payments are reflected on the balance sheet within advance payments line</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The company receives a substantial portion of our revenues from the Medicare and Medicaid programs. Included in Managed Care and other third-party payors is operating revenues from insurance companies with which we have insurance provider contracts, Medicare managed care, insurance companies for which we do not have insurance provider contracts, workers’ compensation carriers and non-patient service revenue, such as rental income and cafeteria sales. In the future, we generally expect the portion of revenues received from the Medicare and Medicaid programs to increase over the long-term due to the general aging of the population and the impact of the Affordable Care Act. The Affordable Care Act has increased the number of insured patients in states that have expanded Medicaid, which in turn, has reduced the percentage of revenues from self-pay patients. However, it is unclear whether the trend of increased coverage will continue, due in part to the impact of the COVID-19 pandemic and the elimination of the financial penalty associated with the individual mandate, effective January 1, 2019. Further, the Affordable Care Act imposes significant reductions in amounts the government pays Medicare managed care plans. Moreover, the trend toward increased enrollment in Medicare and Medicaid managed care may adversely affect our operating revenue. An executive order issued in October 2019 seeks to accelerate this shift away from traditional fee-for-service Medicare to Medicare managed care. We may also be impacted by regulatory requirements imposed on insurers, such as minimum medical-loss ratios and specific benefit requirements. Furthermore, in the normal course of business, managed care programs, insurance companies and employers actively negotiate the amounts paid to hospitals. Our relationships with payors may be impacted by price transparency initiatives and out-of-network billing restrictions. There can be no assurance that we will retain our existing reimbursement arrangements or that these third-party payors will not attempt to further reduce the rates they pay for our services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-based reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for the treatment of patients covered by Medicare, Medicaid and non-governmental payors are generally less than our standard billing rates. We account for the differences between the estimated program reimbursement rates and our standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at net operating revenues. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrZsMmnnBEP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_866_z85R4ZBbX3be">Fair Value of Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The carrying amount of accounts receivable and accounts payable approximate their respective fair values due to the short- term nature. The carrying amount of the line of credit and note payable approximates fair values due to their market interest rates. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zzAl0xk6Ei7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_866_zwEkb7DTP5D">Property and Equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Depreciation of owned assets and amortization of leasehold improvements are computed using the straight-line method over the shorter of the estimated useful lives of the related assets or the lease term. The cost of assets sold or retired, and the related accumulated depreciation are removed from the accounts and any resulting gains or losses are reflected in other income (expense) for the year. Expenditures for maintenance and repairs are charged to expense as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zxZyjnelIRo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_zfdUaL5B0Qv8">Goodwill</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our goodwill represents the excess of the purchase price over the fair value of the net identifiable assets acquired in business combinations. The goodwill generated from the business combinations is primarily related to the value placed on the employee workforce and expected synergies. Judgment is involved in determining if an indicator or change in circumstances relating to impairment has occurred. Such changes may include, among others, a significant decline in expected future cash flows, a significant adverse change in the business climate, and unforeseen competition. There was no goodwill impairment for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company tests goodwill for impairment on an annual basis, and when events or circumstances indicate the fair value of a reporting unit may be below its carrying value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zZXDSG2JHpUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zfyH8ObgeUn8">Long-Lived Assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There were no impairments of long-lived assets for the years presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_z7Mv84z6LjHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zJfYHdRHHBT3">Advertising and Marketing</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company uses advertising and marketing to promote its services. Advertising and marketing costs are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zk05elEHSpl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zXQNKi47e8W6">Earnings (Loss) Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Basic Earnings (loss) per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per common share is determined using the weighted-average of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of the conversion option embedded in convertible debt. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would have an anti-dilutive effect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Fixed grantee stock options (fixed awards) and nonvested stock (including restricted stock) shall be included in the computation of diluted earnings per common share. Even though their issuance may be contingent upon vesting, they shall be considered to be contingently issuable shares. Because issuance of performance based stock options (and performance based nonvested stock) is contingent upon satisfying conditions in addition to the mere passage of time, those options and non vested stock shall be considered to be contingently issuable shares in the computation of diluted earnings per common share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The dilutive effect of outstanding call options and warrants (and their equivalents) are reflected in diluted earnings per common share by application of the treasury stock method unless another method is required. Equivalents of options and warrants include nonvested stock granted under a share based payment arrangement, stock purchase contracts, and partially paid stock subscriptions. Antidilutive contracts such as purchased put options and purchased call options shall be excluded from diluted earnings per common share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company has included shares issuable under its 2021 Incentive Award Plan in deriving its fully diluted earnings per common share using the Treasury Method in accordance with ASC 260-10-45.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zNPwhG3gzxXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_867_zQ4AGCi5tEd7">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company uses the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets, liabilities, the carry forward of operating losses and tax credits, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. An allowance against deferred tax assets is recorded when it is more likely than not that such tax benefits will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Any future benefit arising from losses have been offset by a valuation allowance. Accordingly, no provision for income taxes is reflected in the condensed consolidated financial statements. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. Interest and penalties related to income tax matters, if any, would be recognized as a component of income tax expense. At September 30, 2021 and December 31, 2020, the Company had no liabilities for uncertain tax positions. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Currently, the tax years subsequent to 2017 are open and subject to examination by the taxing authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zRljZhD5Ca3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zgvNJ15EKJpe">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We follow ASC 606, “Revenue from Contracts with Customers.” Revenues are recognized when promised services are transferred to a customer, in an amount that reflects the consideration that we expect to receive in exchange for those services. We derive our revenues from the rendering of services, such as skilled nursing services. The five-step armodel defined by ASC 606 requires us to: (i) identify our contracts with customers, (ii) identify our performance obligations under those contracts, (iii) determine the transaction prices of those contracts, (iv) allocate the transaction prices to our performance obligations in those contracts and (v) recognize revenue when each performance obligation under those contracts is satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Reimbursement rates to provide services in our facilities are determined by the fee schedules set by the government programs and negotiated in contracts with non-governmental third-party payors and private pay patients. Fees are billed to the payors and private pay patients weekly and monthly following billing guidelines and contract requirements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84C_ecustom--NetPatientRevenuePolicyTextBlock_z8I7cEOR6RXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zKuLiAgGqWX">Net Patient Revenue</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The estimates for implicit price concessions are based upon management’s assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z6CxG1QE3Ixi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zAYvMlRnvk25">Reclassification</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Certain amounts from prior periods have been reclassified to conform to the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zasCi5bQuwca" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Basis of Presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying unaudited condensed consolidated financial statements of the Company (“Financial Statements”) have been prepared in accordance with GAAP for interim financial statements and with the instructions to Form 10-Q and Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In the opinion of management, the accompanying condensed consolidated Financial Statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2021, and the results of operations and cash flows for the periods presented. The results of operations for the nine months ended September 30, 2021, are not necessarily indicative of the operating results for the full fiscal year or any future period. These condensed consolidated Financial Statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021 and Current Report on Form 8-K on June 2, 2021. As of April 30, 2021, we had discontinued operations reflected in the accompanying condensed consolidated Financial Statements. As a result of the Plan of Merger completed on March 23, 2021 (see NOTE 3) we have changed our year end reporting period from November to December.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_844_ecustom--CapitalRequirementsLiquidityAndGoingConcernConsiderationsPolicyTextBlock_zDt7MT1MVV19" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_869_zFZTIUDSEhhi">Capital Requirements, Liquidity and Going Concern Considerations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These condensed consolidated Financial Statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Although we had cash and accounts receivable in the amount of approximately $<span id="xdx_900_eus-gaap--AccountsAndOtherReceivablesNetCurrent_iI_pn5n6_c20210930_z6kTKzuYu4wa" title="Cash and accounts receivable">11.4</span> million at September 30, 2021, we had accrued expenses and current notes payable in excess of cash and accounts receivable in the amount of approximately $<span id="xdx_90D_ecustom--AccruedExpensesAndCurrentNotesPayableAccountsAndOtherReceivablesNetCurrent_iI_pn5n6_c20210930_zJQwGmzbCCqa" title="Accrued expenses and current notes payable cash and accounts payable">6.5</span> million, and a deficiency in working capital of approximately $<span id="xdx_90E_ecustom--WorkingCapitalDeficiency_iI_pn5n6_c20210930_zlPx6u3TYcI8" title="Working capital deficiency">20.6</span> million. For the nine months ended September 30, 2021, our net loss was approximately $<span id="xdx_908_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20210101__20210930_zk11XIUm1MQ8" title="Net loss">6.9</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As a result of these factors, we determined it was necessary to review our cash flow for 2021 and an overall analysis of market trends to determine whether or not we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report. We also determined it was necessary to take certain corporate actions, including reducing discretionary expenses (and reduced reliance on agency staffing), improving revenue (including added Therapy and Rehab services), and raising additional capital, in order to ensure we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the three months ended September 30, 2021 we sold <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesOther_pn6n6_c20210701__20210930_zPFkDpM2M91e">5.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million</span><span style="font: 10pt Times New Roman, Times, Serif"> shares for an aggregate total of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueOther_pn6n6_c20210701__20210930_zLPbjSK84qO7">5.0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million. This capital raise will be used for additional growth through acquisitions and for working capital. However, no assurances can be given that we will be successful. If management is not able to timely and successfully raise additional capital and/or refinance indebtedness, the implementation of the Company’s business plan, financial condition and results of operations will be materially affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 11400000 6500000 20600000 -6900000 5000000.0 5000000.0 <p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zbxivMGeeey2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zBs7Vh4NzMs1">Basis of Consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">These condensed consolidated Financial Statements include the accounts of the Company and the wholly-owned subsidiaries, Banyan Pediatric Care Centers – OPS, LLC, Banyan Pediatric Care Centers – St. Petersburg, LLC, Banyan Pediatric Care Centers, - Pasco, LLC and Banyan Pediatric Care Centers – Sarasota, LLC and the discontinued operations of Assisted 2 Live, Inc., the wholly owned subsidiary that was discontinued as of April 30, 2021. All material intercompany balances and transactions have been eliminated. The condensed consolidated Financial Statements also include the accounts of the Trillium Subsidiaries from June 10, 2021, the effective date of the transaction with Trillium.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_843_eus-gaap--UseOfEstimates_zAxcHCD6cdmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_861_zru1C7riGWGk">Use of Estimates and Assumptions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zApAlFyk9wrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zPy3oZJ2iMj4">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company had <span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_do_c20210930_zssx828iGB67" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_do_c20201231_zUGRp9s6C9xa" title="Cash equivalents">no</span></span> cash equivalents at September 30, 2021 and December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 0 0 <p id="xdx_84C_eus-gaap--ReceivablesPolicyTextBlock_zrQt7UJpIwC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zNiK6i0xjJU9">Accounts Receivable</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Accounts receivable primarily consists of amounts due from third-party payers (non-governmental), governmental payers and private pay patients and is recorded net of contractual allowances and reserves for doubtful accounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s Financial Statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimation of net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies’ denial of claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s accounts receivable from third-party payers are recorded net of estimated contractual adjustments and allowances from third-party payers, which are estimated based on the historical trend of the Company’s facilities’ cash collections and contractual write-offs, accounts receivable aging, established fee schedules, relationships with payers and procedure statistics. While changes in estimated reimbursement from third-party payers remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on the Company’s financial condition or results of operations. The Company’s collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of the facilities to ensure the proper collection and aged category. The operating systems generate reports that assist in the collection efforts by prioritizing patient accounts. Collection efforts include direct contact with insurance carriers or patients and written correspondence.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zuX4mghzHt2k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zuFn4SegWQEk">Allowance for Doubtful Accounts, Contractual and Other Discounts</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Management estimates the allowance for contractual and other discounts based on its historical collection experience and contracted relationship with the payers. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account may be written-off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84A_ecustom--COVID19PandemicAndCARESActFundingPolicyTextBlock_zPDAgLKi2Bv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zPMqJxsbISij">COVID-19 Pandemic and CARES Act Funding</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">COVID-19 Pandemic. In January 2020, the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel strain of coronavirus. In March 2020, the World Health Organization declared the outbreak of COVID-19, a disease caused by this coronavirus, a pandemic. The resulting measures to contain the spread and impact of COVID-19 and other developments related to COVID-19 have materially affected the Company’s results of operations during 2020. Where applicable, the impact resulting from the COVID-19 pandemic during the year ended December 31, 2020, has been considered, including updated assessments of the recoverability of assets and evaluation of potential credit losses. As a result of the COVID-19 pandemic, federal and state governments have passed legislation, promulgated regulations and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency. Sources of relief include the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020, the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), which was enacted on April 24, 2020, and the Consolidated Appropriations Act, 2021 (the “CAA”), which was enacted on December 27, 2020. In total, the CARES Act, PPPHCE Act and the CAA authorize $178 billion in funding to be distributed to hospitals and other healthcare providers through the Public Health and Social Services Emergency Fund (the “PHSSEF”). In addition, the CARES Act provide for an expansion of the Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers were able to request accelerated payment of up to <span id="xdx_90E_ecustom--PercentageOfAcceleratedPayment_pid_dp_uPure_c20210101__20210930_zS8DFhrMWfWd" title="Percentage of accelerated payment">100</span>% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments. Various other state and local programs also exist to provide relief, either independently or through distribution of monies received via the CARES Act. During the period ended September 30, 2021, the Company was a beneficiary of these stimulus measures, including the Medicare Accelerated and Advance Payment Program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s accounting policies for the recognition of these stimulus monies is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 1 <p id="xdx_848_ecustom--PandemicReliefFundsPolicyTextBlock_z4Aaelcaahfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86D_zcAE5Wi19IZd">Pandemic Relief Funds</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Trillium </span><span style="font: 10pt Times New Roman, Times, Serif">received an aggregate of $<span id="xdx_900_ecustom--ProceedsFromPandemicReliefFunds_c20210101__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrilliumHealthcareGroupLLCMember_zIA8pnIRdJVa">13,487,923 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in PHSSEF payments, of which $<span id="xdx_902_ecustom--ProceedsFromPandemicReliefFunds_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrilliumHealthcareGroupLLCMember_zmnqgauLjdI6">4,242,796 </span></span><span style="font: 10pt Times New Roman, Times, Serif">was applied during 2020. Prior to the acquisition date of June 10, 2021 Trillium had recognized $<span id="xdx_90B_eus-gaap--OtherOperatingIncome_c20210609__20210610__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TrilliumHealthcareGroupLLCMember_zkfYFsC73ai">7,081,557 </span></span><span style="font: 10pt Times New Roman, Times, Serif">as other operating income.</span><span style="font: 10pt Times New Roman, Times, Serif"> During the three and nine-month period ended September 30, 2021 we recognized $<span id="xdx_906_eus-gaap--OtherOperatingIncome_c20210101__20210930_zlZr23e9bBxe">1,385,162 </span></span><span style="font: 10pt Times New Roman, Times, Serif">as other operating income resulting in a remaining balance of $<span id="xdx_90E_ecustom--DeferredHealthAndHumanServicesRevenueCurrent_iI_c20210930_z63VuXS7LWR6">778,408 </span></span><span style="font: 10pt Times New Roman, Times, Serif">which is classified on the balance sheet as Deferred HHS Revenue. The recognition of amounts received is conditioned upon the provision of care for individuals with possible or actual cases of COVID-19 after January 31, 2020, certification that payment will be used to prevent, prepare for and respond to coronavirus and shall reimburse the recipient only for healthcare-related expenses or lost revenues, as defined by HHS, that are attributable to coronavirus, as well as receipt of the funds. Amounts are recognized as a reduction to operating costs and expenses only to the extent the Company is reasonably assured that underlying conditions have been met.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company’s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the CAA and all frequently asked questions and other interpretive guidance issued by HHS, including the Post-Payment Notice of Reporting Requirements issued on January 15, 2021 (the “January 15, 2021 Notice”) and frequently asked questions issued by HHS on January 28, 2021 which clarified previously issued guidance, as well as expenses incurred attributable to the coronavirus and the Company’s results of operations during such period as compared to the Company’s budget. Such guidance, specifically the various Post-Payment Notice of Reporting Requirements and frequently asked questions issued by HHS, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to coronavirus that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. On the basis of guidance available at the time, the Company’s estimate of lost revenues was first based on the negative change in year-over-year net patient care operating revenue, then on the negative change in year-over-year net patient care operating income and finally on the difference between budgeted and actual revenue for calendar year. The calculation as of September 30, 2021 is in accordance with the CAA which indicates that lost revenues may be calculated pursuant to frequently asked questions published by HHS in June 2020, including the difference between a provider’s budgeted and actual revenue if such budget had been established prior to March 27, 2020. The use of funds calculation as of September 30, 2021 takes into account expenses attributable to each respective entity, which primarily relate to incremental labor and supply costs, as well as lost revenues. General fund distributions were allocated among subsidiaries according to total unreimbursed losses. Targeted distributions were not allocated or transferred among subsidiaries. While the CAA, January 15, 2021 Notice and frequently asked questions published by HHS on January 28, 2021 indicate that targeted distribution payments may be allocated or transferred to subsidiaries, distinct conditions exist for such allocations or transfers including that the parent organization have a “direct ownership relationship” with the subsidiary who received the targeted distribution payment. Additionally, the subsidiary that was the recipient of the targeted distribution payment retains responsibility for reporting to HHS on the use of such funds even if they are transferred or allocated to other subsidiaries. There are significant uncertainties as to the meaning and interpretation of conditions specific to the allocation or transfer of targeted distribution payments such that as of September 30, 2021, the Company is not reasonably assured that it can or will choose to comply with such conditions in order to allocate or transfer targeted distribution payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">HHS’ interpretation of the underlying terms and conditions of such PHSSEF payments, including auditing and reporting requirements, continues to evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such PHSSEF payments may result in changes in the Company’s estimate of amounts for which the terms and conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in the Company’s inability to recognize additional PHSSEF payments or may result in the de recognition of amounts previously recognized, which (in any such case) may be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 13487923 4242796 7081557 1385162 778408 <p id="xdx_84D_ecustom--MedicareAcceleratedPaymentsPolicyTextBlock_zApDEobqH6za" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_ziO0zWjKgeDb">Medicare Accelerated Payments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded payments under the Medicare Accelerated and Advance Payment program in accordance with FASB ASC 606 and has recorded amounts as a contract liability under FASB ASC 606-10-45-2. The contract liability will be reduced over time as revenue is recognized for claims submitted for services provided after the recoupment period begins. Effective October 1, 2020, the program was amended such that providers are required to repay accelerated payments beginning one year after the payment was issued. After such one-year period, Medicare payments owed to providers will be recouped according to the repayment terms. <span id="xdx_903_ecustom--AcceleratedPaymentsTerms_c20210101__20210930__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201409Member" title="Accelerated Payments term">The repayment terms specify that for the first 11 months after repayment begins, repayment will occur through an automatic recoupment of 25% of Medicare payments otherwise owed to the provider. At the end of the eleven-month period, recoupment will increase to 50% for six months. At the end of the six months (or 29 months from the receipt of the initial accelerated payment), Medicare will issue a letter for full repayment of any remaining balance, as applicable. In such event, if payment is not received within 30 days, interest will accrue at the annual percentage rate of four percent (4%) from the date the letter was issued and will be assessed for each full 30-day period that the balance remains unpaid. As of September 30, 2021, $<span id="xdx_907_ecustom--AcceleratedPayments_c20210101__20210930_zsKiZZPc2eG3" title="Accelerated payments">1,671,698</span> of Medicare accelerated payments are reflected on the balance sheet within advance payments line</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The company receives a substantial portion of our revenues from the Medicare and Medicaid programs. Included in Managed Care and other third-party payors is operating revenues from insurance companies with which we have insurance provider contracts, Medicare managed care, insurance companies for which we do not have insurance provider contracts, workers’ compensation carriers and non-patient service revenue, such as rental income and cafeteria sales. In the future, we generally expect the portion of revenues received from the Medicare and Medicaid programs to increase over the long-term due to the general aging of the population and the impact of the Affordable Care Act. The Affordable Care Act has increased the number of insured patients in states that have expanded Medicaid, which in turn, has reduced the percentage of revenues from self-pay patients. However, it is unclear whether the trend of increased coverage will continue, due in part to the impact of the COVID-19 pandemic and the elimination of the financial penalty associated with the individual mandate, effective January 1, 2019. Further, the Affordable Care Act imposes significant reductions in amounts the government pays Medicare managed care plans. Moreover, the trend toward increased enrollment in Medicare and Medicaid managed care may adversely affect our operating revenue. An executive order issued in October 2019 seeks to accelerate this shift away from traditional fee-for-service Medicare to Medicare managed care. We may also be impacted by regulatory requirements imposed on insurers, such as minimum medical-loss ratios and specific benefit requirements. Furthermore, in the normal course of business, managed care programs, insurance companies and employers actively negotiate the amounts paid to hospitals. Our relationships with payors may be impacted by price transparency initiatives and out-of-network billing restrictions. There can be no assurance that we will retain our existing reimbursement arrangements or that these third-party payors will not attempt to further reduce the rates they pay for our services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-based reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for the treatment of patients covered by Medicare, Medicaid and non-governmental payors are generally less than our standard billing rates. We account for the differences between the estimated program reimbursement rates and our standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at net operating revenues. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> The repayment terms specify that for the first 11 months after repayment begins, repayment will occur through an automatic recoupment of 25% of Medicare payments otherwise owed to the provider. At the end of the eleven-month period, recoupment will increase to 50% for six months. At the end of the six months (or 29 months from the receipt of the initial accelerated payment), Medicare will issue a letter for full repayment of any remaining balance, as applicable. In such event, if payment is not received within 30 days, interest will accrue at the annual percentage rate of four percent (4%) from the date the letter was issued and will be assessed for each full 30-day period that the balance remains unpaid. As of September 30, 2021, $1,671,698 of Medicare accelerated payments are reflected on the balance sheet within advance payments line 1671698 <p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zrZsMmnnBEP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_866_z85R4ZBbX3be">Fair Value of Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The carrying amount of accounts receivable and accounts payable approximate their respective fair values due to the short- term nature. The carrying amount of the line of credit and note payable approximates fair values due to their market interest rates. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zzAl0xk6Ei7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_866_zwEkb7DTP5D">Property and Equipment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Depreciation of owned assets and amortization of leasehold improvements are computed using the straight-line method over the shorter of the estimated useful lives of the related assets or the lease term. The cost of assets sold or retired, and the related accumulated depreciation are removed from the accounts and any resulting gains or losses are reflected in other income (expense) for the year. Expenditures for maintenance and repairs are charged to expense as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zxZyjnelIRo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_zfdUaL5B0Qv8">Goodwill</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our goodwill represents the excess of the purchase price over the fair value of the net identifiable assets acquired in business combinations. The goodwill generated from the business combinations is primarily related to the value placed on the employee workforce and expected synergies. Judgment is involved in determining if an indicator or change in circumstances relating to impairment has occurred. Such changes may include, among others, a significant decline in expected future cash flows, a significant adverse change in the business climate, and unforeseen competition. There was no goodwill impairment for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company tests goodwill for impairment on an annual basis, and when events or circumstances indicate the fair value of a reporting unit may be below its carrying value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zZXDSG2JHpUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zfyH8ObgeUn8">Long-Lived Assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There were no impairments of long-lived assets for the years presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_z7Mv84z6LjHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zJfYHdRHHBT3">Advertising and Marketing</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company uses advertising and marketing to promote its services. Advertising and marketing costs are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zk05elEHSpl9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zXQNKi47e8W6">Earnings (Loss) Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Basic Earnings (loss) per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per common share is determined using the weighted-average of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of the conversion option embedded in convertible debt. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would have an anti-dilutive effect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Fixed grantee stock options (fixed awards) and nonvested stock (including restricted stock) shall be included in the computation of diluted earnings per common share. Even though their issuance may be contingent upon vesting, they shall be considered to be contingently issuable shares. Because issuance of performance based stock options (and performance based nonvested stock) is contingent upon satisfying conditions in addition to the mere passage of time, those options and non vested stock shall be considered to be contingently issuable shares in the computation of diluted earnings per common share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The dilutive effect of outstanding call options and warrants (and their equivalents) are reflected in diluted earnings per common share by application of the treasury stock method unless another method is required. Equivalents of options and warrants include nonvested stock granted under a share based payment arrangement, stock purchase contracts, and partially paid stock subscriptions. Antidilutive contracts such as purchased put options and purchased call options shall be excluded from diluted earnings per common share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company has included shares issuable under its 2021 Incentive Award Plan in deriving its fully diluted earnings per common share using the Treasury Method in accordance with ASC 260-10-45.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zNPwhG3gzxXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_867_zQ4AGCi5tEd7">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Company uses the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets, liabilities, the carry forward of operating losses and tax credits, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. An allowance against deferred tax assets is recorded when it is more likely than not that such tax benefits will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Any future benefit arising from losses have been offset by a valuation allowance. Accordingly, no provision for income taxes is reflected in the condensed consolidated financial statements. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. Interest and penalties related to income tax matters, if any, would be recognized as a component of income tax expense. At September 30, 2021 and December 31, 2020, the Company had no liabilities for uncertain tax positions. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Currently, the tax years subsequent to 2017 are open and subject to examination by the taxing authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zRljZhD5Ca3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zgvNJ15EKJpe">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We follow ASC 606, “Revenue from Contracts with Customers.” Revenues are recognized when promised services are transferred to a customer, in an amount that reflects the consideration that we expect to receive in exchange for those services. We derive our revenues from the rendering of services, such as skilled nursing services. The five-step armodel defined by ASC 606 requires us to: (i) identify our contracts with customers, (ii) identify our performance obligations under those contracts, (iii) determine the transaction prices of those contracts, (iv) allocate the transaction prices to our performance obligations in those contracts and (v) recognize revenue when each performance obligation under those contracts is satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Reimbursement rates to provide services in our facilities are determined by the fee schedules set by the government programs and negotiated in contracts with non-governmental third-party payors and private pay patients. Fees are billed to the payors and private pay patients weekly and monthly following billing guidelines and contract requirements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84C_ecustom--NetPatientRevenuePolicyTextBlock_z8I7cEOR6RXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zKuLiAgGqWX">Net Patient Revenue</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The estimates for implicit price concessions are based upon management’s assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z6CxG1QE3Ixi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zAYvMlRnvk25">Reclassification</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Certain amounts from prior periods have been reclassified to conform to the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_809_eus-gaap--BusinessCombinationDisclosureTextBlock_zpCY3aWTDrSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 3</b> – <b><span id="xdx_829_zhitnzDCvDU1">BANYAN MERGER</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Effective March 23, 2021, we entered into a Plan of Merger with Merger Sub and Banyan. Under the terms of the Plan of Merger, Merger Sub merged with and into Banyan with Banyan as the Surviving Entity and wholly owned subsidiary of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Merger has been treated as a recapitalization and reverse acquisition of the Company for financial accounting purposes, and Banyan is considered the acquirer for accounting purposes. This means that the Company’s historical financial statements before the Merger have been replaced with the historical financial statements of Banyan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In connection with the Merger, we issued <span id="xdx_908_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210322__20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zNJqigSHKEA8" title="Number of shares issued upon conversion">4,165,418</span> shares of our common stock in exchange for <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210322__20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zwz0zzDyu9Ch" title="Number of shares converted">49,984,649</span> outstanding shares of Banyan’s common stock held by <span title="Number of shareholders">64</span> shareholders, based on an exchange ratio of one (1) share of our common stock for every twelve (12) shares of Banyan common stock. We also issued a warrant to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210323_zVb91zBDEWCa" title="Warrants to purchase common stock">75,000</span> shares of our common stock (the “Warrant”) in exchange for a warrant to purchase 900,000 shares of Banyan’s common stock. The Warrant is held by one investor and is exercisable for cash only until May 2, 2030 at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210323_zqnDXD4BNUe2" title="Warrants exercise price">0.38 </span>per share. The number of shares of common stock deliverable upon exercise of the Warrant contains provisions for standard anti-dilution adjustments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ConversionOfStockDescription_c20210322__20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember" title="Stock conversion description">The Surviving Entity assumed Banyan’s $<span id="xdx_901_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_c20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_pp0p0" title="Outstanding debt assumed">2,300,000</span> of outstanding debt, and the $<span id="xdx_90A_eus-gaap--ConvertibleDebt_c20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_pp0p0" title="Convertible debt">2,000,000</span> of such debt that was convertible into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210322__20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_z5InHCvI3Xt6" title="Debt conversion shares">20,000,000</span> shares of Banyan common stock was converted at $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210323_zYpf370VgrL2" title="Debt conversion price per share">0.50</span> per share into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210322__20210323_ztjRtH2ZCn6b" title="Debt conversion shares">4,000,000</span> shares of our common stock, effective March 30, 2021. During the three months ended June 30, 2021, shares were issued to the Noteholders of the $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20210401__20210630__srt--TitleOfIndividualAxis__custom--NoteHolderMember_zRjHTs7DrVA9" title="Convertible notes">2,000,000</span> convertible note. The remaining $<span id="xdx_90C_eus-gaap--NotesPayable_iI_pp0p0_c20201106_zXmfeuP4Ldjh" title="Outstanding note">300,000</span> of outstanding debt, evidenced by a promissory note dated November 6, 2020, accrues interest at the annual rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211106_zNlkf2CHmf2f" title="Interest rate">12</span>%. Interest is payable on the sixth day of each month in the amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPaymentInterest_c20210322__20210323_pp0p0" title="Interest payable each month">3,000</span> until the maturity date of this note on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20210322__20210323_zu0QalOuLegl" title="Maturity date">November 6, 2021</span>, at which time, the remaining principal balance, if any, is due and payable</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 4165418 49984649 75000 0.38 The Surviving Entity assumed Banyan’s $2,300,000 of outstanding debt, and the $2,000,000 of such debt that was convertible into 20,000,000 shares of Banyan common stock was converted at $0.50 per share into 4,000,000 shares of our common stock, effective March 30, 2021. During the three months ended June 30, 2021, shares were issued to the Noteholders of the $2,000,000 convertible note. The remaining $300,000 of outstanding debt, evidenced by a promissory note dated November 6, 2020, accrues interest at the annual rate of 12%. Interest is payable on the sixth day of each month in the amount of $3,000 until the maturity date of this note on November 6, 2021, at which time, the remaining principal balance, if any, is due and payable 2300000 2000000 20000000 0.50 4000000 2000000 300000 0.12 3000 2021-11-06 <p id="xdx_803_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zDuiHADRizqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 4 – <span id="xdx_82E_zOpR9x67xeFe">DISCONTINUED OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On April 30, 2021, our Board of Directors (the “Board”) approved the discontinuance of our wholly owned subsidiary, Assisted 2 Live, Inc. (the “Discontinued Subsidiary”). The operations of the Discontinued Subsidiary are reflected on our condensed consolidated statement of operations from the date of the Merger as a loss from discontinued operations in the amount of $<span id="xdx_906_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_pp0p0_c20210429__20210430__srt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zHiXhSo4AGG" title="Loss from discontinued operations">26,500</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The April 30, 2021, Board decision was the result of the Purchase and Sale Option Agreement (the “Option Agreement”) with Romulus Barr (“Barr”) which we entered into on November 7, 2020. The Option Agreement provided us with the option to sell all of our interest in Assisted 2 Live, Inc., consisting of <span id="xdx_90C_eus-gaap--InvestmentOwnedBalanceShares_iI_pid_c20201107__srt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAndSaleOptionAgreementMember_zi8fxzcuOIgb" title="Shares owned">1,000</span> shares of common stock of the discontinued subsidiary, to Barr in exchange for <span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20201107__srt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAndSaleOptionAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RomulusBarrMember_zNrSd99JWsY4" title="Common stock, shares outstanding">200,000</span> shares of our common stock (the “Shares”) held by Barr. The returned Shares were cancelled and included in authorized but unissued shares of common stock of the Company. The number of issued and outstanding shares of common stock was decreased by <span id="xdx_906_ecustom--IssuedAndOutstandingShares_c20210429__20210430_pdd" title="Issued and outstanding shares">200,000</span> as of April 30, 2021. The transfer resulted in a gain on disposal of discontinued operations in the amount of $<span id="xdx_90A_eus-gaap--DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_c20210429__20210430_pp0p0" title="Disposal of discontinued">395,500</span>. A share price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210430_zwhMcFZH91uh" title="Disposal of discontinued price per share">1.85</span> was used to determine the gain on disposal of discontinued operations based on the share price value on April 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p id="xdx_89C_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zK3YzDZc6iT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B8_zELGTIlOQbY1" style="display: none">SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210701__20210930_zp7nwWtsE2I1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20200701__20200930_zdR4OFinDRc6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210101__20210930_zR2XjgKBtvy1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20200101__20200930_zFYakxDFuIbk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, </b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For the nine months ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zn43yFK6qK6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">76,847</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0797">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zQCj95wv6EY" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Cost of net revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0799"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0800"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0801"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0802"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_iT_pp0p0_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zMvLsnqOXLG7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0804"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0805"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0806"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0807"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingExpensesAbstract_iB_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zQXhAnv2VYyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DisposalGroupIncludingDiscontinuedOperationSalaryAndTaxExpense_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zF3bKuhWS3Tg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Salary and tax expense</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0814"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0815"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,813</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0817"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zRFTcfUZHgn" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0819"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0820"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,555</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0822"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationLeaseExpense_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zf7PaTu1a7Pa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Lease expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0824"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0825"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,979</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0827"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_iT_pp0p0_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zCC3Fx4187b6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0829"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0830"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,347</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0832"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_pp0p0_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zcWd6O6oGoja" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income from discontinued operations</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0834"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0835"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0837"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationInterestAndOtherExpenseNet_iN_pp0p0_di_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zXZRUEItIGNb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Interest and other, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0839"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0840"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0841"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0842"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_iT_pp0p0_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zCnnkPOjf661" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income from discontinued operations before income taxes</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0844"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0845"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0847"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_z6vxdxwmeEJh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0850"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0852"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pp0p0_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_znjgBDVndAQl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income from discontinued operations, net of income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0855">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(26,500</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zzg3kvBoy257" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 26500 1000 200000 200000 395500 1.85 <p id="xdx_89C_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zK3YzDZc6iT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B8_zELGTIlOQbY1" style="display: none">SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210701__20210930_zp7nwWtsE2I1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20200701__20200930_zdR4OFinDRc6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210101__20210930_zR2XjgKBtvy1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20200101__20200930_zFYakxDFuIbk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For the three months ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, </b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For the nine months ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zn43yFK6qK6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">76,847</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0797">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zQCj95wv6EY" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Cost of net revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0799"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0800"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0801"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0802"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_iT_pp0p0_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zMvLsnqOXLG7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0804"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0805"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0806"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0807"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingExpensesAbstract_iB_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zQXhAnv2VYyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DisposalGroupIncludingDiscontinuedOperationSalaryAndTaxExpense_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zF3bKuhWS3Tg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Salary and tax expense</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0814"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0815"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,813</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0817"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zRFTcfUZHgn" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0819"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0820"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,555</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0822"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationLeaseExpense_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zf7PaTu1a7Pa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Lease expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0824"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0825"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,979</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0827"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_iT_pp0p0_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zCC3Fx4187b6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0829"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0830"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,347</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0832"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_pp0p0_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zcWd6O6oGoja" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income from discontinued operations</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0834"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0835"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0837"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationInterestAndOtherExpenseNet_iN_pp0p0_di_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zXZRUEItIGNb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Interest and other, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0839"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0840"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0841"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0842"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_iT_pp0p0_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_zCnnkPOjf661" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income from discontinued operations before income taxes</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0844"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0845"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0847"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DiscontinuedOperationTaxEffectOfDiscontinuedOperation_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_z6vxdxwmeEJh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0850"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0852"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_pp0p0_hsrt--ConsolidatedEntitiesAxis__custom--AssistedTwoLivingIncMember_znjgBDVndAQl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income from discontinued operations, net of income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0855">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(26,500</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0857">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 76847 46813 52555 3979 103347 -26500 -26500 -26500 <p id="xdx_802_eus-gaap--AssetAcquisitionTextBlock_zBlYIDUa4xZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 5 – <span id="xdx_82A_zDSLMTjpM0m7">TRILLIUM ACQUISITION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On June 10, 2021, we entered into the Restated Purchase Agreement, by and among the Company, Mason, Bench and Trillium to acquire all of the issued and outstanding ownership interests of the Trillium Subsidiaries from Trillium (the “Transaction”). The Transaction closed and was effective <span id="xdx_90D_eus-gaap--BusinessAcquisitionEffectiveDateOfAcquisition1_dd_c20210101__20210930__us-gaap--BusinessAcquisitionAxis__custom--TrilliumSubsidiariesMember_zQAzJsez509l" title="Effective Date of Acquisition">June 10, 2021</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant to the terms and conditions of the Restated Purchase Agreement, the aggregate purchase price consists of: (i) a cash payment of $<span id="xdx_90F_eus-gaap--CashAcquiredInExcessOfPaymentsToAcquireBusiness_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_pp0p0" title="Cash payment">902,847</span>, minus certain transaction related costs, fees and expenses set forth in the Restated Purchase Agreement and determined post-closing; (ii) <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvrnhDBPeGfi" title="Preferred Stock Shares Issued">2,500,000</span> shares of the Company’s Series A Preferred Stock (the “Preferred Shares”); and (iii) shares of the Company’s common stock (“Common Shares”) having an aggregate value of $<span id="xdx_90B_eus-gaap--BusinessAcquisitionSharePrice_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--TrilliumSubsidiariesMember_pdd" title="Right to receive purchase price">5,000,000</span>, based on the stock price at the time of issuance, upon the earlier of an initial public offering by the Company or June 10, 2022. Trillium will have the right to acquire an additional <span id="xdx_909_ecustom--BusinessAcquisitionAdditionalSharePrice_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSBi0q9e3HK2" title="Additonal Shares Acquired during the period">2,500,000</span> Common Shares during the two-year period after the Transaction closes pursuant to a Business Development Agreement, a copy of which is attached as Exhibit 10.1 to this Quarterly Report.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As a condition to closing, the Trillium Subsidiaries paid with cash on hand $<span id="xdx_908_eus-gaap--Cash_c20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_pp0p0" title="Cash">1,200,000</span> to one of its landlord, CTR Partnership, L.P. (“CTR”), as an additional security deposit under a lease between Greenside Healthcare Properties, LLC, a wholly-owned subsidiary of FHP and CTR and $<span id="xdx_90B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_pp0p0" title="Payment to acquire property">3,000,000</span> to Crete Plus Five Property, L.L.C. (“Omega,” and together with CTR, the “Landlords”) as a deposit on the Company’s purchase of 16 facilities on 14 properties (the “Properties”) currently being leased by FHP’s wholly-owned subsidiaries from Omega and its affiliates. The $<span id="xdx_906_ecustom--BusinessCombinationDepositsNonRefundableAmount_iI_c20210930_zWYpqE1U6h4i">3,000,000</span> deposit to Omega is non-refundable and is subject to forfeiture if the purchase of the Properties is not closed by December 30, 2021. If the $<span id="xdx_908_ecustom--BusinessCombinationOfDepositsAmountForfeited_iI_c20210930_zR4DvXUgMVQ8" title="Deposits Amount Forfeited">3,000,000</span> deposit is forfeited, Trillium forfeits its right to receive $<span id="xdx_904_eus-gaap--BusinessAcquisitionSharePrice_iI_c20210930__us-gaap--BusinessAcquisitionAxis__custom--TrilliumSubsidiariesMember_zbAuoFiwaVGb" title="Right to receive purchase price">3,000,000</span> of the purchase price, first, from the cash payment mentioned in subsection (i) above, and second, from the value of common stock to be issued to Trillium mentioned in subsection (iii) above. In any event, no cash payments may be made to Trillium until the purchase of the Properties closes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Preferred Shares, with respect to rights on liquidation, winding up and dissolution, rank pari passu with the Common Shares. The holders of Preferred Shares have the right to cast one <span id="xdx_903_eus-gaap--BusinessAcquisitionDescriptionOfAcquiredEntity_c20210101__20210930__us-gaap--BusinessAcquisitionAxis__custom--TrilliumSubsidiariesMember" title="Business Acquisition Description">(1) vote for each Preferred Share held of record on all matters submitted to a vote of holders of the Common Shares, including the election of directors, and all other matters as required by law. The Preferred Shares are not convertible into Common shares at the election of the holder. However, the Preferred Shares do automatically convert into Common Shares at a one-to-one ratio two years from date of issuance. In lieu of converting the Preferred Shares, the holders thereof may elect to have the Company redeem one or more Preferred Shares at the redemption price of $1.00 per share two years from the date of issuance. The Company is required to issue the Preferred Shares to Trillium within 30 days after the purchase of the Properties closes. In connection with the issuance of the Preferred Shares, the Company will file a Certificate of Designation with the Nevada Secretary of State prior to such issuance</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In connection with obtaining the Landlords’ consent to the Transaction, the Company entered into: (i) a guaranty agreement with each Landlord under which the Company agreed to guaranty all obligations and liabilities under master leases for property and facilities owned by the Landlords’ and their affiliates and leased by FHP’s direct and indirect wholly-owned subsidiaries; and (ii) a Consent Agreement and Fifth Amendment to Master Lease with Omega (the “Consent”) regarding the Properties. Under the terms of the Consent, until the earlier of the purchase of the Properties closes or the expiration of the master lease agreement for the Properties in 2027: (a) Mason and Bench must remain responsible for, and have authority over, the day to day management and operations of the Properties and related facilities; and (b) the Company may not make any payment, transfer or distribution of cash or any assets to one or more equity holders or any person or entity with possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of the Company, through the ownership of voting securities (an “Affiliate”), or return any capital, redemption of any security, or making or assumption of any loans, advances or extension of credit or capital contribution to, or any other investment in, any Affiliate, including, but not limited to, a fee for management, a payment for services rendered, a reimbursement for expenditures or overhead incurred on behalf of the Company or a payment on any debt of an Affiliate; provided, however, the Company may contribute or transfer cash or other assets to its, direct or indirect, wholly-owned subsidiaries, and pay reasonable cash compensation to the members of the Board and executive officers provided that such compensation does not in the aggregate, exceed $<span id="xdx_907_eus-gaap--ShareBasedCompensation_c20210101__20210930_pp0p0" title="Share Based Compensation Aggregate Amount">600,000</span> in any six month period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The initial purchase price has been allocated to the acquired assets and assumed liabilities based on estimated fair values. The purchase price allocation is preliminary pending a final determination of the fair values of the assets and liabilities. The table below provides a preliminary recording of assets acquired and liabilities assumed as of the acquisition date. During the three month period ended September 30, 2021 certain adjustments were made to the fair value of accounts receivable, share liability and goodwill. The amounts recorded for property, plant and equipment, leasehold improvements and goodwill are preliminary and pending finalization of valuation efforts.</span></p> <p id="xdx_89A_ecustom--ScheduleOfAcquiredAssetsAndLiabiltiesAcquiredTableTextBlock_z05QsY1ozKje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zS58lpP6MiSf" style="display: none">SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Assets acquired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20210930_z28aUhNk51s2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,432,847</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,521,080</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,661,683</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,380,635</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,082,529</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseImprovements_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,213,273</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseRightUseOfAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Lease right of use asset</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,196,092</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total identifiable assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,488,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Liabilities assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--AdvancePayments_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Advance payments</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,905,234</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,783,508</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,162,966</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Loan Payable - other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">453,043</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Lease liability - current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,837,406</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,309,884</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiabilityNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Lease liability - net of current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,383,251</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueFromSeller_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Cash due to seller</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">902,847</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareLiability_iI_pp0p0_zwUxlKrYtV8d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Share liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0_zWwMRzAsctM2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> <span style="display: none; font-family: Times New Roman, Times, Serif">Total identifiable liabilities acquired</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,488,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_z3EyGX376d7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 2021-06-10 902847 2500000 5000000 2500000 1200000 3000000 3000000 3000000 3000000 (1) vote for each Preferred Share held of record on all matters submitted to a vote of holders of the Common Shares, including the election of directors, and all other matters as required by law. The Preferred Shares are not convertible into Common shares at the election of the holder. However, the Preferred Shares do automatically convert into Common Shares at a one-to-one ratio two years from date of issuance. In lieu of converting the Preferred Shares, the holders thereof may elect to have the Company redeem one or more Preferred Shares at the redemption price of $1.00 per share two years from the date of issuance. The Company is required to issue the Preferred Shares to Trillium within 30 days after the purchase of the Properties closes. In connection with the issuance of the Preferred Shares, the Company will file a Certificate of Designation with the Nevada Secretary of State prior to such issuance 600000 <p id="xdx_89A_ecustom--ScheduleOfAcquiredAssetsAndLiabiltiesAcquiredTableTextBlock_z05QsY1ozKje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zS58lpP6MiSf" style="display: none">SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Assets acquired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20210930_z28aUhNk51s2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,432,847</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,521,080</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,661,683</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,380,635</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Goodwill</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,082,529</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseImprovements_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,213,273</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseRightUseOfAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Lease right of use asset</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,196,092</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total identifiable assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,488,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Liabilities assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--AdvancePayments_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Advance payments</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,905,234</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,783,508</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Deferred revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,162,966</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Loan Payable - other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">453,043</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Lease liability - current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,837,406</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,309,884</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiabilityNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Lease liability - net of current portion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,383,251</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueFromSeller_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Cash due to seller</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">902,847</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareLiability_iI_pp0p0_zwUxlKrYtV8d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Share liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0_zWwMRzAsctM2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> <span style="display: none; font-family: Times New Roman, Times, Serif">Total identifiable liabilities acquired</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,488,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 3432847 5521080 2661683 2380635 12082529 1213273 44196092 71488139 2905234 8783508 2162966 453043 7837406 2309884 36383251 902847 9750000 71488139 <p id="xdx_80E_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zfWkJv4b0fB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 6– <span id="xdx_82C_z2KBVG1mnsc2">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zZJh5GVMsF85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our accounts payable and accrued liabilities at September 30, 2021 and December 31, 2020 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zR1agVoonH9l" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20210930_zxUxGh7K5Mtl" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20201231_zUfoKF0rxHO2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,299,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">16,298</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--AccruedCreditCard_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit Card</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,712</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,513,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,832</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Salary</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">995,265</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0936"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Payroll Tax Payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,189</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0939"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTIC_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> <span style="display: none; font-family: Times New Roman, Times, Serif">Accounts Payable and Accrued Liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,879,082</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">148,180</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zquevn6HoSdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zZJh5GVMsF85" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our accounts payable and accrued liabilities at September 30, 2021 and December 31, 2020 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zR1agVoonH9l" style="display: none">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20210930_zxUxGh7K5Mtl" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20201231_zUfoKF0rxHO2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,299,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">16,298</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--AccruedCreditCard_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Credit Card</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,712</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,513,517</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,832</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Salary</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">995,265</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0936"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Payroll Tax Payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">33,189</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0939"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTIC_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> <span style="display: none; font-family: Times New Roman, Times, Serif">Accounts Payable and Accrued Liabilities</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,879,082</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">148,180</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 6299400 16298 37712 1050 3513517 130832 995265 33189 10879082 148180 <p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_z70fhVOkMkBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 7 – <span id="xdx_822_zECeJ077BO3f">NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_ziIqxaPPGubh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Notes payable at September 30, 2021 and December 31, 2020 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_z7xMG2QzwXj2" style="display: none">SCHEDULE OF NOTES PAYABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%; text-align: left">Excel Family Partners, LLLP / Banyan Pediatric Investment, Inc. (Sep 2020)</td><td style="width: 2%"> </td> <td style="width: 4%">a</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember_fKGEp_zyv1zKzo1b73" style="width: 16%; text-align: right" title="Notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember_fKGEp_zBy6y2H7r0Fk" style="width: 16%; text-align: right" title="Notes payable">2,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">NuView Trust Co. (Nov 2020)</td><td> </td> <td>b</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--NuViewTrustCoMember_fKGIp_zNHZF9SG0HW8" style="text-align: right" title="Notes payable">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--NuViewTrustCoMember_fKGIp_zsfSsPwTMPgl" style="text-align: right" title="Notes payable">300,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Grand Trinity Plaza, LLC (Dec 2020)</td><td> </td> <td>c</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember_fKGMp_zJFsbd7bJL7i" style="text-align: right" title="Notes payable">346,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember_fKGMp_zB1P0EQG8zMe" style="text-align: right" title="Notes payable">407,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Reliant</td><td> </td> <td>d.i</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--ReliantMember_fKGkp_zOdRUTf2YGVh" style="text-align: right" title="Notes payable">808,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--ReliantMember_fKGkp_zDxkcEQsynVb" style="text-align: right" title="Notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>HCSG</td><td> </td> <td>d.ii</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--HCSGMember_fKGlpKQ_____zkGxjd6bN1d" style="text-align: right" title="Notes payable">397,191</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--HCSGMember_fKGlpKQ_____zUEfTEUyCnea" style="text-align: right" title="Notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0966">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Medline</td><td> </td> <td>d.iii</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--MedlineMember_fKGlpaSk___zLDS54okmgT3" style="text-align: right" title="Notes payable">242,967</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--MedlineMember_fKGlpaSk___zMPmk2Po9GD8" style="text-align: right" title="Notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0970">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">SLR - RLOC</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">e</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--SLRRLOCMember_fKGUp_zcCRik5evFI" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes payable">5,212,234</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--SLRRLOCMember_fKGUp_zz62nZLEuQY2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--NotesPayableCurrent_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">7,306,876</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesPayableCurrent_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">2,707,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0A_zNcOsvUh0zD5" style="font: 10pt Times New Roman, Times, Serif">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zz3uBxzsmRk4" style="font: 10pt Times New Roman, Times, Serif">On September 18, 2020, through Banyan, we entered into a Convertible Note and Securities Purchase Agreement with two investors for the aggregate principal in the amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_pp0p0" title="Aggregate principal amount">2,000,000</span>. The note had a maturity date of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20200917__20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_zXYsF9m6OGYe" title="Maturity date">September 18, 2022</span>, and an interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_zhuiTcMtutt8" title="Interest rate">8</span>% to be paid quarterly. The principal was funded by two investors (“Purchasers”), both related parties. Excel Family Partners, LLLP invested $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_c20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_pp0p0" title="Aggregate principal amount">1,500,000</span> and Banyan Pediatric Investments, LLC invested $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BanyanPediatricCareCentersIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_pp0p0" title="Aggregate principal amount">500,000</span>. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. Written consent from shareholders holding a majority of the issued and outstanding shares of common stock of Banyan was obtained, not including such shares currently held by the Purchasers or their affiliates, consenting to the note contemplated hereby, in a form and substance acceptable to the Purchasers, in their respective reasonable discretion. Both Purchasers were permitted to convert their respective portions of the note at a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_zOqGQEk6RJt9" title="Debt Instrument, Convertible, Conversion Price">0.10</span> per share. Subsequent to the Merger (see NOTE 3), the Board revised the conversion price of the note to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210323__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_zoSDzisMPbnd" title="Debt Instrument, Convertible, Conversion Price">0.50</span> per share. Effective March 30, 2021, the Purchasers exercised their right to convert all outstanding principal. As of September 30, 2021, and December 31, 2020, there was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--InterestPayableCurrent_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_pp0p0" title="Interest Payable, Current">0</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--InterestPayableCurrent_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_pp0p0" title="Interest Payable, Current">45,589</span> of accrued interest, respectively and is reflected in accrued interest balances on the condensed consolidated balance sheet at September 30, 2021 and December 31, 2020.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0C_z0CdIxnbRH7a" style="font: 10pt Times New Roman, Times, Serif">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zwr0Z2P6Dm2e" style="font: 10pt Times New Roman, Times, Serif">On November 6, 2020, through Banyan, we entered into a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentTerm_dxL_c20201105__20201106__dei--LegalEntityAxis__custom--NuViewTrustCoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zaKflwXaFIki" title="Maturity term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1000">one</span></span>-year note in the principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_c20201106__dei--LegalEntityAxis__custom--NuViewTrustCoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Aggregate principal amount">300,000</span> with NuView Trust Company. The note has a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201106__dei--LegalEntityAxis__custom--NuViewTrustCoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zSipQHddXpT8" title="Interest rate">12</span>% interest rate with interest only payments until date of maturity. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. As of September 30, 2021, and December 31, 2020, there was <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--InterestPayableCurrent_iI_pp0p0_do_c20200930__dei--LegalEntityAxis__custom--NuViewTrustCoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_z1CEVSQjAjgd" title="Interest Payable, Current"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--InterestPayableCurrent_iI_pp0p0_do_c20201231__dei--LegalEntityAxis__custom--NuViewTrustCoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_ztbKahh3153g" title="Interest Payable, Current">no</span></span> accrued interest. (see NOTE 3)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0E_zL1Pawt1WXY7" style="font: 10pt Times New Roman, Times, Serif">c.</span></td> <td colspan="4" style="text-align: justify"><span id="xdx_F18_zsoXqGYiEZ8l" style="font: 10pt Times New Roman, Times, Serif">On December 15, 2020, through Banyan Pediatric Care Centers – Pasco, LLC, we entered into a note payable with Grand Trinity Plaza, LLC in the principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Aggregate principal amount">407,500</span>, which is guaranteed by Banyan. The term of the note is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentTerm_dtM_c20201214__20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zyTaw1WdV8c6" title="Maturity term">48</span> months with an interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_z6wwQ9rwvoLk" title="Interest rate">6</span>%. The maturity date of the note is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20201214__20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zgnlWQSoKyEg" title="Maturity date">January 1, 2025</span>. The note is in conjunction with the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_znLlP1GILIX4" title="Lease term::XDX::P84M"><span style="-sec-ix-hidden: xdx2ixbrl1019">84</span></span>-month facility lease for the Pasco County location, pursuant to which the landlord also provided the construction of the buildout and financed $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--LeaseholdImprovementsGross_c20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Construction costs">407,500</span> of the construction costs.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="4" style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">d.</span></td> <td colspan="4" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In 2019, certain vendors of Trillium agreed to extend payment terms by converting then outstanding amounts of accounts payable balances to long-term debt bearing interest at rates ranging from <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191231__srt--RangeAxis__srt--MinimumMember__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember_z8ffspCnUNLl" title="Interest rate">0</span>% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191231__srt--RangeAxis__srt--MaximumMember__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember_zWp3AJMbx1af" title="Interest rate">6</span>%.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="4" style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F08_zDnRczQLXzRe" style="font: 10pt Times New Roman, Times, Serif">i.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_z5f6SivlvjO2" style="font: 10pt Times New Roman, Times, Serif">Reliant note payable - Past due balances with vendor Reliant were converted to a note payable in <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentPaymentTerms_c20190101__20191231__dei--LegalEntityAxis__custom--ReliantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember" title="Debt Instrument, Payment Terms">36 equal monthly installments</span> of principal and interest of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20190101__20191231__dei--LegalEntityAxis__custom--ReliantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Principal and interest amount">69,568</span> from October 2019 through September 2022. The note bears interest at a rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191231__dei--LegalEntityAxis__custom--ReliantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_ziYwAqgEbdN5" title="Interest rate">6</span>%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20191231__dei--LegalEntityAxis__custom--ReliantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zm3eygHWBFti" title="Maturity date">September 30, 2021</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="4" style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F09_zY8d0rlCDv3l" style="font: 10pt Times New Roman, Times, Serif">ii.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zc6cWwLv3OL2" style="font: 10pt Times New Roman, Times, Serif">HCSG note payable – Past due balances with vendor HCSG were converted to a non-interest-bearing note payable; payable in <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentPaymentTerms_c20190101__20191231__dei--LegalEntityAxis__custom--HCSGMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember" title="Debt Instrument, Payment Terms">36 equal monthly principal installments</span> of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20190101__20191231__dei--LegalEntityAxis__custom--HCSGMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Debt Instrument, Periodic Payment, Principal">33,099 </span>from October 2019 through September 2022. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20191231__dei--LegalEntityAxis__custom--HCSGMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_z72EW1QRCff1" title="Maturity date">September 30, 2021</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F09_zAqEZWxCflgj" style="font: 10pt Times New Roman, Times, Serif">iii.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zXu3rWvTgepc" style="font: 10pt Times New Roman, Times, Serif">Medline note payable – Past due balances with vendor Medline were converted to a note payable; payable in <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentPaymentTerms_c20190101__20191231__dei--LegalEntityAxis__custom--MedlineMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember" title="Debt Instrument, Payment Terms">36 equal monthly installments of principal</span> and interest of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_c20190101__20191231__dei--LegalEntityAxis__custom--MedlineMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Principal and interest amount">20,911</span> from October 2019 through September 2022; note bears interest at a rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191231__dei--LegalEntityAxis__custom--MedlineMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zRVPdNK97Zmb" title="Interest rate">6</span>%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20191231__dei--LegalEntityAxis__custom--MedlineMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zg1aPgIeW4Q6" title="Maturity date">September 30, 2021</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="4" style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F07_zT1ym81RnzLj" style="font: 10pt Times New Roman, Times, Serif">e.</span></td> <td colspan="4" style="text-align: justify"><span id="xdx_F10_zwv6Qvh5tckc" style="font: 10pt Times New Roman, Times, Serif">SLR revolving line of credit - On May 9, 2019, Trillium entered into a financing agreement (“the GHF Line”) with Gemino Healthcare Finance, LLC (DBA SLR Healthcare ABL), the lender, which allows the Trillium Subsidiaries to borrow up to the lesser of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_ztUskVNJNXue" title="Line of credit facility, maximum borrowing capacity">10</span> million or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--PercentageOfFinancingAccountsReceivable_pid_dp_uPure_c20190508__20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zosoRjPT7l55" title="Accounts receivable percentage">85</span>% of eligible accounts receivable. The GHF Line bears interest at the greater of one-month LIBOR or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20190508__20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember_zbjn0nIFWedk" title="Bears interest rate">2</span>%, plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20190508__20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_z6zbxip5J5I" title="Bears interest rate">4.95</span>%, applied daily, and continues to be applied to outstanding principal until the expiration of one business day after such principal has been repaid. The Trillium Subsidiaries also incur monthly collateral management fees under the line of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_ecustom--LineOfCreditFacilityUnusedCapacityManagementFeePercentage_iI_pid_dp_uPure_c20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zcOsHbmj17me" title="Management fee percentage">1</span> % of the average daily balance of the preceding month and is subject to a monthly unused line fee of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_pid_dp_uPure_c20190508__20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zQL3YGr3DZ79" title="Unused capacity, percentage">0.75</span>% of the difference between revolving loan commitment and the average daily balance outstanding during the preceding month. The GHF Line is secured by cash, accounts receivable, and substantially all intangible assets of the Trillium Subsidiaries and terminates on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20190508__20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_z9UfK7IuivP4" title="Maturity date">May 9, 2022</span>. On July 12, 2021, the agreement was amended whereas Assisted 4 Living, Inc was named as the Guarantor of the line. At September 30, 2021, the outstanding balance on the line was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--LineOfCredit_c20210930__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_pp0p0" title="Outstanding balance amount">5,212,234</span>.  On September 30, 2021 we entered into a Second Amendment of the financing agreement with GHF. The Second Amendment amended the Credit Agreement by: <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentDescription_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zkmriP8ZQVgh" title="Debt description">(1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zFQcrjydrn02">September 29, 2023</span>; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; and (7) increasing the maximum amount of the credit facility from $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--LineOfCredit_iI_pn6n6_dd_c20210929__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zk4IubhIGBZk" title="Line of credit facility">10</span> million to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--LineOfCredit_iI_pn6n6_dd_c20210930__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zIZZ5xo43hkl">25</span> million. The above changes are the primary changes to the credit facility</span>.</span></td></tr> </table> <p id="xdx_8A4_zEiL2pAYM3Db" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The entire balance due on each line has been classified as a current liability in accordance with FASB ASC Topic 470-10-45-5, Classification of Revolving Credit Agreements Subject to Lock-Box Arrangements. FASB guidance stipulates that if the contractual provisions of a loan arrangement require, in the ordinary course of business and without another event occurring, the cash receipts of a debtor to be used to repay the existing obligation, the credit agreement should be considered a short-term obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_891_eus-gaap--ScheduleOfDebtTableTextBlock_ziIqxaPPGubh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Notes payable at September 30, 2021 and December 31, 2020 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BA_z7xMG2QzwXj2" style="display: none">SCHEDULE OF NOTES PAYABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%; text-align: left">Excel Family Partners, LLLP / Banyan Pediatric Investment, Inc. (Sep 2020)</td><td style="width: 2%"> </td> <td style="width: 4%">a</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember_fKGEp_zyv1zKzo1b73" style="width: 16%; text-align: right" title="Notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember_fKGEp_zBy6y2H7r0Fk" style="width: 16%; text-align: right" title="Notes payable">2,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">NuView Trust Co. (Nov 2020)</td><td> </td> <td>b</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--NuViewTrustCoMember_fKGIp_zNHZF9SG0HW8" style="text-align: right" title="Notes payable">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--NuViewTrustCoMember_fKGIp_zsfSsPwTMPgl" style="text-align: right" title="Notes payable">300,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Grand Trinity Plaza, LLC (Dec 2020)</td><td> </td> <td>c</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember_fKGMp_zJFsbd7bJL7i" style="text-align: right" title="Notes payable">346,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember_fKGMp_zB1P0EQG8zMe" style="text-align: right" title="Notes payable">407,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Reliant</td><td> </td> <td>d.i</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--ReliantMember_fKGkp_zOdRUTf2YGVh" style="text-align: right" title="Notes payable">808,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--ReliantMember_fKGkp_zDxkcEQsynVb" style="text-align: right" title="Notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>HCSG</td><td> </td> <td>d.ii</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--HCSGMember_fKGlpKQ_____zkGxjd6bN1d" style="text-align: right" title="Notes payable">397,191</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--HCSGMember_fKGlpKQ_____zUEfTEUyCnea" style="text-align: right" title="Notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0966">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Medline</td><td> </td> <td>d.iii</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--MedlineMember_fKGlpaSk___zLDS54okmgT3" style="text-align: right" title="Notes payable">242,967</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--MedlineMember_fKGlpaSk___zMPmk2Po9GD8" style="text-align: right" title="Notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0970">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">SLR - RLOC</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">e</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20210930__dei--LegalEntityAxis__custom--SLRRLOCMember_fKGUp_zcCRik5evFI" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes payable">5,212,234</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--SLRRLOCMember_fKGUp_zz62nZLEuQY2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Notes payable"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--NotesPayableCurrent_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">7,306,876</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesPayableCurrent_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes payable">2,707,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0A_zNcOsvUh0zD5" style="font: 10pt Times New Roman, Times, Serif">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zz3uBxzsmRk4" style="font: 10pt Times New Roman, Times, Serif">On September 18, 2020, through Banyan, we entered into a Convertible Note and Securities Purchase Agreement with two investors for the aggregate principal in the amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_pp0p0" title="Aggregate principal amount">2,000,000</span>. The note had a maturity date of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20200917__20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_zXYsF9m6OGYe" title="Maturity date">September 18, 2022</span>, and an interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_zhuiTcMtutt8" title="Interest rate">8</span>% to be paid quarterly. The principal was funded by two investors (“Purchasers”), both related parties. Excel Family Partners, LLLP invested $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_c20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_pp0p0" title="Aggregate principal amount">1,500,000</span> and Banyan Pediatric Investments, LLC invested $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BanyanPediatricCareCentersIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_pp0p0" title="Aggregate principal amount">500,000</span>. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. Written consent from shareholders holding a majority of the issued and outstanding shares of common stock of Banyan was obtained, not including such shares currently held by the Purchasers or their affiliates, consenting to the note contemplated hereby, in a form and substance acceptable to the Purchasers, in their respective reasonable discretion. Both Purchasers were permitted to convert their respective portions of the note at a conversion price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20200918__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_zOqGQEk6RJt9" title="Debt Instrument, Convertible, Conversion Price">0.10</span> per share. Subsequent to the Merger (see NOTE 3), the Board revised the conversion price of the note to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210323__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_zoSDzisMPbnd" title="Debt Instrument, Convertible, Conversion Price">0.50</span> per share. Effective March 30, 2021, the Purchasers exercised their right to convert all outstanding principal. As of September 30, 2021, and December 31, 2020, there was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--InterestPayableCurrent_c20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_pp0p0" title="Interest Payable, Current">0</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--InterestPayableCurrent_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteAndSecuritiesPurchaseAgreementMember_pp0p0" title="Interest Payable, Current">45,589</span> of accrued interest, respectively and is reflected in accrued interest balances on the condensed consolidated balance sheet at September 30, 2021 and December 31, 2020.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0C_z0CdIxnbRH7a" style="font: 10pt Times New Roman, Times, Serif">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zwr0Z2P6Dm2e" style="font: 10pt Times New Roman, Times, Serif">On November 6, 2020, through Banyan, we entered into a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentTerm_dxL_c20201105__20201106__dei--LegalEntityAxis__custom--NuViewTrustCoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zaKflwXaFIki" title="Maturity term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1000">one</span></span>-year note in the principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_c20201106__dei--LegalEntityAxis__custom--NuViewTrustCoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Aggregate principal amount">300,000</span> with NuView Trust Company. The note has a <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201106__dei--LegalEntityAxis__custom--NuViewTrustCoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zSipQHddXpT8" title="Interest rate">12</span>% interest rate with interest only payments until date of maturity. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. As of September 30, 2021, and December 31, 2020, there was <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--InterestPayableCurrent_iI_pp0p0_do_c20200930__dei--LegalEntityAxis__custom--NuViewTrustCoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_z1CEVSQjAjgd" title="Interest Payable, Current"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--InterestPayableCurrent_iI_pp0p0_do_c20201231__dei--LegalEntityAxis__custom--NuViewTrustCoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_ztbKahh3153g" title="Interest Payable, Current">no</span></span> accrued interest. (see NOTE 3)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0E_zL1Pawt1WXY7" style="font: 10pt Times New Roman, Times, Serif">c.</span></td> <td colspan="4" style="text-align: justify"><span id="xdx_F18_zsoXqGYiEZ8l" style="font: 10pt Times New Roman, Times, Serif">On December 15, 2020, through Banyan Pediatric Care Centers – Pasco, LLC, we entered into a note payable with Grand Trinity Plaza, LLC in the principal amount of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Aggregate principal amount">407,500</span>, which is guaranteed by Banyan. The term of the note is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--DebtInstrumentTerm_dtM_c20201214__20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zyTaw1WdV8c6" title="Maturity term">48</span> months with an interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_z6wwQ9rwvoLk" title="Interest rate">6</span>%. The maturity date of the note is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20201214__20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zgnlWQSoKyEg" title="Maturity date">January 1, 2025</span>. The note is in conjunction with the <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_znLlP1GILIX4" title="Lease term::XDX::P84M"><span style="-sec-ix-hidden: xdx2ixbrl1019">84</span></span>-month facility lease for the Pasco County location, pursuant to which the landlord also provided the construction of the buildout and financed $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--LeaseholdImprovementsGross_c20201215__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Construction costs">407,500</span> of the construction costs.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="4" style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">d.</span></td> <td colspan="4" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In 2019, certain vendors of Trillium agreed to extend payment terms by converting then outstanding amounts of accounts payable balances to long-term debt bearing interest at rates ranging from <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191231__srt--RangeAxis__srt--MinimumMember__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember_z8ffspCnUNLl" title="Interest rate">0</span>% to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191231__srt--RangeAxis__srt--MaximumMember__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember_zWp3AJMbx1af" title="Interest rate">6</span>%.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="4" style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F08_zDnRczQLXzRe" style="font: 10pt Times New Roman, Times, Serif">i.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F13_z5f6SivlvjO2" style="font: 10pt Times New Roman, Times, Serif">Reliant note payable - Past due balances with vendor Reliant were converted to a note payable in <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentPaymentTerms_c20190101__20191231__dei--LegalEntityAxis__custom--ReliantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember" title="Debt Instrument, Payment Terms">36 equal monthly installments</span> of principal and interest of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20190101__20191231__dei--LegalEntityAxis__custom--ReliantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Principal and interest amount">69,568</span> from October 2019 through September 2022. The note bears interest at a rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191231__dei--LegalEntityAxis__custom--ReliantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_ziYwAqgEbdN5" title="Interest rate">6</span>%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20191231__dei--LegalEntityAxis__custom--ReliantMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zm3eygHWBFti" title="Maturity date">September 30, 2021</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="4" style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F09_zY8d0rlCDv3l" style="font: 10pt Times New Roman, Times, Serif">ii.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1A_zc6cWwLv3OL2" style="font: 10pt Times New Roman, Times, Serif">HCSG note payable – Past due balances with vendor HCSG were converted to a non-interest-bearing note payable; payable in <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--DebtInstrumentPaymentTerms_c20190101__20191231__dei--LegalEntityAxis__custom--HCSGMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember" title="Debt Instrument, Payment Terms">36 equal monthly principal installments</span> of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20190101__20191231__dei--LegalEntityAxis__custom--HCSGMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Debt Instrument, Periodic Payment, Principal">33,099 </span>from October 2019 through September 2022. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20191231__dei--LegalEntityAxis__custom--HCSGMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_z72EW1QRCff1" title="Maturity date">September 30, 2021</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F09_zAqEZWxCflgj" style="font: 10pt Times New Roman, Times, Serif">iii.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1F_zXu3rWvTgepc" style="font: 10pt Times New Roman, Times, Serif">Medline note payable – Past due balances with vendor Medline were converted to a note payable; payable in <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--DebtInstrumentPaymentTerms_c20190101__20191231__dei--LegalEntityAxis__custom--MedlineMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember" title="Debt Instrument, Payment Terms">36 equal monthly installments of principal</span> and interest of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_c20190101__20191231__dei--LegalEntityAxis__custom--MedlineMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Principal and interest amount">20,911</span> from October 2019 through September 2022; note bears interest at a rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191231__dei--LegalEntityAxis__custom--MedlineMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zRVPdNK97Zmb" title="Interest rate">6</span>%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20190101__20191231__dei--LegalEntityAxis__custom--MedlineMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zg1aPgIeW4Q6" title="Maturity date">September 30, 2021</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="4" style="text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F07_zT1ym81RnzLj" style="font: 10pt Times New Roman, Times, Serif">e.</span></td> <td colspan="4" style="text-align: justify"><span id="xdx_F10_zwv6Qvh5tckc" style="font: 10pt Times New Roman, Times, Serif">SLR revolving line of credit - On May 9, 2019, Trillium entered into a financing agreement (“the GHF Line”) with Gemino Healthcare Finance, LLC (DBA SLR Healthcare ABL), the lender, which allows the Trillium Subsidiaries to borrow up to the lesser of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_ztUskVNJNXue" title="Line of credit facility, maximum borrowing capacity">10</span> million or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_ecustom--PercentageOfFinancingAccountsReceivable_pid_dp_uPure_c20190508__20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zosoRjPT7l55" title="Accounts receivable percentage">85</span>% of eligible accounts receivable. The GHF Line bears interest at the greater of one-month LIBOR or <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20190508__20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember_zbjn0nIFWedk" title="Bears interest rate">2</span>%, plus <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20190508__20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_z6zbxip5J5I" title="Bears interest rate">4.95</span>%, applied daily, and continues to be applied to outstanding principal until the expiration of one business day after such principal has been repaid. The Trillium Subsidiaries also incur monthly collateral management fees under the line of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_ecustom--LineOfCreditFacilityUnusedCapacityManagementFeePercentage_iI_pid_dp_uPure_c20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zcOsHbmj17me" title="Management fee percentage">1</span> % of the average daily balance of the preceding month and is subject to a monthly unused line fee of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_908_eus-gaap--LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_pid_dp_uPure_c20190508__20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zQL3YGr3DZ79" title="Unused capacity, percentage">0.75</span>% of the difference between revolving loan commitment and the average daily balance outstanding during the preceding month. The GHF Line is secured by cash, accounts receivable, and substantially all intangible assets of the Trillium Subsidiaries and terminates on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20190508__20190509__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_z9UfK7IuivP4" title="Maturity date">May 9, 2022</span>. On July 12, 2021, the agreement was amended whereas Assisted 4 Living, Inc was named as the Guarantor of the line. At September 30, 2021, the outstanding balance on the line was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--LineOfCredit_c20210930__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--DebtInstrumentAxis__custom--GeminoHealthcareFinanceLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_pp0p0" title="Outstanding balance amount">5,212,234</span>.  On September 30, 2021 we entered into a Second Amendment of the financing agreement with GHF. The Second Amendment amended the Credit Agreement by: <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_eus-gaap--DebtInstrumentDescription_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zkmriP8ZQVgh" title="Debt description">(1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zFQcrjydrn02">September 29, 2023</span>; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; and (7) increasing the maximum amount of the credit facility from $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_905_eus-gaap--LineOfCredit_iI_pn6n6_dd_c20210929__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zk4IubhIGBZk" title="Line of credit facility">10</span> million to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE5PVEVTIFBBWUFCTEUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--LineOfCredit_iI_pn6n6_dd_c20210930__srt--ConsolidatedEntitiesAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--CreditFacilityAxis__us-gaap--LineOfCreditMember_zIZZ5xo43hkl">25</span> million. The above changes are the primary changes to the credit facility</span>.</span></td></tr> </table> 2000000 300000 300000 346174 407500 808310 397191 242967 5212234 7306876 2707500 2000000 2022-09-18 0.08 1500000 500000 0.10 0.50 0 45589 300000 0.12 0 0 407500 P48M 0.06 2025-01-01 407500 0 0.06 36 equal monthly installments 69568 0.06 2021-09-30 36 equal monthly principal installments 33099 2021-09-30 36 equal monthly installments of principal 20911 0.06 2021-09-30 10000000 0.85 0.02 0.0495 0.01 0.0075 2022-05-09 5212234 (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; and (7) increasing the maximum amount of the credit facility from $10 million to $25 million. The above changes are the primary changes to the credit facility 2023-09-29 10000000 25000000 <p id="xdx_808_ecustom--LeasesholdImprovementsTextBlock_zh9FouQdTYA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 8 – <span id="xdx_826_zTbzgHv09Wwg">LEASEHOLD IMPROVEMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_ecustom--ScheduleOfLeasesholdImprovementsTableTextBlock_zXSgo5mElSja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company had the following leasehold improvements as of September 30, 2021 and December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B1_zUXrDzfAOYB2" style="display: none">SCHEDULE OF LEASESHOLD IMPROVEMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amortization</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Period</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Leasehold improvements"><span style="font: 10pt Times New Roman, Times, Serif">3,984,470</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Leasehold improvements"><span style="font: 10pt Times New Roman, Times, Serif">2,669,047</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_z5eze4wo6uBd" title="Amortization Period">15</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zQKjJT7zwYSk" title="Amortization Period">17</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Less: amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zrmO9KYc7JRi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: amortization"><span style="font: 10pt Times New Roman, Times, Serif">(218,140</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zeZIwP7ByDB8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: amortization"><span style="font: 10pt Times New Roman, Times, Serif">(54,656</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net"><span style="font: 10pt Times New Roman, Times, Serif">3,766,330</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net"><span style="font: 10pt Times New Roman, Times, Serif">2,614,391</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A6_z1qhXQOL5IW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2020, we recorded $<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" title="Leasehold improvements">2,669,047</span> of leasehold improvements. These amounts include costs related to the build out of the Sarasota location in the amount of $<span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--StatementGeographicalAxis__custom--SarasotaFloridaMember_pp0p0" title="Leasehold improvements">1,245,950</span>. These costs will be amortized over the expected term of the lease including extensions that management expects to be <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--StatementGeographicalAxis__custom--SarasotaFloridaMember_zTsKG89skp38" title="Amortization Period">15</span> years. We also recorded costs in the amount of $<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--StatementGeographicalAxis__custom--NewPortRicheyFloridaMember_pp0p0" title="Leasehold improvements">1,021,793</span> related to the New Port Richey location buildout. The expected amortization of the improvements for the New Port Richey location is <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--StatementGeographicalAxis__custom--NewPortRicheyFloridaMember_zleZRbB7OSJk" title="Amortization Period">17</span> years. Also recorded were $<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--StatementGeographicalAxis__custom--StPetersburgFloridaMember_pp0p0" title="Leasehold improvements">401,303</span> of improvements as part of the St. Petersburg-Kidz Club Acquisition. The expected amortization of the improvements for the St. Petersburg location is <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20200101__20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--StatementGeographicalAxis__custom--StPetersburgFloridaMember_zK2FxOmbydLe" title="Amortization Period">15</span> years. We also recorded $<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__us-gaap--BusinessAcquisitionAxis__custom--TrilliumHealthcareGroupLLCMember_pp0p0" title="Leasehold improvements">1,213,273</span> in lease improvements as part of the Trillium acquisition, during the nine-month period ending September 30, 202.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Amortization expense for the three months ended September 30, 2021 and 2020 was $<span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20210701__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" title="Amortization expense">70,193</span> and $<span id="xdx_906_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_pp0p0_c20200701__20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zgQOWm85CV97" title="Amortization expense">13,593</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Amortization expense for the nine months ended September 30, 2021 and 2020 was $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" title="Amortization expense">218,140</span> and $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_c20200101__20200930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" title="Amortization expense">54,656</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_ecustom--ScheduleOfLeasesholdImprovementsTableTextBlock_zXSgo5mElSja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company had the following leasehold improvements as of September 30, 2021 and December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B1_zUXrDzfAOYB2" style="display: none">SCHEDULE OF LEASESHOLD IMPROVEMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Amortization</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Period</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Leasehold improvements"><span style="font: 10pt Times New Roman, Times, Serif">3,984,470</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Leasehold improvements"><span style="font: 10pt Times New Roman, Times, Serif">2,669,047</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_z5eze4wo6uBd" title="Amortization Period">15</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zQKjJT7zwYSk" title="Amortization Period">17</span> years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Less: amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zrmO9KYc7JRi" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: amortization"><span style="font: 10pt Times New Roman, Times, Serif">(218,140</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zeZIwP7ByDB8" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: amortization"><span style="font: 10pt Times New Roman, Times, Serif">(54,656</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentNet_c20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net"><span style="font: 10pt Times New Roman, Times, Serif">3,766,330</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net"><span style="font: 10pt Times New Roman, Times, Serif">2,614,391</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 3984470 2669047 P15Y P17Y 218140 54656 3766330 2614391 2669047 1245950 P15Y 1021793 P17Y 401303 P15Y 1213273 70193 13593 218140 54656 <p id="xdx_809_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z95zpaKed5a1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 9 – <span id="xdx_82C_zFs4HG29Bifk">PROPERTY AND EQUIPMENT</span></b></span></p> <p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVHSjXHYSU6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B7_zjZVV92b8Akl" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20210930_zZT2tcKxPZK6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20201231_z0LkCW0Y5ZM5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization Period</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--FurnitureAndFixturesGross_iI_zMrjvUDxLXfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">987,904</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">73,594</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_pp0p0_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zPCVbmy0Fvi1" title="Amortization period">5</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CapitalizedComputerSoftwareGross_iI_zLqLmQJ40Ny4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computers / equipment / software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,952</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_pp0p0_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersEquipmentSoftwareMember_zpWJrk4vY8Q7">5</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--MotorVehiclesGross_iI_zwQRpjaTO3Sl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Motor vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,084</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,084</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_pp0p0_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MotorVehiclesMember_zUDBRX6DyQCc">5</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BuildingsAndImprovementsGross_iI_zY1DQ1LEHPhl" style="vertical-align: bottom; background-color: White"> <td>Buildings</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,060,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1137"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_pp0p0_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--BuildingsMember_znEQJBDHghuj">39</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Land_iI_zvfdnk2B6Os4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Land</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1141"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConstructionInProgressGross_iI_zfZgYC26NIQc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,699</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1144"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z6iNT1IrJhNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(76,524</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,604</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zBxGpVLAM4Tf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,680,115</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">128,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_z6BkAVA0y6kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2020 we recorded $<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20201231_zVYBUdhoKXyd" title="Property plant and equipment">136,079</span> in property plant and equipment. These expenses were related to furniture and fixtures and for the new Banyan Sarasota and Pasco locations. We also recorded expenses related to computers and equipment for these new locations, as well as the St Petersburg location acquired in May of 2020. We also purchased buses for the St. Petersburg location, as of the year ended December 2020 we had one bus that was purchased for cash and is being depreciated. Other buses have been purchased with finance leases and are reflected in Right of Use Assets and Lease Liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the nine month period ending September 30, 2021 we recorded additional furniture and fixtures related to the Banyan locations in the amount of approximately $<span id="xdx_907_eus-gaap--FurnitureAndFixturesGross_iI_c20210930__srt--StatementGeographicalAxis__custom--BanyanMember_zynKhK0nvFif" title="Furniture and fixtures">23,000</span>   and additional computers and equipment in the amount of approximately $<span id="xdx_908_eus-gaap--CapitalizedComputerSoftwareGross_iI_c20210930__srt--StatementGeographicalAxis__custom--BanyanMember_zfQ7rGbJhmW6" title="Computers and equipment">41,000</span>. These purchases were related to the completion of the Banyan Sarasota and Pasco locations that opened in May and July of 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Through the Trillium acquisition on June 10, 2021 we recorded approximately $<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentAdditions_pn5n6_c20210609__20210610__us-gaap--BusinessAcquisitionAxis__custom--TrilliumHealthcareGroupLLCMember_zYa9eZU4pa4k" title="Property plant and equipment, addition">3.6</span>M in property, plant and equipment consisting of furniture and fixtures, equipment, leasehold improvements in construction and a building. During the three month period ended September 30, 2021 we recorded approximately $<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentAdditions_pp0p0_c20210701__20210930__us-gaap--BusinessAcquisitionAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zJyEdf8rvTFc">69,487</span> in additional furniture and fixtures for the Trillium locations  .</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVHSjXHYSU6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B7_zjZVV92b8Akl" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20210930_zZT2tcKxPZK6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20201231_z0LkCW0Y5ZM5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization Period</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--FurnitureAndFixturesGross_iI_zMrjvUDxLXfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Furniture and fixtures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">987,904</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">73,594</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_pp0p0_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zPCVbmy0Fvi1" title="Amortization period">5</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CapitalizedComputerSoftwareGross_iI_zLqLmQJ40Ny4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computers / equipment / software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95,952</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_pp0p0_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersEquipmentSoftwareMember_zpWJrk4vY8Q7">5</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--MotorVehiclesGross_iI_zwQRpjaTO3Sl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Motor vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,084</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,084</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_pp0p0_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MotorVehiclesMember_zUDBRX6DyQCc">5</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--BuildingsAndImprovementsGross_iI_zY1DQ1LEHPhl" style="vertical-align: bottom; background-color: White"> <td>Buildings</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,060,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1137"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_pp0p0_dtY_c20210101__20210930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--BuildingsMember_znEQJBDHghuj">39</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Land_iI_zvfdnk2B6Os4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Land</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1141"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConstructionInProgressGross_iI_zfZgYC26NIQc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Construction in progress</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,699</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1144"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z6iNT1IrJhNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: depreciation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(76,524</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,604</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zBxGpVLAM4Tf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,680,115</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">128,475</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 987904 73594 P5Y 95952 50401 P5Y 12084 12084 P5Y 1060000 P39Y 500000 100699 76524 7604 2680115 128475 136079 23000 41000 3600000 69487 <p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zBoQ6k0T71r7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 10 – <span id="xdx_82E_znjmCDgGlaNf">OPERATING AND CAPITAL LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On August 24, 2019, through Banyan Pediatric Care Centers-Sarasota, LLC, we entered into an operating lease with Northeast Plaza Venture I, LLC for the premises located in the Northeast Plaza Shopping Center located on the Northeast corner of 17th Street &amp; Lockwood Ridge Road, in the County of Sarasota, Florida. The initial term of the lease is <span id="xdx_905_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20190824__srt--ConsolidatedEntitiesAxis__custom--BanyanPediatricCareCentersIncMember__dei--LegalEntityAxis__custom--NortheastPlazaVentureILLCMember_zWFCl89U43u5" title="Lease term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1163">five</span></span> years with minimum annual rent of $<span id="xdx_905_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20190824__srt--ConsolidatedEntitiesAxis__custom--BanyanPediatricCareCentersIncMember__dei--LegalEntityAxis__custom--NortheastPlazaVentureILLCMember_pp0p0" title="Minimum annual rent">180,000</span>. <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDescription_c20190823__20190824__srt--ConsolidatedEntitiesAxis__custom--BanyanPediatricCareCentersIncMember__dei--LegalEntityAxis__custom--NortheastPlazaVentureILLCMember" title="Lease description">The landlord granted rent abatement for this lease until February 24, 2020</span>. <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20190823__20190824__srt--ConsolidatedEntitiesAxis__custom--BanyanPediatricCareCentersIncMember__dei--LegalEntityAxis__custom--NortheastPlazaVentureILLCMember" title="Lessee, operating lease, option to extend">The lease end date, including two successive <span id="xdx_907_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20190824__srt--ConsolidatedEntitiesAxis__custom--BanyanPediatricCareCentersIncMember__dei--LegalEntityAxis__custom--NortheastPlazaVentureILLCMember_zNftWQd7uPFe" title="Lease renewal term">5</span>-year renewal options, is January 31, 2035</span>. A right of use asset and lease liability in the amount of $<span id="xdx_902_eus-gaap--OperatingLeaseLiability_c20190824__srt--ConsolidatedEntitiesAxis__custom--BanyanPediatricCareCentersIncMember__dei--LegalEntityAxis__custom--NortheastPlazaVentureILLCMember_pp0p0" title="Lease liability">1,899,869</span> associated with this lease was recognized. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On October 15, 2019, through Banyan, we entered into an assignment and assumption of lease agreement with The Kidz Club – St. Pete, LLC whereby we assumed approximately <span id="xdx_907_eus-gaap--AreaOfLand_iI_usqft_c20191015__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zmCzZ2vHQXrc" title="Area under lease">12,137</span> square feet of space at the southeast corner of 3rd Avenue S. and 9th Street N., Webb’s Plaza, St. Petersburg, FL 33701. The minimum annual rent for the first year of the lease was $<span id="xdx_90F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20191015__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_pp0p0" title="Minimum annual rent">113,681</span>. The current lease termination date, with extensions expected to be exercised, is <span id="xdx_909_ecustom--LesseeOperatingLeaseTerminationDate_dd_c20191014__20191015__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zDUAEV1CqiV4" title="Lease termination date">October 31, 2024</span>. Upon the exercise of each extension the base rent shall increase by <span id="xdx_907_ecustom--LesseeOperatingLeasePercentageOfIncreaseInBaseRent_pid_dp_uPure_c20191014__20191015__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zCVCxxGkVC67" title="Lease percentage of increase in base rent">1.5</span>%. This assignment of lease was subject to the terms of the Asset Purchase Agreement with The Kidz Club-St. Pete, LLC. A right of use asset and lease liability in the amount of $<span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_c20191015__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_pp0p0" title="Lease right of use asset">875,539</span> was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Effective April 1, 2020, through Banyan Pediatric Care Centers – Pasco, LLC, we entered into an <span id="xdx_904_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200402__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember_zqPf8FkXcBk" title="Lease term">84</span>-month facility lease with Grand Trinity Plaza, LLC for the premises located in the shopping center known as the Grand Trinity Plaza located in New Port Richey, Florida. The initial term of the lease had a minimum annual base rent of $<span id="xdx_90A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20200402__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember_pp0p0" title="Minimum annual rent">94,500</span>. <span id="xdx_906_eus-gaap--LesseeOperatingLeaseDescription_c20200401__20200402__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember" title="Lease description">The landlord granted rent abatement until September 2020</span>. <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200401__20200402__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember" title="Lessee, operating lease, option to extend">The lease end date, including two successive <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20200402__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember_zJw6CUUvqRb5" title="Lease renewal term">5</span>-year renewals is August 31, 2037</span>. A right of use asset and lease liability in the amount of $<span id="xdx_90F_eus-gaap--OperatingLeaseRightOfUseAsset_c20200402__dei--LegalEntityAxis__custom--GrandTrinityPlazaLLCMember_pp0p0" title="Lease right of use asset">1,143,743</span> was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On June 9, 2020, through Banyan, we entered into a <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200609__dei--LegalEntityAxis__custom--DexImagingMember_zRa5QSzVCcl7" title="Lease term">36</span>-month copier lease with Dex Imaging. The lease was for one copier and a printer. The minimum annual lease payment is $<span id="xdx_908_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20200609__dei--LegalEntityAxis__custom--DexImagingMember_pp0p0" title="Minimum annual rent">5,376</span> with annual increases not to exceed <span id="xdx_90B_ecustom--LesseeOperatingLeasePercentageOfIncreaseInBaseRent_pid_dp_uPure_c20200608__20200609__dei--LegalEntityAxis__custom--DexImagingMember__srt--RangeAxis__srt--MaximumMember_zvvZPUm5rwm" title="Lease percentage of increase in base rent">12</span>% annually. This lease will auto renew in <span id="xdx_907_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20200609__dei--LegalEntityAxis__custom--DexImagingMember_zqc4tJeafvnc" title="Lease renewal term">12</span>-month increments. <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDescription_c20200608__20200609__dei--LegalEntityAxis__custom--DexImagingMember" title="Lease description">The equipment under this lease has a fixed $1 payment buyout option</span>. This equipment was purchased for the St. Petersburg location. A right of use asset and lease liability in the amount of $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_c20200609__dei--LegalEntityAxis__custom--DexImagingMember_pp0p0" title="Lease right of use asset">16,066</span> was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On August 25, 2020, through Banyan, we entered into a <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200825__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_zZ3qptjYRSQ6" title="Lease term">60</span>-month financing agreement with Ascentium Capital LLC for two 2020 Turtletop Terra Transit passenger buses for the St. Petersburg location. <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20200824__20200825__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember" title="Lease description">This lease is considered an operating lease for accounting purposes because the lease period is less than the economic life of the asset being leased</span>. Minimum annual rent payments under this lease are $<span id="xdx_908_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20200825__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_pp0p0" title="Minimum annual rent">24,859</span>. At our discretion, we may exercise a purchase option, by giving written notice no later than 30 days but not more than 120 days before the expiration of the initial term. The purchase option price is $<span id="xdx_903_ecustom--LesseeOperatingLeasePurchaseOptionPrice_c20200825__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_pp0p0" title="Lease purchase option price">23,920</span> for each bus, based on reasonably predicted fair market value. A right of use asset and lease liability in the amount of $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_c20200825__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_pp0p0" title="Lease right of use asset">102,393</span> was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On October 20, 2020, through Banyan, we entered into a <span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20201020__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_zQHYaWwcpkW8" title="Lease term">60</span>-month financing agreement with Ascentium Capital LLC for a 2020 Eldorado National Advance 220 p/t 14 passenger bus for the St. Petersburg location. <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDescription_c20201019__20201020__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember" title="Lease description">This lease is considered an operating lease for accounting purposes because the lease period is less than the economic life of the asset being leased</span>. Minimum annual rent payments under this lease are $<span id="xdx_904_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20201020__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_pp0p0" title="Minimum annual rent">13,381</span>. At our discretion, we may exercise a purchase option, by giving written notice no later than 180 days but not more than 360 days before the expiration of the initial term. The purchase option price is $<span id="xdx_904_ecustom--LesseeOperatingLeasePurchaseOptionPrice_c20201020__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_pp0p0" title="Lease purchase option price">12,891</span> based on reasonably predicted fair market value. A right of use asset and lease liability in the amount of $<span id="xdx_90D_eus-gaap--OperatingLeaseRightOfUseAsset_c20201020__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_pp0p0" title="Lease right of use asset">55,345</span> was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In April of 2021, through Banyan, we entered into a <span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20210430__dei--LegalEntityAxis__custom--DexImagingMember_zDA6eFu2HWR" title="Lease term">36</span>-month copier lease with Dex Imaging. The lease was for one copy machine. The minimum annual lease payment is $<span id="xdx_903_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20210430__dei--LegalEntityAxis__custom--DexImagingMember_pp0p0" title="Minimum annual rent">4,920</span>. <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDescription_c20210401__20210430__dei--LegalEntityAxis__custom--DexImagingMember" title="Lease description">The equipment under this lease has a fixed $1 payment buyout option</span>. The equipment was purchased for the Banyan Sarasota location. A right of use asset and lease liability in the amount of $<span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_c20210430__dei--LegalEntityAxis__custom--DexImagingMember_pp0p0" title="Lease right of use asset">14,693</span> was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In July of 2021, through Banyan, we entered into a <span id="xdx_909_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20210731__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_zGzUWC5b9POa">60</span>-month financing agreement with Ascentium Capital LLC for a 2021 Diamond VIP 2200 passenger bus for the Pasco location. This lease is considered an operating lease for accounting purposes. Minimum annual rent payments under this lease are $<span id="xdx_90B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20210731__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_zZGVpDiRUxwl">15,654</span> and the purchase option price is $<span id="xdx_902_ecustom--LesseeOperatingLeasePurchaseOptionPrice_iI_pp0p0_c20210731__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_zK4bnisWBVgf">15,193</span> based on reasonably predicted fair market value. A right of use asset and lease liability in the amount of $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210731__dei--LegalEntityAxis__custom--AscentiumCapitalLLCMember_z85QPqThzyT1">65,772</span> was recognized with this lease.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In August of 2021, through Banyan we entered into a <span id="xdx_907_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20210831__dei--LegalEntityAxis__custom--DexImagingMember_zWZINzUgdno8">36</span>-month financing agreement with Dex Imaging. The lease was for one copy machine. The minimum annual lease payment is $<span id="xdx_907_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20210831__dei--LegalEntityAxis__custom--DexImagingMember_zkTb0dW7AMO4">4,920</span>. <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20210801__20210831__dei--LegalEntityAxis__custom--DexImagingMember_z3SiVhWT2pXk">The equipment under this lease has a fixed $1 payment buyout option</span>. The equipment was purchased for the Banyan Pasco location. A right of use asset and lease liability in the amount of $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210831__dei--LegalEntityAxis__custom--DexImagingMember_zXrgxJ5F6Q5d">14,040</span> was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In July of 2021, through Trillium we entered into a <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20210731__dei--LegalEntityAxis__custom--DexImagingMember_zU49b6lr1Aif">60</span>-month financing agreement with Dex Imaging. The lease was for one copy machine. The minimum annual lease payment is $<span id="xdx_903_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20210731__dei--LegalEntityAxis__custom--DexImagingMember_zPwnzz8hiYZ8">1,920</span>. A right of use asset and lease liability in the amount of $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210731__dei--LegalEntityAxis__custom--DexImagingMember_zfJS5kXPrGMd">8,049</span> was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In August of 2021, through Trillium we entered into a <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20210831__dei--LegalEntityAxis__custom--RJKoolMember_z3pyxsfCZNHa">60</span>-month financing agreement with RJKool for a Unimac commercial washing machine. The minimum annual lease payment is $<span id="xdx_90A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20210831__dei--LegalEntityAxis__custom--RJKoolMember_zDGdd0JbFEYj">4,321</span>. A right of use asset and lease liability in the amount of $<span id="xdx_90C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210831__dei--LegalEntityAxis__custom--RJKoolMember_z6bBy3tgY0gd">18,476</span> was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In July of 2021, through Trillium we entered into a <span id="xdx_902_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20210731__dei--LegalEntityAxis__custom--SoutheasternLaundryEquipmentSalesMember_zzV5WR8A2U5l">36</span>-month financing agreement with Southeastern Laundry Equipment Sales for a Unimac commercial washing machine. The minimum annual lease payment is $<span id="xdx_90D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20210731__dei--LegalEntityAxis__custom--SoutheasternLaundryEquipmentSalesMember_zTUE8KQkTFk">5,094</span>. A right of use asset and lease liability in the amount of $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210731__dei--LegalEntityAxis__custom--SoutheasternLaundryEquipmentSalesMember_zkbOqNnBuMi7">13,054</span> was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The leases assumed in the Trillium acquisition effective June 10, 2021 are reflected in accordance with FASB ASC Topic 842-10-65 which states; for leases in which the acquiree is a lessee, the acquirer shall measure the lease liability at the present value of the remaining lease payments, as if the acquired lease were a new lease of the acquirer at the acquisition date. The acquirer shall measure the right-of-use asset at the same amount as the lease liability as adjusted to reflect favorable or unfavorable terms of the lease when compared with market terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Through the Trillium acquisition (see NOTE 5) we assumed two master lease agreements. The first master lease agreement with Omega consists of <span id="xdx_90D_ecustom--NumberOfLeaseAgreementProperties_uProperty_c20210101__20210930__dei--LegalEntityAxis__custom--CretePlusFivePropertyLLCMember_zHFMC8GlcrN" title="Number of Lease Agreement Properties">14</span> properties. The master lease with Omega was entered into on May 13, 2015, with an initial lease term that expires on May 31, 2027. The Omega master lease provides for two <span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20210930__dei--LegalEntityAxis__custom--CretePlusFivePropertyLLCMember_zCtgzetwsMQh" title="Lease renewal term">10</span>-year renewal options. At June 10, 2021 we recognized a right of use asset and lease liability in the amount of $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20210610__dei--LegalEntityAxis__custom--TrilliumHealthcareGroupLLCMember_zz8jZmrnicSh" title="Lease right of use asset">29,906,314</span> in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The second master lease with CTR accounts for <span id="xdx_907_ecustom--NumberOfLeaseAgreementProperties_uProperty_c20210101__20210930__dei--LegalEntityAxis__custom--CTRPartnershipLPMember_zGCGgM16zMr8" title="Number of Lease Agreement Properties">10</span> properties. The master lease with CTR was entered into on August 16, 2019, with an initial lease term that expires on November 30, 2030. The CTR lease provides for two <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20210930__dei--LegalEntityAxis__custom--CTRPartnershipLPMember_zyJrc8Z9nxVd" title="Lease renewal term">5</span>-year renewal options. At June 10, 2021 we recognized a right of use asset and lease liability in the amount of $<span id="xdx_906_eus-gaap--OperatingLeaseRightOfUseAsset_c20210610__dei--LegalEntityAxis__custom--CTRPartnershipLPMember_pp0p0" title="Lease right of use asset">14,468,509</span> in association with this lease. This lease is treated as an operating lease for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--LesseeFinanceLeaseDescription_c20210101__20210930__dei--LegalEntityAxis__custom--TrilliumHealthcareGroupLLCMember" title="Capital lease description">Through the Trillium acquisition we also assumed 27   capital leases</span> for the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2 phone systems for facilities</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">6 van leases for facilities to transport residents</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">15 copy machine leases for use at the facilities</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3 postage machine leases for use at the facilities</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">1 lease for a washing machine at a facility</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These leases are treated as capital leases for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_894_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityTableTextBlock_zBs7nTV87xt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In accordance with ASC 842, we recorded the operating lease right of use asset and lease liability as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_zYGOzcgZbk52" style="display: none">SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210930_zysMS4d7LOZ4" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20201231_zjBCQXPRB1Sc" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Right of Use (ROU) assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">46,089,030</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,977,988</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease obligations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Current</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,311,905</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">189,397</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Non-Current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,089,042</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,864,321</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTIC_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,400,947</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,053,718</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zE6H0vRShGhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zGvNqU7pCd3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Maturity of Operating Lease obligations for period ended September 30, 2021</b> <b>,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zdFdaftH0e98" style="display: none">SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210930_zdJnylLP9Fe9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz6Ed_z8uf7RVDfA9g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">2021 (three months)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,990,630</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz6Ed_zxPx1yw6nOy9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,545,124</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz6Ed_zTN99CQxxf51" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,950,470</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz6Ed_zqhF0vyoLVwc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,305,778</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPz6Ed_zvWUfEiC4vPe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,840,681</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pp0p0_maLOLLPz6Ed_zUbkrHSMksj4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">After 2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,768,262</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz6Ed_zhNCQSmMF9Oh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease obligation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,400,947</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zBqLgILmorBe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Information associated with the measurement of our remaining operating lease obligations as of September 30, 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The operating leases range from a term of <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20210930__srt--RangeAxis__srt--MinimumMember_zXrKrSKhwBtj">2.89</span> years to <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20210930__srt--RangeAxis__srt--MaximumMember_z6Bc6FNzr3li">15.93</span> years with a weighted average lease term of <span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210930_zASGoF7JvfZ7">5.47</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The capital leases range from a term of <span id="xdx_904_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20210930__srt--RangeAxis__srt--MinimumMember_z9gny3gQcXVg">1</span> to <span id="xdx_904_eus-gaap--LesseeFinanceLeaseRemainingLeaseTerm_iI_dtY_c20210930__srt--RangeAxis__srt--MaximumMember_z6u95ZsfXrQg">4.96</span> years with a weighted average lease term of <span id="xdx_908_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210930_zxkTDOEwth5g">3.72</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The weighted average discount rate for operating leases is <span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210930_zC5FdFBff1gl" title="Operating lease, weighted average discount rate, percent">7.80</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The weighted average discount rate for capital leases is <span id="xdx_90F_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210930_zx4tQk7OKzjh" title="Capital lease, weighted average discount rate, percent">7.81</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The lease expense for the three and nine month periods ended September 30, 2021 were $<span id="xdx_909_eus-gaap--OperatingLeaseExpense_pp0p0_c20210701__20210930_zjs83Xbhs75b">2,991,078</span> and $<span id="xdx_904_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20210930_zxiagB38ihC8">3,912,133</span>, respectively, compared to $<span id="xdx_902_eus-gaap--OperatingLeaseExpense_pp0p0_c20200701__20200930_zAcSj6ooYoq7">95,319</span> and $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_pp0p0_c20200101__20200930_zFc8PIuVIYXb">193,365</span>, during the same periods in the prior year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 180000 The landlord granted rent abatement for this lease until February 24, 2020 The lease end date, including two successive 5-year renewal options, is January 31, 2035 P5Y 1899869 12137 113681 2024-10-31 0.015 875539 P84M 94500 The landlord granted rent abatement until September 2020 The lease end date, including two successive 5-year renewals is August 31, 2037 P5Y 1143743 P36M 5376 0.12 P12M The equipment under this lease has a fixed $1 payment buyout option 16066 P60M This lease is considered an operating lease for accounting purposes because the lease period is less than the economic life of the asset being leased 24859 23920 102393 P60M This lease is considered an operating lease for accounting purposes because the lease period is less than the economic life of the asset being leased 13381 12891 55345 P36M 4920 The equipment under this lease has a fixed $1 payment buyout option 14693 P60M 15654 15193 65772 P36M 4920 The equipment under this lease has a fixed $1 payment buyout option 14040 P60M 1920 8049 P60M 4321 18476 P36M 5094 13054 14 P10Y 29906314 10 P5Y 14468509 Through the Trillium acquisition we also assumed 27   capital leases <p id="xdx_894_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityTableTextBlock_zBs7nTV87xt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In accordance with ASC 842, we recorded the operating lease right of use asset and lease liability as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_zYGOzcgZbk52" style="display: none">SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210930_zysMS4d7LOZ4" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20201231_zjBCQXPRB1Sc" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Right of Use (ROU) assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">46,089,030</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,977,988</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease obligations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Current</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,311,905</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">189,397</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Non-Current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,089,042</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,864,321</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTIC_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,400,947</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,053,718</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 46089030 3977988 8311905 189397 38089042 3864321 46400947 4053718 <p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zGvNqU7pCd3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Maturity of Operating Lease obligations for period ended September 30, 2021</b> <b>,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BD_zdFdaftH0e98" style="display: none">SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20210930_zdJnylLP9Fe9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz6Ed_z8uf7RVDfA9g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">2021 (three months)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,990,630</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz6Ed_zxPx1yw6nOy9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,545,124</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz6Ed_zTN99CQxxf51" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,950,470</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz6Ed_zqhF0vyoLVwc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,305,778</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPz6Ed_zvWUfEiC4vPe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,840,681</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_pp0p0_maLOLLPz6Ed_zUbkrHSMksj4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">After 2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,768,262</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz6Ed_zhNCQSmMF9Oh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease obligation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,400,947</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1990630 8545124 9950470 8305778 5840681 11768262 46400947 P2Y10M20D P15Y11M4D P5Y5M19D P1Y P4Y11M15D P3Y8M19D 0.0780 0.0781 2991078 3912133 95319 193365 <p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zZpP0gfvZ3x3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 11 - <span id="xdx_827_zL4JjN1FYqah">EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We have authorized <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210930_zbZ6Gg5bFrDf" title="Preferred stock, shares authorized">25,000,000</span> preferred shares with a par value of <span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210930_zYwQ3FljiFj1" title="Preferred stock, par value">0.0001</span> per share. The Board is authorized to divide the authorized preferred shares into one or more series, each of which shall be so designated as to distinguish the shares thereof from the shares of all other series and classes. As of September 30, 2021 and December 31, 2020, we had no classes of preferred shares designated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As discussed in NOTE 5, as part of the Trillium acquisition, Trillium is entitled to <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210930__dei--LegalEntityAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEhezlVWLzFk">2,500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company’s Series A Preferred Stock. The Preferred Shares, with respect to rights on liquidation, winding up and dissolution, rank pari passu with the Common Shares. The holders of Preferred Shares have the right to cast one (1) vote for each Preferred Share held of record on all matters submitted to a vote of holders of the Common Shares, including the election of directors, and all other matters as required by law. The Preferred Shares are not convertible into Common shares at the election of the holder. However, the Preferred Shares do automatically convert into Common Shares at a one to one ratio two years from date of issuance. In lieu of converting the Preferred Shares, the holders thereof may elect to have the Company redeem one or more Preferred Shares at the redemption price of $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210930__dei--LegalEntityAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zfLtgJHDBOol">1.00 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share two years from the date of issuance. The Company is required to issue the Preferred Shares to Trillium within 30 days after the purchase of the Properties closes. In connection with the issuance of the Preferred Shares, the Company will file a Certificate of Designation with the Nevada Secretary of State prior to such issuance. A liability to issue the <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_c20210930__dei--LegalEntityAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--LongTermDebtMember_zWgwL0blzBdh">2,500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares is reflected as a long-term liability on the condensed consolidated balance sheet as of September 30, 2021in the amount of $<span id="xdx_909_ecustom--LiabilityToIssueSharesForAcquisition_pdp0_c20210101__20210930__dei--LegalEntityAxis__custom--TrilliumHealthcareGroupLLCMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--LongTermDebtMember_zVrsJ1XRWZzi">4,750,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We have authorized <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210930_zZEsEFOKOlKh" title="Common stock, shares authorized">100,000,000</span> Common Shares with a par value of $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210930_zzvcWD8yWCN5" title="Common stock per share">0.0001</span> per share. Each Common Share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought. As of September 30, 2021, we had <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pid_c20210930_zZmIxIMdDlhc" title="Common stock issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20210930_zi2qtYNUH6Gb" title="Common stock, shares outstanding">45,345,418</span></span> Common Shares issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Fiscal Year 2021</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On March 23, 2021, we entered into a Plan of Merger with Banyan (See NOTE 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In connection with the Merger, we issued <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210322__20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zCHfau1WEoI3" title="Number of shares issued upon conversion">4,165,418</span> Common Shares in exchange for <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210322__20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zntoKjtMqP97" title="Number of shares converted">49,984,649</span> outstanding shares of Banyan’s common stock held by 64 shareholders, based on an exchange ratio of one (1) Common Share of our common stock for every twelve (12) shares of Banyan common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In conjunction with the Merger, the previously issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20210322__20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zLkcSSlJpg81" title="Shares issuable for Banyan Acquisition, shares">31,230,000</span> Common Shares prior to the Merger were deemed issued for the Merger.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the period from February 11, 2021 through March 31, 2021 we issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20210211__20210331__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zJNMK4Xea1Tf" title="Shares issuable for Banyan Acquisition, shares">7,080,000</span> Common Shares at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210331__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_z0KyNIvWdSxb" title="Shares issued price per share">0.50</span> per share for an aggregate consideration of $<span id="xdx_900_eus-gaap--CommonStockValue_c20210630__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_pdp0" title="Aggregate consideration amount">3,540,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2021, noteholders of the $<span id="xdx_906_eus-gaap--ConvertibleDebt_iI_pp0p0_c20210630__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zj8vwqBLlT1f" title="Convertible Debt">2,000,000</span> convertible note exercised their right to convert the note with an effective date of March 30, 2021 (see NOTE 3), <span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210401__20210630__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_z2EMQXFeEac9" title="Number of shares issued upon conversion">4,000,000</span> Common Shares were issued for the conversion of the note. The conversion was previously recorded as a liability to issue shares in the amount of $<span id="xdx_908_eus-gaap--ConversionOfStockAmountIssued1_pdp0_c20210401__20210630__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zsj6p9bqqSAd" title="Conversion of Stock, Amount Issued">2,000,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the three months ended June 30, 2021, we issued Common Shares in satisfaction of a liability to issue shares in the amount of $<span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20210630__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--LongTermDebtMember_zTPRfVKEdze7" title="Common stock issued">575,000</span> for stock purchases of <span id="xdx_90A_eus-gaap--PaymentsForRepurchaseOfCommonStock_pdp0_c20210401__20210630__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zVCJfsrdpDh2" title="Purchase of common stock">1,150,000</span> Common Shares at $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210630__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zHuLCaBuKkJh" title="Common stock per share">0.50</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As discussed in NOTE 5, as part of the Trillium acquisition, Trillium is entitled to Common Shares having an aggregate value of $<span id="xdx_903_eus-gaap--CommonStockValue_c20210930__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember__dei--LegalEntityAxis__custom--TrilliumHealthcareGroupLLCMember_pdp0">5,000,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, based on the stock price at the time of issuance, upon the earlier of an initial public offering by the Company or June 10, 2022. A share liability is recorded as a current liability in the amount of $<span id="xdx_904_eus-gaap--LiabilitiesCurrent_iI_pdp0_c20210930__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember__dei--LegalEntityAxis__custom--TrilliumHealthcareGroupLLCMember_zjgtpX9Z2Koi">5,000,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">on the condensed consolidated balance sheet as of September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the three month period ended September 30, 2021 we issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20210701__20210930__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_z7cSU4VO7Ldf">5,000,000</span> Common Shares at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210930__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zKLcJksg6l7f">1.00</span> per share for an aggregate consideration of $<span id="xdx_90F_eus-gaap--CommonStockValue_iI_pdp0_c20210930__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zPlf4EIdCB2d">5,000,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On August 26, 2021, a majority of the stockholders approved, by written consent without a meeting, the 2021 Incentive Award Plan (“Award Plan”). The Award Plan was approved by the board of directors on August 19, 2021, and recommended to the stockholders for their approval. Under the Award Plan, <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210826_z4DhcZeOsDg6">4,500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of our common stock will be initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents or other stock or cash based awards. As of the nine month period ending September 30, 2021 <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210930__srt--TitleOfIndividualAxis__custom--TenEmployeesMember__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneIncentiveAwardPlanMember_zlAJ75oqYT89">2,750,208 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the reserved shares were provided as stock options to 10 employees as part of the 2021 Incentive Award Plan. (See NOTE 14)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Fiscal Year 2020</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2020, $<span id="xdx_90E_eus-gaap--ProceedsFromOtherEquity_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pp0p0" title="Proceeds forn subscription">140</span> was received against a subscription receivable balance for the 2019 authorization of the issuance of Founders shares. On December 31, 2020, we had a subscription receivable of $<span id="xdx_907_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_c20201231_pp0p0" title="Subscription receivable">30</span> for shares issued where payments were not received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On September 19, 2020, we issued <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20200917__20200919__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Debt conversion share issued">2,000,000</span> restricted Common Shares to a noteholder for the conversion of $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20200917__20200919__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_pp0p0" title="Debt conversion principal amount">500,000</span> of note principal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In association with the September 27, 2019, Asset Purchase Agreement (The Kidz Club St Pete, LLC), we issued <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20190927__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zxx4qxr9rFpc" title="Warrants to purchase common stock">75,000</span> common stock warrants (post-merger exchange adjusted) having an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zAfntSEL0Gl9" title="Warrants exercise price">0.38</span> per share. These warrants have an expiration of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20190927__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zAPuuEX3Lxyk" title="Warrants expiration date">September 27, 2029</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQdaedr4dzC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> <span style="display: none"><span id="xdx_8B3_zCnHU03DQGEh" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted-</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Aggregate</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Contractual</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Term</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at January 1, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zPARbtrteP68" style="text-align: right" title="Shares, Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1380">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_iS_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zCNb1Cijl825" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zeD9KJRMFU59" style="width: 12%; text-align: right" title="Shares, Granted">75,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceGranted_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zevX1mzStGub" style="width: 12%; text-align: right" title="Weighted-Average Exercise Price, Granted">0.38</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zrxnF8MWsAs8" title="Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance">10.0</span> Years</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_z4dA8RYqYOX9" style="text-align: right" title="Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1390">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExpired_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zCeNUk92Le9h" style="text-align: right" title="Weighted-Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1392">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zVCTYt7h8u36" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1394">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExercised_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zzLXrPStaaLc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1396">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_z3sYTdbvotw4" style="text-align: right" title="Shares, Outstanding, Beginning Balance">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_iS_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zCeiyY5V6Mn9" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding, Beginning Balance">0.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_z4LjwintO1Ma">9.74</span> Years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_pp2p0_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zKfbErWzj9X1" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning Balance">1.62</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zoHqGplztGV5" style="text-align: right" title="Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1405">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceGranted_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zOsZwCnJRkw9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1406">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zqSAB9AI2wya" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1407">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExpired_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zeXekwg38wVd" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zl86CoJp4tCi" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1409">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExercised_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zX00lSoQnC6f" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding and exercisable September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_ze9o7ICRls99" style="border-bottom: Black 2.5pt double; text-align: right">75,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_iE_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zaFXSkRav50l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Outstanding, Ending Balance">0.38</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span title="Weighted Average Remaining Contractual Term, Outstanding, Ending Balance"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zmkvb1Ota831">8.99</span></span> Years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_pp2p0_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zd8qPsMeTdPc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Ending Balance">3.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_8A7_zsEXQKzkvcHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 25000000 0.0001 2500000 1.00 2500000 4750000 100000000 0.0001 45345418 45345418 4165418 49984649 31230000 7080000 0.50 3540000 2000000 4000000 2000000 575000 1150000 0.50 5000000 5000000 5000000 1.00 5000000 4500000 2750208 140 30 2000000 500000 75000 0.38 2029-09-27 <p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQdaedr4dzC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> <span style="display: none"><span id="xdx_8B3_zCnHU03DQGEh" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted-</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Remaining</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Aggregate</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Contractual</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Intrinsic</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Term</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at January 1, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zPARbtrteP68" style="text-align: right" title="Shares, Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1380">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_iS_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zCNb1Cijl825" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zeD9KJRMFU59" style="width: 12%; text-align: right" title="Shares, Granted">75,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceGranted_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zevX1mzStGub" style="width: 12%; text-align: right" title="Weighted-Average Exercise Price, Granted">0.38</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zrxnF8MWsAs8" title="Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance">10.0</span> Years</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_z4dA8RYqYOX9" style="text-align: right" title="Shares, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1390">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExpired_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zCeNUk92Le9h" style="text-align: right" title="Weighted-Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1392">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zVCTYt7h8u36" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1394">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExercised_pid_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zzLXrPStaaLc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1396">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_z3sYTdbvotw4" style="text-align: right" title="Shares, Outstanding, Beginning Balance">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_iS_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zCeiyY5V6Mn9" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding, Beginning Balance">0.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20200101__20201231__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_z4LjwintO1Ma">9.74</span> Years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iS_pp2p0_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zKfbErWzj9X1" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning Balance">1.62</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zoHqGplztGV5" style="text-align: right" title="Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1405">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceGranted_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zOsZwCnJRkw9" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1406">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zqSAB9AI2wya" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1407">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExpired_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zeXekwg38wVd" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zl86CoJp4tCi" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1409">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExercised_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zX00lSoQnC6f" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding and exercisable September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_ze9o7ICRls99" style="border-bottom: Black 2.5pt double; text-align: right">75,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_iE_pid_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zaFXSkRav50l" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Outstanding, Ending Balance">0.38</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span title="Weighted Average Remaining Contractual Term, Outstanding, Ending Balance"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zmkvb1Ota831">8.99</span></span> Years</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iE_pp2p0_c20210101__20210930__dei--LegalEntityAxis__custom--KidzClubStPeteLLCMember_zd8qPsMeTdPc" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Ending Balance">3.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> 75000 0.38 P10Y 75000 0.38 P9Y8M26D 1.62 75000 0.38 P8Y11M26D 3.12 <p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_za5eXcl93toh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 12 – <span id="xdx_82F_zlO4zO5udRx7">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On February 1, 2021 (the “Effective Date”), we signed an employment agreement with our new CEO, Louis Collier (“Collier”). Collier will be paid a base salary of $<span id="xdx_902_eus-gaap--OfficersCompensation_c20210129__20210201__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Base salary">400,000</span>, which will be reassessed and renegotiated in good faith after we are profitable over a fiscal year. Collier will also receive a signing bonus of $<span id="xdx_90E_eus-gaap--AccruedBonusesCurrent_c20210201__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Bonus payable">150,000</span>, which will be payable as follows: $<span id="xdx_902_eus-gaap--AccruedBonusesCurrent_c20210201__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__srt--StatementScenarioAxis__custom--WithinFiveDaysMember_pp0p0" title="Bonus payable">50,000</span> within five days of the Effective Date (paid); $<span id="xdx_905_eus-gaap--AccruedBonusesCurrent_c20210201__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__srt--StatementScenarioAxis__custom--WithinNinetyDaysMember_pp0p0" title="Bonus payable">50,000</span> within 90 days of the Effective Date; and $<span id="xdx_909_eus-gaap--AccruedBonusesCurrent_c20210201__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__srt--StatementScenarioAxis__custom--WithinOneHundredAndEightyDaysMember_pp0p0" title="Bonus payable">50,000</span> within 180 days of the Effective Date. Collier will also be issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210129__20210201__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zJSIs7RKzO9b" title="Shares issued for services">1,250,000</span> phantom shares within ten days after the approval and adoption a Phantom Equity Plan. The phantom shares will be subject to a phantom unit interest award agreement, which will set forth the vesting of the phantom shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On March 23, 2021, we entered into a Plan of Merger (See NOTE 3) whereas we assumed debt of $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pp0p0_c20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zrjzmtcv0uQ6" title="Convertible Debt">2,000,000</span> that was convertible into <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210322__20210323__us-gaap--BusinessAcquisitionAxis__custom--BanyanPediatricCareCentersIncMember_zn6qegmDpHT9" title="Debt Conversion, Converted Instrument, Shares Issued">20,000,000</span> shares of common stock. After the Merger the debt was converted into <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210322__20210323_zaQ0QTSu94Uh" title="Debt Conversion, Converted Instrument, Shares Issued">4,000,000</span> restricted Common Shares of the Company. One of the debt holders is majority owned by a director of the Company. During the three month period ending June 30, 2021, <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210401__20210630__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zykST7hIvJhk" title="Stock Issued During Period, Shares, New Issues">4,000,000</span> restricted Common Shares were issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the three months ended September 30, 2021 and 2020, we compensated members of the Board $<span id="xdx_90D_eus-gaap--OfficersCompensation_pp0p0_c20210701__20210930__srt--TitleOfIndividualAxis__srt--DirectorMember_zDKJpXg46J78" title="Base salary">42,000</span> and $<span id="xdx_907_eus-gaap--OfficersCompensation_c20200701__20200930__srt--TitleOfIndividualAxis__srt--DirectorMember_pp0p0" title="Base salary">0</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During the three months ended September 30, 2021 accrued payroll of $<span id="xdx_909_ecustom--PaymentOfAccruedPayroll_pp0p0_c20210701__20210930_zcuKTWcqEN67" title="Accrued Salary">60,000</span> was paid and $<span id="xdx_905_eus-gaap--OtherEmployeeRelatedLiabilitiesCurrent_iI_pp0p0_c20210930_ze1h47dP0hLi" title="Accrued interest on payroll">6,277</span> interest was paid.  We had accrued payroll of $<span id="xdx_902_eus-gaap--AccruedSalariesCurrent_c20210930__srt--TitleOfIndividualAxis__custom--PresidentAndChiefExecutiveOfficerMember_pp0p0">60,000</span> and accrued interest on that payroll for the President and the Chief Financial Officer of Banyan. These unpaid amounts were the result of 2020 furloughed salaries. Interest was accrued on these unpaid balances effective May 15, 2020 at a rate of <span id="xdx_901_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210101__20210930__srt--TitleOfIndividualAxis__custom--PresidentAndChiefExecutiveOfficerMember_zXaQNlgf4nG3" title="Interest percentage on accrued payroll">8</span>% per annum.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 400000 150000 50000 50000 50000 1250000 2000000 20000000 4000000 4000000 42000 0 60000 6277 60000 0.08 <p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zE2CxZqXyWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 13 <i>– </i><span id="xdx_82D_zjvQkYLB40Xh">SEGMENT INFORMATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company has adopted provisions of ASC 280-10 Segment Reporting for the three and nine months ended September 30, 2021, and 2020. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. The Company and its Chief Operating Decision Makers determined that the Company’s operations consist of two segments: (i) Banyan’s three pediatric extended care centers (“PPECs”) in southwest Florida, and (ii) the second segment is the Trillium Subsidiaries consisting of senior housing communities including skilled nursing facilities, assisted living facilities and independent living facilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zQa9vKx2uNUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The table below reflects the segment operations for the nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_zlm8F0bFRuOi" style="display: none">SCHEDULE OF SEGMENT REPORTING INFORMATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BA_srt--ConsolidationItemsAxis_us-gaap--OperatingSegmentsMember_us-gaap--StatementBusinessSegmentsAxis_custom--PediatricExtendedCareCentersMember_z4IpGQzm9vbi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">PPEC</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B3_srt--ConsolidationItemsAxis_us-gaap--OperatingSegmentsMember_us-gaap--StatementBusinessSegmentsAxis_custom--TrilliumSubsidiariesMember_zIBL4ncdM3ek" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Trillium</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B1_srt--ConsolidationItemsAxis_us-gaap--IntersegmentEliminationMember_zKT4COBXpsn5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustments, eliminations and unallocated items</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BC_z6eEb2T72h6l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_437_c20210101__20210930_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zF137n23uQua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Total revenue, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,094,905</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">26,998,940</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1457">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">29,093,845</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_43A_c20210101__20210930_eus-gaap--CostOfGoodsAndServicesSold_iN_di_zKXKYYjcKBvk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of Sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(810,114</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,666,956</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1462"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,477,070</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_438_c20210101__20210930_eus-gaap--GrossProfit_zx7txXFlId3b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,284,792</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,331,983</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1467"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,616,775</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_439_c20210101__20210930_eus-gaap--SalariesWagesAndOfficersCompensation_zpIJp9TU3wI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries and payroll expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">610,183</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,521,454</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">540,019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,671,656</td><td style="text-align: left"> </td></tr> <tr id="xdx_430_c20210101__20210930_eus-gaap--GeneralAndAdministrativeExpense_zAgnzCgMZWej" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">828,543</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,409,409</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,591,749</td><td style="text-align: left"> </td></tr> <tr id="xdx_435_c20210101__20210930_eus-gaap--OperatingLeaseExpense_z6DOGqCTSI98" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">383,501</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,528,632</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1482"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,912,133</td><td style="text-align: left"> </td></tr> <tr id="xdx_43E_c20210101__20210930_eus-gaap--ProfessionalFees_zxaOMmSrTsZi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">255,218</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,450,431</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,001,862</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,707,511</td><td style="text-align: left"> </td></tr> <tr id="xdx_438_c20210101__20210930_eus-gaap--MarketingAndAdvertisingExpense_zT8gOUp92AG7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketing and advertising</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172,184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1492"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">336,984</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20210101__20210930_eus-gaap--DepreciationAndAmortization_ziVSPI06TpSf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Depreciation and amortization expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">206,777</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">111,336</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">211</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">318,324</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_43C_c20210101__20210930_ecustom--OperatingLoss_zsPm1o34qFQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating Loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,164,231</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,861,462</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,895,889</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,921,582</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20210930_eus-gaap--Assets_iI_zhnmAYRQmnMg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,206,083</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">73,191,222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,733,979</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">86,131,284</td><td style="text-align: left"> </td></tr> <tr id="xdx_434_c20210930_ecustom--Liabilities1_iI_z6KZFQU2g1rb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,954,086</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">63,148,235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,724,471</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">78,826,792</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_434_c20210101__20210930_eus-gaap--NetCashProvidedByUsedInOperatingActivities_z6U4dml0OKLj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash used in operating activities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(917,789</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(6,699,086</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,395,144</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(10,012,019</td><td style="text-align: left">)</td></tr> <tr id="xdx_434_c20210101__20210930_eus-gaap--NetCashProvidedByUsedInInvestingActivities_zD9dR5CKF78a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash used in investing activities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(51,972</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,620,828</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,568,856</td><td style="text-align: left"> </td></tr> <tr id="xdx_43A_c20210101__20210930_eus-gaap--NetCashProvidedByUsedInFinancingActivities_zD3G5YVJgcqf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash provided by financing activities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(211,903</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,724,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,479,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,991,717</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zwgIK0k8Vf3k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zQa9vKx2uNUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The table below reflects the segment operations for the nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B6_zlm8F0bFRuOi" style="display: none">SCHEDULE OF SEGMENT REPORTING INFORMATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BA_srt--ConsolidationItemsAxis_us-gaap--OperatingSegmentsMember_us-gaap--StatementBusinessSegmentsAxis_custom--PediatricExtendedCareCentersMember_z4IpGQzm9vbi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">PPEC</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B3_srt--ConsolidationItemsAxis_us-gaap--OperatingSegmentsMember_us-gaap--StatementBusinessSegmentsAxis_custom--TrilliumSubsidiariesMember_zIBL4ncdM3ek" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Trillium</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4B1_srt--ConsolidationItemsAxis_us-gaap--IntersegmentEliminationMember_zKT4COBXpsn5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustments, eliminations and unallocated items</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_4BC_z6eEb2T72h6l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_437_c20210101__20210930_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zF137n23uQua" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Total revenue, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,094,905</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">26,998,940</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1457">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">29,093,845</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_43A_c20210101__20210930_eus-gaap--CostOfGoodsAndServicesSold_iN_di_zKXKYYjcKBvk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of Sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(810,114</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,666,956</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1462"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,477,070</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_438_c20210101__20210930_eus-gaap--GrossProfit_zx7txXFlId3b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,284,792</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,331,983</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1467"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,616,775</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_439_c20210101__20210930_eus-gaap--SalariesWagesAndOfficersCompensation_zpIJp9TU3wI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries and payroll expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">610,183</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,521,454</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">540,019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,671,656</td><td style="text-align: left"> </td></tr> <tr id="xdx_430_c20210101__20210930_eus-gaap--GeneralAndAdministrativeExpense_zAgnzCgMZWej" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">828,543</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,409,409</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,591,749</td><td style="text-align: left"> </td></tr> <tr id="xdx_435_c20210101__20210930_eus-gaap--OperatingLeaseExpense_z6DOGqCTSI98" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">383,501</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,528,632</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1482"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,912,133</td><td style="text-align: left"> </td></tr> <tr id="xdx_43E_c20210101__20210930_eus-gaap--ProfessionalFees_zxaOMmSrTsZi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">255,218</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,450,431</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,001,862</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,707,511</td><td style="text-align: left"> </td></tr> <tr id="xdx_438_c20210101__20210930_eus-gaap--MarketingAndAdvertisingExpense_zT8gOUp92AG7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketing and advertising</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172,184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1492"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">336,984</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20210101__20210930_eus-gaap--DepreciationAndAmortization_ziVSPI06TpSf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Depreciation and amortization expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">206,777</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">111,336</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">211</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">318,324</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_43C_c20210101__20210930_ecustom--OperatingLoss_zsPm1o34qFQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating Loss</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,164,231</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,861,462</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,895,889</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,921,582</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20210930_eus-gaap--Assets_iI_zhnmAYRQmnMg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,206,083</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">73,191,222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,733,979</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">86,131,284</td><td style="text-align: left"> </td></tr> <tr id="xdx_434_c20210930_ecustom--Liabilities1_iI_z6KZFQU2g1rb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,954,086</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">63,148,235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10,724,471</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">78,826,792</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_434_c20210101__20210930_eus-gaap--NetCashProvidedByUsedInOperatingActivities_z6U4dml0OKLj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash used in operating activities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(917,789</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(6,699,086</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,395,144</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(10,012,019</td><td style="text-align: left">)</td></tr> <tr id="xdx_434_c20210101__20210930_eus-gaap--NetCashProvidedByUsedInInvestingActivities_zD9dR5CKF78a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash used in investing activities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(51,972</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,620,828</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,568,856</td><td style="text-align: left"> </td></tr> <tr id="xdx_43A_c20210101__20210930_eus-gaap--NetCashProvidedByUsedInFinancingActivities_zD3G5YVJgcqf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash provided by financing activities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(211,903</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,724,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,479,518</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,991,717</td><td style="text-align: left"> </td></tr> </table> 2094905 26998940 29093845 810114 14666956 15477070 1284792 12331983 13616775 610183 5521454 540019 6671656 828543 5409409 353797 6591749 383501 3528632 3912133 255218 1450431 1001862 2707511 164800 172184 336984 206777 111336 211 318324 -1164231 -3861462 -1895889 -6921582 10206083 73191222 2733979 86131284 4954086 63148235 10724471 78826792 -917789 -6699086 -2395144 -10012019 -51972 3620828 3568856 -211903 4724102 5479518 9991717 <p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zGFZnAc5nbQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 14 –<span id="xdx_82D_z6Fjppzb2qqi"> STOCK-BASED COMPENSATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On August 26, 2021, a majority of the stockholders approved, by written consent without a meeting, the 2021 Incentive Award Plan (“Award Plan”). The Award Plan was approved by the board of directors on August 19, 2021 and recommended to the stockholders for their approval. Under the Award Plan, <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210826__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneIncentiveAwardPlanMember_z0h5Ya2ktKx6" title="Common stock reserved for future issuance">4,500,000</span> shares of our common stock will be initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents or other stock or cash based awards. As of the nine month period ending September 30, 2021 <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210930__srt--TitleOfIndividualAxis__custom--TenEmployeesMember__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneIncentiveAwardPlanMember_zZF9n1fQnTP1" title="Shares reserved as common stock">2,750,208</span> of the reserved shares were provided as stock options to 10 employees as part of the 2021 Incentive Award Plan. The shares vest over a <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20210901__20210930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneIncentiveAwardPlanMember_zgCakVZTleC9" title="Vesting peirod">4</span> year period with a vesting commencement date of September 1, 2021, as of September 30, 2021 there were <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_pid_c20210901__20210930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneIncentiveAwardPlanMember_z00Rt1icpLOf" title="Number of shares vested">57,296</span> of the shares vested with <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20210930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneIncentiveAwardPlanMember_zIM521P4HyM5" title="Share options outstanding">2,692,912</span> options outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zFy4l1zhm308" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes our Stock Options activity under the Award Plan for the nine months ended September 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_ztrSafYXLNo5" style="display: none">SUMMARY OF STOCK OPTIONS ACTIVITY </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Vesting Period (Years)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding At December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210930_z3DJt1hG0O7a" style="text-align: right" title="Number of shares outstanding, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1544">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930_zvJ1WPXlcax3" style="width: 12%; text-align: right" title="Number of shares granted">2,750,208</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_ztm9VQotjYd4" style="width: 12%; text-align: right" title="Number of shares outstanding, weighted average exercise price">1.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930_zM4nu6wRPVc2" title="Number of shares outstanding, weighted average remaining vesting period">3.92</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20210101__20210930_z4ewMLkgB7d7" style="text-align: right" title="Number of shares outstanding forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1552">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20210930_zy5CbhEKiGAe" style="text-align: right" title="Number of shares outstanding, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1554">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210930_zJZ6fHkJwcOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding, closing balance">2,750,208</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zhf6kGyr36yl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">At September 30, 2021 the weighted average period over which compensation cost on non-vested Stock Options expected to be recognized is <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210930_zidRdH8aRndf">3.92 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years and the unrecognized expense is approximately $<span id="xdx_905_eus-gaap--StockOptionPlanExpense_pn5n6_c20210101__20210930_zEuqqMRBk2i6">8.1</span></span> <span style="font: 10pt Times New Roman, Times, Serif">million</span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation before income taxes included in salaries and wages in the condensed consolidated statement of operations was $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20210930_zZMLtOfcGzM1" title="Stock based compensation">171,888</span> for the three months ended September 30, 2021. We did not recognize compensation cost in the three or nine month periods ended September 30, 2020 since the Stock Options were not awarded during the period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We did not have any cash proceeds or income tax benefits realized from the exercise of Stock Options for the three and nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Valuation Assumptions</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Calculating the fair value of employee stock options requires estimates and significant judgement. We use the Binomial option pricing model to estimate the fair value of the employee stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We have included shares issuable under the Award Plan in deriving fully diluted earnings per share using the Treasury Method in accordance with ASC 260-10-45. Under the Treasury Method, nonvested stock options granted, where the only satisfying condition is the mere passage of time, shall be assumed exercised at the beginning of the period (or at time of issuance, if later). The proceeds from exercise of stock options shall be assumed to be used to purchase common stock at the average market price during the period using daily closing prices</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> 4500000 2750208 P4Y 57296 2692912 <p id="xdx_892_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zFy4l1zhm308" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes our Stock Options activity under the Award Plan for the nine months ended September 30, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_ztrSafYXLNo5" style="display: none">SUMMARY OF STOCK OPTIONS ACTIVITY </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Vesting Period (Years)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding At December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210930_z3DJt1hG0O7a" style="text-align: right" title="Number of shares outstanding, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1544">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930_zvJ1WPXlcax3" style="width: 12%; text-align: right" title="Number of shares granted">2,750,208</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_ztm9VQotjYd4" style="width: 12%; text-align: right" title="Number of shares outstanding, weighted average exercise price">1.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930_zM4nu6wRPVc2" title="Number of shares outstanding, weighted average remaining vesting period">3.92</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20210101__20210930_z4ewMLkgB7d7" style="text-align: right" title="Number of shares outstanding forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1552">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20210930_zy5CbhEKiGAe" style="text-align: right" title="Number of shares outstanding, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1554">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding September 30, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210930_zJZ6fHkJwcOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding, closing balance">2,750,208</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2750208 1.00 P3Y11M1D 2750208 P3Y11M1D 8100000 171888 <p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_z2Waxldb08xe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 15 – <span id="xdx_821_z0wuoFfg2gBf">CONCENTRATIONS AND CREDIT RISKS</span></b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Cash</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company places its cash with high credit quality financial institutions. The Company had balances in excess of the Federal Deposit Insurance Corporation (“FDIC”) coverage of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20210930_ztkJC5vRG1ha">250,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">at September 30, 2021, the aggregate amount in excess of the coverage limit was approximately $<span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20210930_zws8p2eY7f2j">2.8 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million</span><span style="font: 10pt Times New Roman, Times, Serif"> consisting of three accounts. The Company maintains its cash in accounts at financial institutions, which may, at times, exceed federally-insured limits. The Company has not experienced any losses on such accounts and does not feel it is exposed to any significant risk with respect to cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Revenues and Accounts Receivable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine months ended September 30, 2021, approximately <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--ProductOrServiceAxis__custom--MedicareMember_zWVJ9qBlVXX2" title="Concentration risk percentage, Revenues"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--ProductOrServiceAxis__custom--MedicareMember_zp1bINFm4KFa">15</span></span>% of our revenue was generated from Medicare, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--ProductOrServiceAxis__custom--MedicaidMember_znzJ7JVlYTTb"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--ProductOrServiceAxis__custom--MedicaidMember_zjo715VCSyrk">67</span></span>% was generated from Medicaid and approximately <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210701__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--ProductOrServiceAxis__custom--PrivatePayResidentsMember_zcYCaZzGGtYh"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--ProductOrServiceAxis__custom--PrivatePayResidentsMember_zLu3cTVPePt9">13</span></span>% of our revenue was generated from private pay residents. The balance consisted of other payors including managed care programs, VA programs and commercial insurance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At September 30, 2021 <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--ProductOrServiceAxis__custom--MedicareMember_za1OeqDxHQnc">18</span>% of our accounts receivable balances consisted of Medicare receivables, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--ProductOrServiceAxis__custom--MedicaidMember_zllUTJBqtf0b">54</span>% consisted of Medicaid receivables, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--ProductOrServiceAxis__custom--PrivatePayMember_z9Z9XMUZT5q2">13</span>% consisted private pay and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--ProductOrServiceAxis__custom--CommercialInsuranceMember_zeNOFWXiKKu8">11</span>% consisted of commercial insurance. The balance of the accounts receivable consisted of VA and other payors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 250000 2800000 0.15 0.15 0.67 0.67 0.13 0.13 0.18 0.54 0.13 0.11 <p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_z71QmnwPRAF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE 16 – <span id="xdx_82A_z78JPRlPVze3">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We have evaluated subsequent events from September 30, 2021 through the date of these financial statements were issued and determined the following events require disclosure:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Autumn Accolade</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On September 30, 2021,we entered into an Agreement for the Purchase and Sale of Business Assets and Real Estate (the “Purchase Agreement”), with Autumn Accolade, Inc., (“Asset Seller”), Deborah S. Penn, as Trustee under the provisions of a Trust Agreement dated October 8, 2012, and known as the Denton M. Penn Jr. Trust, as to an undivided one-half interest; Deborah S. Penn, as Trustee under the provisions of a Trust Agreement dated October 8, 2012, and known as the Deborah S. Penn Trust, as to an undivided one-half interest (together, “RE Seller,” and collectively with Asset Seller, the “Seller”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Asset Seller owns and operates a licensed assisted living facility located in Green Valley; Illinois known as Autumn Accolade (the “Business”). Asset Seller also owns various assets in conjunction with the operation of the Business, including all assets that are located at, on or within the Premises including those assets that are affixed to the Premises (collectively, “Assets”). RE Seller is the owner in fee simple of the real estate upon which the Assets are located (the “Premises”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Subject to the terms of the Purchase Agreement, we are acquiring the Assets and the Premises from the Sellers in exchange for $<span id="xdx_908_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zrTkBLGPzpP3" title="Acquisition transaction cost">2,300,000</span> and the assumption of certain liabilities. We paid a $<span id="xdx_903_eus-gaap--DepositAssets_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zBw3GZJ3N4l2" title="Deposits">110,000</span> deposit (the “Deposit”) upon execution of the Purchase Agreement, which is being held in escrow and will be applied to the purchase price at closing or refunded if the closing doesn’t occur. We paid an additional $<span id="xdx_90F_eus-gaap--DepositAssets_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SellerMember_zMykZqF3OfF5">15,000</span> deposit to the Seller upon execution of the Purchase Agreement, which is not refundable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The closing shall take place promptly following the satisfaction or waiver of the conditions to closing (but in no event less than 30 days thereafter unless otherwise agreed to by the parties). In the event the closing has not taken place by March 31, 2022, then either party may terminate the Purchase Agreement by written notice to the other party so long as such party is not then in breach of the Purchase Agreement, and the Deposit will be immediately returned , less $<span id="xdx_909_ecustom--PaymentToSeller_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zhGO8sF0KpJ3" title="Payment to seller">35,000</span> to be paid to the Seller if the Seller is able to close but we have failed to meet a financing contingency prior to the March 31, 2022 closing date. We may extend the March 31, 2022 closing date to no later than June 30, 2022 upon written notice to the Seller prior to the March 31, 2022 and the payment to the Seller of a non-refundable amount of $<span id="xdx_900_ecustom--PaymentToSellerNonRefundableAmount_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zzjZYzEdl3W9" title="Payment to seller non refundable">20,000</span>, which shall not be applied to the purchase price.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Gemino Healthcare Finance</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On September 30, 2021 we entered into a Second Amendment to our credit agreement with Gemino Healthcare Finance, LLC. The Credit Agreement was entered into in connection with a $<span id="xdx_90E_eus-gaap--LineOfCredit_iI_pn6n6_c20210930__dei--LegalEntityAxis__custom--GeminoHealthcareFinanceLLCMember_zciIj9D7FQp7" title="Line of credit facility">10</span> million credit facility to be used for working capital and general business purposes, and secured by a first priority perfected security interest in the assets of Trillium and the Trillium Group. The credit facility terminates on <span id="xdx_90F_eus-gaap--LineOfCreditFacilityExpirationDate1_pn6n6_dd_c20210101__20210930__dei--LegalEntityAxis__custom--GeminoHealthcareFinanceLLCMember_zV1CUxq5V0L8" title="Credit facility termination date">May 9, 2022</span>. Each revolving loan under the credit facility bears interest on the outstanding principal amount thereof from the date made until paid in full, at a rate per annum equal to the greater of: <span id="xdx_900_eus-gaap--DebtInstrumentDescription_c20210101__20210930__dei--LegalEntityAxis__custom--GeminoHealthcareFinanceLLCMember_zaZQ62WpsfKd" title="Debt description">(i) the annual rate reported as the London Interbank Offer Rate applicable to ninety (90) day deposits of United States Dollars as reported in the Money Rates Section of The Wall Street Journal on the date of determination; and (ii) 2.00%, plus 4.95% (together, the “Interest Rate”). The Interest Rate on all amounts outstanding under the credit facility is adjusted daily based on any changes in the amount under subsection (i) above and subsection (ii) above, as applicable. There are also various fees paid in connection with the credit facility, including: (1) a monthly collateral monitoring fee of 1.00% of the average borrowing base during the prior month; (2) a monthly unused line fee equal to 0.75% per annum of the unused portion of the maximum amount of credit facility; (3) a minimum use fee if the outstanding revolving loan balance is less than $2 million equal to the Interest Rate times the minimum balance of $2 million; and (4) a termination fee of $<span id="xdx_900_eus-gaap--LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_iI_pn6n6_dd_c20210930__dei--LegalEntityAxis__custom--GeminoHealthcareFinanceLLCMember_zxDaGfsj4Vn2" title="Termination fees">100,000</span> if the credit facility is terminated by A4L prior to May 9, 2022.</span> The credit facility also contains typical affirmative and negative covenants found in credit facilities of this type and amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The First Amendment amended the Credit Agreement by: <span id="xdx_90D_eus-gaap--DebtInstrumentDescription_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementMember__dei--LegalEntityAxis__custom--TrilliumGroupMember__srt--StatementScenarioAxis__custom--FirstAmendmentMember_zViBtxonBdh7">(1) releasing seven entities from the Trillium Group of their obligations under the credit facility in connection with Trillium’s sale of those entities; (2) increasing to 5.95% the rate used to calculate the Interest Rate; (3) increasing the monthly collateral monitoring fee to 1.50%; (4) lowering the revolving commitment amount from $10 million to $7 million; and (5) waiving borrower’s failure to comply with the fixed charge coverage ratio for the fiscal quarters ending September 30, 2019, December 31, 2019, and March 31, 2020</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Second Amendment further amended the Credit Agreement by: <span id="xdx_904_eus-gaap--DebtInstrumentDescription_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--CreditAgreementMember__srt--StatementScenarioAxis__custom--SecondAmendmentMember_zgv4JbwtBf97">(1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; (7) increasing the maximum amount of the credit facility from $10 million to $25 million; and (8) revising terms regarding financial statements and collateral reports, limitations on certain corporate guarantors and curing defaults</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Debt</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On October 8, 2021 we entered into a guaranty agreement in connection with a loan made to our wholly-owned subsidiary, Assisted 4 Living Consulting, Inc. in the principal amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20211008__us-gaap--TypeOfArrangementAxis__custom--GuarantyAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVGl4yhKd5s" title="Debt principal amount">1,250,000</span> (the “Loan”). Pursuant to the terms of the guaranty agreement, the A4L has unconditionally guaranteed the payment of all indebtedness, liabilities and obligations of every kind and nature of Assisted 4 Living Consulting, LLC to the lender whether absolute or contingent, direct or indirect, due or to become due, heretofore or hereafter created, arising or exiting including any additional advances or future advances, renewals or extensions without limitation as to amount. The Loan is evidenced by a promissory note. Outstanding principal accrues interest at an annual rate of ten percent (<span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211008__us-gaap--TypeOfArrangementAxis__custom--GuarantyAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrSirWqElFi7" title="Debt interest rate">10</span>%). Monthly payments in the amount of $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_pp2d_c20211007__20211008__us-gaap--TypeOfArrangementAxis__custom--GuarantyAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4WLVIgE1z1c" title="Monthly payments">10,416.67</span> commence on November 8, 2021 and continue for 12 months until the maturity date of <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_pid_ddp_c20211007__20211008__us-gaap--TypeOfArrangementAxis__custom--GuarantyAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zB9mQds5pjFh" title="Maturity date">October 8, 2022</span>, at which time the remaining principal balance, if any, is due and payable. The Loan is secured by a first mortgage lien on property that is owned by Borrower and serves as the A4L corporate headquarters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">If any portion of the principal is paid prior to July 8, 2022, then Assisted 4 Living Consulting, LLC must pay a prepayment fee calculated as the difference between nine months of interest on the amount of principal being prepaid and the amount of interest paid to date on the amount of principal being prepaid. The lender is guaranteed nine months of interest regardless of when Loan is paid off.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">After the maturity date or due date of the promissory note, interest shall be charged on the respective principal amount remaining unpaid at a rate equivalent to the highest lawful rate or twenty-five percent (<span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211008__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLExw6Q219Tb" title="Debt rate">25</span>%) per annum, whichever is less, until paid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">If any payment of principal or interest or both is more than five days late, Borrower agrees to pay lender a late charge equal to five percent (5.0%) of the payment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Crete Plus Five Property</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On October 13, 2021 we entered into an Agreement of Purchase and Sale with Crete Plus Five Property, LLC, Iowa Lincoln County Property LLC, Muscatine Toledo Properties, LLC and Avery Street Property, LLC (collectively, “Owners” ). The Owners owns 13 senior housing facilities located in Iowa, Nebraska and Florida (collectively, the “Facilities”) as well the real property underlying the Facilities (the “Properties”). The Agreement of Purchase and Sale is for the purchase of the Facilities, the Properties and all of Owner’s right, title and interest in all of the personal property located at the Properties, other than certain personal property described in Exhibit B attached to the Agreement of Purchase and Sale, such as cash and the tradenames and books and records of Owner. The A4L indirect wholly-owned subsidiaries currently lease the Properties from Owner, and operate the Facilities, pursuant to an Master Lease dated as of May 13, 2015, as amended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The purchase price for the Facilities and the Properties is $<span id="xdx_907_eus-gaap--PaymentsToAcquireProductiveAssets_pid_ddp_c20211012__20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTiE7rw73PA4">59,000,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">. A4L paid a $<span id="xdx_901_eus-gaap--DepositAssets_iI_pp0d_ddp_c20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaWZJnBF4aY8">3,000,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">deposit (the “Deposit”) in June upon execution of a letter of intent with Owner as part of the Trillium transaction, and A4L will receive a credit at closing against the purchase price in the amount of the Deposit. If the Agreement of Purchase and Sale is Terminated prior to closing for any reason other than breach of the agreement by Owner, the Deposit will be paid to Owner as liquidated damages. The closing is to occur on March 1, 2022; provided, however, A4L may extend the March 1, 2022 closing date to no later than March 31, 2022, upon written notice to Owner prior to the February 15, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Grace Care Centers</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On October 18, 2021 we completed the acquisition from Grace Care Centers and its affiliates (collectively, “Grace”) of three skilled nursing facilities located in Texas (the “Skilled Facilities”), including the real property, buildings, structures, improvements, fixtures and certain other assets comprising the Skilled Facilities (together with the Skilled Facilities, the “Assets”) in exchange for an aggregate purchase price of $<span id="xdx_90B_eus-gaap--PaymentsToAcquireBusinessesGross_c20211017__20211018__us-gaap--BusinessAcquisitionAxis__custom--GraceCareCentersMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGo0JWThRQbk" title="Payment to acquire business">7,750,000</span> (the “Purchase Price”). The Assets were acquired pursuant to and in accordance with three Purchase and Sale Agreements and three Management Transfer Agreements (collectively, the “Agreements”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Skilled Facilities, located in Olney, Nocona and Henrietta, Texas, are all 5-star rated by CMS for quality and have a combined 258 beds. The Skilled Facilities will continue to be leased to local hospital districts, who will continue to be the licensed operators of the Skilled Facilities. A4L, through indirect wholly-owned subsidiaries, now owns the Assets and will manage the day-to-day activities of the Skilled Facilities pursuant to management agreements which it assumed in connection with the transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A4L, through its indirect wholly-owned subsidiary, financed part of the Purchase Price with a loan from Arena Limited SPV, LLC (“Lender”) in the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20211018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zM6u02oZTYe8">6,600,000</span> (the “Loan”). <span id="xdx_908_eus-gaap--DebtInstrumentDescription_c20211017__20211018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--GraceCareCentersMember_zf3f6oDTlE6l" title="Debt description">Outstanding principal accrues interest at a rate per annum equal to the sum of the Prime Rate plus 4.125%, with a minimum interest rate per annum of not less than 7.875%. Monthly interest only payments commence on December 15, 2021, and continue each month until the maturity date of the Loan on April 18, 2023, at which time any outstanding principal and accrued and unpaid interest is due and payable. If any principal, interest or any other sums due under the Loan (other than the payment of principal due on the maturity date), is not paid on or prior to the due date, A4L is required to pay Lender upon demand an amount equal to 5% of such unpaid sum. In connection with any repayment or prepayment of principal, a non-refundable fee equal to 0.5% of the principal amount of such repayment or prepayment is due</span>. A4L may prepay the outstanding amount in whole, but not part, upon prior written notice to Lender.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_ecustom--NonRefundableFeeDescription_c20211017__20211018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--GraceCareCentersMember_z0PHDb5q7I3k" title="Non refundable fee description">A4L has the right to extend the initial maturity date to October 15, 2023 upon prior written notice to Lender and the payment to Lender of a non-refundable fee equal to 1% of the outstanding principal balance no later than 30 days prior to the maturity date. A4L may extend the maturity date further, to April 15, 2024, upon prior written notice to Lender and the payment to Lender of a non-refundable fee equal to 1% of the outstanding principal balance prior to the extended maturity date.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Loan is secured by a first priority lien on the Assets, including all amounts received by A4L or any subsidiaries constituting rent or other payment under any leases or management fees under each of the management agreements, which must be deposited into a segregated account at a bank and held in trust for Lender. The Loan is subject to customary affirmative and negative covenants, as well as customary default provisions for late or non-payments or breach of covenants, for loans of this nature. Pursuant to the terms of a guaranty agreement, A4L and several of its direct and indirect wholly-owned subsidiaries, have each unconditionally guaranteed to Lender the payment of all indebtedness, liabilities and obligations of every kind and nature under the Loan.</span></p> 2300000 110000 15000 35000 20000 10000000 2022-05-09 (i) the annual rate reported as the London Interbank Offer Rate applicable to ninety (90) day deposits of United States Dollars as reported in the Money Rates Section of The Wall Street Journal on the date of determination; and (ii) 2.00%, plus 4.95% (together, the “Interest Rate”). The Interest Rate on all amounts outstanding under the credit facility is adjusted daily based on any changes in the amount under subsection (i) above and subsection (ii) above, as applicable. There are also various fees paid in connection with the credit facility, including: (1) a monthly collateral monitoring fee of 1.00% of the average borrowing base during the prior month; (2) a monthly unused line fee equal to 0.75% per annum of the unused portion of the maximum amount of credit facility; (3) a minimum use fee if the outstanding revolving loan balance is less than $2 million equal to the Interest Rate times the minimum balance of $2 million; and (4) a termination fee of $100,000 if the credit facility is terminated by A4L prior to May 9, 2022. 100000000000 (1) releasing seven entities from the Trillium Group of their obligations under the credit facility in connection with Trillium’s sale of those entities; (2) increasing to 5.95% the rate used to calculate the Interest Rate; (3) increasing the monthly collateral monitoring fee to 1.50%; (4) lowering the revolving commitment amount from $10 million to $7 million; and (5) waiving borrower’s failure to comply with the fixed charge coverage ratio for the fiscal quarters ending September 30, 2019, December 31, 2019, and March 31, 2020 (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; (7) increasing the maximum amount of the credit facility from $10 million to $25 million; and (8) revising terms regarding financial statements and collateral reports, limitations on certain corporate guarantors and curing defaults 1250000 0.10 10416.67 2022-10-08 0.25 590000 30000 7750000 6600000 Outstanding principal accrues interest at a rate per annum equal to the sum of the Prime Rate plus 4.125%, with a minimum interest rate per annum of not less than 7.875%. Monthly interest only payments commence on December 15, 2021, and continue each month until the maturity date of the Loan on April 18, 2023, at which time any outstanding principal and accrued and unpaid interest is due and payable. If any principal, interest or any other sums due under the Loan (other than the payment of principal due on the maturity date), is not paid on or prior to the due date, A4L is required to pay Lender upon demand an amount equal to 5% of such unpaid sum. In connection with any repayment or prepayment of principal, a non-refundable fee equal to 0.5% of the principal amount of such repayment or prepayment is due A4L has the right to extend the initial maturity date to October 15, 2023 upon prior written notice to Lender and the payment to Lender of a non-refundable fee equal to 1% of the outstanding principal balance no later than 30 days prior to the maturity date. A4L may extend the maturity date further, to April 15, 2024, upon prior written notice to Lender and the payment to Lender of a non-refundable fee equal to 1% of the outstanding principal balance prior to the extended maturity date. On September 18, 2020, through Banyan, we entered into a Convertible Note and Securities Purchase Agreement with two investors for the aggregate principal in the amount of $2,000,000. The note had a maturity date of September 18, 2022, and an interest rate of 8% to be paid quarterly. The principal was funded by two investors (“Purchasers”), both related parties. Excel Family Partners, LLLP invested $1,500,000 and Banyan Pediatric Investments, LLC invested $500,000. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. Written consent from shareholders holding a majority of the issued and outstanding shares of common stock of Banyan was obtained, not including such shares currently held by the Purchasers or their affiliates, consenting to the note contemplated hereby, in a form and substance acceptable to the Purchasers, in their respective reasonable discretion. Both Purchasers were permitted to convert their respective portions of the note at a conversion price of $0.10 per share. Subsequent to the Merger (see NOTE 3), the Board revised the conversion price of the note to $0.50 per share. Effective March 30, 2021, the Purchasers exercised their right to convert all outstanding principal. As of September 30, 2021, and December 31, 2020, there was $0 and $45,589 of accrued interest, respectively and is reflected in accrued interest balances on the condensed consolidated balance sheet at September 30, 2021 and December 31, 2020. On November 6, 2020, through Banyan, we entered into a one-year note in the principal amount of $300,000 with NuView Trust Company. The note has a 12% interest rate with interest only payments until date of maturity. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. As of September 30, 2021, and December 31, 2020, there was no accrued interest. (see NOTE 3) On December 15, 2020, through Banyan Pediatric Care Centers – Pasco, LLC, we entered into a note payable with Grand Trinity Plaza, LLC in the principal amount of $407,500, which is guaranteed by Banyan. The term of the note is 48 months with an interest rate of 6%. The maturity date of the note is January 1, 2025. The note is in conjunction with the 84-month facility lease for the Pasco County location, pursuant to which the landlord also provided the construction of the buildout and financed $407,500 of the construction costs. Reliant note payable - Past due balances with vendor Reliant were converted to a note payable in 36 equal monthly installments of principal and interest of $69,568 from October 2019 through September 2022. The note bears interest at a rate of 6%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021. HCSG note payable – Past due balances with vendor HCSG were converted to a non-interest-bearing note payable; payable in 36 equal monthly principal installments of $33,099 from October 2019 through September 2022. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021. Medline note payable – Past due balances with vendor Medline were converted to a note payable; payable in 36 equal monthly installments of principal and interest of $20,911 from October 2019 through September 2022; note bears interest at a rate of 6%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021. SLR revolving line of credit - On May 9, 2019, Trillium entered into a financing agreement (“the GHF Line”) with Gemino Healthcare Finance, LLC (DBA SLR Healthcare ABL), the lender, which allows the Trillium Subsidiaries to borrow up to the lesser of $10 million or 85% of eligible accounts receivable. The GHF Line bears interest at the greater of one-month LIBOR or 2%, plus 4.95%, applied daily, and continues to be applied to outstanding principal until the expiration of one business day after such principal has been repaid. The Trillium Subsidiaries also incur monthly collateral management fees under the line of 1 % of the average daily balance of the preceding month and is subject to a monthly unused line fee of 0.75% of the difference between revolving loan commitment and the average daily balance outstanding during the preceding month. The GHF Line is secured by cash, accounts receivable, and substantially all intangible assets of the Trillium Subsidiaries and terminates on May 9, 2022. On July 12, 2021, the agreement was amended whereas Assisted 4 Living, Inc was named as the Guarantor of the line. At September 30, 2021, the outstanding balance on the line was $5,212,234.  On September 30, 2021 we entered into a Second Amendment of the financing agreement with GHF. The Second Amendment amended the Credit Agreement by: (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; and (7) increasing the maximum amount of the credit facility from $10 million to $25 million. The above changes are the primary changes to the credit facility. XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
9 Months Ended
Sep. 30, 2021
Nov. 12, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2021  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --12-31  
Entity File Number 333-226979  
Entity Registrant Name Assisted 4 Living, Inc.  
Entity Central Index Key 0001719435  
Entity Tax Identification Number 82-1884480  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 5115 East  
Entity Address, Address Line Two SR 64  
Entity Address, City or Town Bradenton  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 34240  
City Area Code (855)  
Local Phone Number 668-3331  
Entity Current Reporting Status No  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   45,345,418
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash $ 3,894,536 $ 345,982
Accounts receivable, net 7,490,091 97,073
Prepaid expenses and other current assets 3,747,240 207,592
Total current assets 15,131,867 650,647
Operating Lease right-of-use assets 46,089,030 3,977,988
Goodwill 15,513,677 3,431,148
Leasehold improvements, net 3,766,330 2,614,391
Property and equipment, net 2,680,115 128,475
Other assets 2,950,265
Total assets 86,131,284 10,802,649
Current liabilities:    
Accounts payable and accrued expenses 10,879,082 148,180
Notes payable 7,041,759 2,385,010
Accrued interest, Including related party 42,567 48,601
Loans Payable - other 498,140 63,907
Operating Lease obligations - current portion 8,311,905 189,397
Advanced payments 1,671,698
Deferred Revenue 596,227
Deferred HHS Revenue 778,408 25,703
Liability to issue shares 5,000,000
Due to Seller for acquisition 902,847
Total current liabilities 35,722,633 2,860,798
Operating Lease obligations - net of current portion 38,089,042 3,864,321
Liability to issue shares - long term 4,750,000
Notes payable, net of current portion 265,117 322,490
Total liabilities 78,826,792 7,047,609
Stockholders’ equity:    
Common stock, par value $0.0001; 100,000,000 shares authorized, 45,345,418, and 4,165,418 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively 4,535 417
Additional paid-in capital 17,876,115 7,460,348
Subscription receivable (30)
Accumulated deficit (10,576,158) (3,705,695)
Total stockholders’ equity 7,304,492 3,755,040
Total liabilities and stockholders’ equity $ 86,131,284 $ 10,802,649
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares Authorized 100,000,000 100,000,000
Common Stock, Shares, Issued 45,345,418 4,165,418
Common Stock, Shares, Outstanding 45,345,418 4,165,418
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statement of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net Revenue $ 22,375,092 $ 659,449 $ 29,093,845 $ 1,102,841
Cost of services provided 12,310,011 256,825 15,477,070 409,838
Gross profit 10,065,081 402,624 13,616,775 693,003
Operating expenses        
Salaries and payroll expense 5,068,423 320,404 6,671,656 870,191
General and administrative 4,978,559 205,818 6,591,749 454,482
Lease expense 2,991,078 88,691 3,912,133 193,365
Professional fees 1,722,741 70,819 2,707,511 134,829
Marketing and advertising 236,499 4,276 336,984 12,378
Depreciation and amortization expense 159,750 16,744 318,324 24,135
Total operating expenses 15,157,050 706,752 20,538,357 1,689,380
Loss from operations (5,091,969) (304,128) (6,921,582) (996,377)
Other income (expense)        
Loss on disposal of asset (22,753) (22,753)
Interest expense (179,293) (7,920) (317,881) (7,923)
Total other income (expense) (179,293) (30,673) (317,881) (30,676)
LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES AND RESULTS FROM DISCONTINUED OPERATIONS (5,271,262) (334,801) (7,239,463) (1,027,053)
Income taxes
LOSS FROM CONTINUING OPERATIONS BEFORE DISCONTINUED OPERATIONS (5,271,262) (334,801) (7,239,463) (1,027,053)
Loss from discontinued operations (26,500)
Gain on disposal of discontinued operations 395,500
Income from discontinued operations 369,000
Net loss attributable to common shareholders $ (5,271,262) $ (334,801) $ (6,870,463) $ (1,027,053)
Continuing Operations        
Loss per share - basic and diluted - Continuing operations $ (0.12) $ (0.08) $ (0.24) $ (0.25)
Weighted average number of shares outstanding - basic and diluted 42,783,081 4,221,021 29,984,191 4,064,414
Discontinued operations net income per share        
Earnings per share - basic     $ 0.01  
Earnings per share - diluted     $ 0.01  
Weighted average shares outstanding - basic     29,984,191  
Weighted average shares outstanding - diluted     34,705,065  
Product and Service, Other [Member]        
Net Revenue $ 21,602,984 $ 654,351 $ 27,581,902 $ 1,088,341
Rental revenue [Member]        
Net Revenue 11,275 5,625 22,875 7,500
Other revenue [Member]        
Net Revenue $ 760,833 $ (527) $ 1,489,068 $ 7,000
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscription receivable [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 401 $ 6,618,364 $ (170) $ (2,407,760) $ 4,210,835
Balance, shares at Dec. 31, 2019 4,008,443        
Net loss for the period (443,375) (443,375)
Ending balance, value at Mar. 31, 2020 $ 401 6,618,364 (170) (2,851,135) 3,767,460
Balance, shares at Mar. 31, 2020 4,008,443        
Beginning balance, value at Dec. 31, 2019 $ 401 6,618,364 (170) (2,407,760) 4,210,835
Balance, shares at Dec. 31, 2019 4,008,443        
Net loss for the period         (1,027,054)
Ending balance, value at Sep. 30, 2020 $ 417 7,460,348 (170) (4,570,441) 2,890,154
Balance, shares at Sep. 30, 2020 4,175,110        
Beginning balance, value at Mar. 31, 2020 $ 401 6,618,364 (170) (2,851,135) 3,767,460
Balance, shares at Mar. 31, 2020 4,008,443        
Net loss for the period (692,252) (692,252)
Ending balance, value at Jun. 30, 2020 $ 401 6,618,364 (170) (3,543,387) 3,075,208
Balance, shares at Jun. 30, 2020 4,008,443        
Issuance of stock warrant expense 342,000 342,000
Issuance of shares for the conversion of debt $ 16 499,984 500,000
Issuance of shares for conversion of debt, shares 166,667        
Net loss for the period (1,027,054) (1,027,054)
Ending balance, value at Sep. 30, 2020 $ 417 7,460,348 (170) (4,570,441) 2,890,154
Balance, shares at Sep. 30, 2020 4,175,110        
Beginning balance, value at Dec. 31, 2020 $ 417 7,460,348 (30) (3,705,695) 3,755,040
Balance, shares at Dec. 31, 2020 4,165,418        
Collection on subscription receivable 30 30
Issuance of shares for acquisition $ 3,123 3,039,874 3,042,997
Issuance of shares for acquisition, shares 31,230,000        
Net loss for the period (579,061) (579,061)
Ending balance, value at Mar. 31, 2021 $ 3,540 10,500,222 (4,284,756) 6,219,006
Balance, shares at Mar. 31, 2021 35,395,418        
Beginning balance, value at Dec. 31, 2020 $ 417 7,460,348 (30) (3,705,695) 3,755,040
Balance, shares at Dec. 31, 2020 4,165,418        
Net loss for the period         (6,870,463)
Ending balance, value at Sep. 30, 2021 $ 4,535 17,876,115 (10,576,158) 7,304,492
Balance, shares at Sep. 30, 2021 45,345,418        
Beginning balance, value at Mar. 31, 2021 $ 3,540 10,500,222 (4,284,756) 6,219,006
Balance, shares at Mar. 31, 2021 35,395,418        
Issuance of shares for the conversion of debt $ 400 1,999,600 2,000,000
Issuance of shares for conversion of debt, shares 4,000,000        
Issuance of shares via private placement $ 115 574,885 575,000
Issuance of shares via private placement, shares 1,150,000        
Shares returned and cancelled for transfer of discontinued operations $ (20) (369,980) (370,000)
Shares returned and cancelled for transfer of discontinued operations, shares (200,000)        
Net loss for the period (1,020,140) (1,020,140)
Ending balance, value at Jun. 30, 2021 $ 4,035 12,704,727 (5,304,896) 7,403,866
Balance, shares at Jun. 30, 2021 40,345,418        
Issuance of shares via private placement $ 500 4,999,500 5,000,000
Issuance of shares via private placement, shares 5,000,000        
Stock-based compensation and issuance of employee stock award plan 171,888 171,888
Net loss for the period (5,271,262) (5,271,262)
Ending balance, value at Sep. 30, 2021 $ 4,535 $ 17,876,115 $ (10,576,158) $ 7,304,492
Balance, shares at Sep. 30, 2021 45,345,418        
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities    
Net loss $ (6,870,463) $ (1,027,054)
Adjustments to reconcile net loss to cash used in operating activities:    
Net gain from discontinued operations (369,000)
Depreciation and amortization 318,324
(Increase) decrease in assets    
Prepaid expenses and other current assets (1,824,624) (2,877)
Deposits and other assets (2,003,607)
Accounts receivable 435,016 (145,225)
Increase (decrease) in liabilities    
Accounts payable and accrued expenses 2,373,538 249,999
Deferred Revenues 1,331,333 55,371
Advance payments (3,396,502)
Accrued interest (6,034)
Cash used in operating activities (10,012,019) (870,286)
Cash flows from investing activities    
Goodwill from acquisition (3,431,148)
Non-cash operating lease expense 212,326 28,541
Cash and assets from acquisition 3,432,847
Investment in leasehold improvements (1,852,465)
Purchase of property and equipment (76,317) (61,083)
Cash used in investing activities 3,568,856 (5,316,155)
Cash flows from financing activities    
Repayment of principal on notes payable (776,207)
Proceeds from the sale of common stock 575,000
Proceeds from notes payable 5,212,234 2,664,234
Repayment on loans payable (18,810)
Warrants to be issued 342,000
Proceeds from the issuance of registered shares 4,999,500 328
Cash provided by financing activities 9,991,717 3,006,562
Net increase (decrease) in cash 3,548,554 (3,179,879)
Cash, beginning of year 345,982 4,044,700
Cash, end of period 3,894,536 864,821
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS    
Interest Paid 275,831
Taxes Paid
NON-CASH ITEMS    
Liability to issue shares for acquisition 9,750,000  
Goodwill from acquisition 12,082,529  
Recognition of lease liability and right of use asset at inception 46,089,030 3,976,562
Conversion of notes payable and accrued interest for common stock $ 2,000,000 $ 500,000
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND DESCRIPTION OF BUSINESS
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND DESCRIPTION OF BUSINESS

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Assisted 4 Living, Inc. (“the Company,” “we”, “our” or “us”) was incorporated in the state of Nevada on May 24, 2017, and is based in Bradenton, Florida. Our accounting and reporting policies conform to accounting principles generally accepted in the United States of America (“GAAP”), and the fiscal year end is December 31.

 

As discussed in NOTE 3, on March 23, 2021, we entered into a Plan of Merger with our wholly-owned subsidiary, BPCC Acquisition, Inc., a Florida corporation (“Merger Sub”) and Banyan Pediatric Care Centers, Inc. (“Banyan”). Under the terms of the Plan of Merger, Merger Sub merged with and into Banyan with Banyan surviving the merger (the “Surviving Entity”) and becoming a wholly-owned subsidiary of the Company (the “Merger”). Pursuant to the Merger, we succeeded to the business of Banyan. The Merger has been treated as a recapitalization and reverse acquisition of the Company for financial accounting purposes, and Banyan is considered the acquirer for financial reporting purposes. This means that the Company’s historical financial statements before the Merger have been replaced with the historical financial statements of Banyan before the Merger in this Quarterly Report and future filings with the SEC.

 

Banyan, operates three pediatric extended care centers (“PPECs”) in southwest Florida. A PPEC is a nurse-staffed pediatric day care center for medically complex children age birth to 21 years. Our staff includes Registered Nurses (RNs), Licensed Practical Nurses (LPNs), Certified Nursing Assistants (CNAs) and Caregivers, who attend to the children’s medical conditions throughout the day in classroom, dining, play, and clinical settings. Banyan is fully licensed and accepts Florida Medicaid.

 

As discussed in NOTE 5, on June 10, 2021, we entered into an Amended and Restated Membership Interest Purchase Agreement (the “Restated Purchase Agreement”), by and among the Company, Richard T. Mason (“Mason”), G. Shayne Bench (“Bench”) and Trillium Healthcare Group, LLC, a Florida limited liability company (“Trillium”) to acquire all of the issued and outstanding ownership interests of Fairway Healthcare Properties, LLC (“FHP”) and Trillium Healthcare Consulting, LLC (together with FHP, the “Trillium Subsidiaries”) from Trillium. The transaction closed and was effective June 10, 2021.

 

Trillium subsidiaries lease and operate 26 facilities in four states: Florida, Georgia, Iowa, and Nebraska with 1,685 total licensed beds (1,546 skilled nursing, 139 assisted living) and 36 independent living apartments. The breakdown by state is as follows: Florida – 1 skilled nursing facility; Georgia – 1 skilled nursing facility; Iowa – 16 skilled nursing facilities, 2 independent living centers and 1 assisted living centers; Nebraska – 4 skilled nursing facilities and 1 assisted living center.

 

The facilities provide room and board, routine daily care services, post-acute care including rehabilitation and memory care. The Trillium Subsidiaries were organized under the laws of the State of Florida on February 9, 2012, for the purpose of acquiring and managing long term care facilities, such as skilled nursing facilities and assisted living centers.

 

We are headquartered in Bradenton, Florida.

 

The corporate website is www.assisted4living.com.

 

COVID-19

 

In March 2020, the World Health Organization declared the outbreak of COVID-19 as a pandemic based on the rapid increase in global exposure. COVID-19 continues to spread throughout the world. We are closely monitoring developments and are taking steps to mitigate the potential risks related to the COVID-19 pandemic to the Company, its employees, as well as its residential and consulting clients.

 

Our evaluations of our practices, procedures, and operations, related to COVID-19, is ongoing. Additional updates to policies, procedures and operations will occur as best practices are adopted and as we deem necessary or advisable, or as further governmental guidance or regulations are implemented.

 

 

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company (“Financial Statements”) have been prepared in accordance with GAAP for interim financial statements and with the instructions to Form 10-Q and Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.

 

In the opinion of management, the accompanying condensed consolidated Financial Statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2021, and the results of operations and cash flows for the periods presented. The results of operations for the nine months ended September 30, 2021, are not necessarily indicative of the operating results for the full fiscal year or any future period. These condensed consolidated Financial Statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021 and Current Report on Form 8-K on June 2, 2021. As of April 30, 2021, we had discontinued operations reflected in the accompanying condensed consolidated Financial Statements. As a result of the Plan of Merger completed on March 23, 2021 (see NOTE 3) we have changed our year end reporting period from November to December.

 

Capital Requirements, Liquidity and Going Concern Considerations

 

These condensed consolidated Financial Statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Although we had cash and accounts receivable in the amount of approximately $11.4 million at September 30, 2021, we had accrued expenses and current notes payable in excess of cash and accounts receivable in the amount of approximately $6.5 million, and a deficiency in working capital of approximately $20.6 million. For the nine months ended September 30, 2021, our net loss was approximately $6.9 million.

 

As a result of these factors, we determined it was necessary to review our cash flow for 2021 and an overall analysis of market trends to determine whether or not we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report. We also determined it was necessary to take certain corporate actions, including reducing discretionary expenses (and reduced reliance on agency staffing), improving revenue (including added Therapy and Rehab services), and raising additional capital, in order to ensure we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report.

 

During the three months ended September 30, 2021 we sold 5.0 million shares for an aggregate total of $5.0 million. This capital raise will be used for additional growth through acquisitions and for working capital. However, no assurances can be given that we will be successful. If management is not able to timely and successfully raise additional capital and/or refinance indebtedness, the implementation of the Company’s business plan, financial condition and results of operations will be materially affected.

 

Basis of Consolidation

 

These condensed consolidated Financial Statements include the accounts of the Company and the wholly-owned subsidiaries, Banyan Pediatric Care Centers – OPS, LLC, Banyan Pediatric Care Centers – St. Petersburg, LLC, Banyan Pediatric Care Centers, - Pasco, LLC and Banyan Pediatric Care Centers – Sarasota, LLC and the discontinued operations of Assisted 2 Live, Inc., the wholly owned subsidiary that was discontinued as of April 30, 2021. All material intercompany balances and transactions have been eliminated. The condensed consolidated Financial Statements also include the accounts of the Trillium Subsidiaries from June 10, 2021, the effective date of the transaction with Trillium.

 

Use of Estimates and Assumptions

 

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

 

 

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at September 30, 2021 and December 31, 2020.

 

Accounts Receivable

 

Accounts receivable primarily consists of amounts due from third-party payers (non-governmental), governmental payers and private pay patients and is recorded net of contractual allowances and reserves for doubtful accounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s Financial Statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimation of net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies’ denial of claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.

 

The Company’s accounts receivable from third-party payers are recorded net of estimated contractual adjustments and allowances from third-party payers, which are estimated based on the historical trend of the Company’s facilities’ cash collections and contractual write-offs, accounts receivable aging, established fee schedules, relationships with payers and procedure statistics. While changes in estimated reimbursement from third-party payers remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on the Company’s financial condition or results of operations. The Company’s collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of the facilities to ensure the proper collection and aged category. The operating systems generate reports that assist in the collection efforts by prioritizing patient accounts. Collection efforts include direct contact with insurance carriers or patients and written correspondence.

 

Allowance for Doubtful Accounts, Contractual and Other Discounts

 

Management estimates the allowance for contractual and other discounts based on its historical collection experience and contracted relationship with the payers. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account may be written-off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.

 

COVID-19 Pandemic and CARES Act Funding

 

COVID-19 Pandemic. In January 2020, the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel strain of coronavirus. In March 2020, the World Health Organization declared the outbreak of COVID-19, a disease caused by this coronavirus, a pandemic. The resulting measures to contain the spread and impact of COVID-19 and other developments related to COVID-19 have materially affected the Company’s results of operations during 2020. Where applicable, the impact resulting from the COVID-19 pandemic during the year ended December 31, 2020, has been considered, including updated assessments of the recoverability of assets and evaluation of potential credit losses. As a result of the COVID-19 pandemic, federal and state governments have passed legislation, promulgated regulations and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency. Sources of relief include the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020, the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), which was enacted on April 24, 2020, and the Consolidated Appropriations Act, 2021 (the “CAA”), which was enacted on December 27, 2020. In total, the CARES Act, PPPHCE Act and the CAA authorize $178 billion in funding to be distributed to hospitals and other healthcare providers through the Public Health and Social Services Emergency Fund (the “PHSSEF”). In addition, the CARES Act provide for an expansion of the Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers were able to request accelerated payment of up to 100% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments. Various other state and local programs also exist to provide relief, either independently or through distribution of monies received via the CARES Act. During the period ended September 30, 2021, the Company was a beneficiary of these stimulus measures, including the Medicare Accelerated and Advance Payment Program.

 

 

The Company’s accounting policies for the recognition of these stimulus monies is as follows:

 

Pandemic Relief Funds

 

Trillium received an aggregate of $13,487,923 in PHSSEF payments, of which $4,242,796 was applied during 2020. Prior to the acquisition date of June 10, 2021 Trillium had recognized $7,081,557 as other operating income. During the three and nine-month period ended September 30, 2021 we recognized $1,385,162 as other operating income resulting in a remaining balance of $778,408 which is classified on the balance sheet as Deferred HHS Revenue. The recognition of amounts received is conditioned upon the provision of care for individuals with possible or actual cases of COVID-19 after January 31, 2020, certification that payment will be used to prevent, prepare for and respond to coronavirus and shall reimburse the recipient only for healthcare-related expenses or lost revenues, as defined by HHS, that are attributable to coronavirus, as well as receipt of the funds. Amounts are recognized as a reduction to operating costs and expenses only to the extent the Company is reasonably assured that underlying conditions have been met.

 

The Company’s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the CAA and all frequently asked questions and other interpretive guidance issued by HHS, including the Post-Payment Notice of Reporting Requirements issued on January 15, 2021 (the “January 15, 2021 Notice”) and frequently asked questions issued by HHS on January 28, 2021 which clarified previously issued guidance, as well as expenses incurred attributable to the coronavirus and the Company’s results of operations during such period as compared to the Company’s budget. Such guidance, specifically the various Post-Payment Notice of Reporting Requirements and frequently asked questions issued by HHS, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to coronavirus that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. On the basis of guidance available at the time, the Company’s estimate of lost revenues was first based on the negative change in year-over-year net patient care operating revenue, then on the negative change in year-over-year net patient care operating income and finally on the difference between budgeted and actual revenue for calendar year. The calculation as of September 30, 2021 is in accordance with the CAA which indicates that lost revenues may be calculated pursuant to frequently asked questions published by HHS in June 2020, including the difference between a provider’s budgeted and actual revenue if such budget had been established prior to March 27, 2020. The use of funds calculation as of September 30, 2021 takes into account expenses attributable to each respective entity, which primarily relate to incremental labor and supply costs, as well as lost revenues. General fund distributions were allocated among subsidiaries according to total unreimbursed losses. Targeted distributions were not allocated or transferred among subsidiaries. While the CAA, January 15, 2021 Notice and frequently asked questions published by HHS on January 28, 2021 indicate that targeted distribution payments may be allocated or transferred to subsidiaries, distinct conditions exist for such allocations or transfers including that the parent organization have a “direct ownership relationship” with the subsidiary who received the targeted distribution payment. Additionally, the subsidiary that was the recipient of the targeted distribution payment retains responsibility for reporting to HHS on the use of such funds even if they are transferred or allocated to other subsidiaries. There are significant uncertainties as to the meaning and interpretation of conditions specific to the allocation or transfer of targeted distribution payments such that as of September 30, 2021, the Company is not reasonably assured that it can or will choose to comply with such conditions in order to allocate or transfer targeted distribution payments.

 

HHS’ interpretation of the underlying terms and conditions of such PHSSEF payments, including auditing and reporting requirements, continues to evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such PHSSEF payments may result in changes in the Company’s estimate of amounts for which the terms and conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in the Company’s inability to recognize additional PHSSEF payments or may result in the de recognition of amounts previously recognized, which (in any such case) may be material.

 

Medicare Accelerated Payments

 

The Company recorded payments under the Medicare Accelerated and Advance Payment program in accordance with FASB ASC 606 and has recorded amounts as a contract liability under FASB ASC 606-10-45-2. The contract liability will be reduced over time as revenue is recognized for claims submitted for services provided after the recoupment period begins. Effective October 1, 2020, the program was amended such that providers are required to repay accelerated payments beginning one year after the payment was issued. After such one-year period, Medicare payments owed to providers will be recouped according to the repayment terms. The repayment terms specify that for the first 11 months after repayment begins, repayment will occur through an automatic recoupment of 25% of Medicare payments otherwise owed to the provider. At the end of the eleven-month period, recoupment will increase to 50% for six months. At the end of the six months (or 29 months from the receipt of the initial accelerated payment), Medicare will issue a letter for full repayment of any remaining balance, as applicable. In such event, if payment is not received within 30 days, interest will accrue at the annual percentage rate of four percent (4%) from the date the letter was issued and will be assessed for each full 30-day period that the balance remains unpaid. As of September 30, 2021, $1,671,698 of Medicare accelerated payments are reflected on the balance sheet within advance payments line.

 

 

The company receives a substantial portion of our revenues from the Medicare and Medicaid programs. Included in Managed Care and other third-party payors is operating revenues from insurance companies with which we have insurance provider contracts, Medicare managed care, insurance companies for which we do not have insurance provider contracts, workers’ compensation carriers and non-patient service revenue, such as rental income and cafeteria sales. In the future, we generally expect the portion of revenues received from the Medicare and Medicaid programs to increase over the long-term due to the general aging of the population and the impact of the Affordable Care Act. The Affordable Care Act has increased the number of insured patients in states that have expanded Medicaid, which in turn, has reduced the percentage of revenues from self-pay patients. However, it is unclear whether the trend of increased coverage will continue, due in part to the impact of the COVID-19 pandemic and the elimination of the financial penalty associated with the individual mandate, effective January 1, 2019. Further, the Affordable Care Act imposes significant reductions in amounts the government pays Medicare managed care plans. Moreover, the trend toward increased enrollment in Medicare and Medicaid managed care may adversely affect our operating revenue. An executive order issued in October 2019 seeks to accelerate this shift away from traditional fee-for-service Medicare to Medicare managed care. We may also be impacted by regulatory requirements imposed on insurers, such as minimum medical-loss ratios and specific benefit requirements. Furthermore, in the normal course of business, managed care programs, insurance companies and employers actively negotiate the amounts paid to hospitals. Our relationships with payors may be impacted by price transparency initiatives and out-of-network billing restrictions. There can be no assurance that we will retain our existing reimbursement arrangements or that these third-party payors will not attempt to further reduce the rates they pay for our services.

 

Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-based reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for the treatment of patients covered by Medicare, Medicaid and non-governmental payors are generally less than our standard billing rates. We account for the differences between the estimated program reimbursement rates and our standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at net operating revenues. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known.

 

Fair Value of Financial Instruments

 

The carrying amount of accounts receivable and accounts payable approximate their respective fair values due to the short- term nature. The carrying amount of the line of credit and note payable approximates fair values due to their market interest rates. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Depreciation of owned assets and amortization of leasehold improvements are computed using the straight-line method over the shorter of the estimated useful lives of the related assets or the lease term. The cost of assets sold or retired, and the related accumulated depreciation are removed from the accounts and any resulting gains or losses are reflected in other income (expense) for the year. Expenditures for maintenance and repairs are charged to expense as incurred.

 

Goodwill

 

Our goodwill represents the excess of the purchase price over the fair value of the net identifiable assets acquired in business combinations. The goodwill generated from the business combinations is primarily related to the value placed on the employee workforce and expected synergies. Judgment is involved in determining if an indicator or change in circumstances relating to impairment has occurred. Such changes may include, among others, a significant decline in expected future cash flows, a significant adverse change in the business climate, and unforeseen competition. There was no goodwill impairment for the periods presented.

 

 

The Company tests goodwill for impairment on an annual basis, and when events or circumstances indicate the fair value of a reporting unit may be below its carrying value.

 

Long-Lived Assets

 

Long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There were no impairments of long-lived assets for the years presented.

 

Advertising and Marketing

 

The Company uses advertising and marketing to promote its services. Advertising and marketing costs are expensed as incurred.

 

Earnings (Loss) Per Share

 

Basic Earnings (loss) per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per common share is determined using the weighted-average of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of the conversion option embedded in convertible debt. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would have an anti-dilutive effect.

 

Fixed grantee stock options (fixed awards) and nonvested stock (including restricted stock) shall be included in the computation of diluted earnings per common share. Even though their issuance may be contingent upon vesting, they shall be considered to be contingently issuable shares. Because issuance of performance based stock options (and performance based nonvested stock) is contingent upon satisfying conditions in addition to the mere passage of time, those options and non vested stock shall be considered to be contingently issuable shares in the computation of diluted earnings per common share.

 

The dilutive effect of outstanding call options and warrants (and their equivalents) are reflected in diluted earnings per common share by application of the treasury stock method unless another method is required. Equivalents of options and warrants include nonvested stock granted under a share based payment arrangement, stock purchase contracts, and partially paid stock subscriptions. Antidilutive contracts such as purchased put options and purchased call options shall be excluded from diluted earnings per common share.

 

The Company has included shares issuable under its 2021 Incentive Award Plan in deriving its fully diluted earnings per common share using the Treasury Method in accordance with ASC 260-10-45.

 

Income Taxes

 

The Company uses the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets, liabilities, the carry forward of operating losses and tax credits, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. An allowance against deferred tax assets is recorded when it is more likely than not that such tax benefits will not be realized.

 

Any future benefit arising from losses have been offset by a valuation allowance. Accordingly, no provision for income taxes is reflected in the condensed consolidated financial statements. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. Interest and penalties related to income tax matters, if any, would be recognized as a component of income tax expense. At September 30, 2021 and December 31, 2020, the Company had no liabilities for uncertain tax positions. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Currently, the tax years subsequent to 2017 are open and subject to examination by the taxing authorities.

 

Revenue Recognition

 

We follow ASC 606, “Revenue from Contracts with Customers.” Revenues are recognized when promised services are transferred to a customer, in an amount that reflects the consideration that we expect to receive in exchange for those services. We derive our revenues from the rendering of services, such as skilled nursing services. The five-step armodel defined by ASC 606 requires us to: (i) identify our contracts with customers, (ii) identify our performance obligations under those contracts, (iii) determine the transaction prices of those contracts, (iv) allocate the transaction prices to our performance obligations in those contracts and (v) recognize revenue when each performance obligation under those contracts is satisfied.

 

 

Reimbursement rates to provide services in our facilities are determined by the fee schedules set by the government programs and negotiated in contracts with non-governmental third-party payors and private pay patients. Fees are billed to the payors and private pay patients weekly and monthly following billing guidelines and contract requirements.

 

Net Patient Revenue

 

Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions.

 

The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed.

 

The estimates for implicit price concessions are based upon management’s assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable.

 

Reclassification

 

Certain amounts from prior periods have been reclassified to conform to the current period presentation.

 

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
BANYAN MERGER
9 Months Ended
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
BANYAN MERGER

NOTE 3BANYAN MERGER

 

Effective March 23, 2021, we entered into a Plan of Merger with Merger Sub and Banyan. Under the terms of the Plan of Merger, Merger Sub merged with and into Banyan with Banyan as the Surviving Entity and wholly owned subsidiary of the Company.

 

The Merger has been treated as a recapitalization and reverse acquisition of the Company for financial accounting purposes, and Banyan is considered the acquirer for accounting purposes. This means that the Company’s historical financial statements before the Merger have been replaced with the historical financial statements of Banyan.

 

In connection with the Merger, we issued 4,165,418 shares of our common stock in exchange for 49,984,649 outstanding shares of Banyan’s common stock held by 64 shareholders, based on an exchange ratio of one (1) share of our common stock for every twelve (12) shares of Banyan common stock. We also issued a warrant to purchase 75,000 shares of our common stock (the “Warrant”) in exchange for a warrant to purchase 900,000 shares of Banyan’s common stock. The Warrant is held by one investor and is exercisable for cash only until May 2, 2030 at an exercise price of $0.38 per share. The number of shares of common stock deliverable upon exercise of the Warrant contains provisions for standard anti-dilution adjustments.

 

The Surviving Entity assumed Banyan’s $2,300,000 of outstanding debt, and the $2,000,000 of such debt that was convertible into 20,000,000 shares of Banyan common stock was converted at $0.50 per share into 4,000,000 shares of our common stock, effective March 30, 2021. During the three months ended June 30, 2021, shares were issued to the Noteholders of the $2,000,000 convertible note. The remaining $300,000 of outstanding debt, evidenced by a promissory note dated November 6, 2020, accrues interest at the annual rate of 12%. Interest is payable on the sixth day of each month in the amount of $3,000 until the maturity date of this note on November 6, 2021, at which time, the remaining principal balance, if any, is due and payable.

 

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
DISCONTINUED OPERATIONS
9 Months Ended
Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS

NOTE 4 – DISCONTINUED OPERATIONS

 

On April 30, 2021, our Board of Directors (the “Board”) approved the discontinuance of our wholly owned subsidiary, Assisted 2 Live, Inc. (the “Discontinued Subsidiary”). The operations of the Discontinued Subsidiary are reflected on our condensed consolidated statement of operations from the date of the Merger as a loss from discontinued operations in the amount of $26,500.

 

The April 30, 2021, Board decision was the result of the Purchase and Sale Option Agreement (the “Option Agreement”) with Romulus Barr (“Barr”) which we entered into on November 7, 2020. The Option Agreement provided us with the option to sell all of our interest in Assisted 2 Live, Inc., consisting of 1,000 shares of common stock of the discontinued subsidiary, to Barr in exchange for 200,000 shares of our common stock (the “Shares”) held by Barr. The returned Shares were cancelled and included in authorized but unissued shares of common stock of the Company. The number of issued and outstanding shares of common stock was decreased by 200,000 as of April 30, 2021. The transfer resulted in a gain on disposal of discontinued operations in the amount of $395,500. A share price of $1.85 was used to determine the gain on disposal of discontinued operations based on the share price value on April 30, 2021.

 

   2021   2020   2021   2020 
  

For the three months ended

September 30,

  

For the nine months ended

September 30,

 
   2021   2020   2021   2020 
Net revenues  $-   $-   $76,847   $- 
Cost of net revenues   -    -    -    - 
Gross profit   -    -    -    - 
                     
Operating expenses:                    
Salary and tax expense   -    -    46,813    - 
General and administrative   -    -    52,555    - 
Lease expense   -    -    3,979    - 
Total operating expenses   -    -    103,347    - 
                     
Income from discontinued operations   -    -    (26,500)   - 
Interest and other, net   -    -    -    - 
Income from discontinued operations before income taxes   -    -    (26,500)   - 
Provision for income taxes        -         - 
Income from discontinued operations, net of income taxes  $-   $-   $(26,500)  $- 

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
TRILLIUM ACQUISITION
9 Months Ended
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
TRILLIUM ACQUISITION

NOTE 5 – TRILLIUM ACQUISITION

 

On June 10, 2021, we entered into the Restated Purchase Agreement, by and among the Company, Mason, Bench and Trillium to acquire all of the issued and outstanding ownership interests of the Trillium Subsidiaries from Trillium (the “Transaction”). The Transaction closed and was effective June 10, 2021.

 

Pursuant to the terms and conditions of the Restated Purchase Agreement, the aggregate purchase price consists of: (i) a cash payment of $902,847, minus certain transaction related costs, fees and expenses set forth in the Restated Purchase Agreement and determined post-closing; (ii) 2,500,000 shares of the Company’s Series A Preferred Stock (the “Preferred Shares”); and (iii) shares of the Company’s common stock (“Common Shares”) having an aggregate value of $5,000,000, based on the stock price at the time of issuance, upon the earlier of an initial public offering by the Company or June 10, 2022. Trillium will have the right to acquire an additional 2,500,000 Common Shares during the two-year period after the Transaction closes pursuant to a Business Development Agreement, a copy of which is attached as Exhibit 10.1 to this Quarterly Report.

 

 

As a condition to closing, the Trillium Subsidiaries paid with cash on hand $1,200,000 to one of its landlord, CTR Partnership, L.P. (“CTR”), as an additional security deposit under a lease between Greenside Healthcare Properties, LLC, a wholly-owned subsidiary of FHP and CTR and $3,000,000 to Crete Plus Five Property, L.L.C. (“Omega,” and together with CTR, the “Landlords”) as a deposit on the Company’s purchase of 16 facilities on 14 properties (the “Properties”) currently being leased by FHP’s wholly-owned subsidiaries from Omega and its affiliates. The $3,000,000 deposit to Omega is non-refundable and is subject to forfeiture if the purchase of the Properties is not closed by December 30, 2021. If the $3,000,000 deposit is forfeited, Trillium forfeits its right to receive $3,000,000 of the purchase price, first, from the cash payment mentioned in subsection (i) above, and second, from the value of common stock to be issued to Trillium mentioned in subsection (iii) above. In any event, no cash payments may be made to Trillium until the purchase of the Properties closes.

 

The Preferred Shares, with respect to rights on liquidation, winding up and dissolution, rank pari passu with the Common Shares. The holders of Preferred Shares have the right to cast one (1) vote for each Preferred Share held of record on all matters submitted to a vote of holders of the Common Shares, including the election of directors, and all other matters as required by law. The Preferred Shares are not convertible into Common shares at the election of the holder. However, the Preferred Shares do automatically convert into Common Shares at a one-to-one ratio two years from date of issuance. In lieu of converting the Preferred Shares, the holders thereof may elect to have the Company redeem one or more Preferred Shares at the redemption price of $1.00 per share two years from the date of issuance. The Company is required to issue the Preferred Shares to Trillium within 30 days after the purchase of the Properties closes. In connection with the issuance of the Preferred Shares, the Company will file a Certificate of Designation with the Nevada Secretary of State prior to such issuance.

 

In connection with obtaining the Landlords’ consent to the Transaction, the Company entered into: (i) a guaranty agreement with each Landlord under which the Company agreed to guaranty all obligations and liabilities under master leases for property and facilities owned by the Landlords’ and their affiliates and leased by FHP’s direct and indirect wholly-owned subsidiaries; and (ii) a Consent Agreement and Fifth Amendment to Master Lease with Omega (the “Consent”) regarding the Properties. Under the terms of the Consent, until the earlier of the purchase of the Properties closes or the expiration of the master lease agreement for the Properties in 2027: (a) Mason and Bench must remain responsible for, and have authority over, the day to day management and operations of the Properties and related facilities; and (b) the Company may not make any payment, transfer or distribution of cash or any assets to one or more equity holders or any person or entity with possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of the Company, through the ownership of voting securities (an “Affiliate”), or return any capital, redemption of any security, or making or assumption of any loans, advances or extension of credit or capital contribution to, or any other investment in, any Affiliate, including, but not limited to, a fee for management, a payment for services rendered, a reimbursement for expenditures or overhead incurred on behalf of the Company or a payment on any debt of an Affiliate; provided, however, the Company may contribute or transfer cash or other assets to its, direct or indirect, wholly-owned subsidiaries, and pay reasonable cash compensation to the members of the Board and executive officers provided that such compensation does not in the aggregate, exceed $600,000 in any six month period.

 

The initial purchase price has been allocated to the acquired assets and assumed liabilities based on estimated fair values. The purchase price allocation is preliminary pending a final determination of the fair values of the assets and liabilities. The table below provides a preliminary recording of assets acquired and liabilities assumed as of the acquisition date. During the three month period ended September 30, 2021 certain adjustments were made to the fair value of accounts receivable, share liability and goodwill. The amounts recorded for property, plant and equipment, leasehold improvements and goodwill are preliminary and pending finalization of valuation efforts.

 

Assets acquired     
Cash  $3,432,847 
Accounts receivable   5,521,080 
Prepaid expenses and other current assets   2,661,683 
Property and equipment   2,380,635 
Goodwill   12,082,529 
Leasehold improvements   1,213,273 
Lease right of use asset   44,196,092 
Total identifiable assets acquired  $71,488,139 
Liabilities assumed     
Advance payments  $2,905,234 
Accounts payable and accrued expenses   8,783,508 
Deferred revenue   2,162,966 
Loan Payable - other   453,043 
Lease liability - current portion   7,837,406 
Notes payable   2,309,884 
Lease liability - net of current portion   36,383,251 
Cash due to seller   902,847 
Share liability   9,750,000 
 Total identifiable liabilities acquired  $71,488,139 

 

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 6– ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Our accounts payable and accrued liabilities at September 30, 2021 and December 31, 2020 consisted of the following:

 

   September 30, 2021   December 31, 2020 
         
Accounts payable  $6,299,400   $16,298 
Credit Card   37,712    1,050 
Accrued Expense   3,513,517    130,832 
Accrued Salary   995,265    - 
Payroll Tax Payable   33,189    - 
 Accounts Payable and Accrued Liabilities  $10,879,082   $148,180 

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
NOTES PAYABLE
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
NOTES PAYABLE

NOTE 7 – NOTES PAYABLE

 

Notes payable at September 30, 2021 and December 31, 2020 consisted of the following:

 

      September 30, 2021   December 31, 2020 
Excel Family Partners, LLLP / Banyan Pediatric Investment, Inc. (Sep 2020)  a  $-   $2,000,000 
NuView Trust Co. (Nov 2020)  b   300,000    300,000 
Grand Trinity Plaza, LLC (Dec 2020)  c   346,174    407,500 
Reliant  d.i   808,310    - 
HCSG  d.ii   397,191    - 
Medline  d.iii   242,967    - 
SLR - RLOC  e   5,212,234    - 
      $7,306,876   $2,707,500 

 

a. On September 18, 2020, through Banyan, we entered into a Convertible Note and Securities Purchase Agreement with two investors for the aggregate principal in the amount of $2,000,000. The note had a maturity date of September 18, 2022, and an interest rate of 8% to be paid quarterly. The principal was funded by two investors (“Purchasers”), both related parties. Excel Family Partners, LLLP invested $1,500,000 and Banyan Pediatric Investments, LLC invested $500,000. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. Written consent from shareholders holding a majority of the issued and outstanding shares of common stock of Banyan was obtained, not including such shares currently held by the Purchasers or their affiliates, consenting to the note contemplated hereby, in a form and substance acceptable to the Purchasers, in their respective reasonable discretion. Both Purchasers were permitted to convert their respective portions of the note at a conversion price of $0.10 per share. Subsequent to the Merger (see NOTE 3), the Board revised the conversion price of the note to $0.50 per share. Effective March 30, 2021, the Purchasers exercised their right to convert all outstanding principal. As of September 30, 2021, and December 31, 2020, there was $0 and $45,589 of accrued interest, respectively and is reflected in accrued interest balances on the condensed consolidated balance sheet at September 30, 2021 and December 31, 2020.
   
b. On November 6, 2020, through Banyan, we entered into a one-year note in the principal amount of $300,000 with NuView Trust Company. The note has a 12% interest rate with interest only payments until date of maturity. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. As of September 30, 2021, and December 31, 2020, there was no accrued interest. (see NOTE 3)

 

 

c. On December 15, 2020, through Banyan Pediatric Care Centers – Pasco, LLC, we entered into a note payable with Grand Trinity Plaza, LLC in the principal amount of $407,500, which is guaranteed by Banyan. The term of the note is 48 months with an interest rate of 6%. The maturity date of the note is January 1, 2025. The note is in conjunction with the 84-month facility lease for the Pasco County location, pursuant to which the landlord also provided the construction of the buildout and financed $407,500 of the construction costs.
   
d. In 2019, certain vendors of Trillium agreed to extend payment terms by converting then outstanding amounts of accounts payable balances to long-term debt bearing interest at rates ranging from 0% to 6%.
   
    i. Reliant note payable - Past due balances with vendor Reliant were converted to a note payable in 36 equal monthly installments of principal and interest of $69,568 from October 2019 through September 2022. The note bears interest at a rate of 6%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
 

 

    ii. HCSG note payable – Past due balances with vendor HCSG were converted to a non-interest-bearing note payable; payable in 36 equal monthly principal installments of $33,099 from October 2019 through September 2022. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
         
    iii. Medline note payable – Past due balances with vendor Medline were converted to a note payable; payable in 36 equal monthly installments of principal and interest of $20,911 from October 2019 through September 2022; note bears interest at a rate of 6%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
   
e. SLR revolving line of credit - On May 9, 2019, Trillium entered into a financing agreement (“the GHF Line”) with Gemino Healthcare Finance, LLC (DBA SLR Healthcare ABL), the lender, which allows the Trillium Subsidiaries to borrow up to the lesser of $10 million or 85% of eligible accounts receivable. The GHF Line bears interest at the greater of one-month LIBOR or 2%, plus 4.95%, applied daily, and continues to be applied to outstanding principal until the expiration of one business day after such principal has been repaid. The Trillium Subsidiaries also incur monthly collateral management fees under the line of 1 % of the average daily balance of the preceding month and is subject to a monthly unused line fee of 0.75% of the difference between revolving loan commitment and the average daily balance outstanding during the preceding month. The GHF Line is secured by cash, accounts receivable, and substantially all intangible assets of the Trillium Subsidiaries and terminates on May 9, 2022. On July 12, 2021, the agreement was amended whereas Assisted 4 Living, Inc was named as the Guarantor of the line. At September 30, 2021, the outstanding balance on the line was $5,212,234.  On September 30, 2021 we entered into a Second Amendment of the financing agreement with GHF. The Second Amendment amended the Credit Agreement by: (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; and (7) increasing the maximum amount of the credit facility from $10 million to $25 million. The above changes are the primary changes to the credit facility.

 

The entire balance due on each line has been classified as a current liability in accordance with FASB ASC Topic 470-10-45-5, Classification of Revolving Credit Agreements Subject to Lock-Box Arrangements. FASB guidance stipulates that if the contractual provisions of a loan arrangement require, in the ordinary course of business and without another event occurring, the cash receipts of a debtor to be used to repay the existing obligation, the credit agreement should be considered a short-term obligation.

 

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
LEASEHOLD IMPROVEMENTS
9 Months Ended
Sep. 30, 2021
Leasehold Improvements  
LEASEHOLD IMPROVEMENTS

NOTE 8 – LEASEHOLD IMPROVEMENTS

 

The Company had the following leasehold improvements as of September 30, 2021 and December 31, 2020:

 

   September 30,   December 31,   Amortization 
   2021   2020   Period 
Leasehold improvements   3,984,470    2,669,047    15-17 years 
Less: amortization   (218,140)   (54,656)     
                
Net   3,766,330    2,614,391      

 

During the year ended December 31, 2020, we recorded $2,669,047 of leasehold improvements. These amounts include costs related to the build out of the Sarasota location in the amount of $1,245,950. These costs will be amortized over the expected term of the lease including extensions that management expects to be 15 years. We also recorded costs in the amount of $1,021,793 related to the New Port Richey location buildout. The expected amortization of the improvements for the New Port Richey location is 17 years. Also recorded were $401,303 of improvements as part of the St. Petersburg-Kidz Club Acquisition. The expected amortization of the improvements for the St. Petersburg location is 15 years. We also recorded $1,213,273 in lease improvements as part of the Trillium acquisition, during the nine-month period ending September 30, 202.

 

Amortization expense for the three months ended September 30, 2021 and 2020 was $70,193 and $13,593, respectively.

 

Amortization expense for the nine months ended September 30, 2021 and 2020 was $218,140 and $54,656, respectively.

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
PROPERTY AND EQUIPMENT
9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

NOTE 9 – PROPERTY AND EQUIPMENT

 

   September 30,   December 31,   Amortization Period 
   2021   2020     
Furniture and fixtures   987,904    73,594    5 
Computers / equipment / software   95,952    50,401    5 
Motor vehicles   12,084    12,084    5 
Buildings   1,060,000    -    39 
Land   500,000    -      
Construction in progress   100,699    -      
Less: depreciation   (76,524)   (7,604)     
Net   2,680,115    128,475      

 

During the year ended December 31, 2020 we recorded $136,079 in property plant and equipment. These expenses were related to furniture and fixtures and for the new Banyan Sarasota and Pasco locations. We also recorded expenses related to computers and equipment for these new locations, as well as the St Petersburg location acquired in May of 2020. We also purchased buses for the St. Petersburg location, as of the year ended December 2020 we had one bus that was purchased for cash and is being depreciated. Other buses have been purchased with finance leases and are reflected in Right of Use Assets and Lease Liabilities.

 

During the nine month period ending September 30, 2021 we recorded additional furniture and fixtures related to the Banyan locations in the amount of approximately $23,000   and additional computers and equipment in the amount of approximately $41,000. These purchases were related to the completion of the Banyan Sarasota and Pasco locations that opened in May and July of 2021.

 

Through the Trillium acquisition on June 10, 2021 we recorded approximately $3.6M in property, plant and equipment consisting of furniture and fixtures, equipment, leasehold improvements in construction and a building. During the three month period ended September 30, 2021 we recorded approximately $69,487 in additional furniture and fixtures for the Trillium locations  .

 

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
OPERATING AND CAPITAL LEASES
9 Months Ended
Sep. 30, 2021
Operating And Capital Leases  
OPERATING AND CAPITAL LEASES

NOTE 10 – OPERATING AND CAPITAL LEASES

 

On August 24, 2019, through Banyan Pediatric Care Centers-Sarasota, LLC, we entered into an operating lease with Northeast Plaza Venture I, LLC for the premises located in the Northeast Plaza Shopping Center located on the Northeast corner of 17th Street & Lockwood Ridge Road, in the County of Sarasota, Florida. The initial term of the lease is five years with minimum annual rent of $180,000. The landlord granted rent abatement for this lease until February 24, 2020. The lease end date, including two successive 5-year renewal options, is January 31, 2035. A right of use asset and lease liability in the amount of $1,899,869 associated with this lease was recognized. This lease is treated as an operating lease for accounting purposes.

 

 

On October 15, 2019, through Banyan, we entered into an assignment and assumption of lease agreement with The Kidz Club – St. Pete, LLC whereby we assumed approximately 12,137 square feet of space at the southeast corner of 3rd Avenue S. and 9th Street N., Webb’s Plaza, St. Petersburg, FL 33701. The minimum annual rent for the first year of the lease was $113,681. The current lease termination date, with extensions expected to be exercised, is October 31, 2024. Upon the exercise of each extension the base rent shall increase by 1.5%. This assignment of lease was subject to the terms of the Asset Purchase Agreement with The Kidz Club-St. Pete, LLC. A right of use asset and lease liability in the amount of $875,539 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

Effective April 1, 2020, through Banyan Pediatric Care Centers – Pasco, LLC, we entered into an 84-month facility lease with Grand Trinity Plaza, LLC for the premises located in the shopping center known as the Grand Trinity Plaza located in New Port Richey, Florida. The initial term of the lease had a minimum annual base rent of $94,500. The landlord granted rent abatement until September 2020. The lease end date, including two successive 5-year renewals is August 31, 2037. A right of use asset and lease liability in the amount of $1,143,743 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

On June 9, 2020, through Banyan, we entered into a 36-month copier lease with Dex Imaging. The lease was for one copier and a printer. The minimum annual lease payment is $5,376 with annual increases not to exceed 12% annually. This lease will auto renew in 12-month increments. The equipment under this lease has a fixed $1 payment buyout option. This equipment was purchased for the St. Petersburg location. A right of use asset and lease liability in the amount of $16,066 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

On August 25, 2020, through Banyan, we entered into a 60-month financing agreement with Ascentium Capital LLC for two 2020 Turtletop Terra Transit passenger buses for the St. Petersburg location. This lease is considered an operating lease for accounting purposes because the lease period is less than the economic life of the asset being leased. Minimum annual rent payments under this lease are $24,859. At our discretion, we may exercise a purchase option, by giving written notice no later than 30 days but not more than 120 days before the expiration of the initial term. The purchase option price is $23,920 for each bus, based on reasonably predicted fair market value. A right of use asset and lease liability in the amount of $102,393 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

On October 20, 2020, through Banyan, we entered into a 60-month financing agreement with Ascentium Capital LLC for a 2020 Eldorado National Advance 220 p/t 14 passenger bus for the St. Petersburg location. This lease is considered an operating lease for accounting purposes because the lease period is less than the economic life of the asset being leased. Minimum annual rent payments under this lease are $13,381. At our discretion, we may exercise a purchase option, by giving written notice no later than 180 days but not more than 360 days before the expiration of the initial term. The purchase option price is $12,891 based on reasonably predicted fair market value. A right of use asset and lease liability in the amount of $55,345 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

In April of 2021, through Banyan, we entered into a 36-month copier lease with Dex Imaging. The lease was for one copy machine. The minimum annual lease payment is $4,920. The equipment under this lease has a fixed $1 payment buyout option. The equipment was purchased for the Banyan Sarasota location. A right of use asset and lease liability in the amount of $14,693 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

In July of 2021, through Banyan, we entered into a 60-month financing agreement with Ascentium Capital LLC for a 2021 Diamond VIP 2200 passenger bus for the Pasco location. This lease is considered an operating lease for accounting purposes. Minimum annual rent payments under this lease are $15,654 and the purchase option price is $15,193 based on reasonably predicted fair market value. A right of use asset and lease liability in the amount of $65,772 was recognized with this lease.

 

In August of 2021, through Banyan we entered into a 36-month financing agreement with Dex Imaging. The lease was for one copy machine. The minimum annual lease payment is $4,920. The equipment under this lease has a fixed $1 payment buyout option. The equipment was purchased for the Banyan Pasco location. A right of use asset and lease liability in the amount of $14,040 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

In July of 2021, through Trillium we entered into a 60-month financing agreement with Dex Imaging. The lease was for one copy machine. The minimum annual lease payment is $1,920. A right of use asset and lease liability in the amount of $8,049 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

 

In August of 2021, through Trillium we entered into a 60-month financing agreement with RJKool for a Unimac commercial washing machine. The minimum annual lease payment is $4,321. A right of use asset and lease liability in the amount of $18,476 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

In July of 2021, through Trillium we entered into a 36-month financing agreement with Southeastern Laundry Equipment Sales for a Unimac commercial washing machine. The minimum annual lease payment is $5,094. A right of use asset and lease liability in the amount of $13,054 was recognized in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

The leases assumed in the Trillium acquisition effective June 10, 2021 are reflected in accordance with FASB ASC Topic 842-10-65 which states; for leases in which the acquiree is a lessee, the acquirer shall measure the lease liability at the present value of the remaining lease payments, as if the acquired lease were a new lease of the acquirer at the acquisition date. The acquirer shall measure the right-of-use asset at the same amount as the lease liability as adjusted to reflect favorable or unfavorable terms of the lease when compared with market terms.

 

Through the Trillium acquisition (see NOTE 5) we assumed two master lease agreements. The first master lease agreement with Omega consists of 14 properties. The master lease with Omega was entered into on May 13, 2015, with an initial lease term that expires on May 31, 2027. The Omega master lease provides for two 10-year renewal options. At June 10, 2021 we recognized a right of use asset and lease liability in the amount of $29,906,314 in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

The second master lease with CTR accounts for 10 properties. The master lease with CTR was entered into on August 16, 2019, with an initial lease term that expires on November 30, 2030. The CTR lease provides for two 5-year renewal options. At June 10, 2021 we recognized a right of use asset and lease liability in the amount of $14,468,509 in association with this lease. This lease is treated as an operating lease for accounting purposes.

 

Through the Trillium acquisition we also assumed 27   capital leases for the following:

 

  2 phone systems for facilities
  6 van leases for facilities to transport residents
  15 copy machine leases for use at the facilities
  3 postage machine leases for use at the facilities
  1 lease for a washing machine at a facility

 

These leases are treated as capital leases for accounting purposes.

 

In accordance with ASC 842, we recorded the operating lease right of use asset and lease liability as follows:

 

   September 30, 2021   December 31, 2020 
Right of Use (ROU) assets  $46,089,030   $3,977,988 

 

   September 30, 2021   December 31, 2020 
Operating lease obligations:          
Current  $8,311,905   $189,397 
Non-Current   38,089,042    3,864,321 
Total  $46,400,947   $4,053,718 

 

Maturity of Operating Lease obligations for period ended September 30, 2021 ,

 

      
2021 (three months)  $1,990,630 
2022   8,545,124 
2023   9,950,470 
2024   8,305,778 
2025   5,840,681 
After 2025  $11,768,262 
Total lease obligation   46,400,947 

 

 

Information associated with the measurement of our remaining operating lease obligations as of September 30, 2021 is as follows:

 

The operating leases range from a term of 2.89 years to 15.93 years with a weighted average lease term of 5.47 years.

 

The capital leases range from a term of 1 to 4.96 years with a weighted average lease term of 3.72 years.

 

The weighted average discount rate for operating leases is 7.80%.

 

The weighted average discount rate for capital leases is 7.81%.

 

The lease expense for the three and nine month periods ended September 30, 2021 were $2,991,078 and $3,912,133, respectively, compared to $95,319 and $193,365, during the same periods in the prior year.

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
EQUITY
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
EQUITY

NOTE 11 - EQUITY

 

Preferred Stock

 

We have authorized 25,000,000 preferred shares with a par value of 0.0001 per share. The Board is authorized to divide the authorized preferred shares into one or more series, each of which shall be so designated as to distinguish the shares thereof from the shares of all other series and classes. As of September 30, 2021 and December 31, 2020, we had no classes of preferred shares designated.

 

As discussed in NOTE 5, as part of the Trillium acquisition, Trillium is entitled to 2,500,000 shares of the Company’s Series A Preferred Stock. The Preferred Shares, with respect to rights on liquidation, winding up and dissolution, rank pari passu with the Common Shares. The holders of Preferred Shares have the right to cast one (1) vote for each Preferred Share held of record on all matters submitted to a vote of holders of the Common Shares, including the election of directors, and all other matters as required by law. The Preferred Shares are not convertible into Common shares at the election of the holder. However, the Preferred Shares do automatically convert into Common Shares at a one to one ratio two years from date of issuance. In lieu of converting the Preferred Shares, the holders thereof may elect to have the Company redeem one or more Preferred Shares at the redemption price of $1.00 per share two years from the date of issuance. The Company is required to issue the Preferred Shares to Trillium within 30 days after the purchase of the Properties closes. In connection with the issuance of the Preferred Shares, the Company will file a Certificate of Designation with the Nevada Secretary of State prior to such issuance. A liability to issue the 2,500,000 shares is reflected as a long-term liability on the condensed consolidated balance sheet as of September 30, 2021in the amount of $4,750,000.

 

Common Stock

 

We have authorized 100,000,000 Common Shares with a par value of $0.0001 per share. Each Common Share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought. As of September 30, 2021, we had 45,345,418 Common Shares issued and outstanding.

 

Fiscal Year 2021

 

On March 23, 2021, we entered into a Plan of Merger with Banyan (See NOTE 3).

 

In connection with the Merger, we issued 4,165,418 Common Shares in exchange for 49,984,649 outstanding shares of Banyan’s common stock held by 64 shareholders, based on an exchange ratio of one (1) Common Share of our common stock for every twelve (12) shares of Banyan common stock.

 

In conjunction with the Merger, the previously issued 31,230,000 Common Shares prior to the Merger were deemed issued for the Merger.

 

During the period from February 11, 2021 through March 31, 2021 we issued 7,080,000 Common Shares at $0.50 per share for an aggregate consideration of $3,540,000.

 

 

During the three months ended June 30, 2021, noteholders of the $2,000,000 convertible note exercised their right to convert the note with an effective date of March 30, 2021 (see NOTE 3), 4,000,000 Common Shares were issued for the conversion of the note. The conversion was previously recorded as a liability to issue shares in the amount of $2,000,000.

 

During the three months ended June 30, 2021, we issued Common Shares in satisfaction of a liability to issue shares in the amount of $575,000 for stock purchases of 1,150,000 Common Shares at $0.50 per share.

 

As discussed in NOTE 5, as part of the Trillium acquisition, Trillium is entitled to Common Shares having an aggregate value of $5,000,000, based on the stock price at the time of issuance, upon the earlier of an initial public offering by the Company or June 10, 2022. A share liability is recorded as a current liability in the amount of $5,000,000 on the condensed consolidated balance sheet as of September 30, 2021.

 

During the three month period ended September 30, 2021 we issued 5,000,000 Common Shares at $1.00 per share for an aggregate consideration of $5,000,000.

 

On August 26, 2021, a majority of the stockholders approved, by written consent without a meeting, the 2021 Incentive Award Plan (“Award Plan”). The Award Plan was approved by the board of directors on August 19, 2021, and recommended to the stockholders for their approval. Under the Award Plan, 4,500,000 shares of our common stock will be initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents or other stock or cash based awards. As of the nine month period ending September 30, 2021 2,750,208 of the reserved shares were provided as stock options to 10 employees as part of the 2021 Incentive Award Plan. (See NOTE 14)

 

Fiscal Year 2020

 

During the year ended December 31, 2020, $140 was received against a subscription receivable balance for the 2019 authorization of the issuance of Founders shares. On December 31, 2020, we had a subscription receivable of $30 for shares issued where payments were not received.

 

On September 19, 2020, we issued 2,000,000 restricted Common Shares to a noteholder for the conversion of $500,000 of note principal.

 

Warrants

 

In association with the September 27, 2019, Asset Purchase Agreement (The Kidz Club St Pete, LLC), we issued 75,000 common stock warrants (post-merger exchange adjusted) having an exercise price of $0.38 per share. These warrants have an expiration of September 27, 2029.

 

           Weighted     
       Weighted-   Average     
       Average   Remaining   Aggregate 
       Exercise   Contractual   Intrinsic 
   Shares   Price   Term   Value 
                 
Outstanding at January 1, 2020   -    -    -   $- 
                     
Granted   75,000   $0.38    10.0 Years   $- 
Expired   -    -    -      
Exercised   -    -    -      
                     
Outstanding at December 31, 2020   75,000   $0.38    9.74 Years   $1.62 
                     
Granted   -    -    -      
Expired   -    -    -      
Exercised   -    -    -      
                     
Outstanding and exercisable September 30, 2021   75,000   $0.38    8.99 Years   $3.12 

 

 

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS
9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 12 – RELATED PARTY TRANSACTIONS

 

On February 1, 2021 (the “Effective Date”), we signed an employment agreement with our new CEO, Louis Collier (“Collier”). Collier will be paid a base salary of $400,000, which will be reassessed and renegotiated in good faith after we are profitable over a fiscal year. Collier will also receive a signing bonus of $150,000, which will be payable as follows: $50,000 within five days of the Effective Date (paid); $50,000 within 90 days of the Effective Date; and $50,000 within 180 days of the Effective Date. Collier will also be issued 1,250,000 phantom shares within ten days after the approval and adoption a Phantom Equity Plan. The phantom shares will be subject to a phantom unit interest award agreement, which will set forth the vesting of the phantom shares.

 

On March 23, 2021, we entered into a Plan of Merger (See NOTE 3) whereas we assumed debt of $2,000,000 that was convertible into 20,000,000 shares of common stock. After the Merger the debt was converted into 4,000,000 restricted Common Shares of the Company. One of the debt holders is majority owned by a director of the Company. During the three month period ending June 30, 2021, 4,000,000 restricted Common Shares were issued.

 

During the three months ended September 30, 2021 and 2020, we compensated members of the Board $42,000 and $0, respectively.

 

During the three months ended September 30, 2021 accrued payroll of $60,000 was paid and $6,277 interest was paid.  We had accrued payroll of $60,000 and accrued interest on that payroll for the President and the Chief Financial Officer of Banyan. These unpaid amounts were the result of 2020 furloughed salaries. Interest was accrued on these unpaid balances effective May 15, 2020 at a rate of 8% per annum.

 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENT INFORMATION
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 13 SEGMENT INFORMATION

 

The Company has adopted provisions of ASC 280-10 Segment Reporting for the three and nine months ended September 30, 2021, and 2020. This standard requires that companies disclose operating segments based on the manner in which management disaggregates the Company in making internal operating decisions. The Company and its Chief Operating Decision Makers determined that the Company’s operations consist of two segments: (i) Banyan’s three pediatric extended care centers (“PPECs”) in southwest Florida, and (ii) the second segment is the Trillium Subsidiaries consisting of senior housing communities including skilled nursing facilities, assisted living facilities and independent living facilities.

 

The table below reflects the segment operations for the nine months ended September 30, 2021.

 

   PPEC   Trillium   Adjustments, eliminations and unallocated items   Consolidated 
Total revenue, net  $2,094,905   $26,998,940   $-   $29,093,845 
Cost of Sales   (810,114)   (14,666,956)   -    (15,477,070)
Gross Profit   1,284,792    12,331,983    -    13,616,775 
                     
Salaries and payroll expense   610,183    5,521,454    540,019    6,671,656 
General and administrative   828,543    5,409,409    353,797    6,591,749 
Lease expense   383,501    3,528,632    -    3,912,133 
Professional fees   255,218    1,450,431    1,001,862    2,707,511 
Marketing and advertising   164,800    172,184    -    336,984 
Depreciation and amortization expense   206,777    111,336    211    318,324 
Operating Loss  $(1,164,231)  $(3,861,462)  $(1,895,889)  $(6,921,582)
                     
Total Assets  $10,206,083   $73,191,222   $2,733,979   $86,131,284 
Total Liabilities  $4,954,086   $63,148,235   $10,724,471   $78,826,792 
                     
Cash used in operating activities  $(917,789)  $(6,699,086)  $(2,395,144)  $(10,012,019)
Cash used in investing activities  $(51,972)  $3,620,828        $3,568,856 
Cash provided by financing activities  $(211,903)  $4,724,102   $5,479,518   $9,991,717 

 

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
STOCK-BASED COMPENSATION
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

NOTE 14 – STOCK-BASED COMPENSATION

 

On August 26, 2021, a majority of the stockholders approved, by written consent without a meeting, the 2021 Incentive Award Plan (“Award Plan”). The Award Plan was approved by the board of directors on August 19, 2021 and recommended to the stockholders for their approval. Under the Award Plan, 4,500,000 shares of our common stock will be initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents or other stock or cash based awards. As of the nine month period ending September 30, 2021 2,750,208 of the reserved shares were provided as stock options to 10 employees as part of the 2021 Incentive Award Plan. The shares vest over a 4 year period with a vesting commencement date of September 1, 2021, as of September 30, 2021 there were 57,296 of the shares vested with 2,692,912 options outstanding.

 

The following table summarizes our Stock Options activity under the Award Plan for the nine months ended September 30, 2021:

 

   Shares   Weighted Average Exercise Price   Weighted Average Remaining Vesting Period (Years) 
Outstanding At December 31, 2020   -           
                
Granted   2,750,208   $1.00    3.92 
Forfeited   -    -      
Exercised   -    -      
                
Outstanding September 30, 2021   2,750,208           

 

At September 30, 2021 the weighted average period over which compensation cost on non-vested Stock Options expected to be recognized is 3.92 years and the unrecognized expense is approximately $8.1 million.

 

Stock-based compensation before income taxes included in salaries and wages in the condensed consolidated statement of operations was $171,888 for the three months ended September 30, 2021. We did not recognize compensation cost in the three or nine month periods ended September 30, 2020 since the Stock Options were not awarded during the period.

 

We did not have any cash proceeds or income tax benefits realized from the exercise of Stock Options for the three and nine months ended September 30, 2021.

 

Valuation Assumptions

 

Calculating the fair value of employee stock options requires estimates and significant judgement. We use the Binomial option pricing model to estimate the fair value of the employee stock options.

 

We have included shares issuable under the Award Plan in deriving fully diluted earnings per share using the Treasury Method in accordance with ASC 260-10-45. Under the Treasury Method, nonvested stock options granted, where the only satisfying condition is the mere passage of time, shall be assumed exercised at the beginning of the period (or at time of issuance, if later). The proceeds from exercise of stock options shall be assumed to be used to purchase common stock at the average market price during the period using daily closing prices

 

 

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
CONCENTRATIONS AND CREDIT RISKS
9 Months Ended
Sep. 30, 2021
Risks and Uncertainties [Abstract]  
CONCENTRATIONS AND CREDIT RISKS

NOTE 15 – CONCENTRATIONS AND CREDIT RISKS 

 

Cash

 

The Company places its cash with high credit quality financial institutions. The Company had balances in excess of the Federal Deposit Insurance Corporation (“FDIC”) coverage of $250,000 at September 30, 2021, the aggregate amount in excess of the coverage limit was approximately $2.8 million consisting of three accounts. The Company maintains its cash in accounts at financial institutions, which may, at times, exceed federally-insured limits. The Company has not experienced any losses on such accounts and does not feel it is exposed to any significant risk with respect to cash.

 

Revenues and Accounts Receivable

 

For the three and nine months ended September 30, 2021, approximately 15% of our revenue was generated from Medicare, 67% was generated from Medicaid and approximately 13% of our revenue was generated from private pay residents. The balance consisted of other payors including managed care programs, VA programs and commercial insurance.

 

At September 30, 2021 18% of our accounts receivable balances consisted of Medicare receivables, 54% consisted of Medicaid receivables, 13% consisted private pay and 11% consisted of commercial insurance. The balance of the accounts receivable consisted of VA and other payors.

 

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 16 – SUBSEQUENT EVENTS

 

We have evaluated subsequent events from September 30, 2021 through the date of these financial statements were issued and determined the following events require disclosure:

 

Autumn Accolade

 

On September 30, 2021,we entered into an Agreement for the Purchase and Sale of Business Assets and Real Estate (the “Purchase Agreement”), with Autumn Accolade, Inc., (“Asset Seller”), Deborah S. Penn, as Trustee under the provisions of a Trust Agreement dated October 8, 2012, and known as the Denton M. Penn Jr. Trust, as to an undivided one-half interest; Deborah S. Penn, as Trustee under the provisions of a Trust Agreement dated October 8, 2012, and known as the Deborah S. Penn Trust, as to an undivided one-half interest (together, “RE Seller,” and collectively with Asset Seller, the “Seller”).

 

Asset Seller owns and operates a licensed assisted living facility located in Green Valley; Illinois known as Autumn Accolade (the “Business”). Asset Seller also owns various assets in conjunction with the operation of the Business, including all assets that are located at, on or within the Premises including those assets that are affixed to the Premises (collectively, “Assets”). RE Seller is the owner in fee simple of the real estate upon which the Assets are located (the “Premises”).

 

Subject to the terms of the Purchase Agreement, we are acquiring the Assets and the Premises from the Sellers in exchange for $2,300,000 and the assumption of certain liabilities. We paid a $110,000 deposit (the “Deposit”) upon execution of the Purchase Agreement, which is being held in escrow and will be applied to the purchase price at closing or refunded if the closing doesn’t occur. We paid an additional $15,000 deposit to the Seller upon execution of the Purchase Agreement, which is not refundable.

 

The closing shall take place promptly following the satisfaction or waiver of the conditions to closing (but in no event less than 30 days thereafter unless otherwise agreed to by the parties). In the event the closing has not taken place by March 31, 2022, then either party may terminate the Purchase Agreement by written notice to the other party so long as such party is not then in breach of the Purchase Agreement, and the Deposit will be immediately returned , less $35,000 to be paid to the Seller if the Seller is able to close but we have failed to meet a financing contingency prior to the March 31, 2022 closing date. We may extend the March 31, 2022 closing date to no later than June 30, 2022 upon written notice to the Seller prior to the March 31, 2022 and the payment to the Seller of a non-refundable amount of $20,000, which shall not be applied to the purchase price.

 

 

Gemino Healthcare Finance

 

On September 30, 2021 we entered into a Second Amendment to our credit agreement with Gemino Healthcare Finance, LLC. The Credit Agreement was entered into in connection with a $10 million credit facility to be used for working capital and general business purposes, and secured by a first priority perfected security interest in the assets of Trillium and the Trillium Group. The credit facility terminates on May 9, 2022. Each revolving loan under the credit facility bears interest on the outstanding principal amount thereof from the date made until paid in full, at a rate per annum equal to the greater of: (i) the annual rate reported as the London Interbank Offer Rate applicable to ninety (90) day deposits of United States Dollars as reported in the Money Rates Section of The Wall Street Journal on the date of determination; and (ii) 2.00%, plus 4.95% (together, the “Interest Rate”). The Interest Rate on all amounts outstanding under the credit facility is adjusted daily based on any changes in the amount under subsection (i) above and subsection (ii) above, as applicable. There are also various fees paid in connection with the credit facility, including: (1) a monthly collateral monitoring fee of 1.00% of the average borrowing base during the prior month; (2) a monthly unused line fee equal to 0.75% per annum of the unused portion of the maximum amount of credit facility; (3) a minimum use fee if the outstanding revolving loan balance is less than $2 million equal to the Interest Rate times the minimum balance of $2 million; and (4) a termination fee of $100,000 if the credit facility is terminated by A4L prior to May 9, 2022. The credit facility also contains typical affirmative and negative covenants found in credit facilities of this type and amount.

 

The First Amendment amended the Credit Agreement by: (1) releasing seven entities from the Trillium Group of their obligations under the credit facility in connection with Trillium’s sale of those entities; (2) increasing to 5.95% the rate used to calculate the Interest Rate; (3) increasing the monthly collateral monitoring fee to 1.50%; (4) lowering the revolving commitment amount from $10 million to $7 million; and (5) waiving borrower’s failure to comply with the fixed charge coverage ratio for the fiscal quarters ending September 30, 2019, December 31, 2019, and March 31, 2020.

 

The Second Amendment further amended the Credit Agreement by: (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; (7) increasing the maximum amount of the credit facility from $10 million to $25 million; and (8) revising terms regarding financial statements and collateral reports, limitations on certain corporate guarantors and curing defaults.

 

Debt

 

On October 8, 2021 we entered into a guaranty agreement in connection with a loan made to our wholly-owned subsidiary, Assisted 4 Living Consulting, Inc. in the principal amount of $1,250,000 (the “Loan”). Pursuant to the terms of the guaranty agreement, the A4L has unconditionally guaranteed the payment of all indebtedness, liabilities and obligations of every kind and nature of Assisted 4 Living Consulting, LLC to the lender whether absolute or contingent, direct or indirect, due or to become due, heretofore or hereafter created, arising or exiting including any additional advances or future advances, renewals or extensions without limitation as to amount. The Loan is evidenced by a promissory note. Outstanding principal accrues interest at an annual rate of ten percent (10%). Monthly payments in the amount of $10,416.67 commence on November 8, 2021 and continue for 12 months until the maturity date of October 8, 2022, at which time the remaining principal balance, if any, is due and payable. The Loan is secured by a first mortgage lien on property that is owned by Borrower and serves as the A4L corporate headquarters.

 

If any portion of the principal is paid prior to July 8, 2022, then Assisted 4 Living Consulting, LLC must pay a prepayment fee calculated as the difference between nine months of interest on the amount of principal being prepaid and the amount of interest paid to date on the amount of principal being prepaid. The lender is guaranteed nine months of interest regardless of when Loan is paid off.

 

After the maturity date or due date of the promissory note, interest shall be charged on the respective principal amount remaining unpaid at a rate equivalent to the highest lawful rate or twenty-five percent (25%) per annum, whichever is less, until paid.

 

If any payment of principal or interest or both is more than five days late, Borrower agrees to pay lender a late charge equal to five percent (5.0%) of the payment.

 

Crete Plus Five Property

 

On October 13, 2021 we entered into an Agreement of Purchase and Sale with Crete Plus Five Property, LLC, Iowa Lincoln County Property LLC, Muscatine Toledo Properties, LLC and Avery Street Property, LLC (collectively, “Owners” ). The Owners owns 13 senior housing facilities located in Iowa, Nebraska and Florida (collectively, the “Facilities”) as well the real property underlying the Facilities (the “Properties”). The Agreement of Purchase and Sale is for the purchase of the Facilities, the Properties and all of Owner’s right, title and interest in all of the personal property located at the Properties, other than certain personal property described in Exhibit B attached to the Agreement of Purchase and Sale, such as cash and the tradenames and books and records of Owner. The A4L indirect wholly-owned subsidiaries currently lease the Properties from Owner, and operate the Facilities, pursuant to an Master Lease dated as of May 13, 2015, as amended.

 

 

The purchase price for the Facilities and the Properties is $59,000,000. A4L paid a $3,000,000 deposit (the “Deposit”) in June upon execution of a letter of intent with Owner as part of the Trillium transaction, and A4L will receive a credit at closing against the purchase price in the amount of the Deposit. If the Agreement of Purchase and Sale is Terminated prior to closing for any reason other than breach of the agreement by Owner, the Deposit will be paid to Owner as liquidated damages. The closing is to occur on March 1, 2022; provided, however, A4L may extend the March 1, 2022 closing date to no later than March 31, 2022, upon written notice to Owner prior to the February 15, 2022.

 

Grace Care Centers

 

On October 18, 2021 we completed the acquisition from Grace Care Centers and its affiliates (collectively, “Grace”) of three skilled nursing facilities located in Texas (the “Skilled Facilities”), including the real property, buildings, structures, improvements, fixtures and certain other assets comprising the Skilled Facilities (together with the Skilled Facilities, the “Assets”) in exchange for an aggregate purchase price of $7,750,000 (the “Purchase Price”). The Assets were acquired pursuant to and in accordance with three Purchase and Sale Agreements and three Management Transfer Agreements (collectively, the “Agreements”).

 

The Skilled Facilities, located in Olney, Nocona and Henrietta, Texas, are all 5-star rated by CMS for quality and have a combined 258 beds. The Skilled Facilities will continue to be leased to local hospital districts, who will continue to be the licensed operators of the Skilled Facilities. A4L, through indirect wholly-owned subsidiaries, now owns the Assets and will manage the day-to-day activities of the Skilled Facilities pursuant to management agreements which it assumed in connection with the transaction.

 

A4L, through its indirect wholly-owned subsidiary, financed part of the Purchase Price with a loan from Arena Limited SPV, LLC (“Lender”) in the principal amount of $6,600,000 (the “Loan”). Outstanding principal accrues interest at a rate per annum equal to the sum of the Prime Rate plus 4.125%, with a minimum interest rate per annum of not less than 7.875%. Monthly interest only payments commence on December 15, 2021, and continue each month until the maturity date of the Loan on April 18, 2023, at which time any outstanding principal and accrued and unpaid interest is due and payable. If any principal, interest or any other sums due under the Loan (other than the payment of principal due on the maturity date), is not paid on or prior to the due date, A4L is required to pay Lender upon demand an amount equal to 5% of such unpaid sum. In connection with any repayment or prepayment of principal, a non-refundable fee equal to 0.5% of the principal amount of such repayment or prepayment is due. A4L may prepay the outstanding amount in whole, but not part, upon prior written notice to Lender.

 

A4L has the right to extend the initial maturity date to October 15, 2023 upon prior written notice to Lender and the payment to Lender of a non-refundable fee equal to 1% of the outstanding principal balance no later than 30 days prior to the maturity date. A4L may extend the maturity date further, to April 15, 2024, upon prior written notice to Lender and the payment to Lender of a non-refundable fee equal to 1% of the outstanding principal balance prior to the extended maturity date.

 

The Loan is secured by a first priority lien on the Assets, including all amounts received by A4L or any subsidiaries constituting rent or other payment under any leases or management fees under each of the management agreements, which must be deposited into a segregated account at a bank and held in trust for Lender. The Loan is subject to customary affirmative and negative covenants, as well as customary default provisions for late or non-payments or breach of covenants, for loans of this nature. Pursuant to the terms of a guaranty agreement, A4L and several of its direct and indirect wholly-owned subsidiaries, have each unconditionally guaranteed to Lender the payment of all indebtedness, liabilities and obligations of every kind and nature under the Loan.

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements of the Company (“Financial Statements”) have been prepared in accordance with GAAP for interim financial statements and with the instructions to Form 10-Q and Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements.

 

In the opinion of management, the accompanying condensed consolidated Financial Statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2021, and the results of operations and cash flows for the periods presented. The results of operations for the nine months ended September 30, 2021, are not necessarily indicative of the operating results for the full fiscal year or any future period. These condensed consolidated Financial Statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2021 and Current Report on Form 8-K on June 2, 2021. As of April 30, 2021, we had discontinued operations reflected in the accompanying condensed consolidated Financial Statements. As a result of the Plan of Merger completed on March 23, 2021 (see NOTE 3) we have changed our year end reporting period from November to December.

 

Capital Requirements, Liquidity and Going Concern Considerations

Capital Requirements, Liquidity and Going Concern Considerations

 

These condensed consolidated Financial Statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. Although we had cash and accounts receivable in the amount of approximately $11.4 million at September 30, 2021, we had accrued expenses and current notes payable in excess of cash and accounts receivable in the amount of approximately $6.5 million, and a deficiency in working capital of approximately $20.6 million. For the nine months ended September 30, 2021, our net loss was approximately $6.9 million.

 

As a result of these factors, we determined it was necessary to review our cash flow for 2021 and an overall analysis of market trends to determine whether or not we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report. We also determined it was necessary to take certain corporate actions, including reducing discretionary expenses (and reduced reliance on agency staffing), improving revenue (including added Therapy and Rehab services), and raising additional capital, in order to ensure we have sufficient liquidity to continue as a going concern for a period of at least twelve months from the date of this Quarterly Report.

 

During the three months ended September 30, 2021 we sold 5.0 million shares for an aggregate total of $5.0 million. This capital raise will be used for additional growth through acquisitions and for working capital. However, no assurances can be given that we will be successful. If management is not able to timely and successfully raise additional capital and/or refinance indebtedness, the implementation of the Company’s business plan, financial condition and results of operations will be materially affected.

 

Basis of Consolidation

Basis of Consolidation

 

These condensed consolidated Financial Statements include the accounts of the Company and the wholly-owned subsidiaries, Banyan Pediatric Care Centers – OPS, LLC, Banyan Pediatric Care Centers – St. Petersburg, LLC, Banyan Pediatric Care Centers, - Pasco, LLC and Banyan Pediatric Care Centers – Sarasota, LLC and the discontinued operations of Assisted 2 Live, Inc., the wholly owned subsidiary that was discontinued as of April 30, 2021. All material intercompany balances and transactions have been eliminated. The condensed consolidated Financial Statements also include the accounts of the Trillium Subsidiaries from June 10, 2021, the effective date of the transaction with Trillium.

 

Use of Estimates and Assumptions

Use of Estimates and Assumptions

 

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

 

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at September 30, 2021 and December 31, 2020.

 

Accounts Receivable

Accounts Receivable

 

Accounts receivable primarily consists of amounts due from third-party payers (non-governmental), governmental payers and private pay patients and is recorded net of contractual allowances and reserves for doubtful accounts. The Company’s ability to collect outstanding receivables is critical to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s Financial Statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk of overestimation of net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the risk of non-payment as a result of commercial insurance companies’ denial of claims, (iii) the risk that patients will fail to remit insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not covered by insurance) and (vi) the risk of non-payment from uninsured patients.

 

The Company’s accounts receivable from third-party payers are recorded net of estimated contractual adjustments and allowances from third-party payers, which are estimated based on the historical trend of the Company’s facilities’ cash collections and contractual write-offs, accounts receivable aging, established fee schedules, relationships with payers and procedure statistics. While changes in estimated reimbursement from third-party payers remain a possibility, the Company expects that any such changes would be minimal and, therefore, would not have a material effect on the Company’s financial condition or results of operations. The Company’s collection policies and procedures are based on the type of payor, size of claim and estimated collection percentage for each patient account. The Company analyzes accounts receivable at each of the facilities to ensure the proper collection and aged category. The operating systems generate reports that assist in the collection efforts by prioritizing patient accounts. Collection efforts include direct contact with insurance carriers or patients and written correspondence.

 

Allowance for Doubtful Accounts, Contractual and Other Discounts

Allowance for Doubtful Accounts, Contractual and Other Discounts

 

Management estimates the allowance for contractual and other discounts based on its historical collection experience and contracted relationship with the payers. The services authorized and provided and related reimbursement are often subject to interpretation and negotiation that could result in payments that differ from the Company’s estimates. The Company’s allowance for doubtful accounts is based on historical experience, but management also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the adequacy of the allowance for doubtful accounts. An account may be written-off only after the Company has pursued collection efforts or otherwise determines an account to be uncollectible. Uncollectible balances are written-off against the allowance. Recoveries of previously written-off balances are credited to income when the recoveries are made.

 

COVID-19 Pandemic and CARES Act Funding

COVID-19 Pandemic and CARES Act Funding

 

COVID-19 Pandemic. In January 2020, the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel strain of coronavirus. In March 2020, the World Health Organization declared the outbreak of COVID-19, a disease caused by this coronavirus, a pandemic. The resulting measures to contain the spread and impact of COVID-19 and other developments related to COVID-19 have materially affected the Company’s results of operations during 2020. Where applicable, the impact resulting from the COVID-19 pandemic during the year ended December 31, 2020, has been considered, including updated assessments of the recoverability of assets and evaluation of potential credit losses. As a result of the COVID-19 pandemic, federal and state governments have passed legislation, promulgated regulations and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency. Sources of relief include the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020, the Paycheck Protection Program and Health Care Enhancement Act (the “PPPHCE Act”), which was enacted on April 24, 2020, and the Consolidated Appropriations Act, 2021 (the “CAA”), which was enacted on December 27, 2020. In total, the CARES Act, PPPHCE Act and the CAA authorize $178 billion in funding to be distributed to hospitals and other healthcare providers through the Public Health and Social Services Emergency Fund (the “PHSSEF”). In addition, the CARES Act provide for an expansion of the Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers were able to request accelerated payment of up to 100% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments. Various other state and local programs also exist to provide relief, either independently or through distribution of monies received via the CARES Act. During the period ended September 30, 2021, the Company was a beneficiary of these stimulus measures, including the Medicare Accelerated and Advance Payment Program.

 

 

The Company’s accounting policies for the recognition of these stimulus monies is as follows:

 

Pandemic Relief Funds

Pandemic Relief Funds

 

Trillium received an aggregate of $13,487,923 in PHSSEF payments, of which $4,242,796 was applied during 2020. Prior to the acquisition date of June 10, 2021 Trillium had recognized $7,081,557 as other operating income. During the three and nine-month period ended September 30, 2021 we recognized $1,385,162 as other operating income resulting in a remaining balance of $778,408 which is classified on the balance sheet as Deferred HHS Revenue. The recognition of amounts received is conditioned upon the provision of care for individuals with possible or actual cases of COVID-19 after January 31, 2020, certification that payment will be used to prevent, prepare for and respond to coronavirus and shall reimburse the recipient only for healthcare-related expenses or lost revenues, as defined by HHS, that are attributable to coronavirus, as well as receipt of the funds. Amounts are recognized as a reduction to operating costs and expenses only to the extent the Company is reasonably assured that underlying conditions have been met.

 

The Company’s assessment of whether the terms and conditions for amounts received are reasonably assured of having been met considers, among other things, the CARES Act, the CAA and all frequently asked questions and other interpretive guidance issued by HHS, including the Post-Payment Notice of Reporting Requirements issued on January 15, 2021 (the “January 15, 2021 Notice”) and frequently asked questions issued by HHS on January 28, 2021 which clarified previously issued guidance, as well as expenses incurred attributable to the coronavirus and the Company’s results of operations during such period as compared to the Company’s budget. Such guidance, specifically the various Post-Payment Notice of Reporting Requirements and frequently asked questions issued by HHS, set forth the allowable methods for quantifying eligible healthcare related expenses and lost revenues. Only healthcare related expenses attributable to coronavirus that another source has not reimbursed and is not obligated to reimburse are eligible to be claimed. On the basis of guidance available at the time, the Company’s estimate of lost revenues was first based on the negative change in year-over-year net patient care operating revenue, then on the negative change in year-over-year net patient care operating income and finally on the difference between budgeted and actual revenue for calendar year. The calculation as of September 30, 2021 is in accordance with the CAA which indicates that lost revenues may be calculated pursuant to frequently asked questions published by HHS in June 2020, including the difference between a provider’s budgeted and actual revenue if such budget had been established prior to March 27, 2020. The use of funds calculation as of September 30, 2021 takes into account expenses attributable to each respective entity, which primarily relate to incremental labor and supply costs, as well as lost revenues. General fund distributions were allocated among subsidiaries according to total unreimbursed losses. Targeted distributions were not allocated or transferred among subsidiaries. While the CAA, January 15, 2021 Notice and frequently asked questions published by HHS on January 28, 2021 indicate that targeted distribution payments may be allocated or transferred to subsidiaries, distinct conditions exist for such allocations or transfers including that the parent organization have a “direct ownership relationship” with the subsidiary who received the targeted distribution payment. Additionally, the subsidiary that was the recipient of the targeted distribution payment retains responsibility for reporting to HHS on the use of such funds even if they are transferred or allocated to other subsidiaries. There are significant uncertainties as to the meaning and interpretation of conditions specific to the allocation or transfer of targeted distribution payments such that as of September 30, 2021, the Company is not reasonably assured that it can or will choose to comply with such conditions in order to allocate or transfer targeted distribution payments.

 

HHS’ interpretation of the underlying terms and conditions of such PHSSEF payments, including auditing and reporting requirements, continues to evolve. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such PHSSEF payments may result in changes in the Company’s estimate of amounts for which the terms and conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in the Company’s inability to recognize additional PHSSEF payments or may result in the de recognition of amounts previously recognized, which (in any such case) may be material.

 

Medicare Accelerated Payments

Medicare Accelerated Payments

 

The Company recorded payments under the Medicare Accelerated and Advance Payment program in accordance with FASB ASC 606 and has recorded amounts as a contract liability under FASB ASC 606-10-45-2. The contract liability will be reduced over time as revenue is recognized for claims submitted for services provided after the recoupment period begins. Effective October 1, 2020, the program was amended such that providers are required to repay accelerated payments beginning one year after the payment was issued. After such one-year period, Medicare payments owed to providers will be recouped according to the repayment terms. The repayment terms specify that for the first 11 months after repayment begins, repayment will occur through an automatic recoupment of 25% of Medicare payments otherwise owed to the provider. At the end of the eleven-month period, recoupment will increase to 50% for six months. At the end of the six months (or 29 months from the receipt of the initial accelerated payment), Medicare will issue a letter for full repayment of any remaining balance, as applicable. In such event, if payment is not received within 30 days, interest will accrue at the annual percentage rate of four percent (4%) from the date the letter was issued and will be assessed for each full 30-day period that the balance remains unpaid. As of September 30, 2021, $1,671,698 of Medicare accelerated payments are reflected on the balance sheet within advance payments line.

 

 

The company receives a substantial portion of our revenues from the Medicare and Medicaid programs. Included in Managed Care and other third-party payors is operating revenues from insurance companies with which we have insurance provider contracts, Medicare managed care, insurance companies for which we do not have insurance provider contracts, workers’ compensation carriers and non-patient service revenue, such as rental income and cafeteria sales. In the future, we generally expect the portion of revenues received from the Medicare and Medicaid programs to increase over the long-term due to the general aging of the population and the impact of the Affordable Care Act. The Affordable Care Act has increased the number of insured patients in states that have expanded Medicaid, which in turn, has reduced the percentage of revenues from self-pay patients. However, it is unclear whether the trend of increased coverage will continue, due in part to the impact of the COVID-19 pandemic and the elimination of the financial penalty associated with the individual mandate, effective January 1, 2019. Further, the Affordable Care Act imposes significant reductions in amounts the government pays Medicare managed care plans. Moreover, the trend toward increased enrollment in Medicare and Medicaid managed care may adversely affect our operating revenue. An executive order issued in October 2019 seeks to accelerate this shift away from traditional fee-for-service Medicare to Medicare managed care. We may also be impacted by regulatory requirements imposed on insurers, such as minimum medical-loss ratios and specific benefit requirements. Furthermore, in the normal course of business, managed care programs, insurance companies and employers actively negotiate the amounts paid to hospitals. Our relationships with payors may be impacted by price transparency initiatives and out-of-network billing restrictions. There can be no assurance that we will retain our existing reimbursement arrangements or that these third-party payors will not attempt to further reduce the rates they pay for our services.

 

Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-based reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for the treatment of patients covered by Medicare, Medicaid and non-governmental payors are generally less than our standard billing rates. We account for the differences between the estimated program reimbursement rates and our standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at net operating revenues. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The carrying amount of accounts receivable and accounts payable approximate their respective fair values due to the short- term nature. The carrying amount of the line of credit and note payable approximates fair values due to their market interest rates. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable.

 

Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Depreciation of owned assets and amortization of leasehold improvements are computed using the straight-line method over the shorter of the estimated useful lives of the related assets or the lease term. The cost of assets sold or retired, and the related accumulated depreciation are removed from the accounts and any resulting gains or losses are reflected in other income (expense) for the year. Expenditures for maintenance and repairs are charged to expense as incurred.

 

Goodwill

Goodwill

 

Our goodwill represents the excess of the purchase price over the fair value of the net identifiable assets acquired in business combinations. The goodwill generated from the business combinations is primarily related to the value placed on the employee workforce and expected synergies. Judgment is involved in determining if an indicator or change in circumstances relating to impairment has occurred. Such changes may include, among others, a significant decline in expected future cash flows, a significant adverse change in the business climate, and unforeseen competition. There was no goodwill impairment for the periods presented.

 

 

The Company tests goodwill for impairment on an annual basis, and when events or circumstances indicate the fair value of a reporting unit may be below its carrying value.

 

Long-Lived Assets

Long-Lived Assets

 

Long-lived assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There were no impairments of long-lived assets for the years presented.

 

Advertising and Marketing

Advertising and Marketing

 

The Company uses advertising and marketing to promote its services. Advertising and marketing costs are expensed as incurred.

 

Earnings (Loss) Per Share

Earnings (Loss) Per Share

 

Basic Earnings (loss) per common share is computed by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per common share is determined using the weighted-average of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of the conversion option embedded in convertible debt. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would have an anti-dilutive effect.

 

Fixed grantee stock options (fixed awards) and nonvested stock (including restricted stock) shall be included in the computation of diluted earnings per common share. Even though their issuance may be contingent upon vesting, they shall be considered to be contingently issuable shares. Because issuance of performance based stock options (and performance based nonvested stock) is contingent upon satisfying conditions in addition to the mere passage of time, those options and non vested stock shall be considered to be contingently issuable shares in the computation of diluted earnings per common share.

 

The dilutive effect of outstanding call options and warrants (and their equivalents) are reflected in diluted earnings per common share by application of the treasury stock method unless another method is required. Equivalents of options and warrants include nonvested stock granted under a share based payment arrangement, stock purchase contracts, and partially paid stock subscriptions. Antidilutive contracts such as purchased put options and purchased call options shall be excluded from diluted earnings per common share.

 

The Company has included shares issuable under its 2021 Incentive Award Plan in deriving its fully diluted earnings per common share using the Treasury Method in accordance with ASC 260-10-45.

 

Income Taxes

Income Taxes

 

The Company uses the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets, liabilities, the carry forward of operating losses and tax credits, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. An allowance against deferred tax assets is recorded when it is more likely than not that such tax benefits will not be realized.

 

Any future benefit arising from losses have been offset by a valuation allowance. Accordingly, no provision for income taxes is reflected in the condensed consolidated financial statements. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. Interest and penalties related to income tax matters, if any, would be recognized as a component of income tax expense. At September 30, 2021 and December 31, 2020, the Company had no liabilities for uncertain tax positions. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Currently, the tax years subsequent to 2017 are open and subject to examination by the taxing authorities.

 

Revenue Recognition

Revenue Recognition

 

We follow ASC 606, “Revenue from Contracts with Customers.” Revenues are recognized when promised services are transferred to a customer, in an amount that reflects the consideration that we expect to receive in exchange for those services. We derive our revenues from the rendering of services, such as skilled nursing services. The five-step armodel defined by ASC 606 requires us to: (i) identify our contracts with customers, (ii) identify our performance obligations under those contracts, (iii) determine the transaction prices of those contracts, (iv) allocate the transaction prices to our performance obligations in those contracts and (v) recognize revenue when each performance obligation under those contracts is satisfied.

 

 

Reimbursement rates to provide services in our facilities are determined by the fee schedules set by the government programs and negotiated in contracts with non-governmental third-party payors and private pay patients. Fees are billed to the payors and private pay patients weekly and monthly following billing guidelines and contract requirements.

 

Net Patient Revenue

Net Patient Revenue

 

Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions.

 

The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed.

 

The estimates for implicit price concessions are based upon management’s assessment of historical write-offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable.

 

Reclassification

Reclassification

 

Certain amounts from prior periods have been reclassified to conform to the current period presentation.

 

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
DISCONTINUED OPERATIONS (Tables)
9 Months Ended
Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]  
SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS

 

   2021   2020   2021   2020 
  

For the three months ended

September 30,

  

For the nine months ended

September 30,

 
   2021   2020   2021   2020 
Net revenues  $-   $-   $76,847   $- 
Cost of net revenues   -    -    -    - 
Gross profit   -    -    -    - 
                     
Operating expenses:                    
Salary and tax expense   -    -    46,813    - 
General and administrative   -    -    52,555    - 
Lease expense   -    -    3,979    - 
Total operating expenses   -    -    103,347    - 
                     
Income from discontinued operations   -    -    (26,500)   - 
Interest and other, net   -    -    -    - 
Income from discontinued operations before income taxes   -    -    (26,500)   - 
Provision for income taxes        -         - 
Income from discontinued operations, net of income taxes  $-   $-   $(26,500)  $- 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
TRILLIUM ACQUISITION (Tables)
9 Months Ended
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED

 

Assets acquired     
Cash  $3,432,847 
Accounts receivable   5,521,080 
Prepaid expenses and other current assets   2,661,683 
Property and equipment   2,380,635 
Goodwill   12,082,529 
Leasehold improvements   1,213,273 
Lease right of use asset   44,196,092 
Total identifiable assets acquired  $71,488,139 
Liabilities assumed     
Advance payments  $2,905,234 
Accounts payable and accrued expenses   8,783,508 
Deferred revenue   2,162,966 
Loan Payable - other   453,043 
Lease liability - current portion   7,837,406 
Notes payable   2,309,884 
Lease liability - net of current portion   36,383,251 
Cash due to seller   902,847 
Share liability   9,750,000 
 Total identifiable liabilities acquired  $71,488,139 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)
9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Our accounts payable and accrued liabilities at September 30, 2021 and December 31, 2020 consisted of the following:

 

   September 30, 2021   December 31, 2020 
         
Accounts payable  $6,299,400   $16,298 
Credit Card   37,712    1,050 
Accrued Expense   3,513,517    130,832 
Accrued Salary   995,265    - 
Payroll Tax Payable   33,189    - 
 Accounts Payable and Accrued Liabilities  $10,879,082   $148,180 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
NOTES PAYABLE (Tables)
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
SCHEDULE OF NOTES PAYABLE

Notes payable at September 30, 2021 and December 31, 2020 consisted of the following:

 

      September 30, 2021   December 31, 2020 
Excel Family Partners, LLLP / Banyan Pediatric Investment, Inc. (Sep 2020)  a  $-   $2,000,000 
NuView Trust Co. (Nov 2020)  b   300,000    300,000 
Grand Trinity Plaza, LLC (Dec 2020)  c   346,174    407,500 
Reliant  d.i   808,310    - 
HCSG  d.ii   397,191    - 
Medline  d.iii   242,967    - 
SLR - RLOC  e   5,212,234    - 
      $7,306,876   $2,707,500 

 

a. On September 18, 2020, through Banyan, we entered into a Convertible Note and Securities Purchase Agreement with two investors for the aggregate principal in the amount of $2,000,000. The note had a maturity date of September 18, 2022, and an interest rate of 8% to be paid quarterly. The principal was funded by two investors (“Purchasers”), both related parties. Excel Family Partners, LLLP invested $1,500,000 and Banyan Pediatric Investments, LLC invested $500,000. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. Written consent from shareholders holding a majority of the issued and outstanding shares of common stock of Banyan was obtained, not including such shares currently held by the Purchasers or their affiliates, consenting to the note contemplated hereby, in a form and substance acceptable to the Purchasers, in their respective reasonable discretion. Both Purchasers were permitted to convert their respective portions of the note at a conversion price of $0.10 per share. Subsequent to the Merger (see NOTE 3), the Board revised the conversion price of the note to $0.50 per share. Effective March 30, 2021, the Purchasers exercised their right to convert all outstanding principal. As of September 30, 2021, and December 31, 2020, there was $0 and $45,589 of accrued interest, respectively and is reflected in accrued interest balances on the condensed consolidated balance sheet at September 30, 2021 and December 31, 2020.
   
b. On November 6, 2020, through Banyan, we entered into a one-year note in the principal amount of $300,000 with NuView Trust Company. The note has a 12% interest rate with interest only payments until date of maturity. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. As of September 30, 2021, and December 31, 2020, there was no accrued interest. (see NOTE 3)

 

 

c. On December 15, 2020, through Banyan Pediatric Care Centers – Pasco, LLC, we entered into a note payable with Grand Trinity Plaza, LLC in the principal amount of $407,500, which is guaranteed by Banyan. The term of the note is 48 months with an interest rate of 6%. The maturity date of the note is January 1, 2025. The note is in conjunction with the 84-month facility lease for the Pasco County location, pursuant to which the landlord also provided the construction of the buildout and financed $407,500 of the construction costs.
   
d. In 2019, certain vendors of Trillium agreed to extend payment terms by converting then outstanding amounts of accounts payable balances to long-term debt bearing interest at rates ranging from 0% to 6%.
   
    i. Reliant note payable - Past due balances with vendor Reliant were converted to a note payable in 36 equal monthly installments of principal and interest of $69,568 from October 2019 through September 2022. The note bears interest at a rate of 6%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
 

 

    ii. HCSG note payable – Past due balances with vendor HCSG were converted to a non-interest-bearing note payable; payable in 36 equal monthly principal installments of $33,099 from October 2019 through September 2022. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
         
    iii. Medline note payable – Past due balances with vendor Medline were converted to a note payable; payable in 36 equal monthly installments of principal and interest of $20,911 from October 2019 through September 2022; note bears interest at a rate of 6%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
   
e. SLR revolving line of credit - On May 9, 2019, Trillium entered into a financing agreement (“the GHF Line”) with Gemino Healthcare Finance, LLC (DBA SLR Healthcare ABL), the lender, which allows the Trillium Subsidiaries to borrow up to the lesser of $10 million or 85% of eligible accounts receivable. The GHF Line bears interest at the greater of one-month LIBOR or 2%, plus 4.95%, applied daily, and continues to be applied to outstanding principal until the expiration of one business day after such principal has been repaid. The Trillium Subsidiaries also incur monthly collateral management fees under the line of 1 % of the average daily balance of the preceding month and is subject to a monthly unused line fee of 0.75% of the difference between revolving loan commitment and the average daily balance outstanding during the preceding month. The GHF Line is secured by cash, accounts receivable, and substantially all intangible assets of the Trillium Subsidiaries and terminates on May 9, 2022. On July 12, 2021, the agreement was amended whereas Assisted 4 Living, Inc was named as the Guarantor of the line. At September 30, 2021, the outstanding balance on the line was $5,212,234.  On September 30, 2021 we entered into a Second Amendment of the financing agreement with GHF. The Second Amendment amended the Credit Agreement by: (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; and (7) increasing the maximum amount of the credit facility from $10 million to $25 million. The above changes are the primary changes to the credit facility.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
LEASEHOLD IMPROVEMENTS (Tables)
9 Months Ended
Sep. 30, 2021
Leasehold Improvements  
SCHEDULE OF LEASESHOLD IMPROVEMENTS

The Company had the following leasehold improvements as of September 30, 2021 and December 31, 2020:

 

   September 30,   December 31,   Amortization 
   2021   2020   Period 
Leasehold improvements   3,984,470    2,669,047    15-17 years 
Less: amortization   (218,140)   (54,656)     
                
Net   3,766,330    2,614,391      
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
PROPERTY AND EQUIPMENT (Tables)
9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT

 

   September 30,   December 31,   Amortization Period 
   2021   2020     
Furniture and fixtures   987,904    73,594    5 
Computers / equipment / software   95,952    50,401    5 
Motor vehicles   12,084    12,084    5 
Buildings   1,060,000    -    39 
Land   500,000    -      
Construction in progress   100,699    -      
Less: depreciation   (76,524)   (7,604)     
Net   2,680,115    128,475      
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
OPERATING AND CAPITAL LEASES (Tables)
9 Months Ended
Sep. 30, 2021
Operating And Capital Leases  
SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY

In accordance with ASC 842, we recorded the operating lease right of use asset and lease liability as follows:

 

   September 30, 2021   December 31, 2020 
Right of Use (ROU) assets  $46,089,030   $3,977,988 

 

   September 30, 2021   December 31, 2020 
Operating lease obligations:          
Current  $8,311,905   $189,397 
Non-Current   38,089,042    3,864,321 
Total  $46,400,947   $4,053,718 
SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY

Maturity of Operating Lease obligations for period ended September 30, 2021 ,

 

      
2021 (three months)  $1,990,630 
2022   8,545,124 
2023   9,950,470 
2024   8,305,778 
2025   5,840,681 
After 2025  $11,768,262 
Total lease obligation   46,400,947 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
EQUITY (Tables)
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
SCHEDULE OF WARRANTS OUTSTANDING

 

           Weighted     
       Weighted-   Average     
       Average   Remaining   Aggregate 
       Exercise   Contractual   Intrinsic 
   Shares   Price   Term   Value 
                 
Outstanding at January 1, 2020   -    -    -   $- 
                     
Granted   75,000   $0.38    10.0 Years   $- 
Expired   -    -    -      
Exercised   -    -    -      
                     
Outstanding at December 31, 2020   75,000   $0.38    9.74 Years   $1.62 
                     
Granted   -    -    -      
Expired   -    -    -      
Exercised   -    -    -      
                     
Outstanding and exercisable September 30, 2021   75,000   $0.38    8.99 Years   $3.12 

 

XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENT INFORMATION (Tables)
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
SCHEDULE OF SEGMENT REPORTING INFORMATION

The table below reflects the segment operations for the nine months ended September 30, 2021.

 

   PPEC   Trillium   Adjustments, eliminations and unallocated items   Consolidated 
Total revenue, net  $2,094,905   $26,998,940   $-   $29,093,845 
Cost of Sales   (810,114)   (14,666,956)   -    (15,477,070)
Gross Profit   1,284,792    12,331,983    -    13,616,775 
                     
Salaries and payroll expense   610,183    5,521,454    540,019    6,671,656 
General and administrative   828,543    5,409,409    353,797    6,591,749 
Lease expense   383,501    3,528,632    -    3,912,133 
Professional fees   255,218    1,450,431    1,001,862    2,707,511 
Marketing and advertising   164,800    172,184    -    336,984 
Depreciation and amortization expense   206,777    111,336    211    318,324 
Operating Loss  $(1,164,231)  $(3,861,462)  $(1,895,889)  $(6,921,582)
                     
Total Assets  $10,206,083   $73,191,222   $2,733,979   $86,131,284 
Total Liabilities  $4,954,086   $63,148,235   $10,724,471   $78,826,792 
                     
Cash used in operating activities  $(917,789)  $(6,699,086)  $(2,395,144)  $(10,012,019)
Cash used in investing activities  $(51,972)  $3,620,828        $3,568,856 
Cash provided by financing activities  $(211,903)  $4,724,102   $5,479,518   $9,991,717 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
STOCK-BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
SUMMARY OF STOCK OPTIONS ACTIVITY

The following table summarizes our Stock Options activity under the Award Plan for the nine months ended September 30, 2021:

 

   Shares   Weighted Average Exercise Price   Weighted Average Remaining Vesting Period (Years) 
Outstanding At December 31, 2020   -           
                
Granted   2,750,208   $1.00    3.92 
Forfeited   -    -      
Exercised   -    -      
                
Outstanding September 30, 2021   2,750,208           
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative)
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Restated purchase agreement Trillium subsidiaries lease and operate 26 facilities in four states: Florida, Georgia, Iowa, and Nebraska with 1,685 total licensed beds (1,546 skilled nursing, 139 assisted living) and 36 independent living apartments. The breakdown by state is as follows: Florida – 1 skilled nursing facility; Georgia – 1 skilled nursing facility; Iowa – 16 skilled nursing facilities, 2 independent living centers and 1 assisted living centers; Nebraska – 4 skilled nursing facilities and 1 assisted living center
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
shares in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Jun. 10, 2021
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]        
Cash and accounts receivable   $ 11,400,000 $ 11,400,000  
Accrued expenses and current notes payable cash and accounts payable   6,500,000 6,500,000  
Working capital deficiency   $ 20,600,000 20,600,000  
Net loss     6,900,000  
Stock Issued During Period, Shares, Other   5    
Stock Issued During Period, Value, Other   $ 5,000,000.0    
Cash equivalents   0 $ 0 $ 0
Percentage of accelerated payment     100.00%  
Other Operating Income     $ 1,385,162  
Deferred HHS Revenue   $ 778,408 778,408 25,703
Accelerated payments     $ 1,671,698  
Accounting Standards Update 2014-09 [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Accelerated Payments term     The repayment terms specify that for the first 11 months after repayment begins, repayment will occur through an automatic recoupment of 25% of Medicare payments otherwise owed to the provider. At the end of the eleven-month period, recoupment will increase to 50% for six months. At the end of the six months (or 29 months from the receipt of the initial accelerated payment), Medicare will issue a letter for full repayment of any remaining balance, as applicable. In such event, if payment is not received within 30 days, interest will accrue at the annual percentage rate of four percent (4%) from the date the letter was issued and will be assessed for each full 30-day period that the balance remains unpaid. As of September 30, 2021, $1,671,698 of Medicare accelerated payments are reflected on the balance sheet within advance payments line  
Trillium Healthcare Group, LLC [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Proceeds from pandemic relief funds     $ 13,487,923 $ 4,242,796
Other Operating Income $ 7,081,557      
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
BANYAN MERGER (Details Narrative) - USD ($)
3 Months Ended
Mar. 23, 2021
Jun. 30, 2021
Nov. 06, 2021
Nov. 06, 2020
Business Acquisition [Line Items]        
Warrants to purchase common stock 75,000      
Warrants exercise price $ 0.38      
Debt conversion shares 4,000,000      
Debt conversion price per share $ 0.50      
Outstanding note       $ 300,000
Interest rate     12.00%  
Interest payable each month $ 3,000      
Maturity date Nov. 06, 2021      
Note Holder [Member]        
Business Acquisition [Line Items]        
Convertible notes   $ 2,000,000    
Banyan Pediatric Care Centers, Inc [Member]        
Business Acquisition [Line Items]        
Number of shares issued upon conversion 4,165,418 4,000,000    
Number of shares converted 49,984,649      
Stock conversion description The Surviving Entity assumed Banyan’s $2,300,000 of outstanding debt, and the $2,000,000 of such debt that was convertible into 20,000,000 shares of Banyan common stock was converted at $0.50 per share into 4,000,000 shares of our common stock, effective March 30, 2021. During the three months ended June 30, 2021, shares were issued to the Noteholders of the $2,000,000 convertible note. The remaining $300,000 of outstanding debt, evidenced by a promissory note dated November 6, 2020, accrues interest at the annual rate of 12%. Interest is payable on the sixth day of each month in the amount of $3,000 until the maturity date of this note on November 6, 2021, at which time, the remaining principal balance, if any, is due and payable      
Outstanding debt assumed $ 2,300,000      
Convertible debt $ 2,000,000 $ 2,000,000    
Debt conversion shares 20,000,000      
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS (Details) - USD ($)
3 Months Ended 9 Months Ended
Apr. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:          
Income from discontinued operations   $ 369,000
Assisted 2 Living, Inc [Member]          
Net revenues   76,847
Cost of net revenues  
Gross profit  
Operating expenses:          
Salary and tax expense   46,813
General and administrative   52,555
Lease expense   3,979
Total operating expenses   103,347
Income from discontinued operations   (26,500)
Interest and other, net  
Income from discontinued operations before income taxes   (26,500)
Provision for income taxes      
Income from discontinued operations $ 26,500 $ (26,500)
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
DISCONTINUED OPERATIONS (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Apr. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Nov. 07, 2020
Loss from discontinued operations   $ 369,000    
Common stock, shares outstanding   45,345,418   45,345,418   4,165,418  
Issued and outstanding shares 200,000            
Disposal of discontinued $ 395,500 $ 395,500    
Disposal of discontinued price per share $ 1.85            
Assisted 2 Living, Inc [Member]              
Loss from discontinued operations $ 26,500 $ (26,500)    
Assisted 2 Living, Inc [Member] | Purchase and Sale Option Agreement [Member]              
Shares owned             1,000
Assisted 2 Living, Inc [Member] | Purchase and Sale Option Agreement [Member] | Romulus Barr [Member]              
Common stock, shares outstanding             200,000
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED (Details)
Sep. 30, 2021
USD ($)
Business Combination and Asset Acquisition [Abstract]  
Cash $ 3,432,847
Accounts receivable 5,521,080
Prepaid expenses and other current assets 2,661,683
Property and equipment 2,380,635
Goodwill 12,082,529
Leasehold improvements 1,213,273
Lease right of use asset 44,196,092
Total identifiable assets acquired 71,488,139
Advance payments 2,905,234
Accounts payable and accrued expenses 8,783,508
Deferred revenue 2,162,966
Loan Payable - other 453,043
Lease liability - current portion 7,837,406
Notes payable 2,309,884
Lease liability - net of current portion 36,383,251
Cash due to seller 902,847
Share liability 9,750,000
 Total identifiable liabilities acquired $ 71,488,139
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
TRILLIUM ACQUISITION (Details Narrative) - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Business Acquisition [Line Items]      
Cash $ 3,894,536   $ 345,982
Payment to acquire property 76,317 $ 61,083  
Business Combination Deposits Non Refundable Amount 3,000,000    
Deposits Amount Forfeited 3,000,000    
Share Based Compensation Aggregate Amount $ 600,000    
Series A Preferred Stock [Member]      
Business Acquisition [Line Items]      
Preferred Stock Shares Issued 2,500,000    
Purchase Agreement [Member]      
Business Acquisition [Line Items]      
Cash payment $ 902,847    
Cash 1,200,000    
Payment to acquire property $ 3,000,000    
Purchase Agreement [Member] | Common Stock [Member]      
Business Acquisition [Line Items]      
Additonal Shares Acquired during the period $ 2,500,000    
Trillium Subsidiaries [Member]      
Business Acquisition [Line Items]      
Effective Date of Acquisition Jun. 10, 2021    
Right to receive purchase price $ 3,000,000    
Business Acquisition Description (1) vote for each Preferred Share held of record on all matters submitted to a vote of holders of the Common Shares, including the election of directors, and all other matters as required by law. The Preferred Shares are not convertible into Common shares at the election of the holder. However, the Preferred Shares do automatically convert into Common Shares at a one-to-one ratio two years from date of issuance. In lieu of converting the Preferred Shares, the holders thereof may elect to have the Company redeem one or more Preferred Shares at the redemption price of $1.00 per share two years from the date of issuance. The Company is required to issue the Preferred Shares to Trillium within 30 days after the purchase of the Properties closes. In connection with the issuance of the Preferred Shares, the Company will file a Certificate of Designation with the Nevada Secretary of State prior to such issuance    
Trillium Subsidiaries [Member] | Purchase Agreement [Member] | Common Stock [Member]      
Business Acquisition [Line Items]      
Right to receive purchase price $ 5,000,000    
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Accounts payable $ 6,299,400 $ 16,298
Credit Card 37,712 1,050
Accrued Expense 3,513,517 130,832
Accrued Salary 995,265
Payroll Tax Payable 33,189
 Accounts Payable and Accrued Liabilities $ 10,879,082 $ 148,180
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF NOTES PAYABLE (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Short-term Debt [Line Items]    
Notes payable $ 7,041,759 $ 2,385,010
Notes Payable [Member]    
Short-term Debt [Line Items]    
Notes payable 7,306,876 2,707,500
NuView Trust Co [Member]    
Short-term Debt [Line Items]    
Notes payable [1] 300,000 300,000
Grand Trinity Plaza LLC [Member]    
Short-term Debt [Line Items]    
Notes payable [2] 346,174 407,500
Reliant [Member]    
Short-term Debt [Line Items]    
Notes payable [3] 808,310
HCSG [Member]    
Short-term Debt [Line Items]    
Notes payable [4] 397,191
Medline [Member]    
Short-term Debt [Line Items]    
Notes payable [5] 242,967
SLR - RLOC [Member]    
Short-term Debt [Line Items]    
Notes payable [6] 5,212,234
Excel Family Partners, LLLP and Banyan Pediatric Investment, Inc [Member]    
Short-term Debt [Line Items]    
Notes payable [7] $ 2,000,000
[1] On November 6, 2020, through Banyan, we entered into a one-year note in the principal amount of $300,000 with NuView Trust Company. The note has a 12% interest rate with interest only payments until date of maturity. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. As of September 30, 2021, and December 31, 2020, there was no accrued interest. (see NOTE 3)
[2] On December 15, 2020, through Banyan Pediatric Care Centers – Pasco, LLC, we entered into a note payable with Grand Trinity Plaza, LLC in the principal amount of $407,500, which is guaranteed by Banyan. The term of the note is 48 months with an interest rate of 6%. The maturity date of the note is January 1, 2025. The note is in conjunction with the 84-month facility lease for the Pasco County location, pursuant to which the landlord also provided the construction of the buildout and financed $407,500 of the construction costs.
[3] Reliant note payable - Past due balances with vendor Reliant were converted to a note payable in 36 equal monthly installments of principal and interest of $69,568 from October 2019 through September 2022. The note bears interest at a rate of 6%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
[4] HCSG note payable – Past due balances with vendor HCSG were converted to a non-interest-bearing note payable; payable in 36 equal monthly principal installments of $33,099 from October 2019 through September 2022. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
[5] Medline note payable – Past due balances with vendor Medline were converted to a note payable; payable in 36 equal monthly installments of principal and interest of $20,911 from October 2019 through September 2022; note bears interest at a rate of 6%. As discussed in NOTE 5, through the Trillium transaction we assumed the balance of the debt at the transaction date of June 10, 2021, the condensed consolidated balance sheet reflects the balance of the note due at September 30, 2021.
[6] SLR revolving line of credit - On May 9, 2019, Trillium entered into a financing agreement (“the GHF Line”) with Gemino Healthcare Finance, LLC (DBA SLR Healthcare ABL), the lender, which allows the Trillium Subsidiaries to borrow up to the lesser of $10 million or 85% of eligible accounts receivable. The GHF Line bears interest at the greater of one-month LIBOR or 2%, plus 4.95%, applied daily, and continues to be applied to outstanding principal until the expiration of one business day after such principal has been repaid. The Trillium Subsidiaries also incur monthly collateral management fees under the line of 1 % of the average daily balance of the preceding month and is subject to a monthly unused line fee of 0.75% of the difference between revolving loan commitment and the average daily balance outstanding during the preceding month. The GHF Line is secured by cash, accounts receivable, and substantially all intangible assets of the Trillium Subsidiaries and terminates on May 9, 2022. On July 12, 2021, the agreement was amended whereas Assisted 4 Living, Inc was named as the Guarantor of the line. At September 30, 2021, the outstanding balance on the line was $5,212,234.  On September 30, 2021 we entered into a Second Amendment of the financing agreement with GHF. The Second Amendment amended the Credit Agreement by: (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; and (7) increasing the maximum amount of the credit facility from $10 million to $25 million. The above changes are the primary changes to the credit facility.
[7] On September 18, 2020, through Banyan, we entered into a Convertible Note and Securities Purchase Agreement with two investors for the aggregate principal in the amount of $2,000,000. The note had a maturity date of September 18, 2022, and an interest rate of 8% to be paid quarterly. The principal was funded by two investors (“Purchasers”), both related parties. Excel Family Partners, LLLP invested $1,500,000 and Banyan Pediatric Investments, LLC invested $500,000. The proceeds of this note were used for operational expenses and for the payment of the remainder of the buildout of the Pasco County and the Sarasota locations. Written consent from shareholders holding a majority of the issued and outstanding shares of common stock of Banyan was obtained, not including such shares currently held by the Purchasers or their affiliates, consenting to the note contemplated hereby, in a form and substance acceptable to the Purchasers, in their respective reasonable discretion. Both Purchasers were permitted to convert their respective portions of the note at a conversion price of $0.10 per share. Subsequent to the Merger (see NOTE 3), the Board revised the conversion price of the note to $0.50 per share. Effective March 30, 2021, the Purchasers exercised their right to convert all outstanding principal. As of September 30, 2021, and December 31, 2020, there was $0 and $45,589 of accrued interest, respectively and is reflected in accrued interest balances on the condensed consolidated balance sheet at September 30, 2021 and December 31, 2020.
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) - USD ($)
9 Months Ended 12 Months Ended
Mar. 23, 2021
Dec. 15, 2020
Nov. 06, 2020
Sep. 18, 2020
May 09, 2019
Sep. 30, 2021
Dec. 31, 2019
Nov. 06, 2021
Sep. 29, 2021
Dec. 31, 2020
Sep. 30, 2020
Apr. 02, 2020
Short-term Debt [Line Items]                        
Maturity date Nov. 06, 2021                      
Interest rate               12.00%        
Debt Instrument, Convertible, Conversion Price $ 0.50                      
Interest Payable, Current           $ 42,567       $ 48,601    
Trillium Healthcare Group, LLC [Member] | Line of Credit [Member]                        
Short-term Debt [Line Items]                        
Maturity date           Sep. 29, 2023            
Line of credit facility           $ 25,000,000     $ 10,000,000      
Debt description           (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; and (7) increasing the maximum amount of the credit facility from $10 million to $25 million. The above changes are the primary changes to the credit facility            
Trillium Healthcare Group, LLC [Member] | Gemino Healthcare Finance, LLC [Member] | Line of Credit [Member]                        
Short-term Debt [Line Items]                        
Maturity date         May 09, 2022              
Line of credit facility, maximum borrowing capacity         $ 10,000,000              
Accounts receivable percentage         85.00%              
Bears interest rate         4.95%              
Management fee percentage         1.00%              
Unused capacity, percentage         0.75%              
Line of credit facility           $ 5,212,234            
Trillium Healthcare Group, LLC [Member] | Gemino Healthcare Finance, LLC [Member] | Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]                        
Short-term Debt [Line Items]                        
Bears interest rate         2.00%              
Minimum [Member] | Trillium Healthcare Group, LLC [Member]                        
Short-term Debt [Line Items]                        
Interest rate             0.00%          
Maximum [Member] | Trillium Healthcare Group, LLC [Member]                        
Short-term Debt [Line Items]                        
Interest rate             6.00%          
NuView Trust Co [Member] | Notes Payable, Other Payables [Member]                        
Short-term Debt [Line Items]                        
Aggregate principal amount     $ 300,000                  
Interest rate     12.00%                  
Interest Payable, Current                   0 $ 0  
Maturity term     1 year                  
Grand Trinity Plaza LLC [Member]                        
Short-term Debt [Line Items]                        
Lease term                       84 months
Grand Trinity Plaza LLC [Member] | Notes Payable, Other Payables [Member]                        
Short-term Debt [Line Items]                        
Aggregate principal amount   $ 407,500                    
Maturity date   Jan. 01, 2025                    
Interest rate   6.00%                    
Maturity term   48 months                    
Lease term   84 months                    
Construction costs   $ 407,500                    
Reliant [Member] | Notes Payable, Other Payables [Member]                        
Short-term Debt [Line Items]                        
Maturity date             Sep. 30, 2021          
Interest rate             6.00%          
Debt Instrument, Payment Terms             36 equal monthly installments          
Principal and interest amount             $ 69,568          
HCSG [Member] | Notes Payable, Other Payables [Member]                        
Short-term Debt [Line Items]                        
Maturity date             Sep. 30, 2021          
Debt Instrument, Payment Terms             36 equal monthly principal installments          
Debt Instrument, Periodic Payment, Principal             $ 33,099          
Medline [Member] | Notes Payable, Other Payables [Member]                        
Short-term Debt [Line Items]                        
Maturity date             Sep. 30, 2021          
Interest rate             6.00%          
Debt Instrument, Payment Terms             36 equal monthly installments of principal          
Principal and interest amount             $ 20,911          
Excel Family Partners, LLLP and Banyan Pediatric Investment, Inc [Member] | Convertible Note And Securities Purchase Agreement [Member]                        
Short-term Debt [Line Items]                        
Aggregate principal amount       $ 2,000,000                
Maturity date       Sep. 18, 2022                
Interest rate       8.00%                
Debt Instrument, Convertible, Conversion Price $ 0.50     $ 0.10                
Interest Payable, Current           $ 0       $ 45,589    
Excel Family Partners, LLLP [Member] | Convertible Note And Securities Purchase Agreement [Member]                        
Short-term Debt [Line Items]                        
Aggregate principal amount       $ 1,500,000                
Banyan Pediatric Care Centers, Inc [Member] | Convertible Note And Securities Purchase Agreement [Member]                        
Short-term Debt [Line Items]                        
Aggregate principal amount       $ 500,000                
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF LEASESHOLD IMPROVEMENTS (Details) - USD ($)
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Leasehold improvements   $ 136,079
Less: amortization $ (76,524) (7,604)
Net 2,680,115 128,475
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Leasehold improvements 3,984,470 2,669,047
Less: amortization (218,140) (54,656)
Net $ 3,766,330 $ 2,614,391
Leasehold Improvements [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Amortization Period 15 years  
Leasehold Improvements [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Amortization Period 17 years  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
LEASEHOLD IMPROVEMENTS (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Property, Plant and Equipment [Line Items]          
Leasehold improvements         $ 136,079
Leasehold Improvements [Member]          
Property, Plant and Equipment [Line Items]          
Leasehold improvements $ 3,984,470   $ 3,984,470   2,669,047
Amortization expense 70,193 $ 13,593 218,140 $ 54,656  
Leasehold Improvements [Member] | Trillium Healthcare Group, LLC [Member]          
Property, Plant and Equipment [Line Items]          
Leasehold improvements $ 1,213,273   $ 1,213,273    
Leasehold Improvements [Member] | Sarasota [Member]          
Property, Plant and Equipment [Line Items]          
Leasehold improvements         $ 1,245,950
Amortization Period         15 years
Leasehold Improvements [Member] | New Port Richey [Member]          
Property, Plant and Equipment [Line Items]          
Leasehold improvements         $ 1,021,793
Amortization Period         17 years
Leasehold Improvements [Member] | St. Petersburg [Member]          
Property, Plant and Equipment [Line Items]          
Leasehold improvements         $ 401,303
Amortization Period         15 years
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Furniture and fixtures $ 987,904 $ 73,594
Computers / equipment / software 95,952 50,401
Motor vehicles 12,084 12,084
Buildings 1,060,000
Land 500,000
Construction in progress 100,699
Less: depreciation (76,524) (7,604)
Net $ 2,680,115 $ 128,475
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Amortization period 5 years  
Computers Equipment Software [Member]    
Property, Plant and Equipment [Line Items]    
Amortization period 5 years  
Motor Vehicles [Member]    
Property, Plant and Equipment [Line Items]    
Amortization period 5 years  
Buildings [Member]    
Property, Plant and Equipment [Line Items]    
Amortization period 39 years  
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
3 Months Ended
Jun. 10, 2021
Sep. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]      
Property plant and equipment     $ 136,079
Furniture and fixtures   $ 987,904 73,594
Computers and equipment   95,952 $ 50,401
Trillium Healthcare Group, LLC [Member]      
Property, Plant and Equipment [Line Items]      
Property plant and equipment, addition $ 3,600,000    
Trillium Healthcare Group, LLC [Member] | Furniture and Fixtures [Member]      
Property, Plant and Equipment [Line Items]      
Property plant and equipment, addition   69,487  
Banyan [Member]      
Property, Plant and Equipment [Line Items]      
Furniture and fixtures   23,000  
Computers and equipment   $ 41,000  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Operating And Capital Leases    
Right of Use (ROU) assets $ 46,089,030 $ 3,977,988
Operating lease obligations:    
Current 8,311,905 189,397
Non-Current 38,089,042 3,864,321
Total $ 46,400,947 $ 4,053,718
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY (Details)
Sep. 30, 2021
USD ($)
Operating And Capital Leases  
2021 (three months) $ 1,990,630
2022 8,545,124
2023 9,950,470
2024 8,305,778
2025 5,840,681
After 2025 11,768,262
Total lease obligation $ 46,400,947
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.2
OPERATING AND CAPITAL LEASES (Details Narrative)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 20, 2020
USD ($)
Aug. 25, 2020
USD ($)
Jun. 09, 2020
USD ($)
Apr. 02, 2020
USD ($)
Oct. 15, 2019
USD ($)
ft²
Aug. 24, 2019
USD ($)
Aug. 31, 2021
USD ($)
Apr. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Property
Sep. 30, 2020
USD ($)
Jul. 31, 2021
USD ($)
Jun. 10, 2021
USD ($)
Dec. 31, 2020
USD ($)
Minimum annual rent                 $ 46,400,947   $ 46,400,947        
Lease liability                 46,400,947   46,400,947       $ 4,053,718
Lease right of use asset                 $ 46,089,030   $ 46,089,030       $ 3,977,988
Operating Lease, Weighted Average Remaining Lease Term                 5 years 5 months 19 days   5 years 5 months 19 days        
Finance Lease, Weighted Average Remaining Lease Term                 3 years 8 months 19 days   3 years 8 months 19 days        
Operating lease, weighted average discount rate, percent                 7.80%   7.80%        
Capital lease, weighted average discount rate, percent                 7.81%   7.81%        
Operating Lease, Expense                 $ 2,991,078 $ 95,319 $ 3,912,133 $ 193,365      
Maximum [Member]                              
Lessee, Operating Lease, Remaining Lease Term                 15 years 11 months 4 days   15 years 11 months 4 days        
Lessee, Finance Lease, Remaining Lease Term                 4 years 11 months 15 days   4 years 11 months 15 days        
Minimum [Member]                              
Lessee, Operating Lease, Remaining Lease Term                 2 years 10 months 20 days   2 years 10 months 20 days        
Lessee, Finance Lease, Remaining Lease Term                 1 year   1 year        
Kidz Club - St. Pete, LLC [Member]                              
Minimum annual rent         $ 113,681                    
Area under lease | ft²         12,137                    
Lease termination date         Oct. 31, 2024                    
Lease percentage of increase in base rent         1.50%                    
Lease right of use asset         $ 875,539                    
Grand Trinity Plaza LLC [Member]                              
Lease term       84 months                      
Minimum annual rent       $ 94,500                      
Lease description       The landlord granted rent abatement until September 2020                      
Lessee, operating lease, option to extend       The lease end date, including two successive 5-year renewals is August 31, 2037                      
Lease renewal term       5 years                      
Lease right of use asset       $ 1,143,743                      
Dex Imaging [Member]                              
Lease term     36 months       36 months 36 months         60 months    
Minimum annual rent     $ 5,376       $ 4,920 $ 4,920         $ 1,920    
Lease description     The equipment under this lease has a fixed $1 payment buyout option       The equipment under this lease has a fixed $1 payment buyout option The equipment under this lease has a fixed $1 payment buyout option              
Lease renewal term     12 months                        
Lease right of use asset     $ 16,066       $ 14,040 $ 14,693         $ 8,049    
Dex Imaging [Member] | Maximum [Member]                              
Lease percentage of increase in base rent     12.00%                        
Ascentium Capital LLC [Member]                              
Lease term 60 months 60 months                     60 months    
Minimum annual rent $ 13,381 $ 24,859                     $ 15,654    
Lease description This lease is considered an operating lease for accounting purposes because the lease period is less than the economic life of the asset being leased This lease is considered an operating lease for accounting purposes because the lease period is less than the economic life of the asset being leased                          
Lease right of use asset $ 55,345 $ 102,393                     65,772    
Lease purchase option price $ 12,891 $ 23,920                     $ 15,193    
RJ Kool [Member]                              
Lease term             60 months                
Minimum annual rent             $ 4,321                
Lease right of use asset             $ 18,476                
Southeastern Laundry Equipment Sales [Member]                              
Lease term                         36 months    
Minimum annual rent                         $ 5,094    
Lease right of use asset                         $ 13,054    
Crete Plus Five Property LLC [Member]                              
Lease renewal term                 10 years   10 years        
Number of Lease Agreement Properties | Property                     14        
Trillium Healthcare Group, LLC [Member]                              
Lease right of use asset                           $ 29,906,314  
Capital lease description                     Through the Trillium acquisition we also assumed 27   capital leases        
CTR Partnership LP [Member]                              
Lease renewal term                 5 years   5 years        
Lease right of use asset                           $ 14,468,509  
Number of Lease Agreement Properties | Property                     10        
Banyan Pediatric Care Centers, Inc [Member] | Northeast Plaza Venture I, LLC [Member]                              
Lease term           5 years                  
Minimum annual rent           $ 180,000                  
Lease description           The landlord granted rent abatement for this lease until February 24, 2020                  
Lessee, operating lease, option to extend           The lease end date, including two successive 5-year renewal options, is January 31, 2035                  
Lease renewal term           5 years                  
Lease liability           $ 1,899,869                  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF WARRANTS OUTSTANDING (Details) - Kidz Club - St. Pete, LLC [Member] - $ / shares
9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Shares, Outstanding, Beginning Balance 75,000
Weighted-Average Exercise Price, Outstanding, Beginning Balance $ 0.38
Shares, Granted 75,000
Weighted-Average Exercise Price, Granted $ 0.38
Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance   10 years
Shares, Expired
Weighted-Average Exercise Price, Expired
Shares, Exercised
Weighted-Average Exercise Price, Exercised
Weighted Average Remaining Contractual Term, Outstanding 8 years 11 months 26 days 9 years 8 months 26 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance $ 1.62  
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance 75,000 75,000
Weighted-Average Exercise Price, Outstanding, Ending Balance $ 0.38 $ 0.38
Aggregate Intrinsic Value, Outstanding, Ending Balance $ 3.12 $ 1.62
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.21.2
EQUITY (Details Narrative) - USD ($)
2 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 23, 2021
Sep. 19, 2020
Mar. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Sep. 30, 2021
Dec. 31, 2020
Aug. 26, 2021
Apr. 30, 2021
Sep. 27, 2019
Class of Stock [Line Items]                        
Preferred stock, shares authorized       25,000,000       25,000,000        
Preferred stock, par value       $ 0.0001       $ 0.0001        
Liability to issue shares for acquisition               $ 9,750,000        
Common stock, shares authorized       100,000,000       100,000,000 100,000,000      
Common stock per share       $ 0.0001       $ 0.0001 $ 0.0001      
Common stock issued       45,345,418       45,345,418 4,165,418      
Common stock, shares outstanding       45,345,418       45,345,418 4,165,418      
Shares issued price per share                     $ 1.85  
Aggregate consideration amount       $ 4,535       $ 4,535 $ 417      
Liabilities, Current       35,722,633       35,722,633 2,860,798      
Common Stock, Capital Shares Reserved for Future Issuance                   4,500,000    
Subscription receivable             30      
Debt conversion share issued 4,000,000                      
Warrants to purchase common stock 75,000                      
Warrants exercise price $ 0.38                      
Notes Payable, Other Payables [Member]                        
Class of Stock [Line Items]                        
Debt conversion principal amount   $ 500,000                    
Common Stock [Member]                        
Class of Stock [Line Items]                        
Shares issuable for Banyan Acquisition, shares           31,230,000            
Proceeds forn subscription                 $ 140      
Debt conversion share issued         4,000,000   166,667          
Common Stock [Member] | Notes Payable, Other Payables [Member]                        
Class of Stock [Line Items]                        
Debt conversion share issued   2,000,000                    
2021 Incentive Award Plan [Member]                        
Class of Stock [Line Items]                        
Common Stock, Capital Shares Reserved for Future Issuance                   4,500,000    
10 Employees [Member] | 2021 Incentive Award Plan [Member]                        
Class of Stock [Line Items]                        
Common Stock, Capital Shares Reserved for Future Issuance       2,750,208       2,750,208        
Banyan Pediatric Care Centers, Inc [Member]                        
Class of Stock [Line Items]                        
Common stock per share         $ 0.50              
Number of shares issued upon conversion 4,165,418       4,000,000              
Number of shares converted 49,984,649                      
Shares issuable for Banyan Acquisition, shares 31,230,000   7,080,000 5,000,000                
Shares issued price per share     $ 0.50 $ 1.00   $ 0.50   $ 1.00        
Aggregate consideration amount       $ 5,000,000 $ 3,540,000     $ 5,000,000        
Convertible Debt $ 2,000,000       2,000,000              
Conversion of Stock, Amount Issued         2,000,000              
Purchase of common stock         $ 1,150,000              
Debt conversion share issued 20,000,000                      
Long-term Debt [Member] | Banyan Pediatric Care Centers, Inc [Member]                        
Class of Stock [Line Items]                        
Common stock issued         575,000              
Series A Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Preferred Stock, Shares Issued       2,500,000       2,500,000        
Trillium Healthcare Group, LLC [Member] | Banyan Pediatric Care Centers, Inc [Member]                        
Class of Stock [Line Items]                        
Aggregate consideration amount       $ 5,000,000       $ 5,000,000        
Liabilities, Current       $ 5,000,000       $ 5,000,000        
Trillium Healthcare Group, LLC [Member] | Long-term Debt [Member]                        
Class of Stock [Line Items]                        
Preferred Stock, Shares Issued       2,500,000       2,500,000        
Liability to issue shares for acquisition               $ 4,750,000        
Trillium Healthcare Group, LLC [Member] | Series A Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Preferred stock, shares authorized       2,500,000       2,500,000        
Preferred stock, par value       $ 1.00       $ 1.00        
Kidz Club - St. Pete, LLC [Member]                        
Class of Stock [Line Items]                        
Warrants to purchase common stock                       75,000
Warrants exercise price                       $ 0.38
Warrants expiration date                       Sep. 27, 2029
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Mar. 23, 2021
Feb. 01, 2021
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Dec. 31, 2020
Issuance of shares for conversion of debt, shares 4,000,000            
Accrued Salary     $ 60,000        
Accrued interest on payroll     6,277     $ 6,277  
Accrued Salaries, Current     995,265     995,265
Restricted Common Stock [Member]              
Stock Issued During Period, Shares, New Issues       4,000,000      
Banyan Pediatric Care Centers, Inc [Member]              
Convertible Debt $ 2,000,000     $ 2,000,000      
Issuance of shares for conversion of debt, shares 20,000,000            
Chief Executive Officer [Member]              
Base salary   $ 400,000          
Bonus payable   $ 150,000          
Shares issued for services   1,250,000          
Chief Executive Officer [Member] | Within Five Days [Member]              
Bonus payable   $ 50,000          
Chief Executive Officer [Member] | Within 90 Days [Member]              
Bonus payable   50,000          
Chief Executive Officer [Member] | Within 180 Days [Member]              
Bonus payable   $ 50,000          
Director [Member]              
Base salary     42,000   $ 0    
President and Chief Executive Officer [Member]              
Accrued Salaries, Current     $ 60,000     $ 60,000  
Interest percentage on accrued payroll           8.00%  
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.2
SCHEDULE OF SEGMENT REPORTING INFORMATION (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Segment Reporting Information [Line Items]          
Total revenue, net $ 22,375,092 $ 659,449 $ 29,093,845 $ 1,102,841  
Cost of Sales (12,310,011) (256,825) (15,477,070) (409,838)  
Gross Profit 10,065,081 402,624 13,616,775 693,003  
Salaries and payroll expense     6,671,656    
General and administrative 4,978,559 205,818 6,591,749 454,482  
Lease expense 2,991,078 95,319 3,912,133 193,365  
Professional fees 1,722,741 70,819 2,707,511 134,829  
Marketing and advertising     336,984    
Depreciation and amortization expense 159,750 $ 16,744 318,324 24,135  
Operating Loss     (6,921,582)    
Total Assets 86,131,284   86,131,284   $ 10,802,649
Total Liabilities 78,826,792   78,826,792    
Cash used in operating activities     (10,012,019) (870,286)  
Cash used in investing activities     3,568,856 (5,316,155)  
Cash provided by financing activities     9,991,717 $ 3,006,562  
Operating Segments [Member] | Pediatric Extended Care Centers [Member]          
Segment Reporting Information [Line Items]          
Total revenue, net     2,094,905    
Cost of Sales     (810,114)    
Gross Profit     1,284,792    
Salaries and payroll expense     610,183    
General and administrative     828,543    
Lease expense     383,501    
Professional fees     255,218    
Marketing and advertising     164,800    
Depreciation and amortization expense     206,777    
Operating Loss     (1,164,231)    
Total Assets 10,206,083   10,206,083    
Total Liabilities 4,954,086   4,954,086    
Cash used in operating activities     (917,789)    
Cash used in investing activities     (51,972)    
Cash provided by financing activities     (211,903)    
Operating Segments [Member] | Trillium Subsidiaries [Member]          
Segment Reporting Information [Line Items]          
Total revenue, net     26,998,940    
Cost of Sales     (14,666,956)    
Gross Profit     12,331,983    
Salaries and payroll expense     5,521,454    
General and administrative     5,409,409    
Lease expense     3,528,632    
Professional fees     1,450,431    
Marketing and advertising     172,184    
Depreciation and amortization expense     111,336    
Operating Loss     (3,861,462)    
Total Assets 73,191,222   73,191,222    
Total Liabilities 63,148,235   63,148,235    
Cash used in operating activities     (6,699,086)    
Cash used in investing activities     3,620,828    
Cash provided by financing activities     4,724,102    
Intersegment Eliminations [Member]          
Segment Reporting Information [Line Items]          
Total revenue, net        
Cost of Sales        
Gross Profit        
Salaries and payroll expense     540,019    
General and administrative     353,797    
Lease expense        
Professional fees     1,001,862    
Marketing and advertising        
Depreciation and amortization expense     211    
Operating Loss     (1,895,889)    
Total Assets 2,733,979   2,733,979    
Total Liabilities $ 10,724,471   10,724,471    
Cash used in operating activities     (2,395,144)    
Cash provided by financing activities     $ 5,479,518    
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF STOCK OPTIONS ACTIVITY (Details)
9 Months Ended
Sep. 30, 2021
$ / shares
shares
Share-based Payment Arrangement [Abstract]  
Number of shares outstanding, beginning balance
Number of shares granted 2,750,208
Number of shares outstanding, weighted average exercise price | $ / shares $ 1.00
Number of shares outstanding, weighted average remaining vesting period 3 years 11 months 1 day
Number of shares outstanding forfeited
Number of shares outstanding, exercised
Number of shares outstanding, closing balance 2,750,208
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.2
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2021
Aug. 26, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares reserved as common stock       4,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term     3 years 11 months 1 day  
Stock or Unit Option Plan Expense     $ 8,100,000  
Stock based compensation   $ 171,888    
2021 Incentive Award Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares reserved as common stock       4,500,000
Vesting peirod 4 years      
Number of shares vested 57,296      
Share options outstanding 2,692,912 2,692,912 2,692,912  
2021 Incentive Award Plan [Member] | 10 Employees [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares reserved as common stock 2,750,208 2,750,208 2,750,208  
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.21.2
CONCENTRATIONS AND CREDIT RISKS (Details Narrative)
3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
Concentration Risk [Line Items]    
Cash, FDIC Insured Amount $ 250,000 $ 250,000
Cash, Uninsured Amount $ 2,800,000 $ 2,800,000
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Medicare [Member]    
Concentration Risk [Line Items]    
Concentration risk percentage, Revenues 15.00% 15.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Medicaid [Member]    
Concentration Risk [Line Items]    
Concentration risk percentage, Revenues 67.00% 67.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Private Pay Residents [Member]    
Concentration Risk [Line Items]    
Concentration risk percentage, Revenues 13.00% 13.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Medicare [Member]    
Concentration Risk [Line Items]    
Concentration risk percentage, Revenues   18.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Medicaid [Member]    
Concentration Risk [Line Items]    
Concentration risk percentage, Revenues   54.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Private Pay [Member]    
Concentration Risk [Line Items]    
Concentration risk percentage, Revenues   13.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Commercial Insurance [Member]    
Concentration Risk [Line Items]    
Concentration risk percentage, Revenues   11.00%
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.21.2
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
9 Months Ended
Oct. 18, 2021
Oct. 13, 2021
Oct. 08, 2021
Mar. 23, 2021
Sep. 30, 2021
Nov. 06, 2021
Subsequent Event [Line Items]            
Debt rate           12.00%
Maturity date       Nov. 06, 2021    
Subsequent Event [Member]            
Subsequent Event [Line Items]            
Deposits   $ 30,000        
Debt principal amount $ 6,600,000          
Debt rate     25.00%      
Payments to Acquire Productive Assets   $ 590,000        
Subsequent Event [Member] | Grace Care Centers [Member]            
Subsequent Event [Line Items]            
Payment to acquire business $ 7,750,000          
Gemino Healthcare Finance, LLC [Member]            
Subsequent Event [Line Items]            
Line of credit facility         $ 10,000,000  
Credit facility termination date         May 09, 2022  
Debt description         (i) the annual rate reported as the London Interbank Offer Rate applicable to ninety (90) day deposits of United States Dollars as reported in the Money Rates Section of The Wall Street Journal on the date of determination; and (ii) 2.00%, plus 4.95% (together, the “Interest Rate”). The Interest Rate on all amounts outstanding under the credit facility is adjusted daily based on any changes in the amount under subsection (i) above and subsection (ii) above, as applicable. There are also various fees paid in connection with the credit facility, including: (1) a monthly collateral monitoring fee of 1.00% of the average borrowing base during the prior month; (2) a monthly unused line fee equal to 0.75% per annum of the unused portion of the maximum amount of credit facility; (3) a minimum use fee if the outstanding revolving loan balance is less than $2 million equal to the Interest Rate times the minimum balance of $2 million; and (4) a termination fee of $100,000 if the credit facility is terminated by A4L prior to May 9, 2022.  
Termination fees         $ 100,000,000,000  
Grace Care Centers [Member] | Subsequent Event [Member]            
Subsequent Event [Line Items]            
Debt description Outstanding principal accrues interest at a rate per annum equal to the sum of the Prime Rate plus 4.125%, with a minimum interest rate per annum of not less than 7.875%. Monthly interest only payments commence on December 15, 2021, and continue each month until the maturity date of the Loan on April 18, 2023, at which time any outstanding principal and accrued and unpaid interest is due and payable. If any principal, interest or any other sums due under the Loan (other than the payment of principal due on the maturity date), is not paid on or prior to the due date, A4L is required to pay Lender upon demand an amount equal to 5% of such unpaid sum. In connection with any repayment or prepayment of principal, a non-refundable fee equal to 0.5% of the principal amount of such repayment or prepayment is due          
Non refundable fee description A4L has the right to extend the initial maturity date to October 15, 2023 upon prior written notice to Lender and the payment to Lender of a non-refundable fee equal to 1% of the outstanding principal balance no later than 30 days prior to the maturity date. A4L may extend the maturity date further, to April 15, 2024, upon prior written notice to Lender and the payment to Lender of a non-refundable fee equal to 1% of the outstanding principal balance prior to the extended maturity date.          
Purchase Agreement [Member]            
Subsequent Event [Line Items]            
Acquisition transaction cost         2,300,000  
Deposits         110,000  
Payment to seller         35,000  
Payment to seller non refundable         20,000  
Purchase Agreement [Member] | Seller [Member]            
Subsequent Event [Line Items]            
Deposits         $ 15,000  
Credit Agreement [Member] | Second Amendment [Member]            
Subsequent Event [Line Items]            
Debt description         (1) adding Assisted 4 Living, Inc as a guarantor to the credit facility and releasing Trillium and it’s four principal individuals from their obligations under the credit facility; (2) increasing the term of the credit facility so that it now expires on September 29, 2023; (3) revising the termination fee to reflect the increase in the term of the credit facility; (4) modifying the fixed percentage used to calculate the Interest Rate from 5.95% to a range of 4.50% to 3.90%, depending on the outstanding loan balance during the preceding three months, with the rate decreasing as the amount borrowed increases; (5) reducing the collateral monitoring fee from 1.50% to 1.00%; (6) reducing the unused line fee from 0.75% to 0.50%; (7) increasing the maximum amount of the credit facility from $10 million to $25 million; and (8) revising terms regarding financial statements and collateral reports, limitations on certain corporate guarantors and curing defaults  
Credit Agreement [Member] | Trillium Group [Member] | First Amendment [Member]            
Subsequent Event [Line Items]            
Debt description         (1) releasing seven entities from the Trillium Group of their obligations under the credit facility in connection with Trillium’s sale of those entities; (2) increasing to 5.95% the rate used to calculate the Interest Rate; (3) increasing the monthly collateral monitoring fee to 1.50%; (4) lowering the revolving commitment amount from $10 million to $7 million; and (5) waiving borrower’s failure to comply with the fixed charge coverage ratio for the fiscal quarters ending September 30, 2019, December 31, 2019, and March 31, 2020  
Guaranty Agreement [Member] | Subsequent Event [Member]            
Subsequent Event [Line Items]            
Debt principal amount     $ 1,250,000      
Debt rate     10.00%      
Monthly payments     $ 10,416.67      
Maturity date     Oct. 08, 2022      
EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( JN;%,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " *KFQ3EB8!>^\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O;15D=#E9<,G!<&!XEM(;EM8DX;DI-VW-ZU;A^@'$/*2NW]^ M]SM(JX/0?<27V >,9#'=C*[S2>BP8@>B( "2/J!3J>$E1E!4Q. M$\-I[%JX B88873INX!F(<[5/[%S!]@Y.2:[I(9A*(=FSN4=*GA_?GJ=URVL M3Z2\QOPJ64&G@"MVF?S6K#?;1R9K7E=%E4^SY;6X?1#\[F-R_>%W%7:]L3O[ MCXTO@K*%7_]"?@%02P,$% @ "JYL4YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" *KFQ3& 5[8P,% #5% & 'AL+W=O-:VJ"0@ M^?<]DHU-&'-,(VFX$_*G6G&NR6N6YNJZL])Z__I6BG M>J<)/#S>J]_9CX>/>6&*3T3Z9Q+KU76GWR$Q7[!-JI_$[G=>?E!H]"*1*ON? M[(IG0[=#HHW2(BN#@2!+\N*7O9:). B@_1,!M R@1P%><"+ +P-\^Z$%F?VL MSTRST5"*'9'F:5 S!S8W-AJ^)LE-,\ZUA+L)Q.G11&RY)%VB5DQR-70T:)H[ M3E3&WQ3Q]$3\@'P1N5XIHU\$SP M\*G87A*/-H6_P_&K_/A6ST?S\_?X16D)7>X?1#*H) ,K&9R0_"RB#0P$39[? MUKPIXWBXYW8?$8JPH@A1F3$@Q!;C+F7+)@P\?L%2Q1&.7L71.R\;CQLF-9?I M&WGB:R%U$Q(NI>4&([JJB*[.;!_)P*ZLVYQ&PK7:LM2OF/KG,_01),^M;0V%-V2+7[7JTZZ-HM$:CJ-9MKA/]!F0I)]-- M]L)E(Q NXOM^E]+>X&J ,=7>Z_GG,#WQ96+L%Q(W95ESHG"AL5*@P../!/X" M\I!LDWQY0>[SZ!(#K1W=PSVY!)U VTIHUWNHA:_D#_[6B(I+N:[K77F#P \Q MLMKE/=RF2[)G]DKN8\!+%DG$K*4AC8Q+]FG7Z_>#H.]BA+7_>[AKEX30%D*" MR5JX"S+7,"2(D&0B-I!4R*V(FUL>5Y]^QR#KDN#A/EY"CN,89DGJ8G\ /2GG MY&O>3(9+AIX7VOYXRY3&(.L:X>'6CD(^[T0C9$NU>"*] (.KBX2'^_HQW,2< M0?L^BUW>"(;+W4AFNK/($3A:5PN*&_PQ7-7[9E* 542-[=NB>?> H=4E@^(> M?XPV$TJ#Q?R5K$\.B19%/Z !-G1I73,H;O>V#<>P>CR-@@O\T@_#7S&4NE10 MW.$?A)UZK$2.E:\6D5ZOWX42AA546M<$>EY-*$M^,8.$LF,[5_,TI$5Q*C"P MNB30LTK"?0ZS[6(5;>8?;$_:"(8K_CA>.;XGJTL!/:L4F#D(&#\,P:60C36T M16F<_T&"GH%XS%;L[PY=[A@&UEM^+3%\,U.#21_*F E)<@WQ8E><7+[JKG9 M*CA<714KAD98_!UMRRN_K@#^615@ON+0L$CV6F1:@6K?]\_R?4#)($-S+:*? M4)?L+@WYNM%0!/(8&KQIAZ14#JVRV;/A]8:8#*I+R!82ZEU?P>EGLH14G6JSM-M2+ MT%ID]G#%H8A+\P#<7PBA]R?F!=5.YN@_4$L#!!0 ( JN;%-<"T<=OP8 M "H; 8 >&PO=V]R:W-H965T&ULI9EO;]LV$,:_"N$5 MPP8X,?](HI0F =($6PMT6U"OVVM&HF.ADJA)E-/LT^\H*Y8C4FR:!4@BV7?D M2OR-U_J":+^U62HV^ED757BRV6M=GJU6;;F4IVE-5RPJ^V:BF%!INF_M5 M6S=29+U36:PHQM&J%'FUN#SO/[MM+L]5IXN\DK<-:KNR%,WC.UFHAXL%63Q] M\"F_WVKSP>KRO!;WJ^+O/-/;BT6\0)GSD$U M,5='V?]'#8(L7*.U: MK;7_+[X.B3AR(,&, QT->D"-L8;6 MS$6?F]X;HLDK\QC7NH%O<_#3E]>JRN"AR S!5:N*/!,:;MZ)0E2I1&O3<(M. MT.?U#?KIS<_G*PV=&M=5.G3P;M\!G>E@+>M3Q/ 244R)P_W:[WXC4W GO3M^ M[KZ"4 _QTD.\M&^/S<7;-8VL-!)M"X&=>5IDAQ99WV(PUZ)HMZZT[+VBWLM, MIMTEBY,@9-'Y:G<J0H.J@*OJJLT55T%CZZ1JAH5?H;2-KD6=(?JW-.&R1J#*D]%8V M,/R/GY5+>6@I8CS@-, 3Y;8=Q3Q,9G(<':1'7NE_*BV*%ZB,K-Y)2!B)(SZ1 M:1M&(8X"[I;)#S*Y5^8?M6R$SJM[]%'"@H<:L[*=J,U)!S?SJKDE)HAPG& V M3:YMR!+.DSAVRXX/LF.O[%^5RA[RHG!IBQT9A91&?)I1VY %C)!@1EMRT)9X MM?6)W*HB0WE9-VHG 6RZG9U@B6.81A&S,FG;T8@$[&@B/E-+\+C(XV],,N!^ MHQ_[R27_Z?+:")[5.[3V7$B,"0DG@AV&A,8!#V<$'U&)^,=LOP#,#\[!_9G" M),0TLA1Z^S%%TEE;BU1>+* *:F6SDXM+Y*$"&4%#Z M6!T\(U HACF!9@/Q- M8[ M"8XAV""9R?/(+L)>A,,B%W=YD>M<>IE(1OR0%_*G%H\&/OW($VG:=')< MZYUIL2D#P?($'Q%Q2(O#,HA)C&>2,A*)^)'TN]+R(-RIT>8)QP$!HDPE.L## MXA"3.8TC>HB?/5=#*O-*2QBX,)<_5&G196:9;V31%W&U@"GOU&^#)J"AA2.7 M61SAN=5HY!'Q ^FC$E6+;H>!<;*GO5.G@T%)3"R\.^PBEN 9;I*10,2/H"DY MU5V1WPNS_3 E\1/X:]68CYP!V/R) 3\)MI8I!]'B!#@Z$\((*N(GU56V,X6\ M&0R//:2<,FWPD(B3*(FG,KV=??]J2D>"43_!;N1&0KHS]$GN9-4YIR6U:10F M$:73<>WOZA51C%BC?JP=HGC_?NV-Q,8;YW& I\_#84=#CF=*D%?M]14@C8*D?L,\W'T?\=H9CHY*%G%*H0:S%3,=*0J]5/5OYA")8K4YB5K*G5L^F*S,0FF!8+3,@H8G2$8'>E+ M_?2=G1\02:$@1(!RZ13O0"H/77/%*^ 5 VND,_73^5GUL_R>!V-3&.IQ0JPY MX]@P4AHD,S41'7%-_;C>3XEO306;M#R.:<03:_@X+'' (SQ3==,1RC3Q5MUK MK=(O9OLHF_;''V)*^-M^5Z8?O0=2(RR9'Y;7JBQ5A5K3S=*4@6@G"ABC;_ I MC#3R%A&,EWC_^S1P1:>WJLG_E=D2!>&2P6] XF5?MP=+$O6W3\;]D,_V1S6= M;C5PF%V]GY[%3N.&]E M. BL!#7[<+0+.Q=2E&#LD(K9F ] M"R[B\WGFXGW G8"=W1LS5\E*ZWLWN2EG0>2 0$*!SH'3Y0'F(*4S(HR?G6?0 MIW3"_?&3^[6OG6I9<0MS+;^)$JM9+Q$4'2"9+7"M).D/I"6S)?UA5'GD^-WC'C MHLG-#7QOO)JJ$"92,1E9+47*DR2677!7 EL[8LO<+ M;D!A!2@*+C^PC^P="YFM:-5.0R0.YQ867<[+-F=R).<2MB.61B+_T& Y2R;0QD>DUNQ:*"A=3-U"?LQMIF&'GR%\AXDHXGX_CL&?% 8)P=Q!WP9CUO]A^\ M7QJTR%4IU&8(.GLM]$#@('2X=Z2XX_PS-QNA+).P)F4T.B4+TQZ1[03UUI\R M*XUT9OEA15\5,"Z [J^UQJ>).[CZ[U3^!U!+ P04 " *KFQ3O?O,AE<( M "#)@ & 'AL+W=O8Y*Q2-29R]Y\:-<2:G(SW6:E>>#E5*;T^&PG*_D.BZ_Y!N9P7^6>;&. M%9P63\-R4\AX43=:IT-.J3=+TR3IY6J+@POSC;QDYQ)];"Y*^!LN(NR2-8R*Y,\(X5R4*OS03 @"[F,MZF:YB__EBTAMXHWS].R M_DM>6BP=D/FV5/FZ;0PC6"=9\QO_;(78:P!Q\ :\;<#U!DY/ ]$V$&_MP6D; M.&_MP6T;U-2'#?=:N'&LXHNS(G\A186&:-5!K7[=&O1*LBI19JJ _R;03EV, M\FP!MUTN"!R5>9HL8@4G,P4_D ^*Y$LRV<@BKFYK23X]9/%VD0#D,SDA#[,Q M^?2OSV=#!2.IX@WG;:]73:^\IU=!;O),K4H20>\+I/W8WCZTM!^" CL9^*L, M5]P:<"8W7XB@OQ%..4/&,WI[HW_<^X$88I<3HH[G],2[A?HTE<\R MVTKLUC:-O;IQ58>>+S@7ODM#?C9\WM?,!'INZ#CA(6R,Q MI* +'/01&)I Q MR@.'[7 '=)T=7<=*=Y27=9J7LGA.YK(DFR)_3O"\O&I"N?MCX()1RIA&W@1R MUPNXQFF,Q',=WZ<^U&@0AP[NZ.NVOE_JW(RYKP,E$87=<<'LQ +@UT MNB;0H=SCCD87B2<\YOF^?J]-H!<*2@5.U]O1]>IVHH=N6\FR)R)_;JJR5UH> M%W\7U+=J.(O3N$@@;^)L03;Q7T6>IJ_Q,4U]@YI+O<#A0I/4Q E.':I+:L(\ MSV>>ZVF*FKC IRSL>7B"'?G GD R TG3FGN\@ DJ*54E\3-*/3"S)/0#U]5* MPLC$<>H&+-"HFS H,,S7*TR$=.LZ3L!QZN&.>FBE_EV"0;'=Z-!D$8:,^AJ- MD8D+ B_4GK"QB1(AXTQH:1.9.!8*X;DX648[HT"M=.^@2,BR,HAPNY=2?W3: M:9^:O?N<^XY>+Q"@#U5%GQL0&(?BZ.KE-L(Z%G"+PQ[:>_Z(66G?Q,4/69>, M)L6?9:&2$LY1^LP\R3N''T%?MU#N3_;BY8$K^->SBKA6 1=!D0G.<[>H5#8((%0I]<(@3' M'2;Z,K^S0\SNA^YS!2F?'YD[6NH"HL83@" %=1C7:SP& M]$+.W(#K]!%D&'K"]WOH=R:)N7;;H%:R($DVS]>2?&IO_V>+=6"=(6'><67A M:5HDY28OJS1;DK@L)>K&[+&J-8739MI !U)!E7:% M+OX'=1@=[_!0O\Y[,;OYNLZ4A*Z5M1R9UN>$^2$/=<>% 0%'=540F&!^H)OB MJ"=>'^G.T.\XVI_([TY*8A[$E/#(FF)P;$TQ-#VM.S,Z3<;D@[&P+3 MY3S/P(UMY>*()[''?$_.?E"@,3=]Z@GW7*HO^7Q AX="=XZ7VQWOMSC)=%?R M'LFMT=\C^0<%&G/3&HO0123_]0X/)>\L-K=;[+;TOCN[K5'?(_4'!1ISTX;# M2RLUI?[U#@^E[NP\MR]Z5NO;:55*8J6*Y'&KXL<4)KVDUAD:3;:L?IA.QU?R3GF\Z"?0GH%V:(C\*H_H*) MPXS%A1Y8S^("[[P\MWOY/^JM3! @?@;.3Y)DV_4C*%5M2%1BP=OA5I4*I*J$ M091#%4)6/+D?"'/='D5R5N]#' P?:$RPD)2SW&8TZ-59_IY:$W0 M,5X7208/=/L>M$LRVSY8YX>%W0]'<9&![$CN8I6O#;:?(I!O/0OLHO.'PNX/ MT4'TW_QQ&^Z-P^C,E[";+R-1^],3'16R.*?GS^'(]K8K[6[E;2.S*8:X Z=: MLNM;-1?=M"[LT_I=D2^V8T<7Q.L^W9 MFK,&9Q[EQF+R"$%ZKB-H&N(](M-70< M[GU4LY;%4_TU4PD><9NIYEN*W=7=%U.7]7="VO4K=CIBR/4Q.XV:[Z&Z\,WG M63=Q\93 O);*)71%O_APRXOFBZ?F1.6;^I.>QURI?%T?KF0,?K4"P/^7>:Y> M3ZH.=M^=7?P?4$L#!!0 ( JN;%/ZH>3>Z@@ / Y 8 >&PO=V]R M:W-H965T&ULO9MM;]LX$H#_BF #DY^6^D")N&NW2 M.?;]8+X323:[O6[^]JFXOGLW&?=\/+SB_9U M<_/J9NY%*1=Y^N\DKK8WLW#FQ?)!'-+J<_[\3WFZ(5;KV^1IV?SO/1]E>33S M-H>RRG>GQLJ"79(=?XOO)T=<-,"XIP$^-<"=!B3H:4!.#4BW >EI0$\-:- MZMLAJ7YX;[YDXA G2OA7[\K[1\K4U2FBM3[))+X*LF\A=@GE;JV*%W:E=X=[LM- MD>RKXRC:R.1)W*?2IG%EU_A95FJP*_^N1)$EV6-IT[6VZ_HS5W?7;C97P3]G M #YG &[TT!X]'^1CDM7&J!&:BFPC?_.>1'J0GJB\I=R\]0CZS<,^BJ#@'E4' MC>IZ$GNZI3ZZGC]=1LZ4"0(4DH"VY9:FW!7B?EMH!0AAZG,>= 37@&48^2%A M9[F6M\C96\3NK1O%Z5^[%1M[,U.I4RN))SFX]:! ZTK-TI&=%#<]>*;<2 MSCK),"S7B@ [1X!9([#*8GC,C V?* 8$#A. ) MSQ2T3GCAV5NA\PDOG!:XZ&Q*Y&C"6T> :WW,?49A$Y"O>"=W3D*7EM>#C]"PDSR () ]D!1EW*>TD[1K0!*'D8]Z/79!F&AJ M!@W["IDIA+B:KWJF(:1I![T>=P9G)#2&=TY"P^,?$(1""$C!4S<@:9V[D88> M-)EZAGTU$7N0YA[D#'SLFB:0CRM%2U>*5@B FB#"F.%N6@P+M@.A\0>]DG_^ M=<@&QO<8 $)C"0@0A 82($68PL"0=ST&0)#/&?;#'H]I"D*3,6C85Q,Y"&D0 M0G82^KTL#[4Y]4-^V3R!/XNB$.JI7W[?UU4!T!RKSBE#RB060K'O^]WH.NIP MY4K1>MCR=D T:R$[;+4"NK+6-Y78'!"8URAH#NL #R+ MHB@T1I75UBE^=Z1H#5C.?+_?[QHLD9TL>_QN^OQEX(*^-Z$3!>H?AZW#&CFQ M'3DGK'=V31,&IRM%2U>*5A@"W@[3GTH_(R3;H= LB^TL^WKZ/RFVTS\VL1>F M?T 0*I8!4C#] Y)6^L<7U<4!WGX%_6,39*WTCS7(X@&0'??LWV,6&1-"$WM[ M0F@*7A$C@I"02N0@ZL(_($DX8S[M\YG&;6S';7L%H,=5)G-2%#"*>@@*:^;$ M=N9$2/6B25>^4J=&1HB6&,+.; (XZ6]L[:P=#XRRVXVS/NBDV MWPY)V6S(@)$(C'%$$";=@61B+_%)%')CW\!JXY05QI&B-6@ZQ5'4AP*:V/$$ M8@<=;B,4#'"KTD.F$S@P 0&(0*XX.>"A#1;$?L M;#?J>09.;FHF$>N6I!?$Y$#$0QX@Q+IIY*HN"G2IGOZ8ZI.%W5PS1;E:J&G4 M4QDEFE*)G5('GGI@CYJ$ICQ*+GG7!;NN4 M2)M=]JP+@*1]7=! 1@8VDU^S+@ 89E\7-(:1O[F 2,P"(NU69!?$I!<415%@ ME&[MUDX)M:L2(F Z]BTU1*+!B_P?:HC$!!AJ,X]J@*%V@ ',>TJ$MR_4$W.E M5I]4>:\^\ <>'S)WKHT)?$%-VF&7PCR-%:]!RUN]S36G43FEC M?6[+"&KRD/*])2,T#U$[#]T=+2ID=2CJ,XDBB[U-;6Z:JJMFVBA$5C[(HLG< MI%2I7"7907V9*U@1]=,F;#)T2*\[AU!@6YL$411VYQ#[74S)%T>*UJ#IW!(2 M#874#H5.0F+-)@ EL6U^N3B,Z.XTHK/CB,[.(SH[D C")_91EY?68R3;H=#P M21ULRX-D0J%M>0/JJ0FJ"*O'$8YY=^PZJEZN@"ZOF$+U,.JB'B#)U3V$00_J M40W1]*?V[F&'0GOW-J:GFCSIY%+@^ 7=/,;(#,JCP(E"17F&X-)NZ)0HN]J@ M!TQG5HS2@$TG _;T);UO&[O/.LV@U,Z@S6L45_6;-FK=R'?U&0YQ?(%'+23) MA>ERMT_S'U*>CGV(9U'$M?%@O=[>Z93Y&J@=W;-4T(@RM%2U>*5@S8L6>8(QQT#[.-D6R'0M,Z<["W#\[R#"BHFK4P M0*JG%F8W=(I?S2[[:F& J+46QO1S!ONI$P"P1X&Z*UP+FU^\^U:_"_E1%(]) M5GJI?%!-_;=+ZI\W[P.=Y]75;YK/FZEB&51"ZCO'_*\>KFHW[ [ MO^1Y^S]02P,$% @ "JYL4QTDLS2J!P +2 !@ !X;"]W;W)KQ#"TQJ\:*+@R1 ZJ0[ =+4B)OM M,R/1,;>RZ*%DIYE?OX>48MD212>=+8I:E@]YKCP?*?7L6>F?Y5*("OU:Y45Y M/EI6U?IT/"[3I5CQ\I-:BP)^62B]XA5\U4_CV^F+\[4ILIE(68:E9O5BNN7SR)7S^;['P4&(M$ M+M+*3,'A8RNF(L_-3&#'7\VDHYU.,W#_^G7V+]9Y<.:1EV*J\A\RJY;GHV2$ M,K'@F[RZ5\]_BL:AT,R7JKRT_Z+G6C8F(Y1NRDJMFL%@P4H6]2?_U01B;P#, MXQY F@&D.X -#*#- !NY<6V9=>N*5_SB3*MGI(TTS&8N;&SL:/!&%B:-\TK# MKQ+&51=35620%)$AN"I5+C->P9=Y!1^0K:I$:H&FO%RB+Y#Q$GUX*/@FDR#S M$9V@A_D5^O"OCV?C"DPQ$X[31NWG6BT94#M!7U51+4MT#>JSP_%C<&'G!WGU MXS/Q3C@7ZT^(!G\@$A#LL&?Z]N&!QQRZ"RNU\]&AL)J(+6S$%EJM$"P[S2M9 M/-5U*RLI2H\:ME/#K!HVH.8.UGFNRM*5@'ID9$>:Q;R].(F2.& 1/1MO]R/C M$,0!B8.0[00/C MWQH7>&%QF_X7ZK8NH4K#F4U6D,A>H:*PV=U,3J(VI/UDX MHW3J"5.TLR0Z&J8G:&EU+C)9@B6@9@-:&Y50^ZX8UM.&^Z&AT20(@DX(O>I- M)SXMUSP5YR-HM:706S&Z0!Z_XIU?L=>O*P'SI9+7#;'($%\I7 P_V.G29IFIC>@.4L)!;_I@+ MIRNXYPJC88"CKB-]N1/,0D+"@:OYA@U LZ3;5I4Z\EZXP0[7E.:$Q#FG1#Y!!D$_@S$*&60MB/H2NQ M$+!^,G0OM@+:JMM,UM..*86_71XY!,.0QGC RA9'./0'.-OR(A4FOA9*3B-# M1\>GDR@,2-=*K[+?6#@MS+"?9I=-3Y=?T&TZTY,)^ M=$V/<=_I59]?L%4), GPI.N90Q1V/R2)!LJHA13V4ZJ[M9/%%I+PYJT=;FF% M_;CZMU+9L\SS6@U/_]I( , V?USO2F33> <_**,8LP2=^1(BS#B1]B=*D[L M?J_-=VX;:]/=7'Z1/LD()I1TV[]++@G90-,@+:6(GU(VV[836]B^*1>DCR*( M($E8%[Y^W>]??J1E&B%>MVYLT9HV:%%FLK!4.2S&U5JKK1CLC_YIWU%FS42= M_50(&ZH!7I,6I,0/TME&ITM35G!R!6^@UJH7FT(!65L;UYR>]>%X$D<4]W+F MD(MPD- !LUN($C]$#SKB\:;26-UG)0VC) E[ZZ,O>!)2'.%P*-XM5XG_G-=M MB M9 &??W!!)"S[B!]^]:-!=9U:"DC7/$9Q]"E6)W<;)&2<'#^,X(KW]L-^$ MWUB2+1&)GX@SK5(ALB:(L,%')<]M$:=JM0(GRTJE/YW.]5D7QF'_E.HWX#=\ M:YE)DG?X=CQ;2=\AZ/JDMW]Q")(H8ON"AQ:W\"5^^.[5&O1'Q0N_P<[388)[ M&?CGE#Y\'-6RE_K9^X-KS9LG,8]PK"[+3?>Y6^V*?YYW='C:)S)E9+\J#UUI MD4S]2.XO%..-W=K#8M'B299F8YRA4-+;.QNT]-,!O'/4HY!&D01&%$!FS?>[#IIZMYEB;=)V*S MMW-:W4$I7Z3ZJUL<(\Z '0"2V5>ZGV#ZLTF;"0=N'O$$PB MEI"!W3%MB4PC+_KG#[/9[?77Z[OOE[?HZF8^O?TV?[B_1M^^H.GE_$_TY?;; MC[FO?[5TI'XZWC2'733CTAV,/@1)'"84=V/Q?X8@;2%(_1#\SG\!]@;M]PY^ M3]_]YQ,=.M@RDTZ\U7#W[>[$IOWF^_577]I9BRWFQ]9M\Y#MQ7#+0JOIZFBA M]+%S&.L3:&+W10,+E+4(8GX$O>MHSOH,P21(2$@&NAIK0<+\(+D7J7HJK&;3 M*NK3=+Z+F3GT:/,>T_P(1XOZ$(NX[>!B/6AP'QXL"I))0+MX=$C223R,&=9B MAODQ,U5P M)EX]C!CO'@P>CK0S!;#\O M*Z&?[/OH$MD'N?6[R]W=W3OO2_NFMW/_,SZ=UF^NVVGJ%^E?N09FE9#;!4P9 M?(HAV+I^-UU_J=3:OMY]5%6E5O9R*7@FM!& WQ<*@M=\,0IV_T/@XG]02P,$ M% @ "JYL4\&K]B%5"0 ;!4 !@ !X;"]W;W)KO(+S 01=0?GP"[V@9;&%A%) M5$DJKO?7[S>D)"MMDW->SDMB2L/A7+[Y9JB3K3;W-B-RXGN1E_9TD#E7O1V- M;))1(>U05U3BS5J;0CHLS69D*T,R]9N*?#0=CX]'A53EX.S$/UN8LQ-=NUR5 MM##"UD4AS>Z<#V>3M^2'+>X$_%&UM[[=@3U9:W_/B*CT=C-D@RBEQK$'BWP/-*<]9$Q.&O;)@V&Z;>[G"0M_*]=/+LQ.BM,"P- M;?S#N^IWPSA5_9W=7-M9A=OQ?O+Y;SVZN%7]]< MBO,ORZOKB^7R9.1P&N\9)8WF\Z!Y^H3F-^*S+EUFQ4694OIX_PA6=J9.6U// MI\\J7%(U% ?C6$S'T\DS^@XZUP^\OH.G7#<;6:K_249'+.:ZM#I7J0Q@*5.Q M,&2I=.&!7HM+53R>3=^*OGBYFUBKK*(T.Q2?UH,I- M+*[*9"A>L*;I^)W+".$L*EGN8O\(RIM76VH>Q.T379M61IOV86V;9_\46VF% M*A-M*FT0]10+P0=8S@'2$EW3@TRE0(X^RYV8'C(^)J]BGT)E?=&ID@9 MY_HRUP:9'HJ;VH 7$EV7#F[X+89PD%]5@$.BR(I$E\Q^PNF^<&5@EJIR"&RH M)"/S?!?A/54]*[^4BE<>,)9!-"O(J$1VL?HPFRU:7X/-O&VM; *<[4@:0<&/ M]Y10L2(C#B9#9"!*(5+;QC?.I#B(0Q!,DHGI02B36&P)&AP9+\@>B$4N/9X_ MD]E WU:Y3" +8IMIN/!2;TO(VGIE5:K T[$X7\SG8I9\JY55H5@XW; V:@(I MVO1PI;2>->J7]:K+);MW#E3@_ 5!N4,HQ%P:P,7;:'\ 4I!MMP\1S10:.4 0 M+GP\L8@>.Q2+_&T5VW1V0HGA41L(B&S4#$6@+BB:R4DWE#?@WN'Y L*[//]H M-(H R&Q)L%\*-=)OR<:]#$?*%P[\]]AC/5ZU@5F/%?4JKM$S%'<9MA.#,'&S;(8)$_T]8%N-'; M2TTH=AC\KUH:(#/?B5OODP_'NG8US%@KXZ;"99B"I&B!+3H);Q: MKZ%R?TH*YN0#HG" 3U"!MPF3&M)8@.:^BR13>6H0/4QK8J4,.Z+%=.)YR@8V M];J9L/,ZA3NWM.%6P0BXYK-A^NVU!=-]4CB*V6O!S=.'O17XM&"):$X Q5HU M.QD>H>](SL:+^?7,AN)C_MBH!\\>J#XA'4>L+9#6Y@XUC5N,S=2CW,=,)DNG56'(,7=NFDN.\KCEJ>>LARX>^ M8-NL #ALA4J?H/(C3^6_UR6)R?A))B^YFWAP\!&WY-&:0C?W"9NI"FS*\D # M."4!&9"8;8 O1O0C"FKW1C_+[9O3:A=<*71#DVV/%[<*FTPJ[H9H/[;? WBU MU_!A*):9W,&KYU6?4:,[H_)(>X5'F]SJ](5@5VG,$ M%;'HY:M3L6P[#$[M#ED;772G,)>"K RH5(:+4)+K%I8\7!&XP%^-'N-MV&F( M;.\0D1/#PTD'S"U5'AQY7>RE!%U[0R MTM[+0(J3^/CU$9*#QK0OGA6EJ/9)?'1X'-E[&(1G9>"#6$P.WJ"CA6$46[@] MAQ ?',..E"JN#D ]O!*R CU[-@]!6:$IWJ=(,$,[S)/,DBA@]'"]W1O?C<@3 MT=@0-3:TGN_>M?[]+"M^EN40[ 6/GY+T4)K^RI6F$43L[.3'&+1OW^T#W)YU M^,Q1XCEE'+"H)UL9_8#6+I@@PPRDP0 QUC50S"2J\M!3!-\VD$ZX@N;N7LJD M1J#]F] F^!!#62C?_4!24*%-4!'2U>&Q#WJP(A3I<)6#T74W(N9RVTZ(8?[V M9=LD%&=<(C8UCV9O_(UA&ONNQ]+-&,+R@2?:NT$A2[GA10X*C'@[TTX41 M+6,,_4FEN1H@$PA(PO-UNA^T)A^&$(6A1 MS&_^N'K_G4^;$2 MI)M2@6DB7+ETN $9C)KL0&(\<<"33:Y7*''ZCB!C,AI&G1KT9("GYC%(B_"1 MZD=^!F90HJ_PQ=6Q M.IZ!_0%A=.BHGJ>(P$:8G")<8_-:AHD$L64.K<)LY$O':(RK"%&X M;W!K;,PH $@U9U[,TC#JP(*Z2L.6#A=^>]I*^V<+OQ/KE8R+(#W:PU M-0L^H/O >O9_4$L#!!0 ( JN;%-E.3_'A2< !IT 8 >&PO=V]R M:W-H965T&ULS5U9^NV^^_;8:^*FM_W>;=L-FX]OX'7S5WWSTZ M?V1??"A7ZQY?//[^VZU;^1O?_[J];NG3XS!*46Y\W95-G;=^^=VCR_-O?GB* MY_F!OY?^KDO^G6,G\Z;YA ]OB^\>G6%!OO*+'B,X^L^MO_)5A8%H&?_0,1^% M*?%B^F\;_0WOG?8R=YV_:JK?RJ)??_?HY:.\\$LW5/V'YNXGK_MYAO$63=7Q M_^=W\NS3)X_RQ=#US49?IA5LREK^ZSXK'9(77IX=>.%"7[C@=_UW]_\^N[=Y8?_S-^_R6_>_OC+ MVS=OKRY_^9A?7EV]__67CV]_^3&_?O_SVZNWKV^^?=S3?'CK\4+'_D'&OC@P M]M?YNZ;NUUW^NBY\,7[_,:TS+/;"%OO#Q8,#WOCM:?[D;)9?G%VD[#Y M)SS>DP/C72X6S5#W9;W*KYNJ7)2^R__KX.G_"74? M'!O2^DVW=0O_W2,2Q\ZWM_[1][^\__@ZN\A/\C\^<_Z#Z\HN:Y;Y-8:I>\?B M\G'M,T?TV6Q=?0\*#;4;BK+W1;YHZ#SK3O[5$>$*AZ^79>WJ1>FJO*,Q/$EN MW^4T;+_V^96,DQ_]Z[^\O+@X^^N;\.Q->)9_.O_K<;YVMSZ?>U_GM+&M:WV1 ME9#?1=,6])8G$>G7^8^7E]<^\S"Z[\8NA+7LP"EYY_7FQ=O6*][VH]/\DA=/9*SN9QCV/B^:O&YZ4+!WV%U5T?)$R;*VHM&73=/3 M,S17Z_\QE$2'?'[/=!"FS;9M21O>5O3$RM>^I4'X=[_%DFG4O0U@5Y<;(M?" M,>U<70]$L"G2G>9OZPP#--NRQI+HU8VK25/C9]Y%/F*0 VPQ==2C;?- Q>^D MZ^2WVB]\UY&%R(\P4-GQ7IN:]D9+J$&BBBA"!]%B6EI#2WOHCG&B6V%A'C-N M:MMT9:];2+G1,3UN0*[-W+=!MI@?*INAL$;XXA11-CQ%>JDFL\XWH20\].;V>UC.[&&W*ZIYDHJ!CA%&S M?>GP1!2;TV99#A5.N5L0->Z]:W,^^WOZOA]:6SDOM_-_YB"S;MT,%?$EMNF8 MY^B=WX=:;&Z0O"\K"M"T]14_($Q/[[6>SI1XO!J*R-!Z>A"N\Q=_[?)+YN'L M@]\V;9_3K";6_T8S53Z1?Q))_/[.M8MU?BZTY8FOB)? -CMCO*0AZ-]_&^B( M+N1Q$F41(I*]*CF@.T]JJ\@*(G$#X1QHWN2T"6H A\1-_&\EA^=W>KYV[M>5 M8]Y^Y]N5;S.,7'F,$#9[\41W>]1YG\-*Y$^.9='$/J+$Z/&A%>[P?!B@!98G MW)$OVV:3_]+<"F_2P;PB9L2_3_,KMRU[/@/64[S26?YS29_(9-PSC7]L,-95 M0PJ\K?'?KBP"?9CQLC^C02 19A[RH*[>>6Q%9>O M&CT)+&^6W:U+(AO.TA,QG?(CF+PJ_^E,F;BN\\J[%6\V_%*5;EY68BGTR%5S MT6+:CD5VCF63.-.95CW)T6JM;"3*A4;-=.U@H(4O;WFYQD$;_,*KV&[;YG-) MEL/3OK_*S\]/G^;/3Y_1B9\^IW]\33R3[? ,K6!)(*=I.^;=@MBE)7@)!NWS M.Y=J82)/ZV\!L,$?0>^Q;@D2! :\9MHWCM?W0;U MR@Q,@MN[_$B4'SWD60F6C'* HB=%_=0DT24 M>G5,@V[HK&]ET%L/>AS%>5P!-4FRU+KMO6*:M9OG (37 Y#,JZ=>M_Z+AQ-I)CQ3YL].S;%-6%>V6 M3!;IC$[A#Y%XU?H5INT;H@ F_RI]'$:1UJ($8MH!@!*?D\T;H*MHH"R2,E^1 MC\#VIF6)=@LBE<"/3E%=RYXJDTE&/>O.A*^"&^0U_(7I*EVR;IR<>T2C): MK'FA<@H_)UT*;27(KX2)V01O80RLS#1GIN%R4J'U+#'\T/1E +K3",GV";W6 MEJ+3ETNVHJ?1:;D*ED*]EC]I1Q1=!*,\3'@MA@;OU@VMXJ2Y@TKHACE9L)*P MF">:_$#/T6%=>_JF)WA-)K'UV15@8-OE3)#SO^;OKV_(+/Y\=>#Y?/?Y&^+Y M:VBA;CZTJS_RZHQ\OVM'((0?9AOR!Z=RK>M( L)[O.-#> 8(J ,TIZ\OR-#? M^AFY"XO364*G?(=.]YEP,*F)T;!N E#!)%;AY,7%4\"4SUTETL&+)$GI5.4F MCB/I4%+<+F#P:8[(II$%=/]#;/&QA6H8-OE-P@*BPQ@JG@=4B*<]\RQ0>E1N M/EUWQOC4!CW-?R4.IJ=>D]^S8>"!?1*UA\TV@*5,H,](^/Z,6RXX'>XFE'CT MI]71[!)M @VR@:GSHP6YN" Y5Y%-14E0USC:32#<""I%;(3/X(:J85M##PIC MK##SH7=DEI2<8>_9%_S.]#L1+"L-)A#GAH/]#A9OG5#LM 9M*S@BU5 M\G8$TH@&] /[L*+V%NQ"%25-V 932)IYU0!U.QS.@>4">7=K]D?QC_PUG=ZM MJW@GX!)38 M%VQT[W.2SM?T)L WQP:TWOYNY #BN+5T M^PI:G3B#]#,C0A]G%@+;U/"*R*AIJ*TC%R$ V?!= FY)"VS8O3&FC M(@@2J1\"SF<'5YA")C/UNTL$.>5[HP '^,ONDWAU1^4Q8T%\PQNE,U3^5VV' M::/8R5( 0!J[#J#B.U9ME1*4O*;4E@ M->*=C2BID3].5FI#MDJLE@*Y7$P7Z2ZE +D6=2E@$%V!3'5-I)&("'UU M;P/KNQ(]CR8?6CU;$8$]6+RO3D;5,- MXS/DD2.+E&1RQ)UVBFDS,E,U8//1[4'::: 5HCZ:7R)C94O>4;7$:49@D;A4 MBP8_T?D4<,_ZD@53'%[:%_0Z&7 S0B";1G7!LQRN#10_YM>.;A]@):;)4/,K M]+9MX335Y5&13,CU(=T(L=K5:V92BK&&2P*QO,VH\3!XMC_X+)=8">:(8R)3 MQO$G[)4K,[4I">>'?936LZ1Z:, M@#,MC#Z6W1J@@ P9DIO%4 &Y<] 18Z_+K1K!D:5HR"D'- &"0"QZ0>?QV[JL M+&P&ALSBQEM?;N:(\,03G3@0DF$.?R,TW95B$F8C_A1]JD*$+\AU6X-7<$)NS.IV[-$8+>6 M5!M14MAQQ"#]_98%GZC3D#1WY3]]T(V"JQ)FC<.34H-I7WF69N\6:Y,9"YR- ML0A'IO[IIV6'R,PC*&]&7DQ"(:P%6U @70?+">*G"UKAJFGO9=80C<^Z>W*4 M-I:DZ$Z!QM?^2.3"BQ"7ALNC% MUTBL@&O)>6D9T@6-R3DSFJWW'->B$]LRO%YX=LM$'V0@^2O#/ ;E9O#'HS*A M@=YSD.\5'#ZF^+L8IHB@EKTL&UG0]Z0U M?#$2^2QD!T0TY>PL8I:[H2>T3/Q8&!/?EH5^L'3%6.0=NS&@'7F^O[,+T8@# M2V:PC]F]FEBE+^4S^" 3-R#"E6C7P24[[L&>X 9B'H"=(^KN856 .R9I1JM) MR!EI.,OG0Y^ZA>PD(08*7I,P8(SHRXFN6(I=X(T%6;42$(,T(H>%^%PT]T+F MJ6XVY4*#Q1G#%T\^Q2 I+4D3DI_A%O0[L3NY)%LW$W'B'Z%F($7<<3-2Y! ,/M;U-^H7\^O1C$L5H MQXMR*X<\]7A_I_"; "I*R>$"497-T-'ZTW='@PJU!9&3-F@V/D+"-HZ&1S=$ M6-(B[__^]M7)^=?9-9V+QU&P8WGYX?4-7-;\S< ^ROYS2!7G?W/U $Q_<79Q M)J;LQB/8C>\LEWYZO"W;@7/< MEB$+R_ZM:4D.=6'OVQ4!=\WXA.DYV3KT\]8[!G%&D5GFH*.\0Q;5<71X?B_! M[&36&>Q^(%U,$8.V&WJ7;:0&UIV:!2FY8CJ5Q*6+/ITVU9"$M*MF*\E94U T M5GB4X-RD^4W=7WSL;A*-,QXEMN&Q*F MG@$0RT]>-1AO,N^ZMY<9@4NH0+%9''-*8A :H-QB[B*K_*KLQ [-8%7)1W8!WF&RV=4Y5M9S3VK MF2.\IL(?E(^I /,V$$7VM9CSF.5^,4OD^-K=$\I??,JO6SI3T>'TSU7K!%.J MA',T_'6]AN)D6+*[ANOKZY^N7O^!14@(^^*I+<*"Z%=I2/(2R5IZ4 ^81K7, M_&C;EV&N;'*N(!ZV9U9EG,)2/\(H-\OC!N*2+B\CM,F_.G_Q4IQN *HZ7ZJB M%S-6@-]*LO[$M/3-NNDX2]0E_#+);)8!X[,0YDFT_4TC\253]Z^#XH:9&1_ M3SE>EG<,HZX M5E?<&.4.ZHW=^(BZB1(B/%.D(.Y>E1+)-$+'HQ M>_'U\PPLS(:"1AS9D&MX-Q9E2A*F(1T\2JO$_ M*)73; .A?Y2]F9R_/9\^> MO:25E/C; ""@: $M]&@L3*>LI9'E0BI6,6SDJT73 M&7P)*ZYCJ-9_[G<"KAF'[UU'RYH#]G428^0=T"I09F&E:.5N-G7C^P,QR "U M1.*EHHNN7/R#P'$\]0$XN1+FFDS@Q ML_$+N?0BS1]"UB\MBK.AFN@OG3^; ![/\K P1'B0I*PH6QW0Z,%IY-=O#0E M)O5MY,Z(>DD<2GW9=L^,;_P;F(UH +^]&'%^IMRW*XY_VK7@6*?J8==)KJ(5 M=3 UUGPH5F#1&[P6UIUU6Q)Y*!GX.9QAH-W2'O_DD8UIO<<\.\Q!;@7X7&-* MXL"#-,3 :Q0'0P;^,3@RXDL6N( 7$@RUIXPX YYJH]/\/:3]P7<.JR1-V-?" M\YK&@7>%>''0FNIMRK<-X;>5.9-1L7+0WW:@Z6 $;9'X>V\62VL!@SBY6U=6 M3)0D=S>;/%F+:G%)94H QL/+LJ6O1I'D&ABE##6M0+-P*D_@A)VP>XGTAV$Y M1G%IU30/SDNI__)Y')V<^_Z.=%PF;*QT=U8C(%5^ M'!-%?KUP4J.K=2VN6MBEA4/5[#C"B?L3IA\5;$@QN5?>&--:0VD?6IXE4+D5SR#,,#Z4:*,G^; UK MCEU&(><@A;ELEE/:9@=IFP1 +?AW4 (YO0#4HO5 B#,@[2,G$"L?1)0U;"=: MB#9)$H-"0R[B(Q!]+Q!@I)UW5,2/4@O-VXE>G-36L4M"RFGAM*Z%M6Y2SN2L MAH"5+I=&#G74#9F%13ZZ5LYC8@(N0@R3@.RH>A*\.C&GY=64,V?[)E)U]1>L MWQ[731E 8WA!0/W4+F($7@7@X%[Z)AN7 Q9\:T7R+H9^_&?$92#(S*0ZF)33 MQ>&ZD52H@H3U \9*@Y&:UU/ (&F>#"5W+=(:HQR'PH8H][$F#[5Z$8NQ,GZ( M%(150[FH7F5*![,"OVP'<"^_/'*.4'')5R4 ZRTIRO2*%53$BWJ@?117)J?( M+'@?:H!^);YH_>B4@#[#"0)-B_D;<>!'"6(0LN*3@[\3F;"0R M,%XYKXDE'+/$]^K#WM"!363CHJ589/!%@)16)XI-.3CW8:=K[B4-T<\R*W,9 M51ZH*K0,PJY"F'Q^L@0K;(%P4:R)"^YO>CMAAT(XC?UABX,1C\2WB=ZUF=TC M0*.P:(*2Q_M;M*AAED8-KVTUB6,Y0.GNO:TG'.#D_.WGZ[.0B5$GOOF+1&+N= M0K MM78\L>*N+B$L%P9H!1GIU@VRDW+K(2358Q8]Y%[Q_K"5[8O?-_>K$C4FKT/] M]/M%WT#3G:=1?B,6!Q=5-'&6@F-C$%8X7J_1,J.AY&LB"MO)S*S7FUIS4G&A M(4SES/4C$>!?F8/H#7$*9!>S+)QZY-X["VR% '$@,HB@5]8B^)(:8IV7Q=D" M?*,O.O^1$AZ(NO=V\=[4;E2J@05TTQQ_$L[E26 Q8@::M\#[IB M-7S7-I(3BH@UPT[(E^.",6_*^1MF(0UWELO :\&(*TR#*B#E\.0L+[@VD4T1 MD@I2O8X+T=[J8O6&=U(KU:JY6.(ZGWZ?'3W]RW$D2"' V-NV(K/KA7KA5PG_ MJ72S=\-[?W)V4J#J4^0X@%@+70LEH!FWKBSL0FT ,ED$,HBM/W]!__OZ)6O9 MQ:AX%TB,T5OO)&&KY9@<4AK:Z+Z&;86CPR;D0UF8!N%B@'C36.J4"DD/Q@!A M4LN7<;4:YU3V0@@ZZ40%L.AQS>GIS;JDEE?%(ZCB+F&XC2X)'V;QI2R.'2T_ M[G0VL?[OX1E0]$MZ*!1=TGCDP0HB"Q5BG"7A8E6)=*@V#T&33+P:F +V5Y/0 MQ\(M/=O2O'.5EZH+"7_C]CE?0(WW=J7P471M/-! UR $DZ>:[9UJ<*.A,\1Z M@:_)]Y0;$%HF@B]U#5(S:LI@VVQ#@$5#F;$ Y\N4194L(]_)=:]/\T^3O_ MYMI6(X/5 Z/W9IGOEOV""[M>Z^.<'B1G-,&BMM%9".#D1,QZIHB K;5HW"CY M*1V9?*'T.98:AYN()>L=\GPJF+-1;-]J>.-.I+QBI4K18/4,U,VXE*WMC@2ORR+T?=?FP3!4D!JIL%B]A92&F "5S_O5I M_F9HL;/9H,5_8FF*9E$JF[IUN21W],YI43]IE>! +;T_(8J>F+((JT< M;H ,H+Y\8N$LO1RIBFO1_Y<7I"4@[*0H2J=%-'7"$];,BEP735 M"0)7.><;-%=HKOF;=Q4\3JLDCHQ*?FV+8Z O70.*"WN%>KT M8DPAU..+('H1(P.XH)=CU3?*"^5N<(QW2V5;.(G!J3.H MP!G;4Y714X0F8LXIB?I%-(I9@SL=I_HOO]V/^L6#: M*)[<9;C?N0[)4%TVPJJ"'I@62W&XB U"S-<@G9:$9Z&HN+.8 ,*Z)Y+3V*%6 M4IXE@VA.B>UIK(BY\^KLA#P.K6_W[@H]!BLN%BLY@OI)+,$:=622-P8ET48:HL/P(".(%+3Y'W)2#@K1+0JT4 M/?\6[NF&9<6$0F<9!;$LX63->1P1.FO#1FH M,G4_I"[B]\2H\F5LO8+UE6V:WUG2 G(4E_HNA9ER_99]=E0Q#ZW4ZTRM@Z$J MFJ5 +T@YJLB-W%W=74)W8,JRM48LP5-4J8E4*2-5-'1BA;#5?62E)+(L!2G\O0VV;OWO"8PI'RJ ^#2)#'Q46C],;6:O3BUSY\ M[?2R%A-)C +OT5^@E<>8YB=%5BW:',4.5OFR??GT8X9'/?2 MR;C"/8S-SBCW04@JCNF 2:1B&R&T1/%K]"D939FT..)*]M6Z/V'. M$"T=/)N,N4M3"2-=-W0>=R,JMO6A+KH*)=-F@KTLA_G3PH)=GUSAYX8JG)7I M2R[!-L0>1HMTSE(ZJUG:-"/W+9RXA9MC,3S?A-!*K,Y;#"_II&5%.RSV1YIX M/0X&0/+DK_$UG2_*ZCDXB? #\;:SFT&(U91J=A9KY"X8:NEPN8O5+J?YCTU3 M,! A])6M[$/KM>=;I]57:+(2/,BAI5%9.W.AB?F@45;M22A_\LU1&U**;"O/ M+#1N25L.+55HSW/UCSIQ.,-R[)Y90N7)U^#@[::=0Y&-K(PQ1(]0&G5GC]=F&&JR,0&K-,;,.MH&*1Q:)LB8U@ M?1?L]E?.,H# M&7+@\/9Y5 E'\Y-DGC@-(IBNEF>U(OQ]8O4E\.M#DA26<=+ M[-H7+UZJWWU)_:MDO6,J5RQUDD,9T&B#V(-O+FRV)#:]-A8"CN:^4DT\O&1W M#S<6#$D'TN3$)&$ KM:,@W#@PL* 7(PC$JOWJPQ[C\F=9,=W&=4EV;2!W(=, M/8TY&OSR=;Q@R/B=T_QG!%O0(Z;(+H6A^9N*OS$61R&17,30>&*R!2P508ET MN3$M=G#E&G?7(OA*Q,IL?$5+0EMOFJL8JZ[7KH74 M==G1SZ1.C_-K(N@->F%Q,Z5%9K_G1Q7_+K=<-R0Y.;?,DH)A-4>$#CG*@HFA MMMBK'O?4LW?[9O$)Q@U>[EP*\>ZX6;(O3IR&C4(4+$MG[-+6&*.[*-I(Y559 M\6J\+7UJS4D;MVA$]U:@K1O"U-F#4\\4=RJOBK=1213%+E@O1Q1(D<[,L%$2 M9Z1OH%$8$6SEOB&1! W=,FG6P\<.TJ(5EQCFPV3,#Y.1C!-T8G=P=8#1N+NF MR)%U:,=]BOB"JM2=0*/TYAYY:,#^V.$R(T0UGSOP8,[+,YB]R8D+65PU/N.%GW'<:9>*2G'G?#[\3ZN M_.)"2)%EJNW2 #4"(=W0WBMQ%)L/M;@?6F^KWY:QK?/IJ'$35T1/K-X"5#L' MK\)FP29G"V0F"4UJ8J1MIHL+L#1)!#&GP=UG9XUCCGK,P[Q;M.56(X"7=+3A M%,+[(0-D0Z-.M!]M)OXR.J7 1:J<%+C^07Y([VT'U6",9A(HU($MY?*_M^RY M8OF7'&[G%KH,3UMI"X0GI4WBEYE!@FA@@(_& ._TD/=+.%!YX:B%GKI$8$X@OO24" & MK/2J_A11TVY9/(7DTY!'(!I\\GPE@7@.2#1&LYADDH?0LI" 5"7*@!7<9^J> MZ).T6L&#+#1*M'A[!\UQ/,?S7!ZO.L?6 N-V87637 #;Y2W9E2K*+"CQ/]QW M<-R.1>B#+'[D4\P8JBV9'-:\O4O)2$N<"\Y$YPPG\#/<#X^74Y03%?EKRB(I M? OA$0BBAL;$W"*_6)KCZ=,F"EC4!CD(N)+LPMYKOYULOG]_"R:NJ34VGHR@ M&)T+5B;JRK&(B2OP:0 .Y>UT6JGDCJB7C:@W)KUF:"7AKFX7W^XIY?X-G=B@ M?RX :5BM<9Q):+CC^^J2YWJR0/'P2W/:?74@4JW]!XT@-J$S* 0F]&\F- M-*Q(\#>TL8$@6#W*&CBWG5[A.I)^#0H67E$P?^R*GZ6W]"(&5+ MF]TTA:_2NY-6P!BZC0Z(LWZ#SG^9QK_NI=GXF/!&(FF7=YR/GDT1LMY68JUA M!9C-&.I(O[W8CES@6VS*RL$ZC>'MO7I[' N?=U[,]474ES^P*M:=HW&U/=QQ M4@*K9Z*M<)SXXD&@>->.S M&W"[##1./^_D750=R)M\-6>L$T*;U%%OTPF*[JJ(V!PD98?T;IO]C9"1+MOS M_1 K)3CA#_!K)I7+?'^E&-HD#Q(RO;5%[_=4JY"MTXSG:!U65RPJ:(^FL52* MP]'DKR0!W9"?G.W$C$;7"W=KUT-R6/(&,2JX5^L\T_ZZR87N4+SO[:"1C[2C6JFK:A20VB59];0:2&*7 /)45VD M_7([<]PE^EY#[P=2]_NC%\F]L?OKR4O_<8'Y>_ MFOF.S Z2Y)5?TJMGIR^>/2(UQW^)4C[TS9;_^N.\Z0D[\S_IQ(DM\ #]CC\R M9Q\P0?ASH-__#U!+ P04 " *KFQ3QI0^.GL# " MU&HA.U-S@0\*=-?L-S/%/+ ME\M:NR^-%SX/_MZSL,%8!Z_ DC.@,3Y[0TY+W]FAJT6 M2IY 66UBLX(+U:').2YL479&T2DGG%EMUO=_KN_A;OOXZ_9Q$1FBM =1?H9O M/#QY!7X-=U*82L-6%%B\Q$?DRN!/TONS2=XDW&$[AC0.(8F3R1M\Z1!?ZOC2 MU^+K-.UH#;>RV7/!?"N( M9:4\NO\R\=U]SM_K7>:Z.H3?Y^PVXVV,VS_ MYO5-N+V*-[IE.2X#NFL:U1&#U?WO'[:C%%Y0P[8LT77VZ(ZIO((D];D+X82 MPJ#" K@P$A@\U$R +.$.U0$5=9JI>GG7[5U:-DP\,3&&CU1/!:9"((9&6Y1= MO&0(+]&-%8N1([5,SJ:G\Y;.,M..:=>I(S]R<:#6,=P\.2ZYPB,J MC30)GHO^DAEHRD%);2)RSFI2S&5'WI&3;:=:J5&'%UD"KD>YI/E4N"1;'D>M MR"U+]!VX=9UKRA43-@W,7%K_\=T\F5S]I(%4C%0\)Q>>G=&&PJ-Q:&R\1(\. MZK,PJM@1?1H4MC7U3>%S;E7^BXU2T%?]O; !B?/$'!CZ:E-'<:T[(L_"R6P: M9I,Y9-?A]3P+9]DUS#*XFH9Q'$,\3N>N2-]6F? -]AD<(OX!DC"-8P=.[-=+ M\2#&XVE,5N-O='K4)('4"??RB,V>2C#S%P&^=YNCBXGI&M>^"QIYU56YCF>)4@\F31.@??8S5]J[:K.X/9G(363YH]+J9V. <[7,VU;1KE%Q" MF6!JI$I!X_JN&C1O^FW&.\"?$K?F8 ULR5*I[[P9AG=5CQ7"&%>6.0CZO. ] MQC$S(C7^V?&LEB*9\'"]Y_[H;"=;EL+@O8J_RM!&=]6K*H2X%GEL9VK[!7?V M=)C?2L7&_8=M@>UTJK#*C57)CI@T2&1:?,7KS@\'!%?>$0)_1^ [O0M!3LL' M846OJ]46-*.)&R^#,?/@P>83 >S8#&< MC.?=AB7F#&FL=HSZ!2/_"*-K&*G41@8&:8CA>_H&*55JYN\UZ_LG&5:D #>H7K/;&D\6@TH8_?KOR MF\U;."(,)FDER+2,2X_60.4:^DKH$-2:/*"I3I0V<&8C=.Q\[]9=NW7S]A.( M+-/JA;S'B+!TITA7R"R8WS92(*^F:WI:$,#4%FYK,7H%IKE<1-2*7N7,1(V6SZW#! M1F-AQJ%?_WM9AG,K;00SE>1Q;BI]H36<[<-.FS=8)%<1;!&(%C59)U.KV*%C MRH5D2:ZX=.I[180^Z,(Y(ZDE0&X*D=;%T:&($37H& 3]U+K"(9).BK'LN7W2 MP&'2U#B*?"[3#;ND6?/(F_0(O?NVKCO.R\WZ50?FSZ-1,/L&DT>X#V:S;\/Q M9PA&D^?Q8LYGP7P^H%4P?H"G8= ?/@T7PT&QOP_F7^#Q:?+5 8\45X6#YUP MY:I";X:SU$;D"$B*WHC<&X$ZFRT\QY'? U.J]A.XGPH9TZNM\04IZPQEUOGN M=WE1NVI?\J9RKXQ+G/00>5[\5:C;4?Y2@-;2EH>[UDC.Q=>,B\7<5"C+7$U1 MPEGQNK]P!&V2U6PQ,TR),'8@$=)3);F%\IOK$G+N'+%JUZ\MK MNEDH2_3J@WP':GJM6HN,.J]0$J@$3Y<=4YSM"NV3H]EE%6NGR-VZYERR-_I7 M>"Z19B"DO'10\@-^E#/E9'>U2]@/T%\14^A%$7M'_!;;-VF\_]GSU#B8!A)N M5CSS&*H:ZD#%8%">EF-54$P3;_!B)AL)O9%D>HQK(O7JES3%Z&+.*39696ZV M6"I+DXI;1C0:HF8 W:^5LOL-"RB'S=Z_4$L#!!0 ( JN;%,&PO=V]R:W-H965T%^_.SIRV4:5TAV:6E5XLS*VE!ZW M=GWD:JMDSIO*XF@T&!P?E5)7!V- ^^*;7&T\/CLX^U'*M%LI_KV\M[HXZ*;DN5>6TJ815JX\'\^&[\PFMYP5_ MTVKK>M>"/%D:\X-NKO*/!P,R2!4J\R1!XL^]NE!%08)@QA]1YD&GDC;VKUOI MG]EW^+*43EV8XN\Z]YN/![,#D:N5; K_S6Q_5]&?*>>-PQ/GQ(4IE[J2@1%5+N;.@?GS[(]&.\U/_SE?.F_!EG^]H'?2Z9VP MWLG_">^+4B@QW[E:9NKC 3+/*7NO#LZ^?+W[E$S%G_\T&PV'[\5SFL37*OE+ M4RDQC$BF8JN$JKRR*A>Z\D;XC1+?E//2X\EM8[,-*"[F:ZL44L^G8OG .,G2 M5&M>#01K63VDXD8Z4Z7B7%79AM?<65T4NBD%Y$I"U"HABT*854(;M7,-E-!* M5 >HK'(-F69;*>LVNB:#8)CS#CM852=PT2R=SK6T6CFQLJ;#] MG965DYSN_&3X_LVAN&-!W8LD*XR+9FRE$VJU4EP9Q!Y2A(5K9.63"!),*QWO MR@P,)U&=G2\"2 OD&O=K+!%UNZ*V.E,DR^G@\3OQ6K\14F32;40M'V@W*7@E M3@>C=#8Y$:-T.ABD@\% 3.F7KW;/YBZ1.]LH!N0I$$Y?P+*6&C!HOPEJL6]# M+KX2PW04Y8X[72]? >?D%B5562+78B,1RC3(QE4-D,DF2U72D:)"@R$Y9R(M M"V1H:H8X!U=,T81WB-T/&&HU?D"A(#(R$:R,JD*@-Z;(P:8$N#VV!9XAR+2/ M;6" I /$B/KKX1MQ;Q >=#FA)/C\:+?8J"*G:%B5&9N3_<1L= 7PPJ&E+4OM MB0%$_2 *K(_6M#39LS<%W;.B8:_I9=>GL#A'YF3>6"SBW*,($ MRRE!"[D-[C_Q&3])93SQXEY9KY>%"GD?;7%QF7]B@^_0/!2_FZW"]D"D)SIR MN-R@3R&4&4Q]:)7U%26+3I$DQ-]Z\Y: MQ1_X;=&/"AI8V[GDN'C@B&K3!V* M*Z*+:NAAZTF$[2GC=H8[NK8*FTKY$)RC;.YX$"L9H,R1K$P$A+\T]CD@ T*T MM*P9HY# E*##0]"_1G@8ST+8G'B5W/?VZ%TW8QW7R>:CQMLMC2@-=H4E" M^@,,7($9O*LK,3&*MQ8C'!##?JY]CO$$CE6(=M(E5&O>;N=SX+9F;V&(6&DP M2HH+4K!"_(.?E\KI=>RRG?0OZE[F4BQ49I7' $@+%YZ+HM7&4FA<@]3KK+A" ML>ZL#'+,TF/0;(-_C>PHD(Z.F^#)>RZG5#9CS>Z5_7W3^RVPK;OK1F*Y1[MK M:W=02>4@:36)!@..%=N-SC9[$GD3AV\GA])V6>BU#,V"4KG0NI4>8)TOU9UVDQ7F@+)B H&KA&E229R\3GWV_C M:A=+#"^@TLLW6Z1-\?"6]5!)Z]I$D/Y:,TX7 >.D:W'\\K-> :LY[O,R1N F M>'9-^@.47TLTP;V.'86UW5I0E[3Y+KE;YAZ*[XS6KA,'BB910 HTO2Y"%9,6 MQ<*V)/Z?Z4!)S_M^UMK*?OWKQZ9'BU7 M(&F$YMK4KZ!4T/S#K@6&M;"0L*$NBWCYA\"+VD"$AF>[06P!8TQJ4VA,TZE51\#PMJ:9ATR>C>/8A4Z.9'1 MJ:RQ(0M?RZHE[[Q-M):^*9F#XM;8BKW-9*V]+-)>VZ#)A%Y%B0^\!=CS)&P) MRR;VE[BP,(@":)+?4TUD(-5/'T_%% G(UA$'UD9%(,ZY=J(XO5HW"Q/[L).4"=JZ4/ MD.W<>4^E]%[G9,*F/\+TN=^AI]UJ&IK\NGB'%82Y MH,(@*?59? 8S$$C9SNO,6%4NXP!+M^<&Y9 %J)]@#)]3#/S+**=:[[ 2XPGW MSCV1N4$4*(2H.WNGD!32,FI7K\1Q;WI'8_4:!'IT1L$E J%XXC69C%,N"\SB MU!+QX6&5&*SV.]V2.Q L O-T&&D)[IH^X]<2WCWHV]FP+RCT'94F?J%I4Z3355QL&?T[352>K M\_]1:V]!D#OMO2\,- T>BDOD?^QS*#](JY(^H5"%U ;AI@\IF)5JSX1(VF\A M I&G$0@%X=]-R&.'0[VE6I>K-C []]G:+#,-K8,/2M^3KVF<55NCP["Q-B:G MJ2Z @B-_NPN>4\PPI+7#22KJ0L9>1*6^#J6 6R75?*%+ E(% _O"Z4RRARRG M1PPJAU3_IXLE^1!N<$XWUB->B^\W-_-O_Q!?/X=/'=\^78KY8O'I;B'F7R[% M]=7\_.KZZN[JTX(>?[_Y=)G,]\.57%#VO<+9=3+FDW4R?XH0SMC3T3 =S 9T MJN5S,IJ4!BX5!$,0<,H/3X>IL>S<7+;'^(Z@+!@/!NDQ^-I\EL+QW $ M)3C&CTZ3Z^?1PUE\.$Y')^.P()Y?@0[U/=8L)I-T>'J<#DY'R9VA)@ &5S21 MLRN/Z?I*G S3R6R6#L=0^I2WR3QTF[;(.NP8I:>#:3H:3W9@X6T03VF?99:^ M[G08S=*3V3B=#F;)97N(L*C %2@Y2H?'$'=\G%RCN8G;*.9MQ'0R':>#2>OL MCJ%O.[1K,($X<9+.QB?I9'"[0P"RH/3=#:;/".C4@S=8U'C8T0&($^' M@1UYP\GD5%' I/@%)IQB>^).TY,IU\_G4-\K",]!+Y[[P'C4^Y9;*KOF+]88 M50GR\%FW>]I]%)^';\&[Y>&+^HVT:XT!L5 K;!T2!)Y@( &,& M 9 >&PO=V]R:W-H965T#22S)YZ0-8N]ISSNY: M6@_V4CWH+:*!QT*4>NAMC:DN@D!G6RR8/I,5EK2SEJI@ADRU"72ED.4.5(@@ M#L/SH&"\]$8#YUNHT4#NC. E+A3H75$P]6.,0NZ'7N0=';=\LS76$8P&%=O@ M$LU]M5!D!0U+S@LL-93[T0IL0 M"LR,96#T^(X3%,(241K?#IQ>(VF!I^LC^WM7.]6R8AHG4GSBN=D.O9X'.:[9 M3IA;N;_$0ST=RY=)H=T_[.O8-BEF.VUD<0"37?"R?K+'0Q]. +WP"4!\ ,0N M[UK(93EEAHT&2NY!V6ABLPM7JD-3X4N:TA/'ESS!MV _V$J@!E;FD&:9 MVC&AX4NZTD;18?GZC$2[D6@[B?9_Z.ZSS/:N7NB*93CTZ#)J5-_1&UW?W,U: MYV]>]>(H>@;G6JQ+).[TFBHZJZXIC#;%,Q!<+;B@AMNFV6 7H3!8H6J M>1LN>HK9P1LY;PB9I,NK#3'(-9@MPEH*F@*\W%S 0WG?MSO^^TPI'5DC5YKHC#G!B9,Y9!T_6X40^2''0=W1<\>:?!I MA,3O1/;7A8A$>TG<1"R9H#D&_7['C\\[\+9%)TI1A7#''N%PNB!)_*C7I\TF MK<5)AX]45R<=IA1)I]OWPUYLC7:/&$+XUW$,3BY^@6KCQIL&)U3/@,;;3-"T M'AR_PNOQ^X&I#2\U"%P3-#SK=CQ0]4BK#2,K-T96TM!0&ULG5?;;MM($GW75Q0T@X$#4!))W>,+(,EV/ ,G M$2S/+A:+?6B1+:DG%%OI;LKV?/V<:E(7)XIG,0^BR&;7J:I3-_;%DS9?[$I* M1\_K++>7]95SF_>MEDU6#.CZ>@_ MH_']S47+ 9)?M))*?%R*QS\0'])'G;N5I9L\E>EK^19,V=L3[^P9QV\"SN2F M2>TPH#B,HS?PVGO_VAZO_0.\:SEW=*ULDFE;&$G_'9I.[F^O? M ?_Y]K6^V@GX[Z!K-\^)S.A6K%7V0E-A7"Z-#>C^_GY*+1J+_$7D-)6I$LZH MA'[-M](ZU+4+<)\TZ0Q:/-([$O0S-?"+@S ,^5?[5/C2?C0H!9IH[/ZDM]7N M.:SRNW;_M0^&O7\T*E<.MF3B3\&&3.@,9E=2";4[O2#J=Z@3]H,NI!YDID3N M*&TJ&H2#H!V%U*C=368?>$E1>]@/HF&$M8\RY2#Z945Q)PZ&O3[69_:%"2&2 V1A?+5<5; M0$^20)4TB)S*G09%$PT&C5.< IP0/N(SF11&.24M30N3K-"H:+0T4C+1Z"EN M1>Y) X+)U\8B_H;SH":6V+44@-F MD1M1(9=/D7$6A<01L(<182^,SJF 47L ME7^]^P^;$5^ZN%"G&W0'P]K<.XWXE>*]_]]E#3<1*/^)![;[\IH*FVB?(J?4YLSNKMH\AS],L(JR X?'Y%6)1IT!]>@WD1<8 M?U263Y<&AT1,FZ@(K$;#@!*$&#.5MC)/.5X @MHL4\6:! LXT^ MSK!^;6G^PN7N]W3LY%)O($203L3.?+!B-B MRJ&)SJ4P+*X\1ZA&M!^#O+&XYDM^LS!ZC6CW:JI)54W57E'88+Y19\61(D]K MZ>1.")% J"H72C^_B05X:?=(?BU ])H'$#J/RN%AEC$/EGK#H-MCMK_O8#4% M\[BX7]MVE!%O6.B;PFGS\L:.F<:.JF,%YZ>,K^V,/ZZ](S?:[2 <#D\[ 2^J M=O1/'-EULK^C^J39)SFO(9\.;J 4AU%T.@"R2=PPC=SJ;,L\>4L@GJ#VE$.: MH+0_BA<:!E4Q[#/_FP)=J!RN^:3>][HS)B .S[D@I M6%;.)T__G,=#85YE90I%*6)ORS('LH(+\TQA=N#SVE+!O)S2>$YG\3L@8+G4 MR7M\7ZD^1;ZUT++AZ"Y8RT&]0;3I-,/&U'8Z'0;F#R3"C#Q5' A/.QS>U(ZMY_%EO/C#YQ).#[W.OG2 M&.MG&AENHN6&9JEK6:A2O75J4V2^TY:T5*RA!OE#ENMQ8_1661\&[NIHW2*O MB0,F OZU #G!;D[!-:2\X4%1&.N+;UX@.,A,GPGL,F8&[C6V&Y);1M$)4^7S MS5L@[ K(B52;:ISX25&FWEQ2865:PZV1Z"%>0CXC;YF50^($QREPJ&(+]5G* M*/[+-?55+WC9N'(H'2":=.I;OG5T*%I+L_1'/TM^X)7GH_WJ_G0Y*@]5A^WE MT?2C,!AP%H6[@"C7:)U,>=PK'YS>^"/67#L&ULI95M;]HP$,??YU.U> MF^0@49,XLTUI]^EG.Y!1M3!->P/VV??S_^[L2V_+^+-($"6\YEDA^G8B9=EU M'!$EF%-QP4HLU,J*\9Q*->5K1Y0<:6R<\LSQ7;?IY#0M[$'/V.9\T&,;F:4% MSCF(39Y3_C;"C&W[MF?O#??I.I':X QZ)5WC N5C.>=JYM24.,VQ$"DK@..J M;P^][BC4^\V&IQ2WXF ,.I(E8\]Z9O&?;:]S%T]"\B&7"_,*V MVNL'-D0;(5F^!"RPO(' )^*[OG> %=:"! MX07' D55NX1E,=SD)6Y.C7UQ4EC;!OJ^ WP6LI! MB*Y%#Z#PS??:Q M=.(=OC9 T&TTXM^Y47PM(J]DD06 H7DB"C@?C#5>YL72F MWI!R0'UM/X9-8(NJ]T2,Z^6S0QG$#QNDTW"-(*("(JU.H*1!Z'HD<(/*[GL! M\5O!^_#Q5?54H6O$3:UDPA$AKQY0I>1(74S.MJIT9]!RB:O(+QAV &\^A([B;LD0-*D.&?H)6O3#<.P!\5F8N'8 MEH\D-\U^_2@YR=*A[(5E:8"(QK<#IGMR:0S/ MUT?T:QL[Q;)F"J]$^3O/=3%VAR[DN&%MJ1_$[C,>XDD,7B9*9?]AU^G&Y#%K ME1;5P9CDBM?=E[T<\G!F, S>,8@.!I'EW3FR+.=,L\E(BAU(HTUH9F%#M=9$ MCM>F*(]:TBDG.SU9/MPO%P^K/V!Z-X?%KT]?EK>+N]7(UX1M-/SL@#/K<*)W M<%*X%;4N%"SJ'//7]CYQ.A&+CL1FT8> C]A<0"_P( JB\ .\WBG0GL7KO1>H MI(LL]=Z#9/5Y\7\Z6;AW%^_H^)0@C56 M:Y0VRW/,#D+HP;024O._F>V;)4HN4P=0B<*Y;67/=2K0YW/ 7LU:0#@=> M&L0PZ'E)&D/B7(FJ:35*!3[@*=,^*+'1.T;F:>*E201)X,5!2 :W0@L)SUCP MK"3 ,/*"87S\),ZLY67.ZRV=>$$_\((@@)^@ESHWAD<2'';(;TVU;+NNYS4T M4FR)()F12C]-2>6&Q$MJ7DIKQKLP?QSTO22*X1.MO#[%\?UAX(5A M0CR&7CQ(8-Y*(N'H F&/3 *:"_\Z?R9-L$,:6IF0YO1["'M]+QBDY]8UE1LJ MTS70V!P;*#J$UY6QB3\'8WG.#656PN;M4D@LF29-+< XFK%ZSVHH169#528I MM.^P2K14$;$!UE"27C@-.2SWQ#;JV5S&H?VL"BG:;6%)KR0O2]Y6-$ZII,H2 M ?K]TE(PX9MT_X/=N^A#/_7BX0#>ZC7_;)95*+=V8BO(#-5NK)UV3X_"M)N% M_ZIW+\HMDUM.X9:X(=/@8I"X(+LIW0E:-'8RKH6F.6N7!3UL*(T"G6^$T$?! M.#@]E9-_ %!+ P04 " *KFQ33A>,BZ,( -%@ &0 'AL+W=O]5=-4'XZ/=;*2A=!]5:TY_:V+VZRY:KA%\=G)Y58RJEL M;JOK&JOC'9GO9'[X3S@_6;#;YGU&/ M4KD0Z[RY49LOLM,G9'Z)RK7Y3YMVKQ?W*%GK1A4=,1 46=G^BA^='?8((N<9 M J\C\ SN5I!!^4DTXNRD5ANJ>3>X\8-1U5 #7%:R4Z9-C:\9Z)JSJ^N+F]%L M\NU7&GW[1./1]60VNJ3+B]'T8GIRW$ "[SM..F[G+3?O&6XQ?55EL])T4:8R M?4Q_#&0[>-X6WKGW(L.IK/KD.S9YCN>^P,_?J>L;?OYSZE:R%DU6+FE4IC06 M5=:(G"XE_*I?8!_LV >&??"3K/DB-\['#[H2B3SM(>&TK.]D[^S;U>S"Y'>DDD7976:+U$%)$7L W=V*9F5:OUY M^$/0;Z!:U]*:&#Z$(@+YDJ!.D<'DE*M$-(:I>?^4?+I25<4B6EB[[>KI]D35 M);ZK!;E#P( 5N:"]%47UD2Y5\GVC5&K=9.E2THT2J;T5.%;KLKEGN@>%/^>J MSE+1IQDV9&769 @12"]X&Q.U^F::%B@HY$:.[3@.[[9R4::@3FE9BY*!UL!- M8@[0!3^U^H.R90'964Z?Y;Q>HR!V/O(,JVZ'1)2FH&; 2;Y.V1;-1J&&)HG4 MFN6'Y-I1'-O1(&9_7R6-FL,4;GC8X0=]*(_L_0/&N?K^2X8ITT? 06X%GM[LX*0^3T+-!PA4%15K7YDJ*8ROR?7 MLUU_2*[KVX/(I2UTWS5V",CMAQ0-0SOT8[I8+*2IX-:HJF&U=H_SRGC>(;P6 M.E'/!W444!S8H=/YX$_=8KG><&OCT,?';>/]:EI/BP9@?P MDC^@T/:' UB2_UBT_'V=51VZ5#X*MY70H%ED/\#@C4N5N#?[YNM[=&ODLW&X M.["=P6"_YCF?[ ML;^?+I[S=VMI=5K2S],2>>0CCY!64>Q2B- (0IJ47<: CKOH*^,J,);Z*1$5 MV ,8>\+AG=__%1@P-,K8( SXQP6/06@/AYY1J0W.9YC]#2HY@?.\2C/8.\_6 MQ3,Z&1P16,0OJ?(RD\#V/;@ZL@.D__\#Q-0.)PXX:AR8V/0O,PCMJG77)'=, M1 *[Z]_P8EC)?*< M"A!C]-A+KSP3\RS/T.]%LQU#-#OW3N3K75YA-,%99I=55AY4+>8Y4-8(_XWM(%T M5J:/.1GZ\>QF6Y>U*=*@#3FU@T&$ M$2#^<^58GURKG5+>D)+N2-&&KO7VEW@PC#^29U4KA331]T!1M.(6(F%'97O; M!M8=BE<7]H_WL L;C"&ZPM +9W+# ? =J1M:B:KNH6>RPCEBGPDWF2YL#LCT M+;2C!@?POT[J6GL=CC9"KSAMMFQ )[94]^P*_5!@.+YK:69YA.ECHSW7,/M< MYIY6$RXD*"&F>]22OW%P >[3+FQ2B:/;J-2F4ID>2IJ%RG.UT1]H.OYR\>GV M\H*N/N\=L\S1BFXFOWZ9\8=;+$;3Z<7,G+_:CY>3T?GD_7$!&J> M9TO!D:L_6.-U;:;9-VA$OHN6Y(1X=B'+CX?6-U4>;7?X40LA\ @&IC&8\T4 M.\S@"QS'CH,A+]!(,,NZ$7T5./;!GA:T>H!Q^12&<74W]4B^,J #BMF/'/%U M-+N]@6D/.>7![H;P';H@JD]AKB3>LW9V'#OVP'?XNP?%PP!SA1?PTL?<'8<. MVJGY&K!9'!XW(EZ&Z)51X/ QQ1HMFG;6-P9S[2'*A3?P.I,\-?6^A29E>XN& MUUS-59*9##"!S#';E7Y3XF XM:[WNM'3@-XWHS!U^X#M,OTHHKD>/N&C"44% MR;^H%8K;[ISK]:,8-:6/H2OL SI3/DG3@W0N!?UX0'Y_:(XCUL99-ID-\J:M'/\#"*"'_A:?)OR$,,N;8SC#@;S0$6D8-)VX6Y8LS?&&0.720=[UW1%;)>FHM( M/CE E?:V;O=V=]&ULM5AM;]LX$OZN7T'X MBD,#J+8EVTW2)@'<)-UFMTUR<;+%XG ?:(FVN95$+TG9]?[Z>X;4BV,[Q?7# MH6@LD9R99]Z'.ELK_YX5YKRSL';YKM^9I18\=41YUHO[_;>]G,NB2?J MU L/KIY_..L9\&+5GI)1??!T\4OT)VR+ZJP"\.NBU2DS^E[P- MB6L@'^(?,IR(99<-^B&+^W'T WZ#1K&!XS=X2;&_2FDW[-_CJ;$:OO_/#W@. M&YY#QW/XT\;Z(1TEUCNSY(DX[R!SC- KT;FXO7N\#J*(O6&>+;M'/ JM11I, MK$J^L:\B6/"58+RT"Z7EWR)E\2CL]_OTG_6[^!NQL0E2:1 H!MNR8,25C4+& M#5MR;9F:,;L0[%'++)-ECBR 78RDC C;56F8**RT&9A8Q>)PY*4$9L$!N.9R MJ?(E+S;__,=)'!V_-VPBM,3N>!=ZESWB=+/()HY+B-"V"V2R62(E28ZFE 'W M@F42L%+N8:UEDGW-"^^D682?XPI/0QP9/%+C5;B"PEKEHD2J>$ MGV<9LM):$F?*:2[QF ;@RCTK'-Y"LX)@OF(1$C-8PC_.G+OJ$-V>2BY::P!R MRYT 2(?$85MCM\E@R@.D_Z /[AL@G"$T'-6RU,D";:MVX[U&0X?)0)]DRB!7 MR* P9.'='3095<-K*0]9MX:]!A VDP@ISBY)P P!X/6\$D;."Y?<;;[>BA5/ M.4I(HH7%.$ ')Y8H8$NE*7=,B=QK_3Z&V_E49E36GQEFKUPY$\[(Q0"+]. L M4\7\#4R2MSP"H"%JJ)YBR,!)/*'04!FB3.*94]Z/1MSE+7J4%?D4EJT;E?0\ M>*[*PGK_#\/CD2_1W2JQ7J[GD<>]7="'HW" _\/HA'U$8>=9\ >BQPEC=T7P MA<.=+!YX\:B5@BJWT*[ZNWIS#]R$Y(O0%I1_UD6+Y"[V--B)55ILDW-:A"%\<#K M>U5JY&W@SJ&/J-0GR$U#4=]-@A' MPST18 +=S4Z%<(K=H]P^:I7?LI_BW>YU40(620 M&V;&FW++#T6Z:8[O1MSHV(T%+ JCT98=_B^CP7/LB&>JO0@M/I]K,:?T7?&L MK$IA.ZV$ 8W.KE623.,2PA?-JIA:C/K;13%$^Z].(_Y1\+6S3 %- )%G*&S3 M3"981%$B$&A]V_4(Q=LY(/(.B*E^.!,&K6U=G: 67I>)I$1]@UFWCAPP=ZW5 M3U:0X& %Z;X01752^%C:I]N*I];,U'NV7E$OQN4*MK=G( J@2J7HM%$)8Q'Y M,<^]L1"F>WK1+(=%J0,OA&==]H33ODFV.$(D^O[PJTK-DFI(\([-&Y\4X(P[MO$-DA.49P.AEZC $]549J#.P<(4[F2 MB'P$*2H'3(H ,)1X?CYU! %>,5DOF%?54R(7FQI;X*ZT%_&D]H&0CUUKC?LG M047<&+URU1J-D)%[9972%09O.W)"U&>8V3*U$<+L5L(7X[B[U3FCX=%N8W[6 M"&C6JY+V2B25 KYG00V,A\,^36E(S5;!*I3[VTVB[3)5.+*O7./V PNC]>+N MHVKO-ZVW91@?$T-B.T;UM^R^'@+'J-(BIUQ^3?GWFTS_9I=9.<7HQ>Z%1=7] M_/GR:!M'U5OZW<')GH#XE$TN/UU?/7V^9G)X_CVZN; MVU^"K^Z[""*R?GC#QIC9^5P$U2][$/3UB'P^KKM(%N[^7*/DW M>)2%D4E]H[EW'>21YKK?J>T$=Z4UEOL 0F/YE1=^EO#VQ5V;_KUB;X)?R)2M M>J^\@A&&,+=]_7WI!G!'T("IWW>D[/EYA^MI]WCH+@9OXT9NS?A_%D-9YOP/U.8O:H7 M$M!\DKSX+U!+ P04 " *KFQ3[&TM;B(# #1!@ &0 'AL+W=O0YA[3(#&NE[TV.:.&Q$-*, M@MS:\C0,39ICP&;S47 20(8;5@F[4/5G;/,Y='BI$L;_ M0MWX]LDYK8Q511M,"@HNFY4]MG5X%G 2O1*0M &)U]T0>947S++Q4*L:M/,F M-&?X5'TTB>/2?92EU73+*_[5D43"+& MPR"*>E$407S8K"\N<2]I+LBTISN=US);8YU0J* MIBG0-070D[98K(EZ]ZZIOIDS(B\W507-6^.?:>$=C>-W:%/%=.;*XJ7 OS"E MJ:[HJF1/FKY!D]A1(_NHEQP?[S8G\%(7A,_&3.'JYX:I(3UI MQM0?]V;8TX?:ZWRAE M=QM'T/V+C7\#4$L#!!0 ( JN;%- ^J#C @8 .X+ 9 >&PO=V]R M:W-H965T(I! K"QJ+O:)$"2IIT" MS05)YIR'@_- 2[3-B21Z2#INY^MGD;*=%+U@@'F(P\O>:Z]]%8\WVCS:I92. M/O?=8$\F2^=6;Z93VRQE+^R17LD!-W-M>N&P-8NI71DIVJ#4=],DCHMI+]0P M.3T.9[?F]%BO7:<&>6O(KOM>F"_GLM.;DPF?[ [NU&+I_,'T]'@E%O)>NM]7 MMP:[Z1ZE5;T9EP\"_U%R8U^LR7LRT_K1;SZV)Y/8$Y*= M;)Q'$/CW)"]DUWD@T/ASBSG9F_2*+]<[]/?!=_@R$U9>Z.Z_JG7+DTDUH5;. MQ;IS=WKSF]SZDWN\1G"]71Y3&C)(XX3_!2_=>I@$O_2'> H7DZ$ZNM'%J6-#_SF;6&=3$_W\" MG^WALP"?_;L@_A3$=]\;NQ*-/)F@O:PT3W)R>GWS04 MMJVR3:>M) P5(X)I.Y*QH;=:0J-Z(KT8!EA2 VV6JEGZ/49$8 T,L5@8N1 N M&)"TWM[>6'#FK\]]"Y;C-KE1EI'[SMM5"O& MM!PH6/(LK029-MI2(#7&[,&HKE/KGN[7,ZM@VOC\;&G[ ("YE8-"82SUVOH3 MI+%?#\IY034TW;H-^7L$$,@.:Q.DYJ)171 "#^O1<-FIIZ_OHA!W>+GRKH+6 M-Q(A39$3LT[2S'\[_"? SW*[]6ITYT7,=T7\3TKWB.XO?KM\]_NG2[IYO^^J MN\O;F[N'C]_2&D77Z49XIQ5LHK!P MI3ND!4?1@W8H2B.?Y+"6C 9\=%]1PN(Z8W6<^W7!ZKIB=19C\]H?U+A-697E MZ''D&&FY%QTR<%#QF'&>T2$=\(P5!33S KO7V.L#3EK*Y2:/"4%;Q@99E'0!]KP;NS$E^,[CJ4)/*$MBV\36CD M+$?[9WE&>1:SF-=4L*+DK,B+Z(-$Y\)+KR]:A$?Y0>N_O50E%0Y2WA%GES,LI1C%<><546".)=QR7+.HRMA'F6H\I'DD\08#-7+BXQ5<4R\ MA(4J\]92!+;*HG<24[E18GQ+>+7>#\^_QH,=WR3V42R)0S\@IY8MY> I:'?HLT%R .JH?C;57GK*KJ<0L:B'E>X79;1V?62N>! MD!5O.$9F7E&9,HY8)DD2:JM,$:^RQKHJ$+10 %O]3TK,MMV&:Y1@G@&CP+H M1E:!63ZBETF&BN(>O6(5BA05%%T(NZ2U']J80L^#-KRS=J '-2]9^>Q"4=?! M1-BB N$@S[*MO[Z2DE!-AU^#J^%)VN^ YZC?&PO=V]R:W-H965T[!3::-#R?.V@ZE]^MOQDZ[Y2@\ MW0N-[?'G;V:^&9O3I38/MD!T\%2JRIYU"N?JDU[/9@66PG9UC16MS+4IA:.A M6?1L;5#D?E.I>FF2'/9*(:O.^:F?FYCS4]TX)2N<&+!-60JSND"EEV>=?F<] M<2L7A>.)WOEI+18X1?>UGA@:]38HN2RQLE)78'!^UAGU3RX&;.\-[B4N[=8W ML":N..L,.Y#C7#3*W>KE[]CZ<\!XF5;6_X5EL!WL=R!KK--ENYD8E+(* MO^*ICUB)=!*3T%:1CN-&5 M*RQ<53GFS_?WB-6&6KJF=I&^"3C%N@O[20QIDO;?P-O?N+KO\?9?PRN$P3U. M80X3L2)E.1@9(ZH%^N\_1S/K#,GDKS<.&VP.&_C#!O]#7-]$XJH\L;7(\*Q# M96?1/&+G_,OX[BKJ#^#77X9IO_\17CL.QE4T:A:D(T@/0R1C$"2@O[61;@5Z M#JY ()EE#X56.1H+HJZ-?L0\AMD*EF3FL(),5Y:#M)2NH-IF#)*S&7BF>9EH MYM)0(6OB1[7KP.(V/^RFSC^9:45NC,( 3,X5M M;Y/_(-%L#$R9 (QK;D V="".>K/CV#4_J"C_4(92"MY0(3@L9[1E70TG,/UZ MT&32(DR, MS/#E^BUR+V>7[M%RAF&"1NHR':-PXZRCBO#1R\ FSEES?DTM@+_J- MJHHQ?\;O'?2[%-#][G$:43N=H^3U/;)=\PFC;?"7?F\!CERT8YT#N%Q[)%J/ MZL"?9&5@6D%6,_1"6U24 MXQRDC;Q'*XZ,5R$3:*HM$]Y,I4.F0=M/DJX25*OH'0R[?6KI2C&);C@SM*?H M&;\9DC0(H*)9))T]459IH!K6AJS "D62PW#^DASF94^$BC;GPW-?OEK)7+ ; M%& 76A[5%5WO1@0_N?XH3T?]>#@Q[:M>A=81"] R_DOR/-7;@7JO&LHY&E MFFO1+H7*&B58M!&CSH4T0(7>^).QK)5>8=L6R/&PR>"/1G*EL-HY-R&05E(" MYS(C(9G>V#4DZSU%^(P;Q1:D4=4S6<;M(FE[/E.@A8Y()O681P M1]FRC5G!#5)C]WH26:9-+JB91]SM832]I,LCV>LG>X.#[9[YG[TQ5U!;0,]# MO CM(*;J0Q."IRMBR *W\Q5S8:E*'T8J%#8HV;(6UI*@(XX8/05CIJ\4%Z'@ MM/OR6GD-#8A&%[QP2078Y!S(,F@:>^CC;J]>K>4 M&SWWZ063T!P:&S[KQF0%U3*W&E)S&Y"6X[HQT57Q0._NVC?BO#'KI+240Y9R M(2E4F=(\BKRMA5TOE-[6*Y"BM_!O74L$FLJ%!^%F=O.<'H57Y$_S\!:_$8:B M:$'AG+8FW:.##ICPO@T#IVO_IIQI1R]4_UG0OP1HV(#6YUJ[]8 /V/R3&PO=V]R:W-H965T;]OOUWMKB8'I9],@6CAN1323/W"VNHJ M"$Q28,E,7U4HZ4NF=,DL;74>F$HC2QM0*8(X##\$)>/2GTV:LT<]FZC:"B[Q M48.IRY+IXPT*=9CZD7\^6/.\L.X@F$TJEN,&[9?J4=,NZ%A27J(T7$G0F$W] M>71U,W3VC<$?' _F8@TNDIU23VZS3*=^Z 2AP,0Z!D9_>UR@$(Z(9'P]\7)_9[YO8*98=,[A0XD^>VF+JCWU(,6.UL&MU^(2G>$:.+U'"-+]P:&T' M(Q^2VEA5GL"DH.2R_6?/ISQ< ,;A&X#X!(@;W:VC1N4MLVPVT>H VED3FULT MH39H$L>ENY2-U?25$\[.%@^KQ=UJNYYOEP^K#;G[?3 )+ M3IQID)P(;UK"^ W"W^"SDK8P<"=33%_B Q+7*8S/"F_B=PDW6/5A$/8@#N/H M';Y!%_&@X1N\P;?FYLD DRE\D0EJ2X5K.1KX:[XS5E.5_/V.DV'G9-@X&?Y_ M:7V7T/7FE:E8@E.?FL^@WJ,_6SUL[[QH!#_],(ZCZ!K^PRLLF"E@6Z"W4&7% MY!$J08P&N#60N&\';@LHJ) AT9AR"U]K)K@]0L8EDPEG K@TEMO:M93I.S(X MDQ4LI0819. S+0RH#"Q9W6.*FO"W6"E#S$MI:NUL28RNE&9-D_[L0HG# MZ_O;Y:)91M>_0*+V!,W14?T(\2CLA6'H,0M4&A;+'>JN/GJ-+Y;G&G-F:56J M6EI2X[U4TU$*7I*8 Z.*J"JMGCDU.HJC\],?>R47@F1Y"07+*6Z9MP0:B3I) M'/>_DN#FH"NIBZ1RV=D"B7X]E3TX%#PI"'_L.2M+DX\.G6I,O:Q-GCC^REW: M,&UU?W(!C"WWO?6$(UA-'2?HPA>Z^/@ M8E26J//F0:"+-<]"]Q+-_ %!+ P04 " *KFQ3)O,' M+981 #G+@ &0 'AL+W=O:!*E,5.+;HDRXK^_7SG'+(6 M24[GX@)!+*F*AV?]SD*^V#3NJU\9$]2WJJS]ST>K$-8_G9SX8F4J[2?-VM1X MLFQI1\^V]M5H!].7KY8ZUMS8\(?ZVN';R<=E86M3.UM4RMGEC\? M74U_>G5.[_,+?UJS\8//BB29-\U7^O)^\?/1*3%D2E,$HJ#QY\Z\-F5)A,#& MOR+-HVY+6CC\G*B_8]DARUQ[\[HI_[*+L/KYZ-F16IBE;LOPN=G\:J(\%T2O M:$K/_ZN-O#M[?J2*UH>FBHO!065K^:N_13T,%CP[O6?!+"Z8,=^R$7/Y1@?] M\H5K-LK1VZ!&'UA47@WF;$U&N0D.3RW6A9?L_?[S]_8MZ^R?^OWEQ M$D"6'IX4D<0K(3&[A\1S];&IP\JKM_7"+,;K3\!.Q],L\?1J]EV"-V8]46>G MN9J=SJ;?H7?6R7C&],[NH]?.O?E7:^J@WM[A?Z_^]VKN@X-'_-]WR)]WY,^9 M_/E_HL+OD_C]TY>WV?2)^N__>C:;3B_5'DGUE\E6^LXHS0!AU4AF1 M:NF:2D%YP51SXSH-JK!R37N[PE^C%EBKFB5]]D8M;:WKPNI2^8 '%9/9&&>4 M];[%)KI>P,>#<7 ]?,6J;-F4B&1;WZ9M';BP6+*POB@;WSKSD[IJ0UO5V54! M_]0+HS[5V3YC^0;RU" .RK8.#7935[?.,!\*@,,<7[>N6"'NF)<;73+[KUH/ MAKQ75]X;\$#//AO(\98%4<>TDK0Y.[WL"'2T^<'T\E&>;6Q816958C97[^MB MDJOCN)ZW@%[+TKANI7ICYHW3*W4S4=>FKG.EO?KB$+#&J!:!(,RO77-G"< \ M<:WEC8&09(Y%]JD(#2GF&>EE.LM9G*]ULZF)*M%Y@Y>!81]E,_6;FP@IWE8T MATWMG44$JJ8VCU>Z7))2H5P?+G^,V^R'N%4_PNUHMW^'55BNN34@XO(LZO_S MVZC\/&J?-X2M&-GO3+E58L:!G7(U<("QZ2;R8B:_*K M[H,\YR ?OJC2%D@[ MY/[>6T\RE^ 7'K_4A2UMV*JR*5@7ME:_0#NU^E.#VO92O2\1VXWUO4)VO&OD MFLF-.]ZRH1!*E[X1!N^TLTWKB2%R=VQ;-/7?;2VIC<4GLB(#_20AWL5)CB5% MV2Y("'":Z(25#DHC=I,\&F9JZ@RA1S2Q#4>@,Y7UQ@]HA%5#$;E#12^7]AO! M1#->=SPT5JZ&<=6+KCH[ WS8'2$Y?:G5$E[J;;4N$W0!GJJIM/X]X+_?($."%%I#[\BLP7]%9A2ZH*1 MI5H'^'Z/Q[2-A_G]4HM?D!DUE.Z2.'":A0TMX'XJAN!=%42LL*J M-: :0;_U&06DT4OH!L'+CQOZ:6/)"T@U;/3Y5D!/NV"-AVK?BP,)568@;@F= M8KO M51(JS^J*%N=3;E_##C((:Z+&W%5+=9I;=*TA&9_K")B-+&V1 ,R100 MS,DCFYZ20FB5#86#1RK%KO*KC7S1QE#)'%+CV8XW9 -O2!9_8]80+2!N8*T#=286GHF]?X&SU$WV*YPZK IRKG>KT&'.MY:2A :Z 9K'3\_/01.29J$]8ZQ^L?M26:-X%1 M_ W"0CM"S'Z[B&54Y;*(<99 MR47'%D+.)J>G#W/X,F#Z?/+\XN$@E0VST?N4Z8B!'H5H]]$CVI>ANFI:*K/0 M40'O:H9?3MD9!Y28J4M,\%^]^+OEI+70%LY'/&V>2?2&($&2DM)4R%K#;([;LXI"_')!@D*E^4L=3 M[*8J:B\@"641*,;!)OC)AH;1EY(#K#0IK+JFQ QGKA(JQ/?)Q\23V##H MT6R%EZ**\>Z.H-CVC+>U-;_8>MG."M6AN9VY:THN0,H&H#S7)8,#;-TC]8,9 M**'X ?,<$IG8Y\*:*@EYM*VB1@8[$E$MSXG_@;>GG1-07[:I:AWUE&5V$&/ MID_2+.RA"*!9K.K0EVO);)0="%DL)8T^87YQQ LX_ 7=RSHJVR*5S4M[JR6) M]:7K7ASL.ULBR$W6TTO ODX%!14SB0-Q!SBABPQ"D1<CS"]^M9?3EJWC M_/U##J87S,)5JN#/U0>6G;L[QBYU"W8U,IE+Y<&N$X&QK'?4SB&)7QMZW5&B M!9Z@D5Y#"5::&X1@[\SWN>T!3)CM>0T%8 *V70Y](]4W?D._@G!F2:4Z/XZ,F)@N,GI='>9$'+9J%G:Y3=3%5,C8]I[@@QSZ;/*=$B]0?W2PFZ"%BCG!R!/MP MO]C!P&,D(M$===[.\;TPG0%BA1+C+,;-HM.,O\PHKJ"+MDA[W!_=+-LTRB$9 M"WI[LK-^-__P*LD]G(0$'IX._>2>C'/(8PY !8#_8@CB!&_6TH=N8F;&B^ M085WC!;BL!O7-*-"$D]ZON>&^.#-[*+KD_HW.QK\''))A5UG/T10*N;2,)1" M1='\U(G>QZNXL'2O2Y@=8GT@9T@*;I;+B;JB)C?&$[HV"AGARP%'1O-3;L&M M]XW;4L]H\GXGZ=;1!4K:7"0UX>%:YB#[+N,,G:%(=2\:"YD6/*(!ZQV*%>GK MB-#*WJYHHU)OEFWLJL@Y-GAG^WC)&PCNJF.%Z$X^%LT^4FOC!N9TP#B$"512 M-50/4&G)Y&@,H,A+*MM#\5BH8NN)YR!,PW"4(*J;C48( MU<"R&C'4$J!T;- ;V<<6M4X@%_O2E&;1I,H9*N28$6#4M8WZ$="J:!^-($B!7OYNYT_ZK9F;>E4A! M"[V[\Z G?=>12@TI);Z-H9%3FK:MDQ:X>BE3EL_ZM3MSMJ25<8_[#S:ROBLJ MU^EA=)-^HSS.V-(.G'THXO FZZRKS1P=RN%U&TK9I/-T*]UU7G'[@J=537'7HAPP0I MZYGGK#,^<*HPG4\,G*T?M78L6AJM73RGE,MI=Y*1Z *F-'1+#[(X-AHY;!S@ M=0$ L_W6UC)>SLPW4[0I/0/A3 @R525_2F,U5@Y)0J/$Y%E=UP"CU5X&LZ) MXHVGA523$A3I;EP7ND&IOH5[^2#',V.=V-W4.QA#3H#X/^!?I+$O:9HZJ##2 M[J1VRAM49M*Q0._XX\&H'HY>HX\<&HJF3-]IJK1(;>(5"UVA1_#BLHD!R]FE M*>";E$.Y2\SB>/A23M?@,CDP<6/N:%=2*LV(S3?811Q$6LNXJ*/,B9PFB@WG MJRC6[@!:SA;V9LG,?]:IBST3B(L29$O#>UX\4;\X79CL-8W$7G.J\J-$-BAE MN>&WGU&POV"KS7V$2JI40 MK8.3K9UD\L5\TV-8OXGK]C/&\(AI+VGD:M[:DIX!(7QP;8':"FB1V8J,*$U$ M3ATC_RZM0,16\;IXUD2:V>T, M].TM%8]A MD)0D!KG.?YH_O>C'88T@_'(C9'"=.R M,\^- #Y')G%:(IS\&FU;26?Z 8*2;9 X#JXE178'II(4J)D39#B@C0G%:-Y= M2OCGQ)3S:(.+H# ^:6-V*EW3;$%&]-O'H7E,!P-\VT<$C@/9 ZI(J8HD$3(R M5$MHYN.Q(D&R]VUE[AUB#\!=Y,LZ^?BX]KLR;O/84Q,$#U)'!]?7[&O#_I5A MX0KIFHK52LX]KO^,!69TZP])@G@=(DNN_3QF1!A8[D^E'WT\FS MIQYO$2071E3F;<,J*\#5;*WIT& MJYSZ1'D(2/ M5BB7<_>6B.2CAHWW8L"#SF5U/V!D=H\'B7O0<&6C-I#6Q39U)#@!NQR*2I/, MQ\JCU)?Z8LF^MKL1M$B=H7BB)-,%VEQ201W]+^N\YN(AZ9@+WJ@4R,-GR'M# M'"Y)NF;6#2<:0YE@%3!>/W9F"8V0+GYH8>30$3M*R!GS3$1C3X-M!UM0IEB1=[=V_B8>ZL?1G,J3&&,[COJQ! M V!#&^0HD!TQ2S<91"%M5%-LW3S1&20T/H.5=X95^\&4ET<8XWGAW*03]G[. MZDVLA=!R%P6'"B<#/KCGBL24H7A%C267?Z4]NW7"WP=='C?CC8NXUR,/*3+"S3CZKJ7 6%> M .YB[4*@1^:'W:\'=4(Z-HE7Y/:GSCDWG7QN3BV)YAD#50&Q!I IQ#\7/7+= M4S,:=O=VX#O;X:BSCX1A?!!G98F,OS!SV$DN@*%+F ][Y^&!%!88GEA]M;6D M)1%])Y%,#MV6/1EW[GTMT@03KQTS[,Q"*![M.GS_W&[^Z;]E.W\KYWG]=5W7W_ M:-7WFV\?/^[F*[_.N]-FXVOZ9M&TZ[RG/]OEXV[3^KS@E];5XXNSL^>/UWE9 M/_KA._[LNOWANV;HJ[+VUZWKAO4Z;Q]^]%5S__VC\T?VP8=RN>KQP>,?OMOD M2W_C^]\VURW]]3BL4I1K7W=E4[O6+[Y_='G^[8\73_ "/_&OTM]WR;\=CG+; M-)_PQ]OB^T=G@,A7?MYCB9S^<^>O?%5A)8+CW[KHH[ G7DS_;:N_X]ET:^^?_3RD2O\(A^J_D-S_[/7 SW#>O.FZOC_W;T\^_S9(SM7B:5L,_^*C\ M-@%7UKB5F[ZE;TMZK__AYK=W[RX__&_W_HV[>?O3KV_?O+VZ_/6CN[RZ>O_; MKQ_?_OJ3NW[_R]NKMZ]OW-%U4Y7STG?'WSWN:6LL\'BNV_PHVUSLV>8;]ZZI M^U7G7M>%+\;O/R:0 ]P7!O>/%P<7O/&;4_?D;.8NSB[.#ZSW).#A":_W9,]Z ME_-Y,]1]62^='=/]G\O;KF^);O[O@0V>A@V>\@9/]VSP8]Z5G6L6[KKUG:_[ M'$0YA(L?'B[+.ZWF95ZZC-3PQ7\\@]ROOKF0==_0__\?+BXNS M?[P)S]Z$9_FK\W\;]R/UU>7CL2 M+*ZL>]^6Z^G]\[J0QP%%6=.-#,S0G>L;!\YTYV+_E\Z[)C86-'O'E]92IAA MV0=7-*YN>F"PSW&ZJB+P1$ZRO*'5%TW3TS.T5^O_/92$!W?[P'@06LLV;4D' MWE3TQ-+7OJ5%^'N_ "&%3J#MU;^L,"S2;L@9( M].HZKTG8XFL^A1L1R!ZRF+KJT;%YH>(/DE;R7>WGONM(R+LC+%1V?-:FIK,1 M"#505!%&Z"):;$LPM'2&[A@WNA$2YC7CH39-5_9ZA)0:<\;'#="UOO5MD @S M1C^>I.5(0/-CI,I:OILNP[?SO%NY!:FECA&)A^F!LBDZ \(7I^"BZ37"2S6Q MJ%N+>/,0;]/PM)[)Q7!35@_$$P5=(]22G4N7)Z38GK;+8JAPR]VT]BJ\@*0G$# MYAQHW^2VR5B )1$/\;6K]V[]=5SK3]SK=+WV98N?)8(1SVXHF>]JCS MWOWZ_N-K]^18@";R$2%&CP^M4(?GRP N )Y0AUNTS=K]VMP);=+%O")BQ+]/ MW0$-]RQHN&<'-=Q5OBE[.NH'$75\V)G[I:2_2.L\\#7]U "5H8*1?2T8PD+97Y&%X&U3=&[HL#8N=4*B1]'O$M&?;S9DEY&[9*$T!O%EVORJ) $"5GL@B5\X"NU;E?W(3BWG7>>7"B@\;OJG*_+:L M1.:^O&-PC1?6^(:A MV&S:YG-).M#3N?_FSL]/G[KGI\^(=D^?TS^^(>K/MJB?(%B0E=6T'7-A083? MDJD+5NO=?9[J$T)/Z^]@[(/2@P1G*1ED 5CICC%/_\RK!S6\R.OX1&Y.3W*B M@/&0A8W<_]7E' M^][[ZBXH"F9%VC,#60D>",K_'O*68"+,B1P[=;_3)E77? DI??Z)A(!O6263 MH4(O8]U<+*692F#1*\4PQS\@Z$@ZT_>T1N8_;T#MG3L2,4X/>1;G)=MKL&>( MG.*G--P]JG:WR6P&+)28,)'T9 M3/9I6\_.";G6EB+3%PNV!P[JSN=!=S[_<][A55 V>]S#@^M\P3T<+?X5>D[M MN&#^#!/^H=G=]ZN&L'32W$-D=<,M:=B2K%Y/=_8C/4?$=.WIDYX<&7=%3)!= MP>!N.\<7=OX/]_[ZAM3V+U=[GG?;S]\03UY#2G:W0[O\,Z_.W(F[SLGH["I0ICC3:IJZV[P2[F4@B9,[50F)BTXRGA1+'KR=:8K(IBT?Z*9# M9/&QA>@:UNXF(0&1L6R4GP?[&T][YBGX0U'X^A3NC#T!6_0@Z[T(K/?B(.O] M)@;0:W)2UVQ; 55T8<-ZL]T=V22\^G#W[XMF%=,>'^6,HEH(8%M],JX?. VUH-I1:-+*0&4=9 MP3H_>3LZ5X@0]0/'-42!S-FM+DK:L U&!=':LH$GEN-R]H![D*Q?!K)^^05O M3,QVQ_]X301PEU=8?8J>#RZUS\WJ5MG4^DS(I@WFZEIU'"?J5H2R$QBR1*IW MWL)%3*@PVMMR64+W$TX0HWL0.DAL*[J@"BJ4,9O_/NXL-&!;PYDG"^8 M*K\)J/SF("HO3:9]"([/%!(/+C*-1%LYBRN[\%GB9I&\7W/(R&D\39A/Z;8@ M>U<)K&R+$Y(@A+I-_@"T']5-?;*$.U2SA521W9W^:<_A)FF7.W ??43_ZTL. M#^&+DGT^V.(%N1V]\3-"XZ!XNMKF/JH9/9WP4]$,MSV9>$$QC"XI1(!$#*@) M7R'00@Y>3^Q=PYE(4-$!F#D"N B$(;;$#NF4S3:.\6U%<*>%S59YK<).3QBQ-;DF XWV2#=A M\(TT6:IG)$DK"0N0TDL65T!85J1')%>_5N6R%R3FG@X4>-(L3@BO\)$4)I+H MA(2^>K"%%1S@X^X81VZ&EE82ZB.&!UF#:XE=2H;'KF##E]6/H&,V)JP7E>F9 MNZ8:QG?(*T<2*4EE2V G5^\J(S5?PX$[NMN+.TU>@-5'^TNTN6S)3Z\6N,UH M0B;._;S!5W0_!0(%?$T5311D$SP]3[9"+;:EFNFDHNQA$N2&WS,*/&P>+:[^,Q)U Y[ MQ#61/^:8+LY*KGS?M"+'$)/:X[@B-J8VDO$)2[5( BKJ(KS9/0E(3[2[Z*8E M74YZEEPD HS^++L5C"K2LLCY%T,%'XT#^5A[56Y40X\T13.G)^ELL,"0WYG3 M??R^*BL+18,@LWCPUI?K6\0:XXU.7 CQ,*>4D.[I2E$)LQ%]BCQ5)L('W8#0 MJ&YY;YD,\F?*M00/9AEG(8BPR>V2!T"+[/[DT6L2S\.N9N<*)H(%')28T#N3 MLCU+&'9C^>41)H4<1P32/VR8\0D[#7%S5_['!]DH=FE"K'%Y$FI0[4O/W.SS M^0H&4#4^ _;(;+&1-#XVKW)7-5 M18A+$G/>BU>9:(&\)3>U97LS2$S.0]-NO><(*]W8AMV3N3]HKY^?Q4J,L\-F MI@D5OK=79CB9/3A#^"9*)(+F/<>L7R$^,.PQ[ ]ON<8JC"/ORD+_L'SF6'[E[-."$+KA]@_V)QN)NQ 6^YC^KXGN^U+^!E%G MXA-&VRL:*2#Y+5]Q1PH%9.ZQH4?8W3&\8:DR2C.")D%GQ.',W0Y]&B-@CQFI M!3".1-=CHDQN=,DB*0^T,2<57<)>(O'.T5:^%TW.DJZMFW4YUQQ,QK:8)^]M MD)RWU!&01Y?/'TSB?.%49-;7]@=;523]E4NA_QP7'>1T5^U(CZS(/MW0?0X< M6]@1$[034^,]@M(A]=)QC%[W$H-^J.UM$I:G[K?TSR3XUHZ!RIAW*GPI)-AF^:NSC6+M1G(LIJ[E2Q$_-1*_@S..B=Y:[H=1+#@ M%HB+U-*+=V4[<.&.I?T#V+\W+Q]NR3/29._87NN(!GZV];G;$4;1F99 M#KGJG:C92<6)"E=8*C[(]-I%=F12$T_Z^!N> ,=BB9/0EB?60*0*,X5Q9 ME+4&B&' );$^JZ@@<*QBPCV1ZA.Z',@2#J2;>/1%FG =-A*U1-BSZT8U=JJ6J0"NNTVP"Z85:KS*"5:T+?NN\H?D(5N?I:01J2AZK_%N]O#9J;MA/YQQC32V7XSR%%>1[MUE M21?V09[AFD!54U8K^,!BY@BO*?,'X6,BP-P])&Q\+29(+-UY,4OX^#I_(#=K M_LE=MW2GHG?HG\LV%Z->.9P33Z_K%80]FU+;,%Q?7_]\]?I/ "'9HHNG!H3E MJZ[2F/HEZC;H0;U@6M7*C4;'O@Q[99-[!?:P,[,HXVRV.G*&N9F+!X@@75Y& M<\S][?S%2XEZP BLW4(%O:C> O16DL5"1$N?K)J.$\9=0B^3Q&;)<+X+(9Y$ MVM\T$N S7XRN7*I:U>.?>=1 M"-AR\-=7[ V)4+TL[MCVN=98B!'*/<0;QU&BVT.8$.:90@51][*44+(AXIXE MI.;ED2(B^Y(KE0P "\ 0D,,&#YV?G1T*NK 79LZMU2U"QBWKM'BS0]2@)+E" MK+=NZE)BNCE>@2W4?7O02KF(5LK%02LE6 O*V;B_:1_IX#K3-HDMGJ6+A[QD M9G'><5$'EW.SBZ>7LQ>?/,\ Y.Q M*J,51UKN&@ZP!2*3ZHY0NS+*L<9D+.JZ]&+@]OS-O9B=O3R?/7OV(D.&66JA M0BFJ6):GV:LH=24KPSX.H>N$TS-66G.H &:TZ?GLRG$+HL9K]'80'Z2SC6/3F5@TU$AD%12WW&=MY8FJO1A_Q.A"['EHAID MVV!%UE<6O%WCX'+#,H:=*:P2!>N)&7.A@ PYNJ:+J8@9D%V@?$?,3D+W3$,\ MD#^]"'&30ZD]"K*X]\C<*O(WP<2!*H#QHU=CD5PE+4T^%-(H@&4C7%X M*3]DSB)?,P1T;46^N6TRE$/O $;K$0#,(@I"S,(22HE5E\IL<-&7W8Y>#HI8 M MUNP;JA[GF/3[0#:XI@!\I:(?H!^V^)ZE.NU4)N(MYZ,(JY:NZ:;N+$%-NO M35\*-W\(B?6T@M>6:J)'=_YLPD39^5(6#JX:5[V% V7;!QH!G&YV\=*$F!3C MDL,EXB5QT_5E.ST3OM%O(#;" :(AQ8CR,Z6^;7;\R\X/A\-5#N>=I+-:$0=3 M:]T.Q1(D>H/7 MQ9MR&6AY"!)\9)*#HMG?$O7MD8USO$LT4(6>#/# OX>8U MTP?_#RF%(#75'Y9/&[(PE^;N1L'*>2$[@98S(*Z/W/![TUA:$QC8*;_+RXJ1 MDJ1W9Y,W:[%"KO].$< 6^Z)LZ:-1LJ&&C5*&5@+8VW![3^ FGK #C R969ML M9Z;-*KPX@U)__8J[ZI])"#4A*)&KMXS?;B-@DK6TAU+P=R!@I6BQ8'(A*"S*#<0"R.$5;68*A( M(3HD<0RJHKGBF(SH!S$!1M)Y2T3\)(T;?)SH9THA,#M-))SFN9:.L=1-:AMS M*S-AH2OW,;$!5TR'38!VE$"*O3JQIZ5>E3)GNRI29?47 MM-\.U4TI0"-XL8#ZJ5/$O(8RP-ZS]$TVK@TNN%E04G-F_?C/B!R!D9E(=3&I MK8W+=2.N4 $)[0<;*PV7:NI7#0;)!&:HOVV1+!IECM1LB'P?"W11N!MM,1;& MAU!!MFJH;=<.TG0QJ_;-M@SNQ9=7=@AFE]RA!K/>\N:,KUBD2+2H%]I'=F5T M"L^"]B$&Z%NBB]:/;@G69[A!6-.B_D84^%$"KB@)*,D,A_50PT#6@DHI\0S5 M.&N?UU;+LI4XD^(RO?M@B@0G-UQ^>O>,J,.4R&?5S/*^GM$T0U2:4C<#.QM9 M_F7/#1'HGX#;-5\U3:?6PAHRABE&BA,B(:<-+8;0T3$.G^'4:=*!Y'FVBS6^ MV.B03#H2=ND[<8>D<0<]XG8WD8#:43N=5:1WL%S]75/=^93"H\F"CBI_+SIG M+9&!,>0,$W,X=HGOU?N]H3V'R,9U;;$.Y8L&4EH +#IE[][[G:Y;+XF2?I99 M)=2H.$5%H>4XM@7"Y/.357KA"&07Q;+)X/ZFK51;&,)M["Y;[(UX)+Y-]*Y- M[1[!- I DREYO'O$0X&\.)GA_,G!0-YD<%2=D.F WL'UI@-ZMDDVM% M)5WCY/SLY.FSDXO0W+']BL6-K.D/]KD4CO+&:B%V"0EP88B60Y(66",[+'S9R?/%0;_VR1,'4Z]#V\7[>-Y#)YVG&Q)#%85 5(J ZL;AC M0%MX4^Q'0$%#+S4DE9N5OF=;I#7%?Y!2S+-QZ MY+-["\&%8'M ,I"@G<#13)2& MV7!8^%(D!UH*YH08E1 $)AR=GKN!"6U::2-!(*PLF9G@K\M81($GA7ZN*;8$N M:?T\.WKZ]^.(D$),>&_'BL2N$U>$7B50J=S-?AB?_R ,]?T/^^>PBQS4_ MJ@W+26&ZLD<0Q5U"<&L%"7_,XDM97#O:*&B5;V(QZ^$=4,%.#P0V:(]@)=DYW^:?9S^@M6U02.+U0/[&P@PJ[7NLC M<[U(S@Z#1.V@LQ!JJ86 6MKD;B1\U,\,OI"'7^LFP\-WB7+'?+1*JBS M41;""M+C2:149:E"T1R &;";<2ECVQN6Q]C;+:TQ+%OG:>+ )"-_/%FP/9O8 MR,GW?C0&RG)JX!B(LEGL'^N<_;(L&MK]NFJD01U'MD6+HX M6]IY0]S. "HHA6_"?FIJ@6I4JL M6Y4+$T1,3%@%ZA JW,)/A#QYJP0= >>FMD8M$G;3* MJ&D?1AZGWI"4 S,3H<7"Q!&7^P]KZ$9DK/+MO0,IL?!$F@V:3BH#3C.M-U4CG!),GW9?5!7OFWN!MX9;32I93 M]YYUW%0G!K22NELI^C8MKH#C"1SZFC^HJ=.+,@53C[N:M*LH@W%!+\<6!I27 MRLB'= Z$&TU^D- 3$UYPX;=+I5NXL\']-%.!<\NC!A Z4<:+C]]S!>(( 54Q^=Y3Y$LX2;->=Q MA.BL#5W7^S>4!.I$FVO:#C9+C#%6&"(@ERV+(",\B%2RL>[89.=.L] %$[,. M;[CWN2-SO/)I8*%KUM81WT6!(Z'6V'X088IYO:VR3)V!C22$2/GGIUK/)^:EN[NO# M\:4XF//\\&3.-WG9NG_EU&MQ LB:N$@;C)8 M:ZHYJR[BY\18\F&

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end XML 71 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 271 424 1 true 88 0 false 7 false false R1.htm 00000001 - Document - Cover Sheet http://assisted4living.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://assisted4living.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://assisted4living.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statement of Operations (Unaudited) Sheet http://assisted4living.com/role/StatementOfOperations Condensed Consolidated Statement of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://assisted4living.com/role/StatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://assisted4living.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://assisted4living.com/role/OrganizationAndDescriptionOfBusiness ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://assisted4living.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - BANYAN MERGER Sheet http://assisted4living.com/role/BanyanMerger BANYAN MERGER Notes 9 false false R10.htm 00000010 - Disclosure - DISCONTINUED OPERATIONS Sheet http://assisted4living.com/role/DiscontinuedOperations DISCONTINUED OPERATIONS Notes 10 false false R11.htm 00000011 - Disclosure - TRILLIUM ACQUISITION Sheet http://assisted4living.com/role/TrilliumAcquisition TRILLIUM ACQUISITION Notes 11 false false R12.htm 00000012 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://assisted4living.com/role/AccountsPayableAndAccruedLiabilities ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 12 false false R13.htm 00000013 - Disclosure - NOTES PAYABLE Notes http://assisted4living.com/role/NotesPayable NOTES PAYABLE Notes 13 false false R14.htm 00000014 - Disclosure - LEASEHOLD IMPROVEMENTS Sheet http://assisted4living.com/role/LeaseholdImprovements LEASEHOLD IMPROVEMENTS Notes 14 false false R15.htm 00000015 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://assisted4living.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 15 false false R16.htm 00000016 - Disclosure - OPERATING AND CAPITAL LEASES Sheet http://assisted4living.com/role/OperatingAndCapitalLeases OPERATING AND CAPITAL LEASES Notes 16 false false R17.htm 00000017 - Disclosure - EQUITY Sheet http://assisted4living.com/role/Equity EQUITY Notes 17 false false R18.htm 00000018 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://assisted4living.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 18 false false R19.htm 00000019 - Disclosure - SEGMENT INFORMATION Sheet http://assisted4living.com/role/SegmentInformation SEGMENT INFORMATION Notes 19 false false R20.htm 00000020 - Disclosure - STOCK-BASED COMPENSATION Sheet http://assisted4living.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 20 false false R21.htm 00000021 - Disclosure - CONCENTRATIONS AND CREDIT RISKS Sheet http://assisted4living.com/role/ConcentrationsAndCreditRisks CONCENTRATIONS AND CREDIT RISKS Notes 21 false false R22.htm 00000022 - Disclosure - SUBSEQUENT EVENTS Sheet http://assisted4living.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 22 false false R23.htm 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 23 false false R24.htm 00000024 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://assisted4living.com/role/DiscontinuedOperationsTables DISCONTINUED OPERATIONS (Tables) Tables http://assisted4living.com/role/DiscontinuedOperations 24 false false R25.htm 00000025 - Disclosure - TRILLIUM ACQUISITION (Tables) Sheet http://assisted4living.com/role/TrilliumAcquisitionTables TRILLIUM ACQUISITION (Tables) Tables http://assisted4living.com/role/TrilliumAcquisition 25 false false R26.htm 00000026 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://assisted4living.com/role/AccountsPayableAndAccruedLiabilitiesTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://assisted4living.com/role/AccountsPayableAndAccruedLiabilities 26 false false R27.htm 00000027 - Disclosure - NOTES PAYABLE (Tables) Notes http://assisted4living.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://assisted4living.com/role/NotesPayable 27 false false R28.htm 00000028 - Disclosure - LEASEHOLD IMPROVEMENTS (Tables) Sheet http://assisted4living.com/role/LeaseholdImprovementsTables LEASEHOLD IMPROVEMENTS (Tables) Tables http://assisted4living.com/role/LeaseholdImprovements 28 false false R29.htm 00000029 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://assisted4living.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://assisted4living.com/role/PropertyAndEquipment 29 false false R30.htm 00000030 - Disclosure - OPERATING AND CAPITAL LEASES (Tables) Sheet http://assisted4living.com/role/OperatingAndCapitalLeasesTables OPERATING AND CAPITAL LEASES (Tables) Tables http://assisted4living.com/role/OperatingAndCapitalLeases 30 false false R31.htm 00000031 - Disclosure - EQUITY (Tables) Sheet http://assisted4living.com/role/EquityTables EQUITY (Tables) Tables http://assisted4living.com/role/Equity 31 false false R32.htm 00000032 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://assisted4living.com/role/SegmentInformationTables SEGMENT INFORMATION (Tables) Tables http://assisted4living.com/role/SegmentInformation 32 false false R33.htm 00000033 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://assisted4living.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://assisted4living.com/role/Stock-basedCompensation 33 false false R34.htm 00000034 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) Sheet http://assisted4living.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) Details http://assisted4living.com/role/OrganizationAndDescriptionOfBusiness 34 false false R35.htm 00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies 35 false false R36.htm 00000036 - Disclosure - BANYAN MERGER (Details Narrative) Sheet http://assisted4living.com/role/BanyanMergerDetailsNarrative BANYAN MERGER (Details Narrative) Details http://assisted4living.com/role/BanyanMerger 36 false false R37.htm 00000037 - Disclosure - SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS (Details) Sheet http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS (Details) Details 37 false false R38.htm 00000038 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative) Sheet http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative DISCONTINUED OPERATIONS (Details Narrative) Details http://assisted4living.com/role/DiscontinuedOperationsTables 38 false false R39.htm 00000039 - Disclosure - SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED (Details) Sheet http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED (Details) Details 39 false false R40.htm 00000040 - Disclosure - TRILLIUM ACQUISITION (Details Narrative) Sheet http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative TRILLIUM ACQUISITION (Details Narrative) Details http://assisted4living.com/role/TrilliumAcquisitionTables 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Sheet http://assisted4living.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) Notes http://assisted4living.com/role/ScheduleOfNotesPayableDetails SCHEDULE OF NOTES PAYABLE (Details) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) Notes http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical) Details 43 false false R44.htm 00000044 - Disclosure - SCHEDULE OF LEASESHOLD IMPROVEMENTS (Details) Sheet http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails SCHEDULE OF LEASESHOLD IMPROVEMENTS (Details) Details 44 false false R45.htm 00000045 - Disclosure - LEASEHOLD IMPROVEMENTS (Details Narrative) Sheet http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative LEASEHOLD IMPROVEMENTS (Details Narrative) Details http://assisted4living.com/role/LeaseholdImprovementsTables 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 46 false false R47.htm 00000047 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://assisted4living.com/role/PropertyAndEquipmentTables 47 false false R48.htm 00000048 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY (Details) Sheet http://assisted4living.com/role/ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityDetails SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY (Details) Details 48 false false R49.htm 00000049 - Disclosure - SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY (Details) Sheet http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY (Details) Details 49 false false R50.htm 00000050 - Disclosure - OPERATING AND CAPITAL LEASES (Details Narrative) Sheet http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative OPERATING AND CAPITAL LEASES (Details Narrative) Details http://assisted4living.com/role/OperatingAndCapitalLeasesTables 50 false false R51.htm 00000051 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details) Sheet http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails SCHEDULE OF WARRANTS OUTSTANDING (Details) Details 51 false false R52.htm 00000052 - Disclosure - EQUITY (Details Narrative) Sheet http://assisted4living.com/role/EquityDetailsNarrative EQUITY (Details Narrative) Details http://assisted4living.com/role/EquityTables 52 false false R53.htm 00000053 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://assisted4living.com/role/RelatedPartyTransactions 53 false false R54.htm 00000054 - Disclosure - SCHEDULE OF SEGMENT REPORTING INFORMATION (Details) Sheet http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails SCHEDULE OF SEGMENT REPORTING INFORMATION (Details) Details 54 false false R55.htm 00000055 - Disclosure - SUMMARY OF STOCK OPTIONS ACTIVITY (Details) Sheet http://assisted4living.com/role/SummaryOfStockOptionsActivityDetails SUMMARY OF STOCK OPTIONS ACTIVITY (Details) Details 55 false false R56.htm 00000056 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://assisted4living.com/role/Stock-basedCompensationTables 56 false false R57.htm 00000057 - Disclosure - CONCENTRATIONS AND CREDIT RISKS (Details Narrative) Sheet http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative CONCENTRATIONS AND CREDIT RISKS (Details Narrative) Details http://assisted4living.com/role/ConcentrationsAndCreditRisks 57 false false R58.htm 00000058 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://assisted4living.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://assisted4living.com/role/SubsequentEvents 58 false false All Reports Book All Reports form10-q.htm asli-20210930.xsd asli-20210930_cal.xml asli-20210930_def.xml asli-20210930_lab.xml asli-20210930_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 25, "contextCount": 271, "dts": { "calculationLink": { "local": [ "asli-20210930_cal.xml" ] }, "definitionLink": { "local": [ "asli-20210930_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "asli-20210930_lab.xml" ] }, "presentationLink": { "local": [ "asli-20210930_pre.xml" ] }, "schema": { "local": [ "asli-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 574, "entityCount": 1, "hidden": { "http://assisted4living.com/20210930": 35, "http://fasb.org/us-gaap/2021-01-31": 115, "http://xbrl.sec.gov/dei/2021": 4, "total": 154 }, "keyCustom": 75, "keyStandard": 349, "memberCustom": 57, "memberStandard": 23, "nsprefix": "ASLI", "nsuri": "http://assisted4living.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://assisted4living.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - DISCONTINUED OPERATIONS", "role": "http://assisted4living.com/role/DiscontinuedOperations", "shortName": "DISCONTINUED OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - TRILLIUM ACQUISITION", "role": "http://assisted4living.com/role/TrilliumAcquisition", "shortName": "TRILLIUM ACQUISITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "role": "http://assisted4living.com/role/AccountsPayableAndAccruedLiabilities", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - NOTES PAYABLE", "role": "http://assisted4living.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ASLI:LeasesholdImprovementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - LEASEHOLD IMPROVEMENTS", "role": "http://assisted4living.com/role/LeaseholdImprovements", "shortName": "LEASEHOLD IMPROVEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ASLI:LeasesholdImprovementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://assisted4living.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - OPERATING AND CAPITAL LEASES", "role": "http://assisted4living.com/role/OperatingAndCapitalLeases", "shortName": "OPERATING AND CAPITAL LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - EQUITY", "role": "http://assisted4living.com/role/Equity", "shortName": "EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://assisted4living.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SEGMENT INFORMATION", "role": "http://assisted4living.com/role/SegmentInformation", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://assisted4living.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://assisted4living.com/role/Stock-basedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - CONCENTRATIONS AND CREDIT RISKS", "role": "http://assisted4living.com/role/ConcentrationsAndCreditRisks", "shortName": "CONCENTRATIONS AND CREDIT RISKS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SUBSEQUENT EVENTS", "role": "http://assisted4living.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - DISCONTINUED OPERATIONS (Tables)", "role": "http://assisted4living.com/role/DiscontinuedOperationsTables", "shortName": "DISCONTINUED OPERATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ASLI:ScheduleOfAcquiredAssetsAndLiabiltiesAcquiredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - TRILLIUM ACQUISITION (Tables)", "role": "http://assisted4living.com/role/TrilliumAcquisitionTables", "shortName": "TRILLIUM ACQUISITION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ASLI:ScheduleOfAcquiredAssetsAndLiabiltiesAcquiredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "role": "http://assisted4living.com/role/AccountsPayableAndAccruedLiabilitiesTables", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - NOTES PAYABLE (Tables)", "role": "http://assisted4living.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ASLI:LeasesholdImprovementsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ASLI:ScheduleOfLeasesholdImprovementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - LEASEHOLD IMPROVEMENTS (Tables)", "role": "http://assisted4living.com/role/LeaseholdImprovementsTables", "shortName": "LEASEHOLD IMPROVEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ASLI:LeasesholdImprovementsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ASLI:ScheduleOfLeasesholdImprovementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://assisted4living.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://assisted4living.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ASLI:ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - OPERATING AND CAPITAL LEASES (Tables)", "role": "http://assisted4living.com/role/OperatingAndCapitalLeasesTables", "shortName": "OPERATING AND CAPITAL LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ASLI:ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - EQUITY (Tables)", "role": "http://assisted4living.com/role/EquityTables", "shortName": "EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://assisted4living.com/role/SegmentInformationTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://assisted4living.com/role/Stock-basedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ASLI:RestatedPurchaseAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative)", "role": "http://assisted4living.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "ASLI:RestatedPurchaseAgreement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "ASLI:CapitalRequirementsLiquidityAndGoingConcernConsiderationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ASLI:CapitalRequirementsLiquidityAndGoingConcernConsiderationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-5", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-03-23", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - BANYAN MERGER (Details Narrative)", "role": "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "shortName": "BANYAN MERGER (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:ConversionOfStockDescription", "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-11-06", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS (Details)", "role": "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails", "shortName": "SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-09-30_custom_AssistedTwoLivingIncMember", "decimals": "0", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative)", "role": "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "shortName": "DISCONTINUED OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-292021-04-30", "decimals": "INF", "lang": null, "name": "ASLI:IssuedAndOutstandingShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ASLI:ScheduleOfAcquiredAssetsAndLiabiltiesAcquiredTableTextBlock", "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED (Details)", "role": "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails", "shortName": "SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ASLI:ScheduleOfAcquiredAssetsAndLiabiltiesAcquiredTableTextBlock", "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statement of Operations (Unaudited)", "role": "http://assisted4living.com/role/StatementOfOperations", "shortName": "Condensed Consolidated Statement of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:SalariesAndWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - TRILLIUM ACQUISITION (Details Narrative)", "role": "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative", "shortName": "TRILLIUM ACQUISITION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:AssetAcquisitionTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "lang": null, "name": "ASLI:BusinessCombinationDepositsNonRefundableAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "role": "http://assisted4living.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details)", "role": "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "shortName": "SCHEDULE OF NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_custom_NotesPayableMember", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "us-gaap:ConversionOfStockDescription", "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-03-222021-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)", "role": "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "shortName": "SCHEDULE OF NOTES PAYABLE (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "us-gaap:DebtInstrumentDescription", "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-09-30_custom_TrilliumHealthcareGroupLLCMember_us-gaap_LineOfCreditMember", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - SCHEDULE OF LEASESHOLD IMPROVEMENTS (Details)", "role": "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "shortName": "SCHEDULE OF LEASESHOLD IMPROVEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ASLI:ScheduleOfLeasesholdImprovementsTableTextBlock", "ASLI:LeasesholdImprovementsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_us-gaap_LeaseholdImprovementsMember", "decimals": "0", "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - LEASEHOLD IMPROVEMENTS (Details Narrative)", "role": "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "shortName": "LEASEHOLD IMPROVEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ASLI:LeasesholdImprovementsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30_us-gaap_LeaseholdImprovementsMember", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FurnitureAndFixturesGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "role": "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "lang": null, "name": "ASLI:MotorVehiclesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-06-092021-06-10_custom_TrilliumHealthcareGroupLLCMember133767218", "decimals": "-5", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentAdditions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY (Details)", "role": "http://assisted4living.com/role/ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityDetails", "shortName": "SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY (Details)", "role": "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails", "shortName": "SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited)", "role": "http://assisted4living.com/role/StatementOfStockholdersEquity", "shortName": "Condensed Consolidated Statement of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-03-31_us-gaap_RetainedEarningsMember", "decimals": "0", "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - OPERATING AND CAPITAL LEASES (Details Narrative)", "role": "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "shortName": "OPERATING AND CAPITAL LEASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-10-15_custom_KidzClubStPeteLLCMember", "decimals": "0", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_custom_KidzClubStPeteLLCMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)", "role": "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails", "shortName": "SCHEDULE OF WARRANTS OUTSTANDING (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-12-31_custom_KidzClubStPeteLLCMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - EQUITY (Details Narrative)", "role": "http://assisted4living.com/role/EquityDetailsNarrative", "shortName": "EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-09-172020-09-19_us-gaap_NotesPayableOtherPayablesMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "us-gaap:ConversionOfStockDescription", "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-03-222021-03-23", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "lang": null, "name": "ASLI:PaymentOfAccruedPayroll", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - SCHEDULE OF SEGMENT REPORTING INFORMATION (Details)", "role": "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "shortName": "SCHEDULE OF SEGMENT REPORTING INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:SalariesWagesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - SUMMARY OF STOCK OPTIONS ACTIVITY (Details)", "role": "http://assisted4living.com/role/SummaryOfStockOptionsActivityDetails", "shortName": "SUMMARY OF STOCK OPTIONS ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-08-26", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)", "role": "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "STOCK-BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - CONCENTRATIONS AND CREDIT RISKS (Details Narrative)", "role": "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative", "shortName": "CONCENTRATIONS AND CREDIT RISKS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30_us-gaap_ProductConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_MedicareMember", "decimals": "INF", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "us-gaap:ConversionOfStockDescription", "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-11-06", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://assisted4living.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-13_us-gaap_SubsequentEventMember", "decimals": "0", "lang": null, "name": "us-gaap:DepositAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://assisted4living.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "0", "lang": null, "name": "ASLI:IncomeFromDiscontinuedOperationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS", "role": "http://assisted4living.com/role/OrganizationAndDescriptionOfBusiness", "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://assisted4living.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - BANYAN MERGER", "role": "http://assisted4living.com/role/BanyanMerger", "shortName": "BANYAN MERGER", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 88, "tag": { "ASLI_AcceleratedPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accelerated Payments.", "label": "Accelerated payments" } } }, "localname": "AcceleratedPayments", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ASLI_AcceleratedPaymentsTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Payments Terms.", "label": "Accelerated Payments term" } } }, "localname": "AcceleratedPaymentsTerms", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "ASLI_AccruedCreditCard": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Credit card.", "label": "Credit Card" } } }, "localname": "AccruedCreditCard", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_AccruedExpensesAndCurrentNotesPayableAccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses and current notes payable accounts and other receivables net current.", "label": "Accrued expenses and current notes payable cash and accounts payable" } } }, "localname": "AccruedExpensesAndCurrentNotesPayableAccountsAndOtherReceivablesNetCurrent", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ASLI_AdvancePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Advance payments.", "label": "Advance Payments", "verboseLabel": "Advance payments" } } }, "localname": "AdvancePayments", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_AdvancedPaymrents": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments made in advance.", "label": "Advanced payments" } } }, "localname": "AdvancedPaymrents", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "ASLI_AscentiumCapitalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ascentium Capital LLC [Member]", "label": "Ascentium Capital LLC [Member]" } } }, "localname": "AscentiumCapitalLLCMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_AssistedTwoLivingIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assisted 2 Living, Inc [Member]", "label": "Assisted 2 Living, Inc [Member]" } } }, "localname": "AssistedTwoLivingIncMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "ASLI_BanyanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Banyan [Member]", "label": "Banyan [Member]" } } }, "localname": "BanyanMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_BanyanPediatricCareCentersIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Banyan Pediatric Care Centers, Inc [Member]", "label": "Banyan Pediatric Care Centers, Inc [Member]" } } }, "localname": "BanyanPediatricCareCentersIncMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ASLI_BuildingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Buildings [Member]", "label": "Buildings [Member]" } } }, "localname": "BuildingsMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ASLI_BusinessAcquisitionAdditionalSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisition Additional Share Price.", "label": "Additonal Shares Acquired during the period" } } }, "localname": "BusinessAcquisitionAdditionalSharePrice", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ASLI_BusinessCombinationDepositsNonRefundableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination Deposits Non Refundable Amount.", "label": "Business Combination Deposits Non Refundable Amount" } } }, "localname": "BusinessCombinationDepositsNonRefundableAmount", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ASLI_BusinessCombinationOfDepositsAmountForfeited": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination Of Deposits Amount Forfeited.", "label": "Deposits Amount Forfeited" } } }, "localname": "BusinessCombinationOfDepositsAmountForfeited", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ASLI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Accounts Payable and Accrued Expenses.", "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiabilityNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Lease Liability Net.", "label": "Lease liability - net of current portion" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLeaseLiabilityNet", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueFromSeller": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities, due from seller.", "label": "Cash due to seller" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueFromSeller", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Goodwill.", "label": "Goodwill [Default Label]", "verboseLabel": "Goodwill" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseImprovements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed lease improvements.", "label": "Leasehold improvements" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseImprovements", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseRightUseOfAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Lease Right of use assets.", "label": "Lease right of use asset" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeaseRightUseOfAsset", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, shares liability.", "label": "Share liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShareLiability", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_COVID19PandemicAndCARESActFundingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID19 Pandemic and CARES Act Funding Policy Text Block.", "label": "COVID-19 Pandemic and CARES Act Funding" } } }, "localname": "COVID19PandemicAndCARESActFundingPolicyTextBlock", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ASLI_CTRPartnershipLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CTR Partnership LP [Member]", "label": "CTR Partnership LP [Member]" } } }, "localname": "CTRPartnershipLPMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_CapitalRequirementsLiquidityAndGoingConcernConsiderationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital requirements liquidity and going concern considerations policy text block.", "label": "Capital Requirements, Liquidity and Going Concern Considerations" } } }, "localname": "CapitalRequirementsLiquidityAndGoingConcernConsiderationsPolicyTextBlock", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ASLI_CommercialInsuranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial Insurance [Member]", "label": "Commercial Insurance [Member]" } } }, "localname": "CommercialInsuranceMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_ComputersEquipmentSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computers Equipment Software [Member]", "label": "Computers Equipment Software [Member]" } } }, "localname": "ComputersEquipmentSoftwareMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ASLI_ConvertibleNoteAndSecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Note and Securities Purchase Agreement [Member]", "label": "Convertible Note And Securities Purchase Agreement [Member]" } } }, "localname": "ConvertibleNoteAndSecuritiesPurchaseAgreementMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ASLI_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_CretePlusFivePropertyLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Crete Plus Five Property LLC [Member]", "label": "Crete Plus Five Property LLC [Member]" } } }, "localname": "CretePlusFivePropertyLLCMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_DeferredHealthAndHumanServicesRevenueCurrent": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Health and Human Services Revenue Current.", "label": "Deferred HHS Revenue" } } }, "localname": "DeferredHealthAndHumanServicesRevenueCurrent", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ASLI_DexImagingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dex Imaging [Member]", "label": "Dex Imaging [Member]" } } }, "localname": "DexImagingMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_DisclosureLeaseholdImprovementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leasehold Improvements" } } }, "localname": "DisclosureLeaseholdImprovementsAbstract", "nsuri": "http://assisted4living.com/20210930", "xbrltype": "stringItemType" }, "ASLI_DisclosureOperatingAndCapitalLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating And Capital Leases", "terseLabel": "Schedule Of Maturity Of Operating Lease Liability", "verboseLabel": "Schedule Of Operating Lease Right Of Use Asset And Lease Liability" } } }, "localname": "DisclosureOperatingAndCapitalLeasesAbstract", "nsuri": "http://assisted4living.com/20210930", "xbrltype": "stringItemType" }, "ASLI_DisposalGroupIncludingDiscontinuedOperationInterestAndOtherExpenseNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation interest and other expense net", "label": "Disposal Group Including Discontinued Operation Interest And Other Expense Net", "negatedLabel": "Interest and other, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInterestAndOtherExpenseNet", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_DisposalGroupIncludingDiscontinuedOperationLeaseExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation lease expense", "label": "Disposal Group Including Discontinued Operation Lease Expense", "verboseLabel": "Lease expense" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseExpense", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_DisposalGroupIncludingDiscontinuedOperationSalaryAndTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation salary and tax expense", "label": "Salary and tax expense" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationSalaryAndTaxExpense", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Excel Family Partners, LLLP and Banyan Pediatric Investment, Inc [Member]", "label": "Excel Family Partners, LLLP and Banyan Pediatric Investment, Inc [Member]" } } }, "localname": "ExcelFamilyPartnersLLLPAndBanyanPediatricInvestmentIncMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ASLI_ExcelFamilyPartnersLLLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Excel Family Partners, LLLP [Member]", "label": "Excel Family Partners, LLLP [Member]" } } }, "localname": "ExcelFamilyPartnersLLLPMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ASLI_FirstAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Amendment [Member]", "label": "First Amendment [Member]" } } }, "localname": "FirstAmendmentMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_GeminoHealthcareFinanceLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gemino Healthcare Finance, LLC [Member]", "label": "Gemino Healthcare Finance, LLC [Member]" } } }, "localname": "GeminoHealthcareFinanceLLCMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_GoodwillAcquisition": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Goodwill acquisition.", "label": "Goodwill from acquisition" } } }, "localname": "GoodwillAcquisition", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ASLI_GoodwillFromAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Goodwill from acquisition.", "label": "GoodwillFromAcquisition", "verboseLabel": "Goodwill from acquisition" } } }, "localname": "GoodwillFromAcquisition", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ASLI_GraceCareCentersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grace Care Centers [Member]", "label": "Grace Care Centers [Member]" } } }, "localname": "GraceCareCentersMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_GrandTrinityPlazaLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grand Trinity Plaza LLC [Member]", "label": "Grand Trinity Plaza LLC [Member]" } } }, "localname": "GrandTrinityPlazaLLCMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ASLI_GuarantyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Guaranty Agreement [Member]", "label": "Guaranty Agreement [Member]" } } }, "localname": "GuarantyAgreementMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_HCSGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HCSG [Member]", "label": "HCSG [Member]" } } }, "localname": "HCSGMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ASLI_IncomeFromDiscontinuedOperationsNetOfTax": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income from discontinued operations net of tax.", "label": "IncomeFromDiscontinuedOperationsNetOfTax", "negatedLabel": "Net gain from discontinued operations" } } }, "localname": "IncomeFromDiscontinuedOperationsNetOfTax", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ASLI_IncreaseDecreaseInAdvancePayments": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in advance payments.", "label": "Advance payments" } } }, "localname": "IncreaseDecreaseInAdvancePayments", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ASLI_IncreaseDecreaseInDepositsAndOtherAssets": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in deposits and other assets.", "label": "Increase Decrease In Deposits And Other Assets", "negatedLabel": "Deposits and other assets" } } }, "localname": "IncreaseDecreaseInDepositsAndOtherAssets", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ASLI_InvestmentInLeaseholdImprovements": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in leasehold improvements.", "label": "Investment in leasehold improvements" } } }, "localname": "InvestmentInLeaseholdImprovements", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ASLI_IssuanceOfStockWarrantExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of stock warrant expense.", "label": "Issuance of stock warrant expense" } } }, "localname": "IssuanceOfStockWarrantExpense", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ASLI_IssuedAndOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued and outstanding shares", "label": "Issued and outstanding shares" } } }, "localname": "IssuedAndOutstandingShares", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ASLI_KidzClubStPeteLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kidz Club - St. Pete, LLC [Member]", "label": "Kidz Club - St. Pete, LLC [Member]" } } }, "localname": "KidzClubStPeteLLCMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "ASLI_LeaseExpense": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease Expense.", "label": "Lease expense" } } }, "localname": "LeaseExpense", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "ASLI_LeaseholdImprovementsNet": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Leasehold improvements, net amortization.", "label": "Leasehold improvements, net" } } }, "localname": "LeaseholdImprovementsNet", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "ASLI_LeasesholdImprovementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leaseshold Improvements [Text Block]", "label": "LEASEHOLD IMPROVEMENTS" } } }, "localname": "LeasesholdImprovementsTextBlock", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovements" ], "xbrltype": "textBlockItemType" }, "ASLI_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, operating lease, liability, to be paid, after year four.", "label": "After 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_LesseeOperatingLeasePercentageOfIncreaseInBaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease percentage of increase in base rent.", "label": "Lease percentage of increase in base rent" } } }, "localname": "LesseeOperatingLeasePercentageOfIncreaseInBaseRent", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "ASLI_LesseeOperatingLeasePurchaseOptionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease purchase option price.", "label": "Lease purchase option price" } } }, "localname": "LesseeOperatingLeasePurchaseOptionPrice", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ASLI_LesseeOperatingLeaseTerminationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease, termination date.", "label": "Lease termination date" } } }, "localname": "LesseeOperatingLeaseTerminationDate", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "dateItemType" }, "ASLI_Liabilities1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total Liabilities" } } }, "localname": "Liabilities1", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_LiabilityToIssueSharesForAcquisition": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Liability to issue shares for acquisition.", "label": "Liability to issue shares for acquisition" } } }, "localname": "LiabilityToIssueSharesForAcquisition", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ASLI_LiabilityToIssueSharesOfCommonStock": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability To Issue Shares Of Common Stock.", "label": "Liability to issue shares" } } }, "localname": "LiabilityToIssueSharesOfCommonStock", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "ASLI_LiabilityToIssueSharesOfCommonStockNonCurrent": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability to issue shares - long term Non current.", "label": "Liability to issue shares - long term" } } }, "localname": "LiabilityToIssueSharesOfCommonStockNonCurrent", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "ASLI_LineOfCreditFacilityUnusedCapacityManagementFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility unused capacity management fee percentage.", "label": "Management fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityManagementFeePercentage", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "percentItemType" }, "ASLI_LossOnDisposalOfAsset": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss on disposal of asset.", "label": "LossOnDisposalOfAsset", "negatedLabel": "Loss on disposal of asset" } } }, "localname": "LossOnDisposalOfAsset", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "ASLI_MarketingAndAdvertisingExpenses": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Marketing and advertising" } } }, "localname": "MarketingAndAdvertisingExpenses", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "ASLI_MedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicaid [Member]", "label": "Medicaid [Member]" } } }, "localname": "MedicaidMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_MedicareAcceleratedPaymentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare Accelerated Payments Policy Text Block.", "label": "Medicare Accelerated Payments" } } }, "localname": "MedicareAcceleratedPaymentsPolicyTextBlock", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ASLI_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare [Member]", "label": "Medicare [Member]" } } }, "localname": "MedicareMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_MedlineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medline [Member]", "label": "Medline [Member]" } } }, "localname": "MedlineMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ASLI_MotorVehiclesGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Motor Vehicles Gross.", "label": "Motor vehicles" } } }, "localname": "MotorVehiclesGross", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_MotorVehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Motor Vehicles [Member]", "label": "Motor Vehicles [Member]" } } }, "localname": "MotorVehiclesMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ASLI_NetPatientRevenuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Patient Revenue [Policy Text Block]", "label": "Net Patient Revenue" } } }, "localname": "NetPatientRevenuePolicyTextBlock", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ASLI_NewPortRicheyFloridaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Port Richey [Member]", "label": "New Port Richey [Member]" } } }, "localname": "NewPortRicheyFloridaMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_NonRefundableFeeDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Refundable Fee Description.", "label": "Non refundable fee description" } } }, "localname": "NonRefundableFeeDescription", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ASLI_NoncashOperatingLeaseExpense": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash operating lease expense.", "label": "Non-cash operating lease expense" } } }, "localname": "NoncashOperatingLeaseExpense", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ASLI_NortheastPlazaVentureILLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Northeast Plaza Venture I, LLC [Member]", "label": "Northeast Plaza Venture I, LLC [Member]" } } }, "localname": "NortheastPlazaVentureILLCMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_NoteHolderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Holder [Member]", "label": "Note Holder [Member]" } } }, "localname": "NoteHolderMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_NotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Payable [Member]", "label": "Notes Payable [Member]" } } }, "localname": "NotesPayableMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "ASLI_NuViewTrustCoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NuView Trust Co [Member]", "label": "NuView Trust Co [Member]" } } }, "localname": "NuViewTrustCoMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ASLI_NumberOfLeaseAgreementProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Lease agreement properties.", "label": "Number of Lease Agreement Properties" } } }, "localname": "NumberOfLeaseAgreementProperties", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "integerItemType" }, "ASLI_OperatingLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss.", "label": "Operating Loss" } } }, "localname": "OperatingLoss", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "monetaryItemType" }, "ASLI_OtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other revenue [Member].", "label": "Other revenue [Member]" } } }, "localname": "OtherRevenueMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "domainItemType" }, "ASLI_PandemicReliefFundsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pandemic Relief Funds Policy Text Block.", "label": "Pandemic Relief Funds" } } }, "localname": "PandemicReliefFundsPolicyTextBlock", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ASLI_PaymentOfAccruedPayroll": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment Of Accrued Payroll.", "label": "Payment Of Accrued Payroll", "verboseLabel": "Accrued Salary" } } }, "localname": "PaymentOfAccruedPayroll", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ASLI_PaymentToSeller": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment to Seller.", "label": "Payment to seller" } } }, "localname": "PaymentToSeller", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ASLI_PaymentToSellerNonRefundableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment To Seller Non Refundable Amount.", "label": "Payment to seller non refundable" } } }, "localname": "PaymentToSellerNonRefundableAmount", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ASLI_PediatricExtendedCareCentersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pediatric Extended Care Centers [Member]", "label": "Pediatric Extended Care Centers [Member]" } } }, "localname": "PediatricExtendedCareCentersMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "ASLI_PercentageOfAcceleratedPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of accelerated payment.", "label": "Percentage of accelerated payment" } } }, "localname": "PercentageOfAcceleratedPayment", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "ASLI_PercentageOfFinancingAccountsReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of financing accounts receivable.", "label": "Accounts receivable percentage" } } }, "localname": "PercentageOfFinancingAccountsReceivable", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "percentItemType" }, "ASLI_PresidentAndChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "President and Chief Executive Officer [Member]", "label": "President and Chief Executive Officer [Member]" } } }, "localname": "PresidentAndChiefExecutiveOfficerMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_PrivatePayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Pay [Member]", "label": "Private Pay [Member]" } } }, "localname": "PrivatePayMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_PrivatePayResidentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Pay Residents [Member]", "label": "Private Pay Residents [Member]" } } }, "localname": "PrivatePayResidentsMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_ProceedsFromIssuanceOfRegisteredShares": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from the issuance of registered shares.", "label": "Proceeds from the issuance of registered shares" } } }, "localname": "ProceedsFromIssuanceOfRegisteredShares", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ASLI_ProceedsFromPandemicReliefFunds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Pandemic Relief Funds.", "label": "Proceeds from pandemic relief funds" } } }, "localname": "ProceedsFromPandemicReliefFunds", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ASLI_PurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Agreement [Member]", "label": "Purchase Agreement [Member]" } } }, "localname": "PurchaseAgreementMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_PurchaseAndSaleOptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase and Sale Option Agreement [Member]", "label": "Purchase and Sale Option Agreement [Member]" } } }, "localname": "PurchaseAndSaleOptionAgreementMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_RJKoolMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RJ Kool [Member]", "label": "RJ Kool [Member]" } } }, "localname": "RJKoolMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_ReliantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reliant [Member]", "label": "Reliant [Member]" } } }, "localname": "ReliantMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "ASLI_RentalRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rental revenue [Member].", "label": "Rental revenue [Member]" } } }, "localname": "RentalRevenueMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "domainItemType" }, "ASLI_RestatedPurchaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restated purchase agreement.", "label": "Restated purchase agreement" } } }, "localname": "RestatedPurchaseAgreement", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "ASLI_RestrictedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Common Stock [Member]", "label": "Restricted Common Stock [Member]" } } }, "localname": "RestrictedCommonStockMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_RomulusBarrMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Romulus Barr [Member]", "label": "Romulus Barr [Member]" } } }, "localname": "RomulusBarrMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_SLRRLOCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SLR - RLOC [Member]", "label": "SLR - RLOC [Member]" } } }, "localname": "SLRRLOCMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "ASLI_SarasotaFloridaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sarasota [Member]", "label": "Sarasota [Member]" } } }, "localname": "SarasotaFloridaMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_ScheduleOfAcquiredAssetsAndLiabiltiesAcquiredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Acquired Assets And Liabilties Acquired [Table Text Block]", "label": "SUMMARY OF ACQUIRED ASSETS AND LIABILITIES ASSUMED" } } }, "localname": "ScheduleOfAcquiredAssetsAndLiabiltiesAcquiredTableTextBlock", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/TrilliumAcquisitionTables" ], "xbrltype": "textBlockItemType" }, "ASLI_ScheduleOfLeasesholdImprovementsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Leaseshold Improvements [Table Text Block]", "label": "SCHEDULE OF LEASESHOLD IMPROVEMENTS" } } }, "localname": "ScheduleOfLeasesholdImprovementsTableTextBlock", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsTables" ], "xbrltype": "textBlockItemType" }, "ASLI_ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Operating Lease Right Of Use Asset And Lease Liability [Table Text Block]", "label": "SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSET AND LEASE LIABILITY" } } }, "localname": "ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityTableTextBlock", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesTables" ], "xbrltype": "textBlockItemType" }, "ASLI_SecondAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Amendment [Member]", "label": "Second Amendment [Member]" } } }, "localname": "SecondAmendmentMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_SellerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seller [Member]", "label": "Seller [Member]" } } }, "localname": "SellerMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate Intrinsic Value, Outstanding, Balance.", "label": "Aggregate Intrinsic Value, Outstanding, Balance", "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance", "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ASLI_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceBeginningBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-Average Exercise Price, Outstanding.", "label": "Weighted-Average Exercise Price, Outstanding", "periodEndLabel": "Weighted-Average Exercise Price, Outstanding, Ending Balance", "periodStartLabel": "Weighted-Average Exercise Price, Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceBeginningBalance", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ASLI_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-Average Exercise Price, Exercised.", "label": "Weighted-Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExercised", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ASLI_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-Average Exercise Price, Expired.", "label": "Weighted-Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceExpired", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ASLI_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-Average Exercise Price, Granted.", "label": "Weighted-Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePriceGranted", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "perShareItemType" }, "ASLI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Contractual Term, Granted Term.", "label": "Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerm2", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "durationItemType" }, "ASLI_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Remaining Contractual Term, Outstanding.", "label": "Weighted Average Remaining Contractual Term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "durationItemType" }, "ASLI_SharesReturnedAndCancelledForTransferOfDiscontinuedOperationsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares returned and cancelled for transfer of discontinued operations shares.", "label": "Shares returned and cancelled for transfer of discontinued operations, shares" } } }, "localname": "SharesReturnedAndCancelledForTransferOfDiscontinuedOperationsShares", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "ASLI_SharesReturnedAndCancelledForTransferOfDiscontinuedOperationsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares returned and cancelled for transfer of discontinued operations value.", "label": "Shares returned and cancelled for transfer of discontinued operations" } } }, "localname": "SharesReturnedAndCancelledForTransferOfDiscontinuedOperationsValue", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ASLI_SoutheasternLaundryEquipmentSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Southeastern Laundry Equipment Sales [Member]", "label": "Southeastern Laundry Equipment Sales [Member]" } } }, "localname": "SoutheasternLaundryEquipmentSalesMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_StPetersburgFloridaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "St. Petersburg [Member]", "label": "St. Petersburg [Member]" } } }, "localname": "StPetersburgFloridaMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_StockIssuedDuringPeriodSharesPrivatePlacement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares private placement.", "label": "Issuance of shares via private placement, shares" } } }, "localname": "StockIssuedDuringPeriodSharesPrivatePlacement", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "ASLI_StockIssuedDuringPeriodValuePrivatePlacement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value private placement.", "label": "Issuance of shares via private placement" } } }, "localname": "StockIssuedDuringPeriodValuePrivatePlacement", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ASLI_SubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription receivable [Member].", "label": "Subscription receivable [Member]" } } }, "localname": "SubscriptionReceivableMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "ASLI_TenEmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ten Employees [Member]", "label": "10 Employees [Member]" } } }, "localname": "TenEmployeesMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_TrilliumGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trillium Group [Member]", "label": "Trillium Group [Member]" } } }, "localname": "TrilliumGroupMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_TrilliumHealthcareGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trillium Health care Group LLC [Member]", "label": "Trillium Healthcare Group, LLC [Member]" } } }, "localname": "TrilliumHealthcareGroupLLCMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_TrilliumSubsidiariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trillium Subsidiaries [Member]", "label": "Trillium Subsidiaries [Member]" } } }, "localname": "TrilliumSubsidiariesMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_TwoThousandAndTwentyOneIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Twenty One Incentive Award Plan [Member]", "label": "2021 Incentive Award Plan [Member]" } } }, "localname": "TwoThousandAndTwentyOneIncentiveAwardPlanMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_WithinFiveDaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Within Five Days [Member]", "label": "Within Five Days [Member]" } } }, "localname": "WithinFiveDaysMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_WithinNinetyDaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Within 90 Days [Member]", "label": "Within 90 Days [Member]" } } }, "localname": "WithinNinetyDaysMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_WithinOneHundredAndEightyDaysMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Within 180 Days [Member]", "label": "Within 180 Days [Member]" } } }, "localname": "WithinOneHundredAndEightyDaysMember", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ASLI_WorkingCapitalDeficiency": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Working Capital Deficiency.", "label": "Working capital deficiency" } } }, "localname": "WorkingCapitalDeficiency", "nsuri": "http://assisted4living.com/20210930", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r591", "r593", "r594" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r592" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r601" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r586" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r594" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Series [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r582" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r589" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r590" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r599" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://assisted4living.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r126", "r246", "r251", "r259", "r410", "r411", "r415", "r416", "r480", "r578" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r126", "r246", "r251", "r259", "r410", "r411", "r415", "r416", "r480", "r578" ], "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r126", "r178", "r191", "r192", "r193", "r194", "r196", "r198", "r202", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r256", "r258", "r259" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r126", "r178", "r191", "r192", "r193", "r194", "r196", "r198", "r202", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r256", "r258", "r259" ], "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r264", "r300", "r346", "r349", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r541", "r544", "r579", "r580" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r264", "r300", "r346", "r349", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r541", "r544", "r579", "r580" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r204", "r333", "r334", "r498", "r540", "r542" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative", "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r204", "r333", "r334", "r498", "r540", "r542" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative", "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r264", "r300", "r338", "r346", "r349", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r541", "r544", "r579", "r580" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r264", "r300", "r338", "r346", "r349", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r541", "r544", "r579", "r580" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r138", "r142", "r347" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r205", "r206", "r333", "r335", "r543", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r205", "r206", "r333", "r335", "r543", "r564", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r138", "r142", "r244", "r347", "r489" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r210", "r476" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Cash and accounts receivable" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r65" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses", "totalLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/AccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r61", "r485" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r29", "r46", "r211", "r212" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r34", "r35", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Bonus payable" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Expense" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r35", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Payroll Tax Payable" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r34", "r35", "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salary", "verboseLabel": "Accrued Salaries, Current" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r59", "r235" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: amortization", "negatedTerseLabel": "Less: depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r47" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r128", "r129", "r130", "r368", "r369", "r370", "r429" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r131", "r132", "r133", "r134", "r142", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r245", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r383", "r384", "r385", "r386", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r471", "r499", "r500", "r501", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r602", "r603", "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising and Marketing" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r351", "r362", "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area under lease" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionTextBlock": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for asset acquisition.", "label": "TRILLIUM ACQUISITION" } } }, "localname": "AssetAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/TrilliumAcquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_Assets": { "auth_ref": [ "r124", "r186", "r193", "r200", "r221", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r255", "r257", "r259", "r260", "r410", "r415", "r438", "r483", "r485", "r516", "r529" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r30", "r31", "r77", "r124", "r221", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r255", "r257", "r259", "r260", "r410", "r415", "r438", "r483", "r485" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r33", "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r345", "r348" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r345", "r348", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Acquisition transaction cost" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.", "label": "Business Acquisition Description" } } }, "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": { "auth_ref": [ "r391", "r392", "r394" ], "lang": { "en-us": { "role": { "documentation": "Date when the acquirer obtains control of the acquiree, in YYYY-MM-DD format.", "label": "Effective Date of Acquisition" } } }, "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Right to receive purchase price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r399", "r400", "r402" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Due to Seller for acquisition" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "BANYAN MERGER" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMerger" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Total identifiable assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "verboseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Lease liability - current portion" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt", "verboseLabel": "Notes payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Loan Payable - other" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r397", "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Total identifiable liabilities acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Outstanding debt assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r397", "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfAcquiredAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r581" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Computers / equipment / software", "verboseLabel": "Computers and equipment" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r56", "r485", "r558", "r559" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r95" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash and assets from acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business.", "label": "Cash payment" } } }, "localname": "CashAcquiredInExcessOfPaymentsToAcquireBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r37", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r104", "r110", "r116" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r104", "r447" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CASH ITEMS" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r121", "r124", "r146", "r147", "r148", "r151", "r153", "r157", "r158", "r159", "r221", "r246", "r251", "r252", "r253", "r259", "r260", "r298", "r299", "r303", "r307", "r438", "r597" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants to purchase common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "verboseLabel": "Shares reserved as common stock" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r128", "r129", "r429" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/StatementOfStockholdersEquity", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheetsParenthetical", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheetsParenthetical", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheetsParenthetical", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r45", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheetsParenthetical", "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r45", "r485" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $0.0001; 100,000,000 shares authorized, 45,345,418, and 4,165,418 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively", "verboseLabel": "Aggregate consideration amount" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r167", "r168", "r208", "r435", "r436", "r565" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r167", "r168", "r208", "r435", "r436", "r557", "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r167", "r168", "r208", "r435", "r436", "r557", "r565" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "CONCENTRATIONS AND CREDIT RISKS" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisks" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r167", "r168", "r208", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk percentage, Revenues" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r164", "r167", "r168", "r169", "r435", "r437", "r565" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r167", "r168", "r208", "r435", "r436", "r565" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r118", "r412" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Basis of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r113", "r114", "r115" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of notes payable and accrued interest for common stock" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r113", "r114", "r115" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Issued" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r113", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock conversion description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r113", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Number of shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r113", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Number of shares issued upon conversion" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r42", "r518", "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible debt", "verboseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r92", "r498" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of services provided", "negatedLabel": "Cost of Sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r165", "r208" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r113", "r115" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Issuance of shares for the conversion of debt" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r113", "r115" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Issuance of shares for conversion of debt, shares", "terseLabel": "Debt conversion share issued", "verboseLabel": "Debt conversion shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r113", "r115" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion principal amount" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r120", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r278", "r285", "r286", "r287", "r294" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r40", "r41", "r42", "r123", "r126", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r289", "r290", "r291", "r292", "r458", "r517", "r518", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Bears interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r263", "r288" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt conversion price per share", "verboseLabel": "Debt Instrument, Convertible, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r40", "r42", "r315", "r517", "r518", "r526", "r528" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r261", "r289", "r290", "r456", "r458", "r459" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Aggregate principal amount", "verboseLabel": "Debt principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r69", "r262" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate", "verboseLabel": "Debt rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r70", "r264", "r432" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r72", "r123", "r126", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r289", "r290", "r291", "r292", "r458" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r71", "r527" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r72", "r527" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Principal and interest amount", "verboseLabel": "Monthly payments" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to interest.", "label": "Interest payable each month" } } }, "localname": "DebtInstrumentPeriodicPaymentInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maturity term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DepositAssets": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.", "label": "Deposits" } } }, "localname": "DepositAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r108", "r233" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": { "auth_ref": [ "r21", "r108" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortizationDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "auth_ref": [ "r7", "r9", "r11", "r23" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Gain on disposal of discontinued operations", "verboseLabel": "Disposal of discontinued" } } }, "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r19", "r86", "r534" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "totalLabel": "Income from discontinued operations before income taxes" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": { "auth_ref": [ "r7", "r8", "r23" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.", "label": "Loss from discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "auth_ref": [ "r8", "r9", "r10", "r11", "r19", "r23", "r378", "r387", "r389" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.", "label": "Provision for income taxes" } } }, "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r20", "r26" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Cost of net revenues" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "auth_ref": [ "r20", "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "totalLabel": "Gross profit" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Total operating expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r20", "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Net revenues" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r27", "r241" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "DISCONTINUED OPERATIONS" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Continuing Operations" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r154", "r155" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r81", "r82", "r83", "r128", "r129", "r130", "r132", "r139", "r141", "r156", "r225", "r314", "r321", "r368", "r369", "r370", "r385", "r386", "r429", "r448", "r449", "r450", "r451", "r452", "r453", "r547", "r548", "r549", "r606" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/StatementOfStockholdersEquity", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished." } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r467", "r469" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Capital lease, weighted average discount rate, percent" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r466", "r469" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r228", "r229", "r485", "r515" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "verboseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r91", "r124", "r186", "r192", "r196", "r199", "r202", "r221", "r246", "r247", "r248", "r251", "r252", "r253", "r255", "r257", "r259", "r260", "r438" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r232", "r240" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r85", "r186", "r192", "r196", "r199", "r202", "r514", "r520", "r524", "r538" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "LOSS FROM CONTINUING OPERATIONS BEFORE PROVISION FOR INCOME TAXES AND RESULTS FROM DISCONTINUED OPERATIONS" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r124", "r131", "r186", "r192", "r196", "r199", "r202", "r221", "r246", "r247", "r248", "r251", "r252", "r253", "r255", "r257", "r259", "r260", "r409", "r431", "r438" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "LOSS FROM CONTINUING OPERATIONS BEFORE DISCONTINUED OPERATIONS" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Loss per share - basic and diluted - Continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued operations net income per share" } } }, "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r23", "r26", "r390", "r534" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Income from discontinued operations", "verboseLabel": "Loss from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/StatementOfOperations", "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r19", "r23", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r86", "r88", "r147", "r151", "r152", "r522", "r534", "r536", "r537" ], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Earnings per share - basic" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r147", "r151", "r152", "r419" ], "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Earnings per share - diluted" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r125", "r140", "r141", "r184", "r378", "r387", "r388", "r539" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r80", "r376", "r377", "r379", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Taxes Paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r107" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r107" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r107" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenues" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r107" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "(Increase) decrease in assets" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (decrease) in liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r107" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r84", "r180", "r455", "r457", "r523" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r102", "r105", "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r35", "r36", "r67" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest, Including related party", "verboseLabel": "Interest Payable, Current" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r178", "r191", "r192", "r193", "r194", "r196", "r198", "r202" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentOwnedBalanceShares": { "auth_ref": [ "r560", "r563" ], "lang": { "en-us": { "role": { "documentation": "Balance held at close of period in number of shares.", "label": "Shares owned" } } }, "localname": "InvestmentOwnedBalanceShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_Land": { "auth_ref": [ "r32", "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r33", "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Construction costs" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeFinanceLeaseDescription": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's finance lease.", "label": "Capital lease description" } } }, "localname": "LesseeFinanceLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Remaining Lease Term" } } }, "localname": "LesseeFinanceLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lease description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITY" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r468" ], "calculation": { "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Minimum annual rent", "totalLabel": "Total lease obligation" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r468" ], "calculation": { "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r468" ], "calculation": { "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r468" ], "calculation": { "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r468" ], "calculation": { "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r468" ], "calculation": { "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "2021 (three months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfMaturityOfOperatingLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "OPERATING AND CAPITAL LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r66", "r124", "r194", "r221", "r246", "r247", "r248", "r251", "r252", "r253", "r255", "r257", "r259", "r260", "r411", "r415", "r416", "r438", "r483", "r484" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r51", "r124", "r221", "r438", "r485", "r519", "r532" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r68", "r124", "r221", "r246", "r247", "r248", "r251", "r252", "r253", "r255", "r257", "r259", "r260", "r411", "r415", "r416", "r438", "r483", "r484", "r485" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees": { "auth_ref": [ "r481", "r482", "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of early contract termination fees included in liabilities subject to compromise.", "label": "Termination fees" } } }, "localname": "LiabilitiesSubjectToCompromiseEarlyContractTerminationFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r42", "r518", "r528" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of credit facility" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.", "label": "Credit facility termination date" } } }, "localname": "LineOfCreditFacilityExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Unused capacity, percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r67" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable - other" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt [Member]" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r72" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes payable, net of current portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Marketing and Advertising Expense", "verboseLabel": "Marketing and advertising" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Cash provided by financing activities", "totalLabel": "Cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash used in investing activities", "totalLabel": "Cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r104", "r106", "r109" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash used in operating activities", "totalLabel": "Cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r78", "r79", "r83", "r87", "r109", "r124", "r131", "r135", "r136", "r137", "r138", "r140", "r141", "r149", "r186", "r192", "r196", "r199", "r202", "r221", "r246", "r247", "r248", "r251", "r252", "r253", "r255", "r257", "r259", "r260", "r431", "r438", "r521", "r535" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r135", "r136", "r137", "r138", "r143", "r144", "r150", "r153", "r186", "r192", "r196", "r199", "r202" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r94" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r42", "r518", "r530" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Outstanding note" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r65" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Base salary" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations", "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r186", "r192", "r196", "r199", "r202" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r462" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "verboseLabel": "Lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Lease liability", "totalLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating lease obligations:" } } }, "localname": "OperatingLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r461" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease obligations - current portion", "verboseLabel": "Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r461" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease obligations - net of current portion", "verboseLabel": "Non-Current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r460" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease right-of-use assets", "terseLabel": "Lease right of use asset", "verboseLabel": "Right of Use (ROU) assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/ScheduleOfOperatingLeaseRightOfUseAssetAndLeaseLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r467", "r469" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating lease, weighted average discount rate, percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r466", "r469" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r196", "r202" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r28", "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION AND DESCRIPTION OF BUSINESS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/OrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r60" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r67" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accrued interest on payroll" } } }, "localname": "OtherEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncome": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.", "label": "Other Operating Income" } } }, "localname": "OtherOperatingIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Purchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r96", "r401" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payment to acquire business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r97", "r404", "r405", "r406" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r97" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payment to acquire property", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r352", "r363" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r44", "r298" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r44", "r298" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "verboseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r30", "r54", "r55" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r98" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from the sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r98" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Warrants to be issued" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r99" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherEquity": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the issuance of equity classified as other.", "label": "Proceeds forn subscription" } } }, "localname": "ProceedsFromOtherEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r561", "r562" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r26", "r78", "r79", "r83", "r103", "r124", "r131", "r140", "r141", "r186", "r192", "r196", "r199", "r202", "r221", "r246", "r247", "r248", "r251", "r252", "r253", "r255", "r257", "r259", "r260", "r409", "r413", "r414", "r417", "r418", "r431", "r438", "r524" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss for the period", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity", "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property plant and equipment, addition" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r59", "r236" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r241", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r58", "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property plant and equipment", "verboseLabel": "Leasehold improvements" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r38", "r39", "r236", "r485", "r525", "r533" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r57", "r236", "r566", "r567" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r38", "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r38", "r234" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Amortization Period", "verboseLabel": "Amortization period" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r213", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r52", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Allowance for Doubtful Accounts, Contractual and Other Discounts" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r339", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Interest percentage on accrued payroll" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r339", "r474", "r477", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r472", "r473", "r475", "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r101" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayment on loans payable" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r101" ], "calculation": { "http://assisted4living.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayment of principal on notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r48", "r321", "r371", "r485", "r531", "r551", "r556" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r128", "r129", "r130", "r132", "r139", "r141", "r225", "r368", "r369", "r370", "r385", "r386", "r429", "r547", "r549" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r177", "r178", "r191", "r197", "r198", "r204", "r205", "r208", "r332", "r333", "r498" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Net Revenue", "verboseLabel": "Total revenue, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails", "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r119", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r337" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r465", "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Recognition of lease liability and right of use asset at inception" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r89" ], "calculation": { "http://assisted4living.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salaries and payroll expense" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, Excluding Cost of Good and Service Sold", "verboseLabel": "Salaries and payroll expense" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r167", "r208" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ConcentrationsAndCreditRisksDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/AccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "SCHEDULE OF NOTES PAYABLE" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r340", "r341", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r6", "r13", "r14", "r15", "r16", "r17", "r18", "r22", "r24", "r25", "r26", "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "SUMMARY OF CARRYING AMOUNTS OF ASSETS AND LIABILITIES AND CASH FLOWS OF DISCONTINUED OPERATIONS" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r59", "r236" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/LeaseholdImprovementsDetailsNarrative", "http://assisted4living.com/role/PropertyAndEquipmentDetailsNarrative", "http://assisted4living.com/role/ScheduleOfLeasesholdImprovementsDetails", "http://assisted4living.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r186", "r189", "r195", "r230" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r186", "r189", "r195", "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "SCHEDULE OF SEGMENT REPORTING INFORMATION" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r352", "r363" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r73", "r121", "r157", "r158", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r307", "r312", "r315", "r316", "r317", "r318", "r319", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in stock options.", "label": "SUMMARY OF STOCK OPTIONS ACTIVITY" } } }, "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r322", "r350" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SCHEDULE OF WARRANTS OUTSTANDING" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r174", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r191", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r202", "r208", "r242", "r243", "r540" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r174", "r175", "r176", "r186", "r190", "r196", "r200", "r201", "r202", "r203", "r204", "r207", "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "SEGMENT INFORMATION" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation Aggregate Amount" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Vesting peirod" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Shares, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Shares, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r354", "r356" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Number of shares outstanding forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r355", "r363" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of shares outstanding, closing balance", "periodStartLabel": "Number of shares outstanding, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Number of shares outstanding, weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.", "label": "Number of shares vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Number of shares outstanding, weighted average remaining vesting period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Disposal of discontinued price per share", "verboseLabel": "Shares issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetails", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r117", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r12", "r174", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r191", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r202", "r208", "r230", "r237", "r242", "r243", "r540" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfSegmentReportingInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r43", "r44", "r45", "r121", "r124", "r146", "r147", "r148", "r151", "r153", "r157", "r158", "r159", "r221", "r246", "r251", "r252", "r253", "r259", "r260", "r298", "r299", "r303", "r307", "r314", "r438", "r597" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r75", "r81", "r82", "r83", "r128", "r129", "r130", "r132", "r139", "r141", "r156", "r225", "r314", "r321", "r368", "r369", "r370", "r385", "r386", "r429", "r448", "r449", "r450", "r451", "r452", "r453", "r547", "r548", "r549", "r606" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/StatementOfStockholdersEquity", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails", "http://assisted4living.com/role/StatementOfOperations", "http://assisted4living.com/role/StatementOfStockholdersEquity", "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r128", "r129", "r130", "r156", "r498" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/OperatingAndCapitalLeasesDetailsNarrative", "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative", "http://assisted4living.com/role/ScheduleOfWarrantsOutstandingDetails", "http://assisted4living.com/role/StatementOfOperations", "http://assisted4living.com/role/StatementOfStockholdersEquity", "http://assisted4living.com/role/SummaryOfCarryingAmountsOfAssetsAndLiabilitiesAndCashFlowsOfDiscontinuedOperationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r44", "r45", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Issuance of shares for acquisition, shares", "verboseLabel": "Shares issuable for Banyan Acquisition, shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative", "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Shares issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r44", "r45", "r314", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r44", "r45", "r314", "r321", "r358" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Number of shares outstanding, exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r75", "r314", "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Issuance of shares for acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r75", "r314", "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Convertible notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BanyanMergerDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": { "auth_ref": [ "r44", "r45", "r314", "r321", "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).", "label": "Stock-based compensation and issuance of employee stock award plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r108" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r45", "r49", "r50", "r124", "r215", "r221", "r438", "r485" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r122", "r299", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r313", "r321", "r323" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": { "auth_ref": [ "r44", "r45", "r49", "r296" ], "calculation": { "http://assisted4living.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.", "label": "Subscription receivable", "negatedLabel": "Subscription receivable" } } }, "localname": "StockholdersEquityNoteSubscriptionsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/BalanceSheets", "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Collection on subscription receivable" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r454", "r488" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r454", "r488" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r454", "r488" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r454", "r488" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r487", "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOWS" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r131", "r132", "r133", "r134", "r142", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r245", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r383", "r384", "r385", "r386", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r471", "r499", "r500", "r501", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r602", "r603", "r604", "r605", "r606" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards." } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/DiscontinuedOperationsDetailsNarrative", "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical", "http://assisted4living.com/role/SubsequentEventsDetailsNarrative", "http://assisted4living.com/role/TrilliumAcquisitionDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r160", "r161", "r162", "r163", "r170", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates and Assumptions" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/ScheduleOfNotesPayableDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrants expiration date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/EquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r145", "r153" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average number of shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r143", "r153" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares outstanding - basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://assisted4living.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r28": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r294": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e845-128460" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e848-128460" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r407": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r479": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55717-112764" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=d3e56015-112765" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56145-112766" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r582": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r583": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r584": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r585": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r586": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r587": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r588": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r589": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r591": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r592": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r593": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r594": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r595": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r596": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r597": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r598": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r599": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r601": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" } }, "version": "2.1" } ZIP 77 0001493152-21-028267-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-028267-xbrl.zip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�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ʍ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�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